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Abstract
Over decades, one of the central dogmas of immunity has been that immune cells can be
classified as parts of either the adaptive or innate immune system. In recent years, however,
the lines between these two systems have become increasingly blurred. For example, subsets
of innate natural killer (NK) cells have been demonstrated to display memory phenotypes,
while recently identified mucosal-associated invariant CD8 T cells (MAIT cells) realize innate
cytotoxicity. MAIT and NK cells both constitute predominant populations in human blood
and other organs and share a high expression of CD161. NK cells detect virus infected,
and abnormally transformed cells, and MAIT cells are able to identify and directly lyse
bacterial-infected cells. While NK activation is controlled by a multitude of receptors, MAIT
responses essentially depend on a TCRα chain that is invariant, as opposed to what is found
in conventional T cells.
Although NK cell activation is well defined, the underlying signaling networks are still
obscure. In the first part of this thesis, the role of several kinases in NK cell activity was inves-
tigated. It could be shown that chemical inhibition of CaMKII and PKD kinases, respectively,
leads to a significant decrease of NK cell cytotoxicity and cytokine release, underscoring the
importance of kinases CaMKII and PKDs in NK cell activation. Notably, these experiments
also indicate significant donor-variations, inhibitory pathways and further involved cell types,
which concertedly bias drug-modulated NK responses.
In the second part, new mechanisms of innate immunity were investigated for the first time
in primary human MAIT cells. Currently, the exact role of MAIT cells in health and disease
remains widely undefined, and proteomic data about this innate-like T cell subset is missing.
Proteomes of primary human MAIT were quantitatively compared donor-dependently with
innate NK cells and conventional CD8 T cells by mass spectrometry.
In total, 5500 proteins could be identified from five representative human donors. These
data reveal a functional inventory of MAIT cells that integrates phenotypes from both NK
and CD8 cells. Donor-dependent analyses then defined a MAIT-specific profile of effector
molecules, and regulators of exocytosis and proliferation, respectively. Furthermore, this
thesis provides candidates that can now be considered as novel MAIT markers and/or likely
contribute to their anti-bacterial unique phenotype. In this context, the first observation of
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the immunological synapse (IS) of a MAIT cell interacting with a bacterial infected target
cell is presented and recruitment of candidate protein S100A4 to the site of anti-microbial
activity is confirmed.
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1 Introduction
1.1 Functions and components of innate and adaptive
immunity
During the course of evolution, even the smallest of life forms have developed rudimentary
protection mechanisms to shield themselves from the potential harmful influence of infectious
agents. Larger and more complex organisms like Homo sapiens have to deal with a wide
variety of pathogens that can rapidly evolve and adapt. Therefore, humans already possess
several layers of defense that allow the human body to effectively prevent those pathogens
from entering its system or, if this proves to be unsuccessful, fight the intruders with a variety
of interwoven mechanisms.1 The initial lines of defense are made up by physical or chemical
barriers (Fig. 1), like the skin or antimicrobial proteins. When these barriers are breached,
other components of the immune system get activated. Classically these mostly cellular-based
components are divided into two subsystems, namely the innate and the adaptive immune
response. While the innate immune response elicits a rapid, but unspecific response directed
towards a broad range of pathogens, the adaptive immune system takes rather days than
hours to establish protection. Even so, adaptive immunity is highly specific and able to
eliminate infections even more efficiently. (Fig. 1) Importantly, cells of the adaptive immune
response are also capable of exerting a memory phenotype, thereby preventing reinfection
on a second exposure to the pathogen, and giving rise to long-lasting immunity.1
Both subsystems of the immune response are mostly comprised of white blood cells or
leukocytes (Fig. 2). The non-cellular complement system is part of the innate immunity and
made of soluble factors.1 Its components are able to quickly recognize and destroy foreign
organisms. The cellular part of the innate immune response is made up of a variety of different
cells of myeloid origin, namely macrophages, dendritic cells, mast cells and granulocytes.
Macrophages are phagocytic cells and perform functions during innate and the adaptive
immune response. They perform an important role during the first line of innate defense by
phagocytosing invading microorganisms. Furthermore, macrophages coordinate immune
responses by secreting cytokines and activating other immune cells. The name of granulocytes
is derived from the typical densely staining granules, and their group is comprised of three cell
1
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types: neutrophils, eosinophils and basophils. Neutrophils are also phagocytic and efficiently
destroy taken-up microorganisms, while the less abundant eosinophils and basophils release
cytotoxic and inflammatory granules upon activation. Mast cells are not well described,
but have been shown to play a major role in allergic responses and the defense against
parasitic worms. After macrophages and granulocytes, dendritic cells are the third type of
phagocytic cells. They also degrade pathogens they have taken up, but more importantly
are able to activate cells of the adaptive immune response by displaying antigens derived
from the pathogen on their surface. Therefore, they are also called antigen-presenting cells
(APC) and form a link between innate and adaptive immune responses. Natural killer cells
(NK cells) are derived from a lymphoid progenitor, but are nevertheless considered a part
of the innate immune response. The main function of NK cells is to efficiently detect and
lyse abnormal cells, like virus-infected or tumor cells. Importantly, NK cells act rapidly and
their activity is not controlled by receptors specific for certain antigens but rather a variety of
germline-encoded activating and inhibitory receptors.
Cells of lymphatic origin, namely T and B cells, comprise the adaptive part of the immune
response.1 B cells bind to antigens through their B cell receptor (BCR), and afterwards
differentiate into plasma cells. These plasma cells then produce specific antibodies, which
are a secreted form of the BCR with identical specificity and therefore bind the same antigen.
T cells are defined by the expression of the T cell receptor (TCR), and can differentiate into
one of different effector cells. Helper T cells express CD4, and coordinate immune responses.
They influence the function of B cells and macrophages. Regulatory T cells can restrain the
activity of other lymphocytes and thereby dampen immune responses. Cytotoxic T cells show
expression of CD8 and are able to efficiently kill infected cells that present the antigen specific
for their TCR. During the course of an infection or antigen exposure, some B and T cells will
develop into memory cells, that will rapidly become reactivated upon repeated exposure to
the antigen, and by that provide long-lasting immunity.
Interestingly, recent observations have blurred the lines between innate and adaptive cell
types. For example, NK cell subsets have emerged that show a memory phenotype, with
enhanced activity of these already primed NK cells.2,3 Furthermore, T cell subsets like γδ T
cells or NKT cells have been shown to respond rapidly to more unspecific stimuli, displaying
an innate-like phenotype.4,5 Most recently, the subset of mucosal-associated invariant T cells
has been discovered. These so-called MAIT cells are highly abundant in mucosal tissues
and the most abundant T cell subset in peripheral blood. They also display an innate-like
phenotype and are able to detect and lyse bacterially-infected cells without prior activation.6–8
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Figure 1 | The relation between the innate and the adaptive immune response. The first line of defense
against pathogens are physical and chemical barriers, like the skin. Afterwards, pathogens have to face the quick
but rather unspecific innate immune response, while the highly specific adaptive immunity gets active after some
days (adapted from Kumar9).
Figure 2 | Components of the innate and adaptive immune system. The immune system is classically divided
into the innate and the adaptive immune response. While innate-immune cells like dendritic cells, mast cells and
granulocytes are of myeloid origin, adaptive immune cells and NK cells are lymphocytes. Recently, lymphocytes
like γδ T cells, NKT, memory NK cells (not shown) and MAIT cells have been discovered, that display properties
of both innate and adaptive immune cells (adapted from Dranoff10).
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1.2 Function and activation of innate natural killer cells
Natural killer cells (NK cells) are cells that develop from a lymphoid progenitor and play
a crucial role in the defense against viral infections and malignant tumors.11–13 They aid
the immune system through the effective killing of abnormal target cells by degranulating,
as the cytolytic granules released during this process contain granzymes and perforin. The
high cytotoxic potential of NK cells can also be directed against other immune cells, like
dendritic cells (DCs), activated CD4+ T helper cells and hyperactivated macrophages (Fig. 3),
thereby regulating the activity of the immune system.11 Additionally, NK cells can enhance the
capability of immune cells by the release of pro-inflammatory cytokines like tumor necrosis
factor-α (TNF-α), interferon-γ (IFN-γ), thereby shaping the immune response by activating
macropages, dendritic cells (DCs) and T cells.11,14 Degranulation can be detected by the
expression of lysosomal-associated membrane protein-1 (LAMP-1) on the cell surface. In CD
nomenclature, LAMP-1 is known as CD107a, and a marker for cytolytic granules.15 During
the process of degranulation, lytic granules fuse with the NK cell membrane and CD107a
appears on the surface of activated NK cells.
In general, NK cells make up from 5 % to 20 % of the human lymphocyte population, and are
defined as CD3-negative lymphocytes that express neural-cell adhesion molecule 1 (NCAM1),
also known as CD56. Interestingly, NK cells can be classified into functionally distinct subsets
by quantifying expression of CD56. The so-called CD56bright cells express high amounts
of CD56, make up approximately 10 % of all NK cells in peripheral blood and are usually
associated with increased release of cytokines and lower cytotoxic potential.16,17 CD56dim
make up the majority of NK cells in peripheral human blood, show decreased expression of
CD56 and are highly cytotoxic.18,19 Recent studies have revealed a new, CD56neg NK subset
that is very low abundant in healthy individuals but expands during chronic viral infections.20
The exact role of these cells is still under debate.
In contrast to B and T cells, NK cell activity is not controlled by a variable, single receptor.
NK cells rather express a variety of different, germ-line encoded receptors, enabling them to
integrate inhibitory and activating signals that are expressed on target cells and detected by
these receptors. The balance of signaling input then leads to a positive or negative response
of NK cells to different stimuli.21–27 NK cells can also mediate antibody-dependent cellular
cytotoxicity (ADCC), which is mediated by activating FcγRIIIA receptor CD16.28 This enables
NK cells to detect and lyse cells that have been recognized by antibodies produced by B
cells. Furthermore, NK cells can exert natural cytotoxicity independent of antigen recognition
and leads to activation through the lack of inhibitory signals, that are usually mediated
by the expression of MHC class I molecules.29 This “missing self” activation mechanisms
4
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render NK activation with immortalized K562 target cells extremely effective, as this cell lines
does not express MHC class I.30 Additionally, K562 surface ligands also provide signals to
activating NK cell receptors,30 e.g. through ligands for NKG2D,31 NKp3032 and DNAM-1.33
If an NK cell encounters a target cell displaying ligands for its activating receptors, the signal
is mediated through the interaction with signaling adaptors (Fig. 4). A big proportion of
activating receptors like CD16 or NKG2C are associated with adaptor proteins that contain
immunoreceptor tyrosine-based activating motifs (ITAMs), for example CD3ζ and FcεRIγ.34,35
However, adaptor proteins like DAP10 or SAP, that bind to activating receptors NKG2D and
2B4, do not contain ITAM-motifs.22 NK cells also express a panel of inhibitory receptors, that
can prevent them from killing cells presenting ligands to activating receptors. Most but not
all of these inhibitory receptors recognize MHC class-I molecules.36 Inhibitory receptors are
associated with the presence of cytoplasmic immunoreceptor tyrosine-based inhibition motifs
(ITIM), and their signaling can usually override activation signals and thus prevent killing of
healthy cells.13 This activation and inhibition signals have their source at the contact interface
between NK cell and target cell, the immunological synapse (IS).27 Formation of the NK IS is
a multiple-step process that has to be strictly controlled, and finally leads to the secretion
of cytolytic granules and target cell death (Fig. 4). After establishing contact, adhesion
molecules like LFA-1 mediate formation of tight junctions between NK and target cell, thereby
already inducing intracellular signaling. Molecules lile Src, LAT, ZAP70 and PKC kinases
are phosphorylated,37–39 and additionally LFA-1 signaling triggers actin polymerization and
granule polarization.40,41 At the contact site, molecules that mediate adhesion like LFA-1
segregate to the outer region of the synapse, the peripheral supramolecular activation cluster
(pSMAC),40 while activating receptors accumulate at the central SMAC (cSMAC). There, they
trigger the relocalization of signaling molecules like Src kinases, Vav1, ZAP70 and PKC kinases,
as well as scaffolding proteins towards the synapse.27 Also, the microtubule organizing center
(MTOC) with the granules associated to it moves towards the IS, where they finally can be
released.40,42
Although the NK IS and NK cell activation have already been analyzed to a larger extent,
these studies have focused on the components directly at the IS. Systematic studies of the
signaling network that is induced was then carried out in a recent study by König and
colleagues.43 The authors described the kinase phosphorylation response that follows specific
receptor stimulation of either CD16 stimulation, or synergistic stimulation of 2B4 and DNAM-
1. Mass spectrometric analysis of phosphorylated kinase peptides revealed known and novel
signaling components to be phosphorylated quickly after NK cell activation. In total, a
network of 188 modified kinases was identified by mass spectrometry, and reproducible
phosphorylation of SFK member FYN, Calcium/calmodulin-dependent kinase II (CaMKII)
5
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Figure 3 | NK cells adjust immune cell responses. NK cells can promote the immune response by triggering
the release of inflammatory cytokines (red arrows). Additionally, they are also able to exert regulatory functions
and kill activated T cells and macrophages, or immature dendritic cells (adapted from Vivier et al.11).
and protein kinase D2 (PKD2) could be observed after receptor engagement.43 However,
data that show if these kinases actually play a role during NK cell activation are missing until
now.
1.3 The biology of adaptive cytotoxic T cells
1.3.1 Priming and activation of CD8 T cells
As natural killer cells, CD8 T cells are of lymphoid origin. Their mode of action, however, is
completely different. Unlike NK cells, CD8 T cells are part of the adaptive immune response,
and therefore their activation is regulated differently. While NK cell activity depends on a
variety of germ-line encoded receptors, T cells rely on the T-cell receptor (TCR). The TCR is
expressed on every T cell, and made up from highly variant segments. Basically, every T cell
receptor consists of an α and a β chain, and is therefore a heterodimer. Notably, a small subset
of T cells expresses a T cell receptor that is made of γδ chains. Nevertheless, both chains
of the T-cell receptor are built from an amino-terminal variable region, a constant region,
and a short stalk segment that connects both chains via a disulfide bond. Also, both chains
contain a transmembrane domain with which they are anchored in the plasma membrane. In
different T cell clones, the variable region is randomly combined from V and J segments in
6
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Figure 4 | Formation of the immunological synapse in NK cells. When an NK cell encounters a target cell
that presents ligands to its activating receptors, an interface is formed that is called immunological synapse (IS).
Molecules that mediate adhesion relocalize to the peripheral parts of the synapse (pSMAC), while the activating
receptors aggregate at the central part (cSMAC). Linking of these receptors with their ligands on the target cell
results in signaling cascades, that are induced by phosphorylation of various signaling molecules. This promotes
in actin polymerization at the pSMAC, and convergence of the microtubule organizing center (MTOC) and lytic
granules towards the synapse. Afterwards, the granules are released towards the target cell and their contents
induce target cell death by various mechanisms (adapted from Krzewski and Coligan27).
the α chain, and from V, D and J segments in the β chain. This gives rise to a huge diversity
of T cells with different TCRs, with each one specific for a different antigen. Importantly, the
antigens need to be presented by major histocompatibility complex (MHC) proteins to be
recognized by T cells. While MHC class I molecules are expressed ubiquitously, MHC class II
molecules are specific for antigen presenting cells (APCs).1
Usually, mature CD8 T cells circulate in the peripheral blood and lymphoid tissues, and are
known as naïve T cells if they have not encountered their specific antigen. They continuously
sample the peptide:MHC complexes that are presented to them by dendritic cells. The
interaction between the cell types is mediated by lymphocyte function-associated antigen
1 (LFA-1) and CD2 on the T cell and intercellular adhesion molecule 1 (ICAM-1), ICAM-2
and CD58 on the dendritic cell. During this binding step, naïve CD8 T cells efficiently sample
large numbers of MHC class II molecules on the dendritic cell surface. In case of a successful
binding between TCR and peptide:MHC complex, signaling steps induce a conformational
change in LFA-1 that leads to an increase of its affinity to ICAM-1 and ICAM-2. This leads to
an even more stable interaction between T cell and APC.44–46 However, the signal transmitted
by the interaction of TCR and peptide:MHC complex is not sufficient to fully activate the T
cell on its own, and stimulate its proliferation and differentiation. The additionally required
signals are also provided by the APC (Fig. 5A). The best-characterized co-stimulatory signal
is delivered by the interaction of CD28 on the T cell surface and its ligand, B7 molecules,
which results in optimal clonal expension of T cells.47–49 Also, CD28 ligation increases the
7
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Figure 5 | Stimulation and activation of CD8 T cells. (A) A naïve T cell recognizes a specific antigen on an
antigen presenting cell (APC) and gets activated through the TCR:antigen interaction and co-stimulation of CD28.
(B) The activated cell produces IL-2 and drives its own clonal expansion, and finally differentiates into an effector
cell phenotype. (C) The effector cells are able to recognize and kill target cells that present the specific antigen
without the need for co-stimulation (adapted from Janeway’s Immunology1).
production of IL-2, with which the T cell stimulates its own proliferation50 (Fig. 5B). Different
co-stimulatory signals can be provided by inducible co-stimulator ICOS or CTLA-4 (CD152),
which are both related to CD28. Like CD28, both also bind B7 molecules, but while ICOS
ligation regulates the production of cytokines, CTLA-4 even restricts the production of IL-2 and
therefore serves as a negative regulator of T cell proliferation. Other co-stimulatory molecules,
like CD27, 4-1BB (CD137) or OX40 belong to the family of tumor necrosis factor receptor
(TNFR) molecules. They stimulate T cell proliferation through triggering of transcription
factor NFκB, which plays a key role in regulating the immune response.51,52 After a period of
proliferation, activated T cells start to differentiate into effector cells. Most importantly, these
effector cells are independent of co-stimulation from now on. If an effector T cell encounters
a target cell presenting the antigen for the T cells TCR, it can exert its effector functions
quickly and kill the infected target cell (Fig. 5C).53 Also, effector T cells change the expression
pattern of their surface molecules. For example, expression of LFA-1 and the integrin VLA-4 is
increased.54,55 These molecules increase the avidity of T cells for their target cells and ensure
that effector T cells can properly home to sites of infection and inflammation, respectively.
Furthermore, effector T cells show decreased surface expression of L-selectin (CD62L), and
are thereby prevented to circulate through lymph nodes again.56 When in contact with target
cells, CD8 T cells quickly form immunological synapses that allow them to carry out their
effector functions.
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1.3 The biology of adaptive cytotoxic T cells
1.3.2 Formation of the cytotoxic T cell immunological synapse, and CD8+
T cell effector functions
When recognizing a target cell that presents the specific peptide for the effector CD8+ T cell,
the T cell forms a cell to cell contact, called the immunological synapse (IS).45,57,58 There,
the TCR and its co-receptors cluster and give rise to the so called supramolecular activation
complex (SMAC). Other surface molecules are recruited to the site, and build a circle around
the central zone, that is comprised of TCR-microclusters (TCR-MC) and its co-receptors, called
central SMAC (cSMAC). Accordingly, the more distant areas are called peripheral SMAC
(pSMAC), where LFA-1 is located, and distal SMAC (dSMAC, Fig.6).58 Integrin LFA-1, and its
strong binding to ICAM-1 play a vital role in the creation of this contact site. At the same
time, the cytoskeleton is restructured, and the T cell gets polarized. A pivotal component of
this reorganization process is Wiskott-Aldrich syndrome protein (WASP), that is activated by
adapter protein Nck or GTP-binding proteins CDC42 and Rac1. When the T cell is polarized,
actin accumulates at the cell to cell-interface, and later is reorganized into the dSMAC ring.58
Also, in a step by step process, the microtubule-organizing center (MTOC) or centrosome,
reorientates towards the synapse, and so do the cytolytic granules, which are then released
towards the target cell.57–62 Cytolytic granules are a special form of lysosomes, that can
contain different types of cytotoxic effector molecules. Notably, these effector molecules
are stored in their active form, rendering them potentially dangerous also for the effector
cell itself. However, pH controlled conditions in the granules prevent them from causing
damage to any other than the target cell. In CD8+ T cells, cytolytic granules usually contain
perforin, granzymes and granulysin. Perforin is a pore-forming protein that acts both on
the target cell membrane and on the membrane of the granules, allowing entry of cytolytic
proteins into the target cell.63 Granzyme are a group of serine proteases, that are mostly
described for inducing apoptotic pathways in the target cell,64 while granulysin additionally
has antimicrobial activity.65
Also, granules can contain cytokines that shape the immune response.66 The most promi-
nent cytokine for CD8+ T cells is interferon-g (IFN-γ). It can directly inhibit viral replication
or remove virus particles from infected cells. Also, IFN-γ recruits and activates other immune
cells, like macrophages and neutrophils.67 CD8+ T cells can also release different interleukins,
like IL-2 and IL-3 or TNF-α. However, CD4+ effector T cells are a far more powerful producer
of immune shaping cytokines. Importantly, cytotoxic effector T cells can also express effector
molecules bound to their membranes, among those Fas ligand or TNF-α. When Fas ligand
interacts with Fas that is presented by the target cell, target cell apoptosis is induced by a
subsequent signaling cascade.68 Membrane-bound TNF-α can also induce apoptosis when
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Figure 6 | Formation of the immunological synapse. Schematic displays IS initiation (top) and maturation
(bottom), from perspective of the target cell (left) and the side (right). Filamentous actin accumulates at the
IS, and drives TCR-microclusters into the pSMAC. Integrins like LFA-1 cluster in the pSMAC, while f-actin is
reorganized into the dSMAC ring. Also, the MTOC or centrosome relocates from the distal part of the the cell to
the IS (adapted from Le Floc’h and Morgan58).
interacting with a TNF-receptor on the target cell, like TNFR-I.69
1.4 Mucosal-associated invariant T cells
1.4.1 Phenotype of MAIT cells
Usually, different T cell clones express a variety of different T cell receptors (TCR), that
recognize a huge diversity of antigen:MHC complexes. However, in recent years T cell subsets
have been characterized that express invariant or semi-invariant TCRs and are therefore
restricted to the recognition of certain target molecules.70 The first identified invariant T cell
subset expresses an invariant T cell receptor with a unique TCRα-chain, consisting of TRAV10
(Vα24) and TRAJ18 (Jα18) segments, and is now known as the invariant NKT (iNKT) cell
subset.71 To current knowledge, these T cells only recognize lipid and glycolipid antigens
that are presented by CD1d, and display features distinct from CD4 and CD8 T cells.72
More recently, a T cell subpopulation has emerged that expresses the TRAV1-2 (Vα7.2) and
TRAJ33 (Jα33) segments in humans, and TRAV1 (Vα19)/TRAJ33 (Jα33) in mice. This new
subset was first identified as part of the double negative (DN) CD4-CD8- T cells, found to be
conserved in humans, mice and cattle and abundant in the gut lamina propria.73 They were
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therefore named mucosal-associated invariant T (MAIT) cells and are also highly abundant
in blood and liver. There, these cells make up 1-10 % and 20-45 % of the whole T cell
population, respectively.74,75 In mice however, MAIT cells are only 0.1 % of T lymphocytes in
the peripheral blood.76 Human MAIT cells are generally defined as T cells that express the
Vα7.2 segment of the TCR, and have also been shown to express high levels of IL-18 receptor
(IL18-Rα).77,78 In humans, most MAIT cells are either CD8αα, CD8αβ or DN T cells, with
only a small proportion expressing CD4,79 and display an effector (CD95hiCD62Llo) memory
(CD27+CD45R0+CD45RA-CD122+) phenotype in adult human blood.80 They also express
high levels of CD26, multi drug resistance protein 1 (MDR1),80 the receptors for interleukins
12, 18 and 23, and chemokine receptors CCR6, CCR5, CCR9 and CXCR6.76,80,81 Dipeptidyl
peptidase-4 or CD26 has just recently been described as a MAIT cell specific marker,82 and
is usually associated with activated and memory T cells.83,84 MDR1 is associated with
drug efflux, and might reflect the diverse toxins present in the MAIT cell environment.78 It
also allows MAIT cells to survive chemotherapy against acute myeloid leukemia and breast
cancer,80,85 and is additionally associated with long lifespans.86,87 Expression of interleukin
receptors allows MAITs to be specifically activated by cytokine stimulation, which significantly
distinguishes them from other T cell types.78 Chemokine receptors CCR6 and CXCR6 that are
expressed by MAIT cells enable them to traffick to intestine and liver,88,89 where they make
up the predominant T cell subpopulation.80 Notably, MAIT cells also express high levels of
CD161 (NK1.1), a feature shared with NKT cells.77,80 CD161 is a C-type lectin (lanier 1994
NKR-P1A), and expressed by NK cells and a proportion of T cells,80 out of which MAIT cells
represent the majority.90 However, the exact function of CD161 is still under debate. On NK
cells, CD161 acts as an inhibitory receptor upon interaction with its ligand.91,92 On T cells the
situation is less clear. While one group reported no effect of linking CD161 on anti-CD3/CD28
stimulation,92 results from a different publication suggest increased expression of IFN-γ
upon CD161 triggering.93 Furthermore, a recent study has reported that ligation of CD161
decreases MAIT cell cytokine production, but not cytotoxicity.94 The transcription of MAIT
cell genes is suggested to be hugely influenced by high expression of transcription factors
RORγt and PLZF (ZBT1B6),95 high abundance of the latter being a feature MAIT cells share
with NKT and γδ T cells.96,97 Notably, PLZF is absent in conventional T cells and might be a
master transcription factor for MAIT cells.98 Retinoic acid-related orphan receptor γt (RORγt)
has been shown to be associated with high expression of CD161 and a maker for T cells that
secrete IL-17.90,99
In summary, MAIT cells are a recently discovered T cell subpopulation that is highly
abundant in liver, gut and the peripheral blood.7,78,98,100 They express a semi-invariant T cell
receptor, tissue-homing markers and receptors for different interleukins (Fig. 7). Furthermore,
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Figure 7 | Surface markers and transcription factors of a typical, adult MAIT cell. MAIT cells express a
semi-invariant T cell receptor that contains the Vα7.2 segment. They also express tissue homing receptors,
receptors for interleukins and markers of memory T cells. Furthermore, all MAIT cells express high levels of
CD161 and MDR1, and most of them are CD8-positive. Important transcription factors for MAIT cell development
are RORγt and PLZF, that are highly abundant in that subset (adapted from Le Bourhis et al.100).
high expression of NK cell-associated receptor CD161 is a trademark of MAIT cells. That
feature is usually associated with IL17-secreting T cells, and so is the presence of transcription
factor RORγt. Another prominent transcription factor in MAIT cells is PLZF, that is also
present in the semi-invariant NKT cell subset and absent in conventional T cells.
1.4.2 Activation and function of MAIT cells
Until 2010, the exact function of MAIT cell was not well understood. Then, in that particular
year two studies were published that observed MAIT cells to exert antimicrobial activity against
a wide variety of bacteria and yeasts, but not viruses.79,101 Gold and colleagues reported that
MAIT cells were able to respond to Mycobacterium tuberculosis infections, even if the host
had not encountered this bacterium before.101 Also, MAIT cell activation by Escherichia coli,
Salmonella typhimurium and Staphylococcus aureus was observed. The second paper, written
by Le Bourhis and colleagues reported anti-microbial activity of MAIT cells against monocytes
that had been fed with E. coli or other bacteria, like S. aureus or Pseudomonas aeruginosa.79
Notably, not all bacteria could induce MAIT cell activation. For example, incubation with
Enterococcus faecalis did not lead to anti-microbial responses. Additionally, some yeasts like
Candida albicans were able to activate MAIT cells. This activity was dependent on MHC-class
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I-related molecule MR1. MAIT cells have been found to be restricted by MR1, and are absent
in MR1 knockout mice.81 Notably, MR1 is the most conserved MHC class I or MHC class
I-related molecule between mice and humans,102 sharing up to 89 % sequence homology,
especially in the ligand binding groove. This implies strong evolutionary pressure, leading to
very stringent amino acid conservations of this MAIT-restricting protein. The antigens that
are presented by MR1 have been identified just recently, and have already been suspected to
be a conserved microbial product. Investigations revealed that the antigen could neither be
cleaved by proteases, nor did it copurify with lipids.103,104 In 2012, refolding experiments of
MR1, and subsequent mass spectrometry analyses revealed vitamin B metabolites as ligand
for MR1.105 This study therefore presented a whole new class of antigen for MHC-like
molecules and the immune system. However, the structures with the highest affinity to
MR1, a derivative of folic acid, did not activate MAIT cells. As S. typhimurium is described
to induce MAIT cell activation,101 it was assumed that S. typhimurium supernatant would
induce refolding of MR1, indicating the formation of an MR1:ligand complex. Indeed, along
with synthetic ligand that can bind MR1 and activate MAITs, several metabolites from the
synthesis pathway of vitamin B2 (riboflavin) were identified to refold MR1, and the built
complex activated MAIT cells (Fig. 8).105 Strikingly, this is consistent with the observation
that all MAIT-activating microorganisms have a functional pathway for riboflavin synthesis.
Accordingly, all bacteria lacking this pathway are not able to induce MAIT cell activation - and
so are mammals, as they are not able to synthesize riboflavin. However, the biochemical origin
of the identified synthetic ligand, which displayed the strongest activating stimulus of all
activating compunds, could not be determined. Later, analysis of MAIT cell activation through
Lactococcus lactis strains with mutations of specific riboflavin synthesis pathway proteins
revealed early riboflavin synthesis intermediate product 5-amino-6-D-ribitylaminouracil (5-A-
RU) to be a pivotal molecule in MAIT cell activation.106 Although 5-A-RU itself is unable to
bind MR1 or activate MAIT cells directly, it can condensate non-enzymatically to unstable
products that can covalently and reversibly bind MR1. Interestingly, one of these products in
complex with refolded MR1 displayed the same mass as the synthetic ligand identified in the
previous study,105 suggesting this to be the true ligand for MR1.106 Furthermore, in various
bacterial strains different abundances of MR1:ligand complexes were found, indicating that
different bacteria might be able to produce diverse ligands that activate MAIT cells. Most
recently it was also discovered that certain compounds can actually competitively inhibit
MAIT cell activation by binding MR1.107
Although MAIT cell activation is of course also dependent of TCR signaling, some studies
have reported that especially adult MAIT cells are rather responsive to stimulation that are
TCR-independent.76,80,85 However, co-stimuli like CD28 or cytokines like IL-12 and IL-18 can
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Figure 8 | Presentation of riboflavin metabolites activates MAIT cells. MR1 refolds in the presence of several
chemical compounds, among them pterines, lumazines and pyrimidines (left). Not all of them, however, lead
to the activation of MAIT cells. Only riboflavin intermediates are able to to trigger MAIT cell effector functions
(adapted from McWilliams et al.119).
overcome this lack of responsiveness.108 Especially the responsiveness to innate cytokines like
IL-12 and IL-18 is similar to NK cells.109 For example, innate signaling via toll-like receptor 8
is a potent trigger for production of IL-12 and IL-18 and might therefore passively activate
MAIT cells in viral infections, where they can produce IFN-γ.110,111 This would also explain
the presence of MAIT cells during other pro-inflammatory settings that are not associated with
bacterial infection.112–116 Upon activation, MAIT cells readily produce cytokines like IFN-γ,
TNF-α and IL-17 (Fig. 9).77,80 Additionally, MAIT cells have been observed to efficiently lyse
bacterially infected cells, and express perforin and granulysin,94 as well as granzyme A and
B.79,80,101 A recent study also indicated that expression of granzyme B and perforin increases
after activation, and therefore cytotoxic capacity is enhanced.117 Importantly, MAIT cells are
innately pathogen reactive. Even when being inexperienced, and not having been exposed to
antigen, MAIT cells have the capacity to respond to bacterial infections.118 This immediate
functional reaction to new pathogens never encountered before is a key feature of innate
immune cells.
Overall, MAIT cells are restricted by MR1. Antigens that in complex with MR1 activate MAIT
cells have just recently been discovered. These antigens are small compounds, indicating a
new class of antigens for T cells, and are associated with the riboflavin synthesis pathway.
MAIT cells can also be activated by cytokines, and exert cytotoxic activity as well as the
release of cytokines, predominantly IFN-γ and IL-17. They are even capable of immediately
displaying effector functions without being exposed to the antigen before, a clear feature of
innate immune cells.7,78,119
14
1.4 Mucosal-associated invariant T cells
Figure 9 | MAIT cell effector functions. Bacteria are internalized by APCs and the MAIT cell antigen, which is
converted out of 5-A-RU binds to MR1. MR1 translocates to the cell surface, and is presented in combination
with co-stimulatory receptors. TLRs recognize other bacterial parts and lead to the release of cytokines like IL-12
and IL-18. One of these mechanisms then activates the MAIT cell, which then expresses and secretes cytokines
IFN-γ, TNF-α and IL-17. Also, expression of granzyme B and perforin is increased in MAIT cells and can lead to
the death of the target cell (adapted from Ussher et al.78)
1.4.3 Development of MAIT cells
Like other T cells, MAIT cells develop in the thymus, where they arise from uncommited DN
precursors (Fig. 10).6,73,76,120 There, an endogenous ligand for MR1 has been suggested
on hematopoetic cells that select MAIT cells,76,81 as MR1 has been shown to be expressed
on CD3+CD45+ hematopoetic T cells.118 As murine MAITs are selected by double positive
thymocytes,121 this might also be true for human MAITs. The need for a specific educational
program for MAIT cells in the thymus becomes apparent when considering that the MAIT
cells found in cord blood are already displaying a phenotype distinct from conventional
T cells,76,95,118 with high expression of CD161 and IL-18 receptor.76,80 Also, MAIT cells
already express transcription factors RORγt and PLZF.95 The abundance of this transcription
factors is shared with innate-like NKT cells and γδ T cells, suggesting a shared developmental
pathway.96,97 However, MAIT cells exit the thymus as naïve cells, unlike NKT cells.120 In
the mucosal tissues of the fetus, MAIT cells mature without the influence of the commensal
flora or other microorganisms. This maturation process is associated with the acquisition
of PLZF expression.120 Interestingly, and contrary to NKT cells, this process seems to be
independent of the SLAM/SAP pathway, as reportedly the number of MAIT cells was normal
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Figure 10 | Schematic view on MAIT cell development. In the thymus, DN precursors give rise to MAIT cells.
They acquire expression of the invariant T cell receptor and are most likely selected by CD3+CD45+ hematopoetic
T cells. The details of the maturation process, however, are still unclear. MAIT cells then leave the thymus,
displaying a naïve phenotype (CD45RA+CD45ROlow), and expand in the periphery upon interaction with B cells
(adapted from Gapin6).
in SAP-deficient patients.76 Also, MAIT cells that are deficient of SAP express PLZF at normal
levels. Once MAIT cells reach the peripheral tissues, they expand rapidly in a B cell dependent
manner.76 This expansion is also dependent on the commensal flora. Accordingly, MAIT cells
are absent in germ-free mice, as well as in mice lacking B cells.76,81
1.4.4 MAIT cells and diseases
The role of MAIT cells in human diseases has not been fully elucidated to that point.7,78
In mouse models of infections, where mice where infected with Escherichia, Mycobacteria,
Klebsiella and Franciscella, the absence of MAIT cells directly correlated with increased
bacterial load.79,122–124 Also human patients that suffered from bacterial infections like
M. tuberculosis have shown decreased numbers of MAIT cells,79,101,125,126 an observation
that correlates with an increase in susceptibility for secondary infections in critically ill
patients.127 Interestingly, also in HCV and HIV infections, MAIT cells are depleted in peripheral
blood.77,128,129 In HCV infections, the decrease in numbers can be attributed to the movement
of MAIT cells towards the liver, where they are suggested to assume a protective role.77 During
HIV infection, the loss of MAIT cells from the peripheral blood has been described to be early
and irreversible, and numbers do not recover even in patients where anti-retroviral therapy
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is successful.125,128,129 Either activation induced cell death129 or downregulation of CD161
and exhaustion128 have been suggested to be responsible for this depletion. Strikingly, MAIT
cells also seem to play a role in non-infectious diseases. For example, increased MAIT cell
numbers have been reported in the brains of multiple sclerosis patients,114,130 and patients
suffering from inflammatory bowel disease show increased numbers of MAIT cells in the
inflamed tissue.116 It is therefore likely that MAIT cells locate from the blood to the inflamed
tissues in the body, and has shown also to be the case in psoriasis, rheumatoid arthritis
and experimental autoimmune encephalomyelitis.77,113,115,131 Also, MAIT cells have been
reported to be recruited to kindey and brain tumors.132
Taken together, MAIT cells seem to play a role not only in the control of bacterial infections,
where they assume protective roles and decrease susceptibility to secondary infections. They
are also affected in the course of viral infections like HIV and HCV, although they have not
been shown to be activated by viruses until now. Furthermore, MAIT cells also infiltrate
inflamed tissue in auto-inflammatory diseases, and tumors.
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1.5 Aim of thesis
Innate immune cell comprise a crucial part of our immune system. Without this first line of
defense, survival for any species would hardly be possible, as this quick response to pathogen
invasion not only fends off most of the invading pathogens itself, but also provides activating
stimuli for the later, adaptive response. Overall, the aim of this thesis was to shed light on
novel mechanisms of innate immunity, and reveal how the activity of fundamentally different
immune cells is realized.
Natural killer (NK) cells are an important part of the innate defense, and mediate protection
against virus-infected cells, tumors, but also bacteria. Furthermore, they also modulate the
immune response by killing active immune cells and releasing pro-inflammatory cytokines.
Their activity is regulated by a variety of germline-encoded receptors, but the signaling
network that is triggered by engaging these receptors is incompletely understood. Recently,
a proteomic study has identified a number of kinases that are promptly phosphorylated
after NK cell activation and are therefore directly involved in NK cell activity, among them
Fyn, CaMKII and PKD2.43 However, the physiological role of these kinases has never been
assessed. Thus, activity of primary human NK cells that are isolated from human donor
blood will be evaluated after perturbing the activity of of Src kinases, CaMKII and PKD. These
data will allow further characterization of the role of these kinases in NK cell signaling, and
preferentially reveal effects that are independent of the donor.
During the course of these experiments, a new cell type with innate properties came into
focus of the research community. Mucosal-associated invariant T (MAIT) cells recognize a
new class of bacterial ligand and are able fight infections without prior activation. Although
in recent years MAIT cells have been subject to a number of studies, their exact function is still
unclear and their functional inventory undefined. Recent studies have shown that systematic
techniques like proteomics are ideal to define conserved features in different immune cell
subsets.19 It was therefore decided to compare the proteome of primary human MAIT cells
with NK cells and CD8+ T cells, as both of these cell types are prototypic for innate and
adaptive immunity, respectively. Also, both NK and CD8+ T cells share features with MAIT
cells. Thus, this kind of analysis will allow investigation of the differences between MAIT
cells and conventional adaptive T cells, and reveal novel mechanisms through which MAIT
cells realize their innate function. Also, the repertoire of MAIT cell effector molecules can be
defined, and typical features of the MAIT cell phenotype will be characterized.
Furthermore, the MAIT immunological synapse will be investigated for the first time.
Although the effector functions of MAIT cells have been thoroughly investigated in the last
years, the interface between MAIT cell and target cell was never addressed in detail.
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2.1 Equipment and software
2.1.1 Equipment
autoMACS Pro Separator, Miltenyi Biotec
BD Accuri C6 Flow Cytometer, Accuri Cytometers Inc.
BD LSR II Flow Cytometer, BD Biosciences
BD FACSAria II SORP Cytometer, BD Biosciences
Innova CO-170 CO2 incubator, New Brunswick Scientific
Multifuge 1 S-R, Heraeus
Inverted microscope Ti-E, Nikon
MoFlo XDP cytometer, Beckman Coulter
Orbitrap Fusion, Thermo Scientific
LTQ Orbitrap Velos Fourier Transform, Thermo Scientific
RC10101 SpeedVac, Sorvall
Sorvall Discovery MS120SE ultra centrifuge, Hitachi
Ultimate 3000 HPLC, Dionex
2.1.2 Software
BD Accuri CFlow Sampler 1.0.264.21, Accuri Cytometers Inc.
BD Accuri CFlow Analysis Plus 1.0.264.21, Accuri Cytometers Inc.
Chromeleon 6.8, Dionex
19
2 Material and Methods
FACSDiva 6.1, BD Biosciences
FlowJo 10.0.7, TreeStar Inc.
Mascot Server 2.4.1, Matrix Science
MetaCore GeneGo pathway analysis, Thomson Reuter
Microsoft Excel 2010, Microsoft
NIS-Elements AR 4.30.20, Nikon
Pathway Studio 11.0.0.1, Elsevier
ProteomeDiscoverer 1.4.1.14, Thermo Scientific
RStudio 0.98.994, RStudio Inc.
Xcalibur software suite 3.0.63, Thermo Scientific
2.2 Chemicals, buffers and media
If not indicated otherwise, all used chemicals were obtained from the following companies:
PAA Laboratories (Pasching, Austria), Life Technologies/Invitrogen/Gibco (Carlsbad, CA,
USA), Sigma-Aldrich/Fluka (St. Louis, MO, USA), Carl Roth GmbH (Karlsruhe, Germany)
and BD Biosciences (Franklin Lakes, NJ, USA). All buffers and solutions were prepared with
ultra pure water, obtained from a MembraPure Astacus purification system (Membrapure
GmbH, Bodenheim, Germany).
2.2.1 Buffers
Cysteine blocking reagent: Isopropanol with 200 mM methyl methanethiosulfonate (MMTS)
DDM lysis buffer: 50 mM HEPES, 15 mM NaCl, 1 % cOmplete Protease Inhibitor Cocktail
(Roche), 1 % dodecyl-maltoside
Dissolution buffer: 1 M tetraethylammonium bromide (TEAB)
FACS buffer: PBS supplemented with 2 % FBS and 2 mM ethylenediaminetetraacetic acid
(EDTA), sterile filtered
FACS permeabilization solution: FACS buffer supplemented with 0.5 % saponin
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Fixation solution: PBS supplemented with 2 % paraformaldehyde (PFA)
GolgiPlug/GolgiStop-solution: RPMI complete supplemented with GolgiPlug (BD Bio-
science) diluted 1:100 and GolgiStop (BD Bioscience) diluted 1:150
IF permeabilization solution: PBS supplemented with 0.15 % Triton-X
IF blocking solution: PBS supplemented with 1 % bovine serum albumin (BSA), 0.1 %
Tween-20
IF washing solution: PBS supplemented with 0.1 % Tween-20
Isolation buffer: Phosphate buffered saline (PBS) supplemented with 4% fetal bovine serum,
sterile filtered
MS buffer A: 0.1 % formic acid
MS buffer B: 0.1 % formic acid, 80 % acetonitrile
PBS: 1.37 mM sodium chloride, 2.7 mM potassium chloride, 12 mM phosphate (HPO42-/H2PO42-)
Reducing reagent: 50 mM tris(2-carboxyethyl)phosphine (TCEP)
RP buffer A: 0.2 % trifluoroacetic acid (TFA), 3 % acetonitrile (ACN)
RP buffer B: 0.2 % trifluoroacetic acid, 60 % acetonitrile
SCX buffer A: 25 % acetonitrile, 0.065 % formic acid
SCX buffer B: 25 % acetonitrile, 0.065 % formic acid, 500 mM potassium chloride
Urea lysis buffer: 1 M tetraethylammonium bromide (TEAB) supplemented with 8 M urea
2.2.2 Media
Lysogeny broth: 15 g/L yeast extract, 10 g/L tryptone, 7 g/L sodium chloride
LB agar: LB medium with 15 g/L agar
RPMI complete: RPMI 1640 (PAA) supplemented with 10 % FBS (PAA), 1 % Penicillin/Streptomycin
and 1 % L-Glutamine
RPMI K562: RPMI 1640 (PAA) supplemented with 10 % FBS (PAA), 1 % Penicillin/Streptomycin
21
2 Material and Methods
Table 1 | Small molecule kinase inhibitors.
name target kinase manufacturer concentration range
CID755673 PKD Tocris Bioscience 5 µM - 200 µM
CK59 CaMKII Merck 10 µM - 200 µM
Dasatinib SFK/Fyn LC Laboratories 10 nM - 300 nM
Table 2 | Used cell lines
name origin reference name
K562 chronic myelogenous leukemia ATCC CCL-243™
THP-1 acute monocytic leukemia ATCC TIB-202™
2.2.3 Kinase inhibitors
Kinase inhibitors used in this study are shown in table 1. The inhibitors were purchased
from LC Laboratories (Woburn, MA, USA), Merck KGaA (Darmstadt, Germany) and Tocris
Bioscience (Ellisville, MO, USA). Dasatinib was stored at -20°C, CID755673 and CK59 at
4°C. All inhibitors were solubilized in dimethyl sulfoxide (DMSO) and diluted with PBS as
indicated.
2.3 Cells
Primary peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood
of healthy human donors. Buffy coats were kindly provided by the Deutsches Rotes Kreuz
(NSTOB Springe). Used cell lines are shown in Table 2.
2.4 Antibodies
Monoclonal antibodies (mAbs) used for flow cytometric analyses are shown in Table 3. For
immunofluorescence experiments, primary antibodies as well as fluorochrome-conjugated
secondary antibodies were used. These antibodies are shown in Tables 4 and 5, respectively.
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Table 3 | Antibodies used for flow cytometry.
antigen isotype clone conjugate manufacturer
CD3 mouse IgG2a BW264/56 FITC Miltenyi
CD3 mouse IgG2a HIT3a PE BD Bioscience
CD8 mouse IgG1 RPA-T8 PE BD Biosciences
CD14 mouse IgG2b MφP9 APC-Cy7 BD Biosciences
CD19 mouse IgG1 SJ25C1 APC-Cy7 BD Biosciences
CD48 mouse IgG1 BJ40 FITC BioLegend
CD56 mouse IgG1 AF12-7H3 APC Miltenyi
CD56 mouse IgG1 HCD56 PE-Cy5 BioLegend
CD69 mouse IgG1 L78 PE BD Biosciences
CD98 mouse IgG1 MEM-108 FITC BioLegend
CD107a mouse IgG1 H4A3 PE BioLegend
CD161 mouse IgG1 DX12 APC BD Biosciences
IFN-γ mouse IgG2b 25723.11 FITC BD Biosciences
TNF-α mouse IgG1 MAb11 eFluor 450/PacificBlue eBioscience
Vα7.2 mouse IgG1 3C10 PE-Cy7 BioLegend
Table 4 | Primary antibodies used for immunofluorescence.
antigen isotype clone manufacturer
CD107a rabbit IgG1b N/A Cell Signaling
CD107a rabbit IgG polyclonal Abcam
perforin mouse IgG2b δG9 BD Biosciences
α-tubulin rat IgG1 37B5 Synaptic Systems
S100A4 rabbit IgG1 EPR2761(2) LifeSpan Biosciences
secernin-1 rabbit IgG polyclonal Synaptic Systems
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Table 5 | Seconday antibodies used for immunofluorescence.
name reactivity species conjugate manufacturer
A12c anti-mouse goat Alexa Fluor 488 Invitrogen
A13c anti-mouse goat Alexa Fluor 594 Invitrogen
B11c anti-rabbit goat Cy5 Dianova
B12c anti-rabbit goat Alexa Fluor 488 Invitrogen
B13c anti-rabbit goat Alexa Fluor 594 Invitrogen
- anti-rat goat Alexa Fluor 647
C12c anti-rat goat Alexa Fluor 488 Invitrogen
C13c anti-rat goat Alexa Fluor 594 Invitrogen
2.5 Methods of Microbiology
2.5.1 Used bacterial strains
The strain used for activation of MAIT cells was Escherichia coli BL21 with the genotype F− ,
ompT, hsdSB , (rB− , mB− ), dcm, gal, (DE3) (Novagen).
2.5.2 Cultivation and fixation of bacteria
E. coli were cultivated over night at 37 °C in LB medium free of antibiotics. Bacteria were
then plated in different dilutions on LB agar plates, incubated over night and colonies were
counted on the next day to determine bacterial concentration. The suspension was then spun
down at 10 000×g for 10 minutes, washed with 10 mL PBS, fixated in 5 mL fixation solution
for five minutes at RT, washed three times with 10 mL PBS and used directly.
Fixation solution: PBS supplemented with 2
Lysogeny broth: 15 g/L yeast extract, 10 g/L tryptone, 7 g/L sodium chloride
LB agar: LB medium with 15 g/L agar
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2.6 Methods of Cell Biology
2.6.1 Culturing of cells
K562 cells were maintained in RPMI K562 medium. Freshly isolated human peripheral
blood mononuclear cells (PBMCs), NK cells and THP-1 cells were cultured in RPMI complete
medium. All cell types were cultured in culture flasks (Nunc) at a temperature of 37 °C with
7.5 % per volume CO2, at a maximal density of 6× 106 cells per mL (PBMCs) and 1× 106
cells per mL (K562 and THP-1), respectively.
RPMI K562: RPMI 1640 (PAA) supplemented with 10 % FBS (PAA)
RPMI complete: RPMI 1640 (PAA) supplemented with 10 % FBS (PAA), 2 % PenStrep (Gibco) and 1 % L-Glutamine (Gibco)
2.6.2 Isolation of PBMCs from human peripheral blood
Buffy coats from healthy human donors were kindly provided by the Deutsches Rotes Kreuz
(NSTOB, Springe). All donors were tested negatively for HIV, HBV and HCV. B-Test Peripheral
blood obtained from one buffy coat was equally distributed to 50 mL falcon tubes and diluted
with 7.5 mL isolation buffer. Fourteen mL of Biocoll separating solution (Biochrom AG,
Berlin, Germany) were covered carefully with this mixture and the tubes were centrifuged at
840×g for 25 minutes (no deceleration). After centrifugation, the PBMCs were extracted
and the cells were spun down (410×g, 10 minutes) and washed twice with 50 mL isolation
buffer. The cell suspension was filtered to remove aggregates and debris (Cell Strainer 40
µm, Falcon). Subsequently, PBMCs were spun down, resuspended in RPMI medium at a
concentration of 6× 106 cells per mL and processed within two days after isolation.
Isolation buffer: PBS supplemented with 4 % FBS (PAA), sterile filtered
RPMI complete: RPMI 1640 (PAA) supplemented with 10 % FBS (PAA), 2 % PenStrep (Gibco) and 1 % L-Glutamine (Gibco)
2.6.3 Fluorescence activated cells sorting of primary human immune cells
cells
PBMCs were spun down (300×g, 10 minutes), washed with FACS buffer and stained at a
concentration of 2×108 cells per mL with respective antibodies in FACS buffer for 15 minutes
at 4 °C in the dark. After washing twice with FACS buffer, wells were then sorted with the
kind help of Dr. Lothar Gröbe (HZI, Braunschweig). After sortingg, cells were pelleted at
840×g for 20 minutes, frozen at -20 °C and processed further for mass spectrometric analysis
(see 2.7).
FACS buffer: PBS supplemented with 2 % FBS (PAA) and 2 mM EDTA (Roth), sterile filtered
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2.6.4 Immunofluorescence analysis of MAIT cell activation
PBMCs were spun down (300×g, 10 minutes), washed with FACS buffer and stained at
a concentration of 2× 108 cells per mL with antibodies against CD161 and Vα7.2 for 15
minutes at 4 °C in the dark. Cells were then sorted, with MAIT cells defined as Vα7.2+CD161++
cells (see Figure 15). Sorted cells were spun down at 300×g for 10 minutes and cultured
over night in RPMI complete medium. THP-1 cells were fed with PFA-fixed E. coli BL21
(MOI 25) over night and mixed with isolated MAIT cells for the indicated times the next
day at a E:T ratio of 1:1. Cells were then transferred to poly-L-lysin cover slips and co-
incubated for indicated times. Cells were then fixed in fixation solution for 20 minutes and
permeabilized in IF permeabilization solution for 5 minutes. After blocking for one hour in IF
blocking solution, samples were stained with primary antibodies and respective secondary
antibodies. Samples were washed with IF washing solution three times after each working
step. Cover slips were dehydrated with ethanol and subsequently embedded in previously
heated moviol. Microscopy was performed on an inverted microscope (Ti-E; Nikon) using
standard epifluorescence illumination (light source Intensilight, Nikon) and 100×/1.45
plan-apochromatic immersion oil objective. Images were acquired with a back-illuminated,
cooled charge-coupled-device camera (CoolSnap MYO, Roper Scientific). Acquisition was
supported by OPTIGRID structural illumination (Nikon) and driven by NIS-Elements AR
software (Nikon).
Every image was recorded as a z-stack, allowing in silico 3D reconstruction of the cells as
well as maximum intensity projections, displaying the maximum intensities of the layers of
the whole z-stack as one 2D image. Also, 3D deconvolution was possible, an algorithm-based
technique that removes optical distortion from already acquired images. In brief, a point
spread function (PSF) is approximated, that helps to calculate the original light source of
every pixel and therefor removes blurring of the image. Deconvolution was carried out over
50 iteration cycles with NIS-Elements AR software, with all parameters adopted from the
software.
FACS buffer: PBS supplemented with 2 % FBS (PAA) and 2 mM EDTA (Roth), sterile filtered
Fixation solution: PBS supplemented with 2 % paraformaldehyde (PFA)
IF blocking solution: PBS supplemented with 1 % bovine serum albumin (BSA), 0.1 % Tween-20
IF permeabilization solution: PBS supplemented with 0.15 % Triton-X
IF washing solution: PBS supplemented with 0.1 % Tween-20
RPMI complete: RPMI 1640 (PAA) supplemented with 10 % FBS (PAA), 2 % PenStrep (Gibco) and 1 % L-Glutamine (Gibco)
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2.6.5 Flow cytometric analysis of MAIT cell activation
Target cells (THP-1 or primary monocytes) were fed with PFA-fixed E. coli BL21 over night
( 25), and co-incubated with human 500.000 PBMCs for two hours at an E:T ratio of 10:1.
In some cases, anti CD28 antibody was added at a final concentration of 1.25 µg per mL.
Afterwards, cells were washed with 150 µL FACS buffer, fixed with 100 µL fixation solution
(20 min, RT) and stained with monoclonal antibodies (15 min, 4 °C) to be able to exclude
non-MAIT cells from the analysis and furthermore assess the activation state. Alternatively,
PBMCs were fed with PFA-fixed E. coli BL21 directly, incubated for two hours and subsequently
fixed, stained and analyzed as described before.
Analysis of MAIT cell activation was conducted on a BD Accuri C6 Flow Cytometer. The
flow cytometer operating software was Accuri CFlow Sampler, the compensation matrix was
generated with BD Accuri CFlow Analysis Plus. BD CFlow Analysis Plus was also used to
analyze data. Additionally, some data points were acquired on a BD LSR II SORP cytometer,
operated by FACSDiva software. Data analysis was then carried out by FlowJo.
FACS buffer: PBS supplemented with 2 % FBS (PAA) and 2 mM EDTA (Roth), sterile filtered
Fixation solution: PBS supplemented with 2 % paraformaldehyde (PFA)
2.6.6 Magnetic activated sorting of human NK cells
The primary NK cells were isolated from the cultured PBMCs by magnetic activated cell
sorting (MACS) using the NK Cell Isolation Kit (Miltenyi Biotec). The isolation was conducted
according to manufacturer’s instructions, but only 75 % of the suggested amount of antibodies
and magnetic beads were used.
Per isolation 1× 108 PBMCs were used. PBMCs were spun down (300×g, 10 minutes),
resuspended in 400 µL MACS buffer (Miltenyi) and 100 µL of NK Cell Biotin-Antibody
Cocktail (Miltenyi) were added. The cell suspension was incubated at 4 °C for 10 minutes.
Afterwards, 300 µL of MACS buffer were added, as well as 200 µL NK Cell MicroBead
Cocktail (Miltenyi), and PBMCs were incubated at 4 °C for 10 minutes. After adding 10 mL of
MACS buffer, the cells were centrifuged (300×g, 10 minutes), the supernatant was removed
completely and the pellet was resuspended in 500 µL MACS buffer. The cell suspension was
filtered (Partec CellTrics 50 µm, Partec, Görlitz, Germany) and NK cells were isolated via
autoMACS (Miltenyi) according to the manufacturer’s guidelines. The program “DepleteS”
was chosen for negative isolation of NK cells. After isolation, the freshly isolated NK cells
were resuspended in RPMI complete medium at a concentration of 6× 106 cells per mL and
analyzed within to days after isolation.
RPMI complete: RPMI 1640 (PAA) supplemented with 10% FBS (PAA), 2% PenStrep (Gibco) and 1% L-Glutamine (Gibco)
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2.6.7 NK cell degranulation assay
To analyze NK cell degranulation, freshly isolated PBMCs or pure NK cells were used as
effector cells. NK cell-susceptible human leukemia K562 cells were used as target cells.
Effector cell suspension and target cell suspension were resuspended at 6× 106 and 12× 106
cells per mL, respectively. Effector cells were transferred to v-bottomed 96-well plates (100
µL per well) and respective kinase inhibitors (Tab. 1) were used at the indicated dilutions.
Effector cells treated with corresponding amounts of DMSO served as negative controls.
Effector cells were incubated with the inhibitors for 15 min at 37 °C.
Afterwards, 50 µL of the K562 cell suspension were added to a final effector-to-target cell
ratio (E:T ratio) of 1:1 (600 000 effector cells and 600 000 target cells per well). Effector and
target cells were brought in contact by centrifuging (30×g for 3 minutes) and co-cultured
at 37 °C for two hours. Subsequently, cells were centrifuged (450×g for 3 minutes) and
resuspended in 50 µL FACS buffer containing the fluorochrome-conjugated mAbs shown in
table 3. Antibodies were diluted as indicated in table 3. Cells were stained for 15 minutes in
the dark at 4 °C.
After staining, cells were washed, resuspended in 100 µL FACS buffer and subsequently
analyzed by flow cytometry.
FACS buffer: PBS supplemented with 2% FBS (PAA) and 2 mM EDTA (Roth), sterile filtered
2.6.8 NK cell cytokine release assay
For the assessment of NK cell degranulation and cytokine release, freshly isolated PBMCs or
pure NK cells were used. Human leukemia K562 cells were used as target cells. Effector cells
suspension (PBMCs or pure NK cells) were resuspended at 6× 106 and 1.2× 106 cells per
mL, respectively. Effector cells were transferred to v-bottomed 96-well plates (100 µL per
well) and respective kinase inhibitors (Tab. 1) were used at the indicated dilutions. Effector
cells treated with corresponding amounts of DMSO served as controls. Effector cells were
incubated with the inhibitors for 15 min at 37 °C.
Afterwards, 50 µL of the K562 cell suspension were added to a final effector-to-target (E:T)
ratio of 10:1 (600 000 effector cells and 60 000 K562 target cells per well). Effector and
target cells were co-cultured at 37 °C for one hour. After 17 µL GolgiPlug/GolgiStop-solution
were added, cells were incubated for another five hours. Subsequently, cells were centrifuged
(450×g for 3 minutes) and resuspended in 50 µL FACS buffer containing fluorochrome-
conjugated mAbs and LIVE/DEAD near IR Cell Stain (Invitrogen). When staining pure NK
cells, the mAbs directed against CD14 and CD19 were not added to the staining solution.
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Antibodies were diluted as indicated in table 3 and dead cell marker (DCM) was diluted
1:200. Cells were stained for 15 minutes in the dark at 4 °C.
After staining, cells were washed in FACS buffer twice and fixed in 50 µL fixation solution
for 10 minutes in the dark. After fixation, cells were resuspended in 25 µL permeabilization
solution and incubated for 15 minutes at 4 °C in the dark. For intracellular staining of
cytokines, mAbs were diluted in permeabilization solution as indicated and 25 µL of the
mixture were added to each well. Cells were incubated for another 30 minutes at 4 °C in the
dark. Cells were spun down, washed with FACS buffer and subsequently analyzed by flow
cytometry on a BD LSR II SORP cytometer, operated by FACSDiva software. Data analysis
was then carried out by FlowJo.
FACS buffer: PBS supplemented with 2 % FBS (PAA) and 2 mM EDTA (Roth), sterile filtered
FACS permeabilization solution: FACS buffer supplemented with 0.5% saponin (Sigma)
Fixation solution: PBS supplemented with 2 % PFA (Sigma)
GolgiPlug/GolgiStop-solution: RPMI complete supplemented with GolgiPlug diluted 1:100 and GolgiStop diluted 1:150 (both BD Bioscience)
2.6.9 Flow cytometric analysis of NK cell degranulation and cytokine
release
Analysis of NK cell cytokine release was carried out on a BD LSR II Flow Cytometer (BD Bio-
sciences). The operating system was FACSDiva (BD Biosciences), the necessary compensation
matrix was generated with the same software. Here, gating focused on excluding CD14+,
CD19+ and dead as well as adhering cells from the lymphocyte population. The remaining
cells were gated on CD3/CD56 characteristics (Fig. 11).
2.7 Semi-quantitative proteomic analysis
2.7.1 Cell lysis and digestion (urea lysis)
Frozen cell pellets were lysed in 50 µL urea lysis buffer per 1 · 106 sorted cells for 30
minutes at RT, with 1 µL of Benzonase added. After incubation, reducing reagent was added
1:10 for 30 minutes, and subsequently cysteine blocking reagent 1:20 for 15 minutes. For
protein digestion, combined LysC/trypsin reagent was added at a ratio of 1:20 w/w. After
a minimum of 3 hours incubation at RT, the lysate was diluted with H2O from 8 M to 1 M
urea and incubated at 37 °C over night. Peptides were then cleaned up via reverse phase
(see 2.7.2). Afterwards, digestion efficiency was checked with a short LC-MS/MS run and
a subsequent data analysis of the RAW file with RawMeat software (Vast Scientific). Only
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samples containing a high amount of peptides with low numbers of charges were considered
as properly digested.
Cysteine blocking reagent: Isopropanol with 200 mM methyl methanethiosulfonate (MMTS)
Urea lysis buffer: 1 M tetraethylammonium bromide (TEAB) supplemented with 8 M urea
Reducing reagent: 50 mM tris(2-carboxyethyl)phosphine (TCEP)
2.7.2 Reverse-phase peptide clean up and desalting
Samples were acidified with 10 % TFA. The pH was checked with pH indicator paper and
samples were then centrifuged at 16.000×g for ten minutes. Protein amounts were deter-
mined by NanoDrop, samples were then loaded onto according Oasis Extraction Cartridges
(Waters), that had before been preactivated, activated and equilibrated with appropriate
volumes of pure acetonitrile, RP buffer B and RP buffer A, respectively. After loading the
sample twice, columns were washed with RP buffer A twice. Peptide bound to the columns
was then eluted with RP buffer B and the eluate was evaporated in the SpeedVac. Afterwards,
the whole process was repeated with the sample flowthrough to maximize the yield. After
evaporation of the solvent, purified peptides were then frozen at -20 °C and either labeled
with iTRAQTM reagent (see 2.7.3), if already labeled submitted to SCX chromatography (see
2.7.4) or if already fractionated submitted to LC-MS/MS analysis (see 2.7.5). Before labeling
or SCX, samples were checked for digestion and labeling efficiency, respectively.
RP buffer A: 0.2 % trifluoroacetic acid (TFA), 3
RP buffer B: 0.2 % TFA, 60 % ACN, 500 mM potassium chloride
2.7.3 Peptide labeling with iTRAQTM
To be able to analyze the samples quantitatively, peptides were labeled with isobaric Tags
for Relative and Absolute Quantitation (iTRAQ, Sciex). iTRAQ reagents were heated to RT,
solved in 70 µL ethanol and added to generated and cleaned tryptic peptides (see 2.7.1
and 2.7.2, respectively) that had been solved in 30 µL dissolution buffer. One label was
used per sorted cell population. The mixture was then incubated at RT for two hours, and
evaporated in the SpeedVac. After peptide clean-up to remove excess label reagent (see 2.7.2)
and a LC-MS/MS-based check for labeling efficiency, peptide amounts were determined by
integration of the total area of all spectra that were detected in the mass spectrometer (Qual
Browser, Thermo Xcalibur). Same amounts of differently labeled populations were then
combined into one sample that was then submitted to SCX chromatography (see 2.7.4).
Dissolution buffer: 1 M tetraethylammonium bromide (TEAB)
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2.7.4 Subfractionation of complex peptide samples through SCX
chromatography
To increase the sensitive of mass spectrometric analyses, iTRAQ-labeled and RP-purified sam-
ples were fractionated with strong cation exchange chromatography (SCX chromatography).
Samples were solved in SCX buffer A and cleaned up by ultracentrifugation at 109.000×g for
20 minutes. Fractions were generated on a Ettan microLC system, using a Mono-S-PC1.6/5-
column (both GE Healthcare) with a flow rate of 150 µL/min. To elute the peptides from the
column, a linear gradient from 0 % to 35 % SCX buffer B was applied over 15 minutes, while
generating one fraction per minute with a microfraction collector (SunCollect). Fractions
were combined with regard to the peptide elution profile of the specific samples samples that
could be detected by measuring the absorption at 214 nm with a UV detector. Fractions were
then evaporated, desalted (see 2.7.2) and submitted to LC-MS/MS analysis.
SCX buffer A: 25 % acetonitrile, 0.065 % formic acid
SCX buffer B: 25 % acetonitrile, 0.065 % formic acid, 500 mM potassium chloride
2.7.5 Mass spectrometric analyses and data interpretation
LC-MS/MS analyses of purified and desalted peptides were performed on a Dionex UltiMate
3000 n-RSLC system connected to an Orbitrap FusionTM TribridTM mass spectrometer (Thermo
Scientific). Peptides of each fraction were loaded onto a C18 pre-column (3 µm RP18 beads,
Acclaim, 75 μm x 20 mm), washed for 3 min at a flow rate of 6 μL/min and separated on a C18
analytical column (3-μm, Acclaim PepMap RSLC, 75 μm x 25 cm, Dionex) at a flow rate of 350
μl/min via a linear 120 min gradient from 97 % MS buffer A to 25 % MS buffer B, followed by
a 15 min gradient from 25 % MS buffer B to 62 % MS buffer B. The LC system was operated
with the Chromeleon software (version 6.8, Dionex) embedded in the Xcalibur software suite
(version 3.0.63, Thermo Scientific, Dreieich, Germany). The effluent was electro-sprayed
by a stainless steel emitter (Thermo). Using the Xcalibur software, the mass spectrometer
was controlled and operated in the “top speed” mode, allowing the automatic selection of as
many doubly and triply charged peptides in a three second time window as possible, and the
subsequent fragmentation of these peptides. Peptide fragmentation was carried out using the
higher-energy collisional dissociation (HCD) mode in the ion trap. MS/MS raw data files were
processed via the Proteome Discoverer program (version 1.4, Thermo Scientific) on a Mascot
server (version 2.4.1, Matrix Science) using Swiss-Prot/UniProt database. Mascot search
parameters used for protein identification are displayed in Table 6. Results were evaluated
and quantified using Proteome Discoverer software, with the filters shown in Table 7.
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Table 6 | Used Mascot search parameters
parameter setting
protein database SwissProt
species Homo sapiens
enzyme trypsin
maximum missed cleavage site 1
precursor mass tolerance 10 ppm
fragment mass tolerance 0.05 Da
dynamic modifications
iTRAQ4plex (K)
iTRAQ4plex (N-term)
oxidation (M)
static modifications methylthio (C)
mass precision 2 ppm
Table 7 | Used filters in Proteome Discoverer
filter setting
peptide confidence high
search engine rank 1
peptide ion score 30
MS buffer A: 0.1 % formic acid
MS buffer B: 0.1 % formic acid, 80 % acetonitrile
2.8 Statistical evaluation and determination of significantly
regulated proteins
Statistical evaluation was performed together with Prof. Dr. Frank Klawonn as described
before.133 To identify significant protein regulations the variation of the regulation factors
was statistically estimated. In our statistical model we assume that the log2-regulation
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factors (RF) of each protein follow a normal distribution (5 x 3 log2 RFs per protein due to 5
analyzed donors per immune cell subset comparison) with different expected values, but with
the same standard deviation. It is necessary to estimate in order to distinguish significant
(donor-independent) deviations from no regulation. The limited number of replicates (5
donors) required an estimation of the standard deviation by taking RFs of all proteins into
account. In the used model used the mean of the Median Absolute Deviation from the
median (MAD) of all proteins serves as an estimator for the standard deviation of a normal
distribution (with a correction for small sample sizes). In this way many estimates for the
MAD with a large variance are obtained. But averaging this larger number of not very reliable
estimates leads to a reliable estimate of the MAD. Based on the previous estimation it is
possible to construct a hypothesis test for the identification of significantly regulated proteins.
Thereby, the hypothesis of the test encompasses that a protein is considered to be significantly
regulated if its mean regulation deviates significantly from 0. The used function represents
the cumulative distribution function of the standard normal distribution. A strict test is used,
where α is the significance level of the test (here α = 5%; before FDR correction) and where
the absolute value of the log2-regulation exceeds a given threshold in at least m (m = 3, 4,
5) out of the k=5 replicates. nm is the number of proteins which have been measured in
at least m replicates. We used this value for the FDR correction, since we cannot apply the
test to proteins that have been measured in less than m replicates. Taken all the parameters
together we obtained the value for the threshold as follows:
cα = σ0 ·Φ−1

1−

α
2 · nm ·
  k
m
 1m
These thresholds (for m=5, m=4 and m=3 donors) were used to define a set of significantly
and donor-independently regulated proteins.
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3.1 The role of Src kinases, CamKII and PKD kinases in NK
cell activation
3.1.1 Inhibition of Src kinases, CaMKII and PKD kinases decreases NK cell
degranulation and cytokine release in primary human PBMCs
Although NK cells play a pivotal role in the innate defense against viruses and cancer, the
signal pathways coordinating their effector functions aren’t completely understood. In a
recent proteomic study, several kinases were identified to be phoshporylated two minutes
after specific NK cell receptor engagement.134 Among these kinases were Src family member
Fyn, CaMKII and PKD2. To further study the importance of these kinases in NK cell activation,
it was decided to investigate NK cell effector functions with the activity of the specific kinases
perturbed. Although immortalized cells are easier to manipulate on the level of genes, the use
of NK cell lines is only of limited usefulness when assessing effector functions. NK cell lines
are usually hyperactive and display a different phenotyp from primary material. Therefore,
it was decided to use small molecule inhibitors of the specific kinases, and carry out all
experiments in primary human material. Specific inhibitors used were Dasatinib (specific for
Src family kinases), CK59 (CaMKII) and CID755673 (PKD family kinases). These experiments
were partly conducted during a master thesis (Bulitta, 2011), and published later.135
The role of Src family kinases, CaMKII and PKD2 in NK cell activation induced by K562
target cells, was assessed by FACS-based methods that have been previously described.136
In brief, NK cell activity can be assessed by quantifying degranulation and the release of
cytokines. Degranulation can be measured by analyzing the surface expression of CD107a,
which appears on the surface after the fusion of cytolytic granules with the membrane.15
Additionally, intracellular accumulation of cytokines TNF-α and IFN-γ can also be detected by
FACS.
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifu-
gation from human blood of healthy donors. CD3-CD56+ NK cell populations were then
defined by gating PBMCs on lymphocytes, excluding doublets, as well as CD14+, CD19+
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and dead cells (Fig. 11). For activation, PBMCs were co-incubated with K562 target cells,
leading to degranulation and cytokine release of NK cells (Fig. 12). To assess the role of
the kinases, the specific inhibitors were solved in DMSO and added to PBMCs at indicated
concentrations 15 minutes prior to activation with target cells. Pure DMSO added to a mix
of NK and K562 cells served as control. Degranulation was then analyzed after 2 hours of
co-incubation with K562 target cells. Intracellular accumulation of cytokines was analyzed
after 6 hours of co-incubation, and treatment with protein transport inhibitor brefeldin A.
Data are presented relative to the DMSO negative controls.
Application of Dasatinib for Src inhibition significantly reduced NK cell degranulation to
50% at a concentration of 150 nM, and led to complete reduction at higher concentrations
while having no significant effect at lower doses (Fig. 13A). Additionally, Dasatinib signifi-
cantly inhibited the production of TNF-α and IFN-γ, even at lowest concentrations. Compared
to DMSO controls, the amount of cells positive for TNF-α was reduced to 15 % and IFN-γ
production was abrogated almost completely.
Also the application of CK59 (CaMKII inhibition) lead to reduction of NK cell degranulation.
However, the effect was more dose-dependent and gradually, while not showing specific dose
dependency regarding cytokine production (Fig. 13B). In sum, the effect of CK59 on TNF-α
and IFN-γ production was comparable, showing only a moderate reduction at low inhibitor
concentrations (10 - 50 µM). In contrast, higher doses had a significant effect on TNF-α and
IFN-γ production, nearly abrogating it at 150 µM. In total, the effect of CK59 on cytokine
release was at higher concentrations even more pronounced than the effect on degranulation.
PKD kinase inhibitor CID755673 also led to a reduction of NK cells degranulation and
cytokine release (Fig. 13C). While already 5 µM CID755673 significantly reduced the amount
of degranulating cells, higher concentrations reduced the percentage to 40 % positive cells
compared to the controls. Notably, degranulation wasn’t reduced further when increasing
inhibitor concentrations higher than 50 µM while an increase of inhibitor concentration to 100
µM led to pronounced reduction of cytokine release. Production of TNF-α and IFN-γ was also
decreased dose-dependently. A dose of 100 µM CID755673 led to a reduction of TNF-α+ cells
to 25 % and IFN-γ production was almost diminished completely at this concentration. Taken
together, the application of CD755673 resulted in notable inhibition of NK cell degranulation
and cytokine release, and almost completely abrogated IFN-γ accumulation.
In total, treatment of PBMC cultures with Dasatinib, CK59 and CID755673 resulted in
significant inhibition of NK cell degranulation and cytokine release. This indicates pivotal roles
for the inhibited kinases in mediating activating signals after NK cell stimulation. Furthermore,
already in these data donor variations became apparent, with cells of different donors reacting
differently to the inhibitor treatment to validate the results, and exclude effects from other
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cells in the PBMC cultures it was decided to assess the influence of the inhibitors in purified
NK cells.
3.1.2 Donor-specific responses of pure NK cells treated with Dasatinib,
CK59 and CID755673
As the experiments described in 3.1.1 were carried out in cultured PBMCs, it couldn’t be ruled
out that other cells of the culture might have contributed to the observed effects. To validate
the inhibitory influence of the compounds and also check for a possible contribution of other
cells, all experiments were repeated with pure NK cell cultures.135 NK cells were purified
by magnetic associated cell sorting (MACS), and subsequently treated with the inhibitor.
Activation with K562 target cells, the handling of DMSO controls and flow cytometric analyses
were conducted as described before (3.1.1).
Interestingly, for all three inhibitors the variation between individual donors was more
apparent when analyzing pure NK cell cultures. This effect was independent of the used
inhibitor. Regarding degranulation, the effect by Dasatinib was even more pronounced,
completely abrogating it at 100 nM (Fig. 14A). Also, Dasatinib almost completely diminished
the amount of cells positive for TNF-α and IFN-γ at the concentration of 50 nM. Interestingly,
some donors showed a pronounced increase of cytokine release after this initial reduction.
One donor peaked with 30 % positive cells for TNF-α at 200 nM Dasatinib, while another
displayed a slight increase at 100 nM. For two donors the amount of IFN-γ-positive NK cells
relapsed even further to 60 % positive cells at Dasatinib concentration of 100 µM and 150
µM, respectively.
CaMKII inhibitor CK59 also lowered the percentage of CD107a+ cells, already decreasing it
to 75 % at 100 µM and nearly complete reduction at 150 µM (Fig. 14B). Notably, some donors
also showed a small increase of degranulation at the lowest concentration of CK59. The
inhibitor’s effect on TNF-α and IFN-γ release was more pronounced, decreasing the number
of cells positive for TNF-α approximately to 25 % at 100 µM, and reducing it even further
at 150 µM. Again, two donors showed considerably variation from the others, showing an
increased response compared with the DMSO controls. The first peaked with 250 % cells
positive relative to the control at 20 µM CK59, which dose-dependently dropped to 20 %
at higher concentrations. IFN-γ release was also inhibited dose-dependently in two donors,
with one of these showing an increase of positive cells at 10 µM. Interestingly, the number of
IFN-γ+ NK cells increased in two different donors to 140 % at 20 µm CK59, and decreased at
higher concentrations. Another donor even showed a high increase of IFN-γ, that peaked
with 340 % positive cells at 50 µM CK59.
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Figure 11 | Gating strategy to study effector functions of human CD3−CD56+ NK cells. NK cells were
co-incubated with K562 target cells for 6h for assessment of cytokine production and 2 h for investigating
degranulation at 37° C. After stimulation, cells were surface stained with fluorochrome-conjugated mAbs directed
against CD3, CD14, CD19, CD56 and CD107a, as well as with DCM. The depicted gates were used to exclude
(A) non-lymphocytes, (B) doublets, (C) CD14+/CD19+ and dead cells as well as (D) CD3+CD56-cells from the
analysis.
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Figure 12 | NK cell cytokine production is induced by K562 target cells. PBMCs were incubated alone or
activated with K562 target cells for six hours, fixed, permeabilized and stained with fluorochrome-conjugated
mAbs. Profiles show CD107a surface expression and cytokine production of NK cells without activation and after
co-cultivation with K562 target cells. Unactivated cells showed no significant responses (upper panel), incubation
with target cells triggered degranulation and cytokine production (lower panel).
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Figure 13 | Inhibition of Src family kinases, CaMKII and PKD decreases NK cell degranulation and cytokine
release in primary human PBMCs. PBMCs were treated with [A] Dasatinib, directed against Src family kinases;
[B] CK59, targeting CaMKII and [C] CID755673, inhibiting PKD-family kinases and subsequently incubated
with K562 target cells at 37°C for 2 (degranulation) and 6 (cytokine release) hours, respectively. Cells were
mixed with respective fluorochrome-conjugated mAbs and the frequency of degranulating or cytokine producing
NK cells was determined via flow cytometry. Data represent values relative to corresponding DMSO control.
Comparison of every inhibitor-treated group to its corresponding DMSO control group was performed by Wilcoxon
test (*P<0.05,**P<0.01,***P< 0.001). Values represent mean of the indicated number of donors ± SD.
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3.2 MAIT cells isolated from human donor blood are suitable material for proteomic
analyses
Compared to the effect that PKD inhibitor CID755673 had on NK cell activation in PBMC
cultures, the effect on pure NK cell degranulation was moderate (Fig 14C). Application
of the inhibitor only resulted in a small but still significant effect on CD107a+ cells. One
donor showed a pronounced decrease at 200 µM CID755673, while in two other donors a
slight increase of degranulating cells could be detected at 50 µM and 100 µM. A different
donor displayed a similar reaction at concentrations of 100 µM and 200 µM. In all donors,
the accumulation of TNF-α was robustly inhibited at higher doses of CID755673. Two
donors, however, showed a drastically pronounced TNF-α response at lower CID755673
concentrations, while a small increase of TNF-α+ cells could be detected in another donor at
10 µM CID755673. IFN-γ release was almost completely abrogated at concentrations of 100
µM and higher. Again, at lower concentrations donor variations became obvious. Two donors
showed a pronounced increase of IFN-γ positive cells to 270% and 200%, respectively, after
initial reduction at lower concentrations. Two other donors also showed a small recovery of
the IFN-γ response.
Overall, results obtained from purified NK cells were in accordance with results from PBMC
cultures. Taken together, this data suggest that the respective kinases play an important role
in NK cell activation and that tested kinase inhibitors could be used as drugs to modulate NK
cell effector function. Furthermore, donor-dependent responses could be observed, that were
pronounced in cultures of pure NK cells. Therefore, other cells might exert compensatory
effect on NK cells ins PBMC cultures.
3.2 MAIT cells isolated from human donor blood are suitable
material for proteomic analyses
To gain material for proteomic studies, a pipeline for sample generation was established, and
buffy coats generated from healthy human donor blood were obtained from the Blutbank
Springe (Deutsches Rotes Kreuz; cooperation with H. Garritsen, Klinikum Braunschweig).
Although MAIT cells are a predominant human T cell subset, especially in mucosal tissues and
the liver, absolute numbers can be limited in peripheral blood that is the basis for buffy coats.
For a systematic proteomic study it had to be verified that the provided blood samples would
yield enough MAIT cells. As blood samples were provided as buffy coats and had not been
screened for MAIT cell percentages before, it was also of interest if the MAIT cell amounts
would differ from literature. Furthermore, only responsive, inactivated and not exhausted
MAIT cells should be used for proteomics, so that the generated data would to reflect the in
vivo proteome of MAIT cells from healthy donors. Therefore, it had to be excluded that the
cells are preactivated or exhausted, and cells had to be checked for viability.
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Figure 14 | Donor-specific responses of pure NK cells treated with Dasatinib, CK59 and CID755673. Pu-
rified NK cells were treated with [A] Dasatinib, directed against Src kinases; [B] CK59, targeting CaMKII and
[C] CID755673, inhibiting PKD-family kinases and subsequently incubated with K562 target cells at 37°C for 2
(degranulation) and 6 (cytokine release) hours, respectively. Cells were mixed with respective fluorochrome-
conjugated mAbs and the frequency of degranulating or cytokine producing NK cells was determined via flow
cytometry. Data represents values relative to corresponding DMSO control. Comparison of every inhibitor-treated
group to its corresponding DMSO control group was performed by Wilcoxon test (*P<0.05,**P<0.01,***P<
0.001). Values represent mean of the indicated number of donors ± SD.
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3.2 MAIT cells isolated from human donor blood are suitable material for proteomic
analyses
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation from
the blood of healthy human donors and stained with mAbs against CD3, Vα7.2 and CD161.
The percentage of MAIT cells was then quantified by flow cytometry. To detect and quantify
MAIT cells, lymphocytes were first gated on forward scatter (FSC)/sideward scatter (SSC)
characteristics. Out of the lymphocyte populations, a gate was then set on T cells, that are
defined by the expression of CD3 (TCR complex). In the T cell population, MAIT cells express
the semi-invariant TCR chain Vα7.2 as well as high levels of CD161. The respective gating
strategy is shown in Fig 15. Using this strategy, the percentage of MAIT cells in the T cell
population was quantified in 20 different donors, in buffy coats obtained from the Deutsches
Rotes Kreuz. In this study, MAIT cells made up from 0.1 % to 6 % of CD3-positive cells and
showed a decline in numbers with increasing age (Fig. 16). Three donors had significantly
higher numbers of MAIT cells than persons of the same age (age 25, 35 and 62, respectively).
Interestingly, all these donors were male. Notably, data showed no significant deviations
from current literature,137,138 although numbers were slightly lower in average. Additionally,
a peak of MAIT numbers at roughly age 40 could not be detected, as no donors of this age
were analyzed. Also, MAIT numbers are generally higher in women of reproductive age,
which could not be detected in this donor set. In conclusion however, and with regard to
the comparatively small sample size, the used method of MAIT isolation is suitable to isolate
sufficient amounts of MAIT cells from donors healthy and inconspicuous human blood donors.
Additionally, it had to be assured that the isolated MAIT cells reflect their in vivo phenotype
as close as possible, and are still functional and viable. To check for MAIT cell activity, E.
coli were fixed with PFA and co-incubated with ex vivo PBMCs for 2 h, 4 h and over night,
respectively, at different multiplicities of infection (MOI). This leads to presentation of bacterial
ligands on MR-1 present on various cells in the PBMC culture, and subsequent activation
of MAIT cells.128 To enhance the stimulus, an antibody directed against the co-activatory
receptor CD28 was added, while non-stimulated cells and cells co-incubated with anti-CD28
served as negative control. MAIT cell activation was then assessed by surface expression
of activation markers CD69 and CD107a, that could be analyzed by flow cytometry (Fig.
17A, B). The MAIT cells in ex vivo PBMCs showed an increased surface expression of CD69
and CD107a after stimulation, resulting in up to 30% cells showing CD69 or CD107a on
the surface. This indicates a strong activation, and full functionality of the present MAIT
cells. Over time it became apparent, that CD107a is rather a marker for early activation
(Fig. 17C), showing strong surface expression after 2 h and 4 h already. The expression of
CD69 however peaked later, showing the highest number of positive cells after over night
incubation. Both results are in accordance with literature, where CD107a and CD69 are
markers for granule exocytosis and long term activation, respectively.94 Also, co-incubation
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Figure 15 | Gating strategy for primary human MAIT cells. PBMCs were isolated from human donor blood,
stained with mAbs and analyzed by flow cytometry. MAIT cells were gated as lymphocytes (A) that are positive
for CD3 (B), and show expression of Vα7.2 as well as high expression of CD161 (C).
with the anti-CD28 antibody led to an increased response of both CD107a and CD69 surface
expression. Additionally, triggering the cells with higher MOIs also increased the number
of activated cells, showing that the cells can be activated dose-dependently and are not
exhausted. Importantly, no preactivation through the culture medium, isolation protocol or
other outside stimuli could be detected, as the negative controls showed no activated cells.
In summary, MAIT cells in ex vivo isolated PBMCs from healthy human donors can be
activated to a great extend through co-incubation with stimulatory antibodies and fixed E. coli
bacteria. Therefore, these MAIT cells are not pre-activated or exhausted and are suited well
for representative proteomic analysis. Generated data will not be biased by ex vivo culturing,
culture-based stimuli or effects from the sorting protocol, and be representative for prototypic
MAIT cells.
3.3 First insights into the proteome of primary human MAIT
cells reveal T cell specific proteins and pathways
Mucosal-associated invariant T cells (MAIT) cells are T cells, that display an effector memory
phenotype, even without being primed by other immune cells or exposure to their antigen.
Their phenotype is unique among T cells, but the proteome of MAIT cells has never been
investigated before. Therefor, it was decided to conduct a pilot study to define the proteome
of primary human MAIT cells, and get the first insight into their unique proteome.
One representative donors was selected and a strategy was established to sort MAIT cells
from PBMC cultures (2.6.2). PBMCs were stained with monoclonal antibodies directed
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Figure 16 | Percentage of MAIT cells
in various human donors. PBMCs
were isolated from 20 human donors,
and the amount of MAIT cells was quan-
tified by flow cytometry. MAIT cell num-
bers decrease with age, and might have
a small increase until a age of roughly
40 years. Three male donors show an
increased number of MAIT cells, com-
pared with persons their age (age 25, 35
and 62, respectively).
against CD3, CD161 and TCR chain Vα7.2, and sorted by flow cytometry (2.6.3). The chosen
separation strategy is shown in Fig 18. First, lymphocytes were gated due to their unique
characteristics regarding size and granularity, which were assessed by their ability to scatter
forward (FSC, forward scatter) and side light (SSC, side scatter), respectively. Doublets were
excluded on the basis of the fact that such cell aggregates passing the detector show an
disproportional high integrated area of signal intensity when compared with the height of
signal intensity. This mismatch is detectable with both forward and side scatter light (FSC-A vs.
FSC-H and SSC-A vs. SSC-H, respectively). After the exclusion of doublets, MAIT cells were
then defined as CD3-positive cells, that express both CD161 in high amounts, as well as the
invariant T-cell receptor chain Vα7.2 (CD3+Vα7.2+CD161++). This strategy yielded a purity
of 97 % MAIT cells, with 0.7·106 MAIT cells isolated in total. After sorting, cells were pelleted
and lysed. Proteins were then digested with Trypsin (see 2.7.1), the generated peptides were
cleaned up (see 2.7.2), and the proteome of MAIT cells was defined by LC-MS/MS (see 2.7.5)
without prior sample subfractionation. In total, out of 120 795 spectra generated by the mass
spectrometer, 9235 could be assigned to 3975 different peptides with a minimum peptide
score of 30 (for complete search parameters see Tables 6 and 7). These data could be used to
identify 1287 proteins.
Figure 19 shows a representative peptide spectrum. Peptide fragmentation in the mass
spectrometer results in fragment ions that can, together with the knowledge of amino acid
masses, be used to sequence the specific peptide. Mascot software (Matrix Science) then
compares peptide sequence with a database of in silico generated tryptic peptides, that is
generated from the Swiss-Port/UniProt database, and thereby identifies the peptides belonging
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Figure 17 | Activation of primary human MAITs with E. coli. PBMCs were coincubated with different MOI of
fixed E. coli and with or without the presence of anti-CD28 antibody. Surface expression of activation markers
CD107a and CD69 was then analyzed by flow cytometry after different incubation times. (A) After over night
incubation with fixed E. coli and antibody against CD28, upregulation of actvation marker CD69 could be detected
on MAIT cells. (B) Flow cytometry could detect a significant increase of CD107a-positive cells after four hours on
incubation with fixed E. coli and CD28. (C) Also, a time-, CD28- and MOI-dependent increase of CD107a and
CD69 surface expression could be detected. Figure shows one representative donor.
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3.3 First insights into the proteome of primary human MAIT cells reveal T cell specific
proteins and pathways
to the spectrum. Also, a score that allows to judge the reliabilty of the data is calculated
(Mascot Peptide Score). With the peptide identified, it is also possible to determine the
corresponding protein. Furthermore, a score for every protein can be calculated that also
considers the number of different peptides that have been identified and assigned to this
protein. In this study, no proteins were considered that showed a peptide score of below
30. Software ProteomeDiscoverer (Thermo Scientific) was then used to further analyze and
visualize the data. A full list of search parameters and filters can be found in Tables 6 and 7.
In this example, the peptide sequence ISALTALR was then assigned to a unique tryptic peptide
of the pore-forming protein perforin, that is absolutely vital for the function of cytotoxic
immune cells like MAIT cells.
Importantly, proteins with vital crucial immunological functions, like granzymes A and
K could also be identified in MAIT cells (see Table 8). Also, T cell surface markers like
CD8 or CD44, or the degranulation marker lysosome-associated membrane glycoprotein 1
(LAMP-1, CD107a) could be identified. This shows that not only access to important, but
rather low abundant proteins is possible with LC-MS/MS, but also surface proteins can be
identified. To gain an overview about MAIT cell proteins, identified proteins were annotated
in Proteome Discoverer with Gene Ontology terms (GO terms) regarding their localization
(GO cellular component). This annotation of localization (see Fig. 20) showed the majority of
identified proteins to be cytoplasmic (34 %), which other large proportions being located at the
membrane (18 %), in the nucleus (17 %) or in the mitochondria (6 %). Smaller percentages
were identified to be localized in various compartments. This indicates that proteins of the
major compartments of MAIT cells could be isolated and identified with the used protocol,
and the localization of identified proteins also roughly resembles the distribution of proteins
observed in human cells before.139 To check if relevant immunological pathways could also
be covered in this analysis, the list of identified proteins was annotated to Gene Ontology
biological processes with the help of the Database for Annotation, Visualization and Integrated
Discovery (DAVID).140,141 Data revealed that 13 T cell specific processes were covered in this
first snapshot of the MAIT cell proteome (see Table 9), with a minimum of three proteins
identified per process. This shows that the proteomic approach is also suitable to analyze
abundance of proteins and pathways that are relevant for differentiation or activation of T
cells.
Taken together, first analysis of the MAIT cell proteome showed that the used experimental
procedure allows access to proteins from several cellular compartments, with the distribution
of proteins being in accordance with literature. Even low-abundant proteins with immuno-
logical functions could be identified. Also, data indicated the presence of different T cell
specific pathways in this first pilot experiment. Although, the presence of these pathways
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Figure 18 | Gating strategy for
the isolation of primary human
MAIT cells via FACS. PBMCs were
isolated from the blood of a hu-
man donor, stained with antibod-
ies specific for CD3, CD161 and
Vα7.2, and sorted by FACS. MAIT
cells were defined as lymphocytes
(A), that are not doublets (B and
C), express CD3+(D), and are
not positive for Vα7.2 but also
show a high expression of CD161
(Vα7.2+CD161++, E).
suggest a T cell phenotype for MAIT cells, the picture of the MAIT cell proteome is still very
fragmentary. To be able to identify unique mechanisms, MAIT cells have to be compared with
prototypic innate and adaptive immune subsets. This will also allow to assess similarities and
differences between the cell types. Furthermore, it is necessary to increase the resolution of
the mass spectrometric analysis by prior subfractionation, and gain access to a higher number
of proteins even.
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Figure 19 | MS/MS spectrum of cytolytic perforin peptide ISALTALR. The proteins of MAIT cells were digested
with trypsin and the peptides analyzed by mass spectrometry. In the mass spectrometer, peptides were fragmented
and b- and y-ions generated (red and blue, respectively). Peptide sequence ISALTALR could be derived from these
ions through defined amino acid masses. The sequence was then assigned to a unique peptide of the pore-forming
protein perforin from the Swiss-Prot/UniProt database, with using the search parameters and filters displayed in
Tables 6 and 7. (A) shows the detected peptide spectrum and (B) the assigned masses of the ions, from which the
mass differences can be used to define the amino acid sequence. Assigned mascot score for this peptide was 31.
49
Figure 20 | Localization of proteins identified in a proteomic analysis of MAIT cells. The proteome of
isolated MAIT cells was defined by mass spectrometry and the proteins were annotated regarding their subcellular
location with the help of GO terms. The five highest abundances are displayed on the left side. The gray chunk
contains a high variety of lower abundant localizations, and is displayed in detail on the right side. The largest
proportions of annotated proteins are localized in the cytoplasm, membrane and nucleus, respectively.
Table 8 | Selected proteins with immunulogical function identified in MAIT cells
Mascot Unique Unique
Name score Coverage peptides spectra
CD8 alpha chain 78.98 7.66 % 1 2
CD5 29.82 2.24 % 1 1
CD48 59.29 5.76 % 1 2
Lysosome-associated membrane glycoprotein 1 50.94 5.04 % 1 1
Granzyme A 251.38 19.08 % 5 9
Perforin-1 31.12 1.44 % 1 1
CD44 289.32 6.33 % 4 11
Granzyme K 441.84 31.82 % 5 11
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Table 9 | Pilot study of the MAIT proteome indicates the presence of T cell specific pathways
GO Term Name Count Proteins (UniProt Accession)
positive regulation of alpha-beta T cell activation 7 P00491; P43403; P08575;
O00203; Q8WWP7; O75995;
P00813
positive regulation of alpha-beta T cell differentiation 6 P00491; P43403; O00203;
Q8WWP7; O75995; P00813
negative thymic T cell selection 4 P16150; Q92608; P43403;
P08575
negative T cell selection 4 P16150; Q92608; P43403;
P08575
positive regulation of T cell differentiation 7 P00491; P43403; P08575;
O00203; Q8WWP7; O75995;
P00813
positive regulation of T cell activation 12 P16150; P31146; P06239;
P00491; P43403; P10809;
P08575; O00203; Q8WWP7;
P06127; O75995; P00813
regulation of alpha-beta T cell differentiation 6 P00491; P43403; O00203;
Q8WWP7; O75995; P00813
T cell proliferation 6 Q92608; Q07812; P08575;
P62942; P06241; P32119
negative regulation of T cell mediated immunity 3 P16150; P08575; P16298
thymic T cell selection 4 P16150; Q92608; P43403;
P08575
T cell differentiation 10 P01732; P16150; Q92608;
P06239; P43403; P08575;
P35268; Q8WWP7; P78527;
P16298
T cell activation 23 P16150; Q92608; P01732;
P06239; P42768; P08575;
P35268; P39656; P62942;
P09326; P35579; P78527;
P16298; P27487; P10809;
Q07812; P43403; P20701;
Q8WWP7; P06241; P13796;
P32119; P00813
regulation of T cell mediated immunity 7 P16150; P61769; P27487;
P10809; P08575; O75995;
P16298
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3.4 Mass spectrometry generates highly reproducible data
from small cell numbers
The increasing sensitivity of modern mass spectrometers has also lowered the amount of
sample material required for a proteomic analysis of complex samples. With newest tech-
niques, data can be generated from cell numbers as small as 1 000 HeLa cells.142 However,
when working with primary material, usually higher cell numbers are required, due to the
comparatively low protein amount in primary cells. Ideally, proteomics is done with at least
500 000 or 1 000 000 primary cells. The cell number of MAIT cells in buffy coats however
can be limited to a magnitude as small as 250 000 MAIT cells per buffy coat, or even lower.
Thus, a proteomic workflow had to be established that allowed lysis, digestion, labeling,
clean-up and subfractionation of samples while minimizing the loss of material during the
process, while at the same time providing high reproducibility. Also, it had to be tested if
subfractionating these small amounts of proteins would actually increase the sensitivity of the
mass spectrometer and the number of identified proteins, in comparison with not-fractionated
samples as in 3.3. Therefor, the proteome of 250 000 primary PBMCs was to be analyzed
by mass spectrometry, after SCX subfractionation. Another aspect the used protocol had be
checked on was consistency over several experiments. Two factors generally influence the
reproducibility between experiments. First, donor variations increase the variance in different
samples, but allow the identification of important, donor-independently regulated proteins.
More importantly, the analytical pipeline might also lead to different results, even when the
same experiments are repeated.
After isolation of PBMCs from human donor blood (see 2.6.2), 250 000 cells were lysed
with urea (see 2.7.1). The urea based lysis therefore is a protocol which minimizes samples
loss through a minimum of washing or purification steps. However, this might result in
a not completely purified protein mixture, containing contamination with e.g. membrane
fragments. After lysis, cells were digested with trypsin, desalted (see 2.7.1 and 2.7.2) and
subfractionated into 40 fractions by SCX chromatography (see 2.7.4). The chromatogram of
the SCX fraction shows the elution of the peptides after increasing the concentration of the
high salt elution buffer, with a peak of eluting peptides from fractions 13 - 24 (Fig. 21).
First, the SCX fractions 13 to 24, that contain the vast majority of the peptides, were
desalted again (see 2.7.1) and analyzed by mass spectrometry as described (see 2.7.5), but
with a short 60 minute gradient on the upstream LC separation unit. Sixty minutes were
chosen due to the small amount of peptides present in the sample. In this analysis, 2260
proteins could be identified out of 227 000 spectra, that had resulted in the sequencing
of 8198 peptides. This shows that subfractionating the sample, as expected, increases the
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Figure 21 | Chromatogram of SCX subfractionation of 250 000 cells. Tryptic peptides were loaded onto a
Mono-S-PC1.6/5-column and eluted by increasing concentration of the high salt elution buffer (violet). As every
minute a new fraction was collected, the time corresponds with the number of the fraction. The amount of eluted
peptide correlates with the absorption of UV light at 214 nm (blue). Fractions collected at time a points 13 - 24
show the most absorption, the peak at minute 34 is most likely a contamination. Due to the small amount of
peptides in the sample, the peaks are comparatively small. Fractions 13 - 24 were therefor chosen for further
analysis.
sensitivity of detection. Only 1200 proteins could be identified out of 106 cells used in 3.3,
without prior subfractionation, while the peptides of only 250 000 cells resulted in 2260
identified proteins. Also, identified proteins were again annotated regarding their subcellular
localization. Gene Ontology revealed a similar distribution as observed before (see 3.3), with
32 % of the proteins localized in the cytoplasm, 20 % at the membrane, 15 % in the nucleus
and 5 % in the mitochondria. Again, small percentages of proteins were also annotated to
smaller compartments like the endosome.
To investigate if the experimental set-up leads to reproducible results and the variation that
is caused by sample processing is minimal, a tryptic digest of 500 000 cells from one donor
was split into two samples, differentially labeled with isobaric iTRAQ tags (see 2.7.3), and
mixed again. iTRAQ labels allow relative quantification of peptides in the mass spectrometer
and a quantitative comparison of the samples.143 Through their peptide reactive group,
these isobaric tags are chemically linked to every peptide present in the sample mixture.
Every tag also contains a reporter and a balancer group, all these groups having a defined
mass. Upon fragmentation in the collision cell, the reporter and the balancer dissociate
from the labeled peptide, and the former can be detected by the mass spectrometer (Fig.
23). By comparing the intensity of the reporter signals, a relative regulation factor for the
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Figure 22 | Localization of proteins identified in a proteomic analysis of primary human PBMCs. The
proteome of 250 000 PBMCs was defined by mass spectrometry and the proteins were annotated regarding their
subcellular location with the help of GO terms. The five highest abundances are displayed on the left side. The
gray chunk contains a high variety of lower abundant localizations, and is displayed in detail on the right side.
The largest proportions of annotated proteins are localized in the cytoplasm, membrane and nucleus, respectively.
peptide and the corresponding proteins can be calculated. Importantly, the analysis software
Proteome Discoverer also applies a median-based normalization algorithm before comparing
the intensities. This algorithm normalizes all peptide ratios for each channel by the median
peptide ratio. In this experiments, labels with reporter ions of the mass 114 Da and 115 Da
were used, all log2RF display the relation of the intensity of the reporter 115 to the intensity
of the reporter 114. Also, regulation factors (RF) are displayed as logarithm to base 2. A
log2RF of 0 therefore indicates no difference between the two compared reporters, while
log2RF 1 would mean a two-fold increased intensity of 115 compared to 114. After the
labeling process, samples were desalted, mixed, subfractionated, desalted again and analyzed
by mass spectrometry as described before in this chapter.
No donor variation of protein abundance should be detectable, as both samples came
from the same donor. Every visible variation had therefor its basis in the analytical pipeline.
Evaluation of the relative iTRAQ signals and calculation of the regulation factors indeed
indicated a high reproducibility of the experimental set-up (Fig. 24). As expected, most of the
identified proteins didn’t show variation of abundance between the identically treated 114
and 115 samples. Ninety percent of the identified proteins showed log2 RF between -0.27 and
0.34, with minimal and maximal values of -1.18 and 2.96, respectively. Additionally, only six
proteins were annotated with a two-fold increase or decrease in the 115-labeled sample. The
more robust a protein was identified, the higher was the probability of it not being identified
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Figure 23 | MS/MS spectrum of an iTRAQ-labeled peptide of actin. PBMC proteins were digested with
trypsin, labeled with iTRAQ reagent and the labeled peptides analyzed by mass spectrometry. (A) In the mass
spectrometer, peptides were fragmented and b- and y-ions generated (red and blue, respectively). Peptide
sequence QEYDESGPSIVHRK could be derived from these ions through defined amino acid masses, and was
assigned to actin, which is an important component of the cytoskeleton. Also, iTRAQ reporter ions with the
masses 114 and 115, respectively, were detected. (B) The relative intensity of the reporter ions, as seen enlarged
on the right side, can be used to comparatively quantify the amount of actin present in the sample. The amount of
actin in both samples is equal, the calculated regulation factor (RF) 115/114 for this peptide after normalization
is 0.959, resulting in a log2RF of -0.06. The calculated log2RF for actin in the sample is -0.03.
as regulated. This indicates that the proteins that were found with a pronounced difference
of abundance between the identical samples might be an artifact of erroneous quantification.
First, data indicated that the used protocol was suited to generate sufficient amount of
data even from small numbers of primary cells. Although only 250 000 cells were analyzed,
subfractionation allowed identification of 2260 proteins. Also, results illustrated the high
reproducibility of the used experimental procedure. However, artifacts that were found to be
differently expressed in the identical samples underlined the need for a bigger sample size in
following experiments. Also, a statistical model was needed that helps to identify and remove
these variations, and identify proteins that are consistently regulated in every experiment.
Taken together, a protocol was established, tested and improved step by step, that allows
the reproducible proteomic analysis of small numbers of primary human blood cells. With
this protocol it will now be possible to comparatively analyze the proteome of MAIT, NK and
conventional CD8+ T cells.
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Figure 24 | Technical replicates of MS samples show high reproducibility. Two samples of PBMCs of the
same donor were labeled with different iTRAQ labels, and analyzed by mass spectrometry (MS). (A) Most of
the identified proteins show no different abundance between the two identical samples. Ninety percent were
quantified with a log2 RF between -0.27 and 0.34. (B) Proteins that showed an at least two-fold change of
abundance between both samples (red) were identified with a low number of unique spectra.
3.5 Conserved and novel functions in innate immunity in MAIT
cells
3.5.1 Flow cytometry allows the generation of highly pure MAIT cells,
CD8+ T cell and NK cell samples
MAIT cells are a recently discovered T cell subset that is highly abundant in human peripheral
blood, mucosal tissues and displays innate properties. Conventional CD8+(cCD8+) T and NK
cells are major subsets of adaptive and innate immunity that are functionally well defined. In
MAIT cells, mechanisms that are crucial for their innate phenotype are not well defined yet,
but can be revealed by comparative proteomic analyses. For a reproducible proteomic study,
not only a reproducible, sensitive protocol is necessary, that had been established already in
the course of this thesis (3.4). Also sample generation, that in this case was supported by
fluorescence-activated cell sorting, had to be standardized and reproducible. Purity of cell
types needed to be as high as possible, to avoid contamination, while also enough material
for proteomics had to be isolated.
First, an flow cytometric isolation strategy for all these immune cells had to be devised.
PBMCs were isolated from human donor blood of five donors (2.6.2), stained with monoclonal
antibodies directed against CD3, CD8, CD56, CD161 and Vα7.2, and sorted by flow cytometry
(see 2.6.3). The chosen separation strategy is shown in Figure 25A. First, lymphocytes were
gated due to their unique characteristics regarding size and granularity, which were assessed
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by their ability to scatter forward (FSC, forward scatter) and side light (SSC, side scatter),
respectively. Doublets were excluded as before (FSC-A vs FSC-H and SSC-A vs. SSC-H,
respectively; 3.3). After the exclusion of doublets, NK cells were defined as CD3-negative cells
that express CD56 (CD3-CD56+). MAIT cells were sorted and were defined as CD3-positive
cells, that express both CD161 in high amounts, as well as the invariant T-cell receptor chain
Vα7.2 (CD3+Vα7.2+CD161++). Additionally, conventional CD8-positive T cells (cCD8+) were
sorted for analysis. As a significant amount of MAIT cells also expresses CD8, cCD8+ T cells
for this study were defined as CD3+CD8+ single cells that are not MAIT cells. Details about
each sorting experiment are shown in Table 10. Purity was assessed when already sorted
cells were analyzed again by flow cytometry, and defined as percentage of the respective cell
subset compared to the number of total detected events. In most cases, purity of 90 % or
higher could be achieved. However, purified NK cells in general showed a lower purity. This
phenomenon is an fluorochrome effect. Along the sorting process that can take up more than
six hours, CD56-PE/Cy5 signal gets dimmer over time as the fluorochrome degenerates and
becomes less intensive. This lead to a larger number of cells not fitting into the CD56+ gate
anymore at the purity check after sorting is completed (Fig. 25B), and to misprizing of the
purity. Most importantly, no contamination by other cell types could be observed in the NK
cells fraction. Also, no increased amount of dead cells or debris was detected. Therefor, the
low purity is definitely a result of fluorochrome degradation underscoring, and far higher
than displayed.
NK cells and CD8+ T cells are higher abundant than MAIT cells, meaning that the number
of MAIT cells would restrict the number of used cells in every experiment. Thus, donors
were pre-screened and only donors with higher amounts of MAIT cells were selected for
sorting. Although MAIT cell numbers still varied significantly, at least 106 MAIT cells could
be collected for every donor (Tab. 10). Absolute numbers of NK and cCD8+ T cells are
much higher and collection of these high abundant cell types was stopped after collecting a
certain number. Percentages of MAIT cells varied between 2 - 5 % of their parent CD3+ cell
population. Percentages of NK cells and cCD8+ T were significantly higher, varying between
9 - 27 % and 23 - 35 %, respectively.
In summary, buffy coats provide enough material of the established sorting protocol allowed
the standardized sample generation of defined cCD8+, NK and MAIT cell populations. Isolated
cell populations are highly pure and also provide sufficient material for comparative MS
analysis.
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Figure 25 | Isolation of primary human MAIT, NK and CD8+ T cells from PBMC cultures. PBMCs were
isolated from human donor blood , stained with antibodies specific for CD3, CD8, CD56, CD161 and Vα7.2, and
sorted by FACS. (A) NK cells were defined as single cells that are CD56-positive and not T cells (CD3-CD56+), MAIT
cells as single T cells (CD3+) that are positive for Vα7.2 and show a high expression of CD161 (Vα7.2+CD161++)
and conventional CD8+ T cells as single T cells that express CD8 and are not MAIT cells (non-MAIT CD3+CD8+).
(B) After sorting, cells were checked for purity by flow cytometry. NK cells show a loss of CD56 signal. However,
no contamination with other cell types could be observed.
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Table 10 | Donor information, purity and cell number of sorted MAIT, NK and CD8+ T cells
donor information purity [%] cell number [·106 cells] percentage of parent population [%]
donor age sex MAIT NK* cCD8+ MAIT NK cCD8+ MAIT NK cCD8+
1 44 f 90.4 57.5 91.5 3.4 12.0 10.0 3.9 27.0 31.9
2 36 m 92.9 80.2 91.5 9.78 13.5 13.5 5.3 24.1 22.8
3 46 m 92.5 87.3 94.1 1.7 4.5 4.5 2.13 15.0 22.7
4 27 f 93.6 58.6 91.6 4.1 4.5 4.5 2.8 8.9 30.2
5 25 m 93.9 57.7 85.4 2.3 4.5 4.5 5.3 12.7 35.0
*Purity of NK cells is displayed lower than the actual due to degradation of the CD56-PE/Cy7 fluorochrome over
the course of the sorting process.
3.5.2 Protein identification in MAIT, NK and cCD8+ T cells shows large
overlap of proteins in different donors
After generation of highly pure immune cell samples of MAIT, NK and cCD8+cells, the
established proteomic workflow could be executed to generate highly accurate quantitative
proteomic data. The proteome can be defined for every donor and the overlapping proteome
of all five donors can be identified. Also, data will allow first glimpses on the coverage of
immunological pathways.
After isolation, cells were lysed with urea, peptides were digested (both 2.7.1) and each
population (MAIT, NK, cCD8+) were labeled with isobaric tags (2.7.3). Labeling efficiency
was checked for every donor and every channel with a 30 minute LC-MS/MS run, injecting
2 % of the sample. Proteome Discoverer was then used to quantify the percentage of labeled
peptides areas of total peptide area. If label efficiency was below 95 %, samples were relabeled,
desalted and checked again. The same mass spectrometric analysis was then used to quantify
the peptide amount in every sample and channel, by calculating the total area of all precursor
peptides. According to these data, for every donor samples were mixed with the same amount
of labeled material for every channel and submitted to SCX chromatography (2.7.4). A
representative chromatogram is shown in in Figure 26, indicating that the most peptides
were eluted in the fractions 15 - 25. Fractions 1 - 13, 27 - 34 and 34 - 38 were therefore pooled
before desalting, and samples 14 - 26 were processed individually, resulting in 17 samples for
every donor that were prepared for MS analysis (2.7.2). Samples were then analyzed with
an Orbitraq Fusion mass spectrometer and spectra annotated to peptides and proteins with
the help of Mascot and ProteomeDiscoverer software (2.7.5).
About 4000 proteins could be identified for every donor (Tab. 11). In total, 5636 different
proteins could be annotated (see appendix for a complete list), with 2600 proteins being
commonly identified in all five donors (Fig. 27). These 2600 proteins are high abundant in
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Table 11 | Number of identified proteins per donor
donor
1 2 3 4 5
assigned spectra 40196 39753 46227 65056 54496
identified peptides 16655 15997 17863 23803 19559
identified proteins 3887 3690 3865 4256 3981
every donor and cell type, and are expressed donor independently. Additionally, a number
of 3323 proteins could be identified in at least four experiments, 3990 in at least three and
4653 in at least two experiments. All the identified proteins were functionally annotated
with Pathway Studio for systematical analysis. Out of the total number of roughly 5600
proteins, analysis and annotation revealed association of 480 proteins to 38 immunological
pathways. The relevance of the enriched pathways can be visualized by the calculation of a
p-value, that represents significance, and the coverage of the specific pathway by the identified
and annotated proteins. Not only the enriched immunological pathways with the highest
percentage of annotated proteins, and therefor the highest p-values, can be mostly considered
as NK or T cell specific (Fig. 28). Out of all 38 enriched pathways, 22 were exclusive for
NK and T cell specific functions that could be detected with high coverage. Other covered
pathways referred to general immunological processes like antigen presentation or cell death
mediation.
In summary, the established workflow allowed the detection of 5636 proteins, with roughly
50 % of these proteins being detected in all five donors. These data indicate little donor
variation regarding the presence of proteins, and underline the reliability of the data for
further investigation. Also, this core proteome of roughly 2600 proteins contains the major
components of the MAIT, NK and cCD8+ cell proteome. Accordingly, first functional annotation
analysis showed a high coverage of immunological pathways. Specifically, pathways that are
related to T and NK cell activity could be annotated, showing the presence and accessibility
of proteins vital for immunological processes.
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Figure 26 | SCX subfractionation chromatogram shows presence of peptide in different fractions. After
lysis, MAIT, NK and cCD8+ cells were digested and labeled with different iTRAQ reagents. To increase sensitivity
of mass spectrometry analysis, labeled peptides were mixed to the same amount, loaded onto a Mono-S-PC1.6/5-
column and eluted by increasing concentration of the high salt elution buffer (violet). As every minute a new
fraction was collected, the time in minutes is equal to the number of the fraction. The amount of eluted peptide
correlates with the absorption of UV light at 214 nm (blue). Fractions collected at time points 15 - 25 show the
most absorption, and therefore the highest amounts of tryptic peptides. These samples were processed individuall
while fractions 1 - 13, 27 - 34 and 34 - 38 were pooled.
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Figure 27 | Number of identified proteins in MAIT, NK and cCD8+ cells from five human donors. Human
MAIT, NK and cCD8+ cells were isolated from blood of five different healthy donors. In total, 5636 proteins were
identified. A number of 2619 proteins could be found in all five samples, while 3323 proteins could be identified
in at least four, 3990 in at least three and 4653 in at least two experiments.
61
3 Results
Model of T-cell Maturation
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NK Cell Activation through Integrins and non-ITAM-Containing Receptors
Regulatory T-cell Differentiation
MHC1-Mediated Antigen Presentation
T-cell-Independent B-cell Activation
T-cell Receptor Signaling
NK Cell Activation through ITAM-Containing Receptors
NK Cell Activation
-log (p value)
0 5 10 15
Figure 28 | Pathway annotation of all identified proteins in MAIT, NK and cCD8+ cells The proteome of
isolated human MAIT, NK and cCD8+ cells was defined by mass spectrometry. Identified proteins were annotated
to immunological pathways with Pathway Studio, with the coverage of the pathways calculated as p-value, here
shown as negative logarithm. Among the fifteen highest enriched pathways, ten are directly associated with NK
and T cell activity (red and blue, respectively).
3.5.3 Differential protein expression in MAIT, NK and cCD8+ T cells
3.5.3.1 MAITs cells are a cell type distinct from NK and cCD8+ T cells on the
proteomic level
Additional to protein identification, MS analysis also permits relative quantification of iTRAQ
labeled peptides. This allows the calculation of regulation factors for single proteins, and these
can be used to estimate the difference of the cell types on the proteomic level. Furthermore,
when comparing regulation factors for the same proteins between donors, donor variation on
the level of protein abundance can already be estimated.
Only proteins that were identified in all five donors were used for this analysis. Figure 29
shows a representative spectrum of this analysis, with the b- and y-ions that are generated
in the collision cell shown in red and blue, respectively. As before, these ions were used for
software based peptide sequencing and subsequent protein identification (3.3, 3.4, 3.5.2).
Relative peptide and protein quantification could be carried out with the help of iTRAQ labels,
with every reporter ion representing the relative abundance of the protein in either MAIT,
NK or conventional CD8+ T (cCD8+) cells. The normalized intensity of these reporter ions
was used to calculate three relative regulation factors, that display the relative abundance of
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every protein in the different cell populations: MAIT:NK, MAIT:cCD8+ and NK:cCD8+. These
three regulation factors (RF) can be calculated for every protein in every donor, resulting in
15 calculated RF for every protein. Again, these RF are displayed as log2 values. An example
of reporter ion intensities is also displayed in Figure 29. Here, the difference in abundance of
the alpha chain of surface protein CD8 is shown. CD8 is a prototypic marker for cCD8+ T
cells and a large subsets of MAIT cells. Accordingly, the highest abundance of this protein was
detectable in cCD8+ T cells, and an almost equal amount could be identified in MAIT cells.
NK cells only showed a low expression of CD8 (log2 RF MAIT/NK: 1.13, MAIT/cCD8: -0.36,
NK/cCD8: -1.48). As most of MAIT cells, and all cCD8+ T cells are positive for CD8, while
NK cells show a variable expression,144 these data is in accordance with expected values.
Analysis of the distribution of these regulation factors for every protein revealed a sym-
metrical distribution of the log2 RF around the median, which is close to 0 in every case
(Fig. 30). This distribution indicated that most identified proteins are not regulated in the
different cell types. Importantly, it also becomes apparent that on, the level of the proteome,
MAIT cells indeed are as different from cCD8+ T cells as cCD8+ cell from NK cells. Data
also revealed that the distribution of the regulation factors is similar in every donor, with
50 % of all log2 RF being distributed between roughly ±0.2, for MAIT:NK, MAIT:cCD8+ and
NK:cCD8+, respectively. Only donor 2 showed donor variation and broader distribution of
log2 RF, with 50 % of all log2 RF being distributed between ±0.6, ±0.3 and ±0.5 for MAIT:NK,
MAIT:cCD8+ and NK:cCD8+, respectively.
Analysis of the donor specific patterns of the log2 RF for every individual protein additionally
revealed that all donors, except donor 2, depicted a highly similar regulation pattern, and
displayed similar log2 RF for the same proteins (Fig. 31). This again indicated high robustness
of the acquired data. Donor 2 exhibited donor variation, with his proteins showing different
log2 RF values than the proteins of the other four donors.
Summarized, iTRAQ labels allowed relative quantification of protein abundance levels
in MAIT, NK and cCD8+ T cells. This enabled the binary comparison of the pairs MAIT:NK,
MAIT:cCD8+ and NK:cCD8+ and revealed consistent distribution of the calculated regulation
factors, except for for some minor donor variations. Albeit these variations, no donor was
excluded from the analysis as such donor variations have always to be considered when
working with primary material. Most importantly, data also showed that MAIT cells are
indeed a cell type as distinct from CD8+ T cells as from NK cells.
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Figure 29 | MS/MS spectrum of an iTRAQ-labeled peptide of marker protein CD8, alpha chain. Proteins
of MAIT, NK and cCD8+ T cells were digested with trypsin and labeled with different iTRAQ reagents. Labeled
peptides were mixed and analyzed by mass spectrometry. In the mass spectrometer, peptides were fragmented
and b- and y-ions generated (red and blue, respectively). Peptide sequence GAAASPTFLLYLSQNKPK could be
derived from these ions through defined amino acid masses, and assigned to CD8 alpha chain. CD8 is a marker
for CD8 T cells and expressed on large amounts of the MAIT cell population. Also smaller percentages of NK cells
express CD8. Here, iTRAQ reporter ions with the masses 114 (MAIT), 116 (NK) and 117 (cCD8+), respectively,
could be detected. The relative intensity of the reporter ions, as seen enlarged on the right side, can be used to
comparatively quantify the amount of CD8 present in the different cell types. NK cells show the lowest abundance
of this peptide and the respective protein, while MAIT and cCD8+ T cells contain roughly the same amount (log2
RF MAIT/NK: 1.13, MAIT/cCD8+: -0.36, NK/cCD8+: -1.48).
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Figure 30 | Distribution of the regulation factors in five donors shows distinct differences between MAIT,
NK and cCD8+ T cells. Human MAIT, NK and cCD8+ T cells were isolated from five different donors, and
proteins were identified and quantified by mass spectrometry. The relative intensities are displayed as log2
regulation factors. The thick line indicates the median and boxes the range that contains 50 % of the data, while
the whiskers indicate the minimum and maximum of the data, as long these do not differ more than 1.5-fold as
the interquartile distance from the median. Data points that lie outside this distance are considered as outliers
and displayed as points. All donors show a symmetrical distribution of unregulated proteins around log2 RF 0.
The log2 RF of donor 2, however, show a greater variation. In general, the log2 RF already indicate that MAIT
and cCD8+ T cells differ on the proteomic level, as well as MAIT and NK cells.
65
Figure 31 | Heat maps of log2 regulation factors determined by iTRAQ-based LC-MS/MS from primary
human MAIT, NK and cCD8+ T cells. 2619 proteins from primary human MAIT, NK and cCD8+ cells were
identified and quantified by iTRAQ-based LC-MS/MS. Colored boxes in one row display the regulation of a single
protein in five different human donors, and one column depicts protein regulations in one blood donor. The color
code shows down-regulation as red, and up-regulation as green with the intensity of the color corresponding with
the strength of the regulation. No regulation is depicted in black. Four donors show similar regulation patterns,
while donor 2 shows distinct donor variation with substantial differences in regulation. Histograms below display
the distribution of protein regulation factors and the corresponding color code.
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3.5.3.2 Robust identification of regulated proteins in MAIT, NK and cCD8+ T
cells indicates distinct proteomic profiles
Regulation factors (log2 RF) themselves already allowed estimations about the similarity
and difference of the analyzed cell types. Robust identification of proteins with statistical
differences in abundance between cell types, however, does not only help to refine the analysis
of the relation of MAIT, NK and cCD8+ T cells. Also, it allows to check for individual marker
proteins in every population, and to identify proteins that are vital for the MAIT cell phenotype
and effector functions. Visible donor variations made a robust statistical method necessary,
that allowed identification of significantly regulated proteins.
After calculation of the log2 RF for every protein in every donor, a statistical approach had
to be used to determine the significantly regulated proteins between the cell types (2.8). In
brief, it was assumed that the log2 regulation factors (RF) for each protein were following
the normal distribution, with the same standard deviation for every protein. The Median
Absolute Deviation from the median (MAD) of all detected proteins was then used to robustly
estimate the standard deviation. This allowed the calculation of the probability if the log2 RF
can be explained by the calculated standard deviation from the expected value. A protein was
considered as significantly regulated if this probability was lower than 5 % in every donor.
This means that when speaking of a regulated protein, usually a protein regulated in all five
donors is meant, if not indicated otherwise.
With this method, 135 proteins were determined to be significantly regulated in all five
donors when comparing MAIT and NK cells, 160 proteins for the MAIT:cCD8+ T cell compar-
ison and 231 proteins were identified to be regulated between NK and cCD8+ T cells (Tab.
12). Between MAIT and NK cells, 77 proteins were significantly regulated up and 58 were
regulated down, while in MAIT and cCD8+ T cells 110 were found to be upregulated and
50 downregulated. NK cells showed an upregulation of 113 proteins when compared with
cCD8+ T cells, 118 proteins were downregulated. A summary of regulated proteins can be
found in Table 13.
To check consistency and reliability of data, proof of concept proteins were checked for
their regulation factors (Tab. 14), and if these log2 RF were in accordance with literature
and expected data. Data in Table 14 show median log2 RF for several proteins. The number
of experiments the protein was identified in is indicated by asterisk, while colored asterisks
symbolize an experiment in which the protein was identified to be significantly regulated.
Detected abundance of CD3ε was in accordance with values expected after sorting, as cells
were labeled for sorting with an antibody specific for CD3ε. The differential expression of
CD3ε that cells were sorted on, with MAIT and cCD8+ T cells being positive and NK cells
67
3 Results
Table 12 | Number of regulated proteins per compared cell types
identified regulated proteins
MAIT:NK MAIT:cCD8+ NK:cCD8+
upregulated 77 110 113
downregulated 58 50 118
total 135 160 231
being negative for CD3ε, could be detected in the mass spectrometer also. CD8α chain was
found to be higher expressed in MAIT and cCD8+ T cells as in NK cells, again proving that
mass spectrometry is able to correctly detect differences of protein abundance that have been
determined by cell sorting before. The same is valid for CD56, being highly expressed in
NK cells. Large percentages of NK cells typically express high amounts of Fc receptor CD16
on the surface,17 also detectable in the present data set. CD26, a dipeptidyl peptidase, has
recently been determined as a marker for MAIT cells,82 and its high, MAIT-specific expression
also resulted in a substantial log2 RF MAIT:cCD8
+ of 2.39, and significant regulation. CD26
was also the protein with the highest median log2RF between MAIT and cCD8
+ T cells.
Additionally, Dusseaux and colleagues already observed the high expression of multi-drug
resistance transporter MDR1 in MAIT cells when compared with non-MAIT CD8+ T cells,80
which could also be detected in this study with a log2 RF MAIT:cCD8
+ of 1.07. The same study
reported that MAIT cells characteristically express low amounts of CD62L (L-selectin). Again,
proteomic data showed the same result, with log2 RF MAIT:cCD8
+ of -2.43 and significant
regulation in all donors the protein was identified in. The characteristically high abundance of
intracellular perforin in NK cells145 could also be detected with mass spectrometry. Summed
up, semiquantitative mass spectrometry is a reliable tool for detecting differences in abundance
of proteins, and used statistical methods are suitable to identify significantly regulated proteins
in MAIT, NK and cCD8+ T cells. Generated data is in accordance with expected values, like
CD3ε or CD8α, and data from literature, like CD26 or MDR1.
A recent study by Fergusson and colleagues has generated transciptomic data, compara-
tively analyzing the difference between CD8+CD161- T cells and CD8+CD161++ T cells.146
Almost all CD8+CD161++ T cells are MAIT cells, and as the majority of MAIT cells analyzed in
the proteomic study of this thesis (CD3+Vα7.2+CD161++) are also CD8-positive, this transcrip-
tomic comparison roughly matches the proteomic comparison between MAIT cells and cCD8+
T cells. To further verify the generated proteomic data, results of both studies were compared.
In the transciptomic study, 544 genes were found to be differentially regulated between MAIT
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Table 13 | List of proteins regulated in all five donors
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3 Results
Table 14 | Significantly regulated proof of concept-proteins in MAIT, NK and cCD8+ T cells
log2 regulation factor median
Protein name MAIT:NK MAIT:cCD8+ NK:cCD8+
CD3 epsilon chain144 1.70 **** -0.07 **** -1.76 ****
CD8 alpha chain144 1.28 **** -0.24 **** -1.59 ****
CD16a144 -2.88 *** -0.05 *** 2.82 ***
CD2682 2.61 ***** 2.39 ***** -0.25 *****
CD56144 -0.51 *** 0.44 *** 1.51 ***
CD62L80 -1,43 *** -2,34 *** -0,77 ***
MDR180 0,55 **** 1,07 **** 0,42 ****
Perforin117 -2.30 ***** 0.26 ***** 2.74 *****
Asterisks indicate the number of experiments the protein was identified in. Asterisks in red and green indicate
significant down- or upregulation.
cells and classic CD8+ T cells, identifying 195 upregulated genes and 349 as downregulated.
For 160 of these genes the corresponding proteins were identified in the proteomic study of
this thesis. The overlap of actually regulated proteins was 19. Accordingly, 141 proteins that
were identified in both the transciptomic and proteomic dataset, and assigned as regulated
with transcriptomics were not identified as regulated in the proteomic study. Furthermore,
none of the other proteins that were identified to be regulated in the proteomics study were
found to be regulated on the transciptomic level. Of the 19 genes and proteins that were
found to be consistently regulated in both transciptomic and proteomic analysis, data was
in full accordance with all regulation factors showing the same tendency regarding up- and
downregulation. Respective proteins are indicated with italics in Tab. 13. Taken together, the
transcriptional data identify a different set of genes to be regulated between MAIT cells and
cCD8+ T cells than the proteomics study. However, no contradictory data could be located in
the proteins or corresponding genes that were found to be regulated in both studies.
In summary, the determination of the numbers regulated proteins yielded further infor-
mation about the similarity and differences in human MAIT, NK and cCD8+ T cells, and
indicated specific proteomic profiles for each of the subsets. Data was also in accordance
with transcriptomic studies, and also the abundance of proof of concept and marker proteins
was as expected.
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Figure 32 | Expression of CD48 and CD98 on MAIT, NK and cCD8+ T cells PBMCs were isolated from human
donor blood, and expression of CD98 and CD48 were analyzed by flow cytometry (A and B, respectively). (A)
Expression of CD98 is highest in MAIT cells, and lowest in cCD8+ T cells. (B) MAIT cells express more CD48 on
their surface than cCD8+ T cells. Every dot represents one human donor, lines indicate the median.
3.5.3.3 Proteomic data is validated by flow cytometry
After checking if data was in accordance with expected values and recent literature (see
3.5.3.2), proteomic data was also to be complemented by flow cytometry. PBMCs were
isolated from human donor blood (see 2.6.2), stained with antibodies and analyzed by flow
cytometry. Abundance of the analyzed proteins was assessed by median fluorescence intensity
(MFI) in the specific cell types. Cell types were gated as described before (see 3.5.1, Figure 25),
proteins checked for surface and internal expression were CD48 and CD98. In the proteomic
data set, CD98 was significantly regulated in all five donors between MAIT and NK cells, and
MAIT and cCD8+ T cells with median log2 RFs of 2.01 and 2.38, respectively, indicating a
high abundance in MAIT cells. The log2 RF NK:cCD8+ was determined to be 0.34. Flow
cytometric data showed the same regulation (Fig. 32A), with the highest abundance detected
in MAIT cells and the lowest in cCD8+ cells. The expression in NK cells is not significantly
higher as in cCD8+ cells. CD48 showed a significant difference of protein abundance between
MAIT and cCD8+ T cells, with a log2 RF of 0.78. This increased amount of CD48 could also be
detected in the flow cytometric analysis (Fig. 32B). Taken together, FACS analysis confirmed
the difference of protein abundance that was determined by mass spectrometry before and
further underlines reliability of the generated data.
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3 Results
3.5.4 Immunological effector proteins show distinct abundance in MAIT
cells
3.5.4.1 MAIT cells possess a unique set set of effector molecules
After isolation of the cells from human donor blood, 2600 proteins were identified from
human MAIT, NK and non-MAIT CD8+ T cells (cCD8+ cells), and several hundred where
identified to be regulated when comparing the abundance in the different cell types with
iTRAQ-based relative quantification (3.5.2, 3.5.3.1, 3.5.3.2). Several specific markers could
be identified, but the abundance of effector molecules which MAIT cells realize their unique
functions has not been assessed proteomically.
Interestingly, several important immunological effector molecules were among those reg-
ulated proteins, and all five human granzymes (A, B, H, K, M, see Tab. 15). Granzyme A
was upregulated in MAIT and NK cells, when compared with cCD8+ cells, while Granzyme B
showed the highest abundance in NK cells and was equally abundant in MAIT and cCD8+ T
cells. Granzyme H was also highest expressed in NK cells, but showed significant regulation
between MAIT and cCD8+ T cells also, being downregulated in MAIT cells. Granyzme K was
highly abundant in MAIT cells, and identically expressed in NK and cCD8+ T cells. Also the
abundance of cytolytic protein granulysin, that had been shown to be expressed in MAIT cells
before could be detected. Granulysin abundance, however, was lower than in NK cells, and
similar to cCD8+ T cells, like the other major cytolytic protein perforin (3.5.3.2, Tab. 14). The
expression and secretion of granzymes A, B and K in MAIT cells has recently been analyzed
by flow cytometry.80,117 FACS data also showed an increased expression of closely related
granzymes A and K in MAIT cells when compared with cCD8+ T cells, but also indicated a
small population expressing granzyme B in cCD8+ T cells.117 This difference was not detected
in the proteomic dataset.
These data indicate a specific immunological phenotype for MAIT cells that is realized
through differential expression of immunological active proteins. MAIT cells possess a
different arsenal of effector molecules, enabling them to execute functions that vary from
innate NK cells but also closely related conventional, non-MAIT CD8+ T cells. This phenotype
is most likely heavily dependent on closely related granzymes A and K, that are both serine
proteases. Interestingly, MAIT cells also express granyzme M in larger amounts than cCD8+
T cells, but still lower amounts than the innate NK cells.
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Table 15 | Regulation of effector molecules in MAIT, NK and cCD8+ T cells
log2 regulation factor median
Protein name MAIT:NK MAIT:cCD8+ NK:cCD8+
Granzyme A -0.08 ***** 1.60 ***** 1.78 **** *
Granzyme B -2.08 ***** 0.05 ***** 1.82 *****
Granzyme H -2.44 ***** -0.71 ***** 1.64 *****
Granzyme K 1.66 ***** 1.91 ***** 0.29 *****
Granzyme M -0.84 **** * 0.92 ***** 1.90 **** *
Granulysin -1.82 **** 0.28 **** 2.13 ****
Asterisks indicate the number of experiments the protein was identified in. Asterisks in red and green indicate
significant down- or upregulation.
3.5.4.2 Proteins regulating exocytosis and proliferation are upregulated in MAIT
cells
Distinct proteomic profiles, especially of immunologically active effector molecules in MAIT,
NK and conventional CD8+ T cells (cCD8+ T cells, 3.5.4.1) already indicated a MAIT specific
phenotype. One of the most important questions, however, still remains: what determines the
distinct phenotype of MAIT cells, when compared with cCD8+ T cells? Do they exert different
functionality, that has not been discovered yet? To be able to answer these questions, it is
necessary to not exclusively look for effector proteins that are already known to be important.
Rather, systematic analyses have to be executed, allowing to determine whole processes that
show different abundances in MAIT cells than in cCD8+ T cells.
Bioinformatical tools like Pathway Studio or Gene Go make it possible to analyze the
enrichment of proteins that are associated with specific pathways or cellular functions. To
further investigate the innate-like phenotype of MAIT cells, and analyze the consequences
of protein regulation, the list of proteins that were found to be upregulated in all five
donors were loaded into GeneGo analysis tool (Thomson Reuters). To gain knowledge about
processes that are typical for MAIT cells, and additionally distinguish them from cCD8+ T
cells the analysis was focused on the proteins that were highly upregulated in MAITs when
comapared to cCD8+ T cells, meaning regulated with a median log2 RF of 0.8 or higher
(Fig. 33). These proteins were annotated to GeneGo molecular processes. Interestingly,
all except one of the top ten pathways that where found to be upregulated and therefore
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Figure 33 | GeneGo enrichment
analysis of MAIT proteins, com-
pared to cCD8+ T cells. Pro-
teins being upregulated between
MAIT and cCD8+ T cells in all five
donors, with a minimum median
log2 RF of 0.8 were checked for
pathway enrichment in GeneGo
analytical software. Coverage of
the pathways is calculated as p-
value, here shown as negative log-
arithm. Analysis shows enrich-
ment of pathways connected to
transport, secretion and exocyto-
sis.
enriched in MAIT cells were associated with secretion, transport and exocytosis. The strong
upregulation of proteins annotated to these processes indicates that the transport and secretion
system of MAIT cells might play a pivotal role in these cells. Proteins associated with the
GO pathway exocytosis are shown in Table 16, all of them have been shown to promote
exocytosis. For example, secernin-1 (median log2 RF MAIT:cCD8+ 1.07, MAIT:NK 0.94) has
been shown to increase both the extent of secretion in mast cells, and the sensitivity of mast
cells to stimulation with calcium.147 Its pronounced abundance in MAIT cells might be an
indicator for a crucial role of this protein in the MAIT cell phenotype, and might result in
MAIT cells being not only very sensitive for stimulation but secernin-1 might also boost the
secretion of this innate-like T cell subtype. Alpha-actinin 4 (median log2 RF MAIT:cCD8+
1.07) is an calcium-dependent actin-binding protein mediating interactions between the
membrane and actin filaments.148 Annexin IV (median log2 RF MAIT:cCD8+ 0.81) has also
been shown to play a role in exocytotic processes, involving neuronal synapses where it
associates with synaptotagmin.,149 while unconventional myosins like myosin-If (median
log2 RF MAIT:cCD8+ 1.39) are suspected to share similar properties to myosin, which is
an actin-dependent motor protein.150 Synaptotagmin-like protein 2 (Slp2, median log2 RF
MAIT:cCD8+ 0.96) contributes to secretory lysosome exocytosis from cytotoxic lymphocytes
and has been shown to be associated with the immunological synapse.151
Strikingly, calcium-binding protein S100A4 was also identified to be highly abundant in
MAIT cells, when being compared with both cCD8+ T cells and NK cells (median log2 RF
MAIT:NK 1.06, MAIT:cCD8+ 1.43). In a previous study it could be shown that S100A4 is
highly expressed in a cytotoxic NK cells subset,19 and has been discussed as being pivotal for
NK cell cytotoxicity and directed granule exocytosis (M. Heyner, unpublished data).
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Table 16 | Proteins strongly upregulated in MAIT:cCD8+ and associated with GeneGo molecular process “exocy-
tosis”
log2 RF median
Protein name MAIT:NK MAIT:cCD8 NK:cCD8
Alpha-actinin 4 -0.27 1.03 ***** 1.29 *****
Annexin IV -0.31 0.81 ***** 1.25 ****
Unconventional myosin-If -0.13 1.39 ***** 1.32 *****
Secernin-1 0.94 ***** 1.07 ***** 0.10
Synaptotagmin-like protein 2 0.07 0.96 ***** 0.82 ******
All proteins were identified in all five donors. Asterisks indicate the number of donors the proteins was identified
as regulated in.
When having a look at the twenty strongest regulated proteins between MAIT and cCD8+
T cells, more proteins associated with exocytosis appear, like annexin 2 or cystatin-F (Tab.
17). Also, effector proteins like granzyme A and K are among the proteins with the highest
difference in abundance. Interestingly, also proteins that are annotated with regulation of
proliferation like CD98, L-amino-acid oxidase and galectin-1 are expressed in much higher
amounts in MAIT cells than in cCD8+ T cells. High abundance of these proteins indicates
distinct regulation of proliferation in MAIT cells. The protein identified with the highest
different in abundance ist CD26, a MAIT cell marker.82
More evidence for a pivotal role of proteins like CD98, L-amino-acid oxidase, secernin-1,
and annexins in the definition of MAIT cells phenotype becomes apparent when investigating
the proteins that are exclusively upregulated in MAIT cells (Tab. 18). The first eleven proteins
on this list overlap with Table 17, this prominent abundance in MAIT cells when compared
with the other analyzed cells underlining their potential importance for the innate-like MAIT
cell phenotype. Functional annotation of the proteins that had not been covered in Table
17 revealed association with various different functions, like Ras/Rab-signaling (UniProt
accessions P63092, P31150, Q9NP72), metabolic processes (Q96C23, Q15120) or T cell
activation (P09326/CD48). Additionally, proteins linked to reorganization of microtubules
(Q9HC35, Q8TDX7) and proliferation (P51812) could be identified, as well as anti-coagulant
annexin V and the inhibitor of the complement system CD59. Importantly, all these proteins
can potentially serve as markers to discriminate MAIT cells from conventional CD8 T cells,
due to their increased abundance in the former.
75
Table 17 | Top twenty regulated proteins between MAIT cells and cCD8+ T cells
log2 RF median
Protein name MAIT:NK MAIT:cCD8 NK:cCD8
Dipeptidyl peptidase 4 (CD26) 2.61 2.39 -0.25
Large neutral amino acids transporter subunit 1 (CD98) 2.01 2.38 0.37
L-amino-acid oxidase 1.82 2.00 0.02
Granzyme K 1.66 1.91 0.29
Granzyme A -0.08 1.60 1.78
Galectin-3 1.19 1.49 0.05
Protein S100-A4 1.06 1.43 0.42
Unconventional myosin-If -0.13 1.39 1.32
Cystatin-F -0.63 1.33 1.93
Annexin A2 0.75 1.32 0.59
Protein S100-A10 0.92 1.30 0.25
Annexin A1 0.63 1.22 0.61
4F2 cell-surface antigen heavy chain (CD98) 1.06 1.14 -0.03
Carbonic anhydrase 2 1.16 1.08 -0.19
Glycogenin-1 0.76 1.07 0.42
Secernin-1 0.94 1.07 0.10
Caspase-1 1.17 1.04 0.15
G protein-regulated inducer of neurite outgrowth 3 0.45 1.03 0.39
Alpha-actinin-4 -0.27 1.03 1.29
Plasma membrane calcium-transporting ATPase 4 0.38 0.98 0.72
Italic font indicates association with exocytotic processes.
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In summary, highly upregulated proteins between MAIT and cCD8+ T cells show strong
association to exocytosis and secretion. Interestingly, these are mostly proteins like secernin-1
that actively promote secretion, or proteins that can directly be associated with the formation
of synapses. Additionally, the activity of all the proteins is influenced by calcium, a vital
messenger during T cell activation. Furthermore, a set of proteins with pronounced abundance
in MAIT cells was identified, that partly overlaps with the aforementioned proteins highly
upregulated between MAIT and cCD8+ T cells. This list additionally includes proteins with a
variety of different functions, like coordinating Ras/Rab-signaling, metabolic processes or
microtubule reorganization.
3.6 First-time characterization of the MAIT cell immunological
synapse
3.6.1 Formation of the MAIT immunological synapses
Although the cellular functions of MAIT cells have been investigated quite thoroughly, the
molecular mechanisms coordinating their effector functions still need to be elucidated. MAIT
cells are T cells after all, so the signaling pathways that result in activation might be very much
the same as in conventional T cells. MAIT cells however, have a innate-like immunological
function that is different from conventional cytotoxic T cells and has a far broader spectrum
of possible targets. Also, MAIT cells showed increased abundance of proteins regulating
exocytosis, like secernin-1 or S100A4. This indicates that their effector functions can be
coordinated differently. How MAIT cells form the interface with the target cells, the so-called
immunological synapse (IS), a contact that subsequently results in the death of the target
cell, has not been investigated at all.
MAIT cells can be activated with antigen-presenting cells. Here, PBMCs were isolated from
the blood of healthy human donors (2.6.2), and cells were stained with antibodies against
CD161 and Vα7.2. CD3 was not stained to prevent overloading the cells with antibodies
and effectively blocking fluorescence channels at the microscope with antibodies that were
used for sorting and are still fluorescent and attached to the cells. Additionally, 95 % of
Vα7.2+CD161++ cells are also positive for CD3. For this experiment, MAITs were therefore
defined as Vα7.2+CD161++ cells and sorted by flow cytometry (2.6.3). Sorted MAIT cells were
co-incubated with monocytic THP-1 cells that had been fed with fixed E. coli over night before
for different time periods on cover slips. Cells were then fixed, permeabilized and stained
with DAPI (4’,6-diamidino-2-phenylindole) and various antibodes. Slides were analyzed on a
Nikon inverted fluorescence microscope (2.6.4).
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Table 18 | Proteins exclusively upregulated in MAIT cells
log2 RF
Protein name MAIT:NK MAIT:cCD8+ NK:cCD8+
Dipeptidyl peptidase 4 (CD26) 2.61 2.39 -0.25
Large neutral amino acids transporter small subunit 1 (CD98) 2.01 2.38 0.37
L-amino-acid oxidase 1.82 2.00 0.02
Granzyme K 1.66 1.91 0.29
Galectin-3 1.19 1.49 0.05
Annexin A2 0.75 1.32 0.59
Annexin A1 0.63 1.22 0.61
4F2 cell-surface antigen heavy chain (CD98) 1.06 1.14 -0.03
Carbonic anhydrase 2 1.16 1.08 -0.19
Secernin-1 0.94 1.07 0.10
Caspase-1 1.17 1.04 0.15
Aldose 1-epimerase 1.40 0.90 -0.40
Annexin A5 1.92 0.85 -0.93
CD48 antigen 0.76 0.78 0.06
Receptor expression-enhancing protein 5 0.48 0.78 0.13
ADP-ribosylation factor-like protein 3 0.77 0.70 -0.30
Echinoderm microtubule-associated protein-like 4 0.97 0.68 -0.43
Guanine nucleotide-binding protein G(s) subunit alpha isoforms short 0.76 0.67 -0.09
Rab GDP dissociation inhibitor alpha 0.60 0.65 -0.22
Ras-related protein Rab-18 0.73 0.63 0.17
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3 0.63 0.56 -0.33
Serine/threonine-protein kinase Nek7 0.59 0.54 -0.15
CD59 glycoprotein 0.75 0.50 -0.23
Ribosomal protein S6 kinase alpha-3 0.72 0.44 -0.19
All listed proteins are upregulated in MAIT cells, when compared with both NK and cCD8+ T cells.
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To visualize the interface between MAIT cell and the target cell, samples were stained with
DAPI and for perforin. DAPI is a fluorescent stain for DNA152 and perforin a lytic, pore-forming
protein and key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.153 It is
located in for lytic granules, and can therefor serve as a marker. After establishing contact
with THP-1 target cell, immunofluorescence microsopy shows MAIT cells to polarize (Fig. 34).
While unstimulated MAIT cells show an equal spreading of lytic, perforin-containing granules
(Fig. 34A), MAIT cells in contact with a THP-1 target cell quickly establish a polarization and
the lytic granules are located at the IS (Fig. 34B).
To summarize, MAIT IS formation and degranulation could be documented for the first
time. Translocation of perforin-containing granules toward the interface between MAIT cell
and target cell is in perfect accordance with the cellular cytotoxicity that MAITs exert against
their target cells.94
3.6.2 S100A4 is associated with microtubules in MAIT cells
Calcium-binding protein S100A4 was found to be highly upregulated in MAIT cells when
compared to conventional CD8+ T cells and even NK cells (15). S100A4 has also been shown
to locate to the NK cell synapse after activation19 and might play a role in coordinating
directed granule release in NK cells (M. Heyner, in preparation). Therefore, it was of interest
to investigate if highly upregulated S100A4 also plays a role in MAIT cells. Furthermore, it
has also been speculated that S100A4 can colocalize with microtubules in activated primary
human T cells (N. Amsberg, personal communication). However, when analyzing MAIT cells
regarding the subcellular localization of S100A4, it was not only of interest to investigate the
association of S100A4 with the MAIT:target cell interface.
Microscopic imaging of localization of S100A4 in sorted MAIT cells (2.6.3, 2.6.4) also
revealead a not strictly cytosolic distribution of the protein. S100A4 localization was instead
rather focused on specific areas, and showed formation of defined structures (Fig. 35A).
Analysis of microtuble formations in MAIT cells did not show colocalization of both proteins
(Fig. 35B), but rather formation of common connected structures and a close association of
both molecules (Fig. 35D).
To further investigate these structures, and their possible involvement in the formation
of the MAIT IS, sorted MAIT cells were incubated with THP-1 cells that had been fed with
E. coli before. Samples were then fixed, permeabilized, stained with DAPI and antibodies
against α-tubulin and S100A4 and analyzed with a wide-field fluorescence microscope (Fig.
36). Interestingly, analysis of S100A4 localization in MAIT cells in contact with a target cell
for fifteen minutes revealed not only high abundance of S100A4 in the MAIT cells, but also
accumulation of S100A4 at the interface between MAIT cell and target cell (Fig. 36A). Staining
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Figure 34 | Formation of the MAIT immunological synapse. Sorted MAIT cells were co-incubated with THP-1
cells that had been fed with fixed E. coli before. Cells were then fixed, permeabilized and stained with DAPI and
monoclonal antibody against pore-forming protein perforin. Microscopical analysis was carried out on an inverted
fluorescence microscope. Every image depicts the maximum intensity projection of a z-stack, displaying the
maximum intensities of the layers of the whole z-stack as one 2D image. (A) shows a single non-polarized MAIT
cell, with lytic granules containing perforin distributed equally in the cytoplasm. (B) displays an activated MAIT
cell in contact with the THP-1 target cells, the lytic granules now polarized and localized at the immunological
synapse.
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of α-tubulin and microtubules showed that after fifteen minutes, the microtubule organizing
center (MTOC) had relocated to the interface between MAIT cell and target cell (Fig. 36B).
Noticeably it became visible that under these circumstances, S100A4 and microtubules show a
partial colocalization (Fig. 35, arrows). S100A4 does not completely colocalize with α-tubulin
and vice versa, but S100A4 is visibly partially located along microtubules.
In summary, partial colocalization of S100A4 and microtubules could be observed in
activated MAIT cells. In MAIT cells without contact with a target cells, S100A4 is also located
close to microtubules although no overlap or colocalization could be detected. Rather, a close
association of both proteins could be observed. Hence, S100A4 localization is apparently
coordinated by microtubules, and might even be recruited to the cytoskeleton upon activation.
However, it became apparent that S100A4 might also indeed move to the interface between
MAIT cell and target cell, when the MAIT cell is in an activated cell, and might therefor be a
factor influencing formation of the MAIT IS.
3.6.3 S100A4 localizes at the MAIT IS in a time-dependent manner
MAIT cells form immunological synapses upon contact with target cells. S100A4 is a calcium-
dependent protein, that has been shown to coordinate NK cell degranulation (M. Heyner, in
preparation), and is highly upregulated in MAIT cells. Upon activation with a target cell,
S100A4 can associate with microtubules and also localize to the interface of MAIT cell and
target cell.
To further investigate a possible role of S100A4 in MAIT cell immunological synapse (IS)
formation, sorted MAIT cells were incubated with E. coli-fed THP-1 cells, and settled on cover
slips for different time periods. Samples were then fixed, permeabilized, stained with DAPI
and antibodies against perforin and S100A4 and analyzed on a fluorescence microscope
(2.6.3, 2.6.4).
Microscopic analysis revelead increased localization of S100A4 at the interface between
MAIT cell and target cell. While non-activated MAIT cells show an equal distribution of
S100A4 in the cell body (Fig. 37A), significantly higher abundance of S100A4 can be
detected at the interface of MAIT cells and THP-1 target cell (Fig. 37B). This becomes even
more apparent in plots that graphically display the intensity of fluorescence detected of the
secondary antibody that is bound to S100A4 (Fig. 37C, D). The by far highest intensity is
localized in the polarized cells at the immunological synapse. To verify these data, intensity in
the respective channel of S100A4 was measured in several cells at different time points (Fig.
37E). Intensity was measured on a straight line, directed from the cell side not in contact with
the target cells towards the IS (see schematic in Fig. 37E). Values are displayed as percent
of intensity relative to the maximal intensity of all cells and time points were analyzed.
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Figure 35 | S100A4 forms structures with microtubules in MAIT cells. Sorted MAIT cells were fixed, perme-
abilized, stained with DAPI and antibodies against α-tubulin and S100A4. Images were acquired by wide-field
fluorescence microscopy, and deconvoluted afterwards with NIS-Elements software. Z-stacks were recorded and
are displayed as a 3D model using perspective projection. Deconvoluted single channels images of S100A4 and
α-tubulin (A, B) do not show colocalization of these proteins. Merged channels however reveal a formation of
structures of S100A4 and microtubules, and close associations of these proteins (C, arrow). (D) shows a merged
image of all channels. One graticule is 1 µm. Different blending modes for creating the 3D image are used in A, B,
C (alpha blending) and D (MaxIP). While alpha blending uses physical principles of light absorbing to accentuate
object surfaces, MaxIP displays only pixels with the highest intensity values of the Z-sequence.
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Figure 36 | S100A4 recruitment towards microtubules and the immunological synapse upon activation.
Sorted MAIT cells were co-incubated with THP-1 cells that had been fed with fixed E. coli before. Cells were then
fixed, permeabilized and stained with DAPI and monoclonal antibodies against α-tubulin and S100A4. Images
were acquired by wide-field fluorescence microscopy, and deconvoluted afterwards with NIS-Elements software.
Z-stacks were recorded and are displayed as a 3D model using perspective projection. Images display a MAIT
cell (M) and associated target cell (T) after 15 minutes of coincubation. (A) Single channel image of S100A4,
showing accumulation of S100A4 at the interface between MAIT cell and target cell. (B) Single channel image of
α-tubulin, showing the microtubule-organizing center (MTOC, arrow) located at the immunological synapse. (C)
Merge of S100A4 (red) and α-tubulin (green). Note the overlap of both proteins on microtubules that originate
at the MTOC (arrows). (D) Merge of DAPI (blue), S100A4 (red) and α-tubulin (green).
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Interestingly, most unstimulated cells are also slightly polarized, displaying an unequal
distribution of S100A4. When in contact with the target cell, however, this polarization
increases drastically after 2 and 5 minutes, with large amounts of S100A4 relocating to
the immunological synapse. This is accompanied by a loss of intensity of S100A4 signal
at the side of the cell opposite from the IS. The intensity at the IS, at roughly 5 - 6 µm
after start of measurement, does not only significantly increase, but also shows a broader
distribution, indicating a larger area on which the present S100A4 is spread. After 10 and 30
minutes, intensity of S100A4 is distributed more equally again, indicating the dissolution of
the immunological synapse. Interestingly, data also indicate an accumulation of target cell
S100A4 on the target cell’s side of the IS. This is displayed by the intensity peak that can be
seen shortly behind the peak on the MAIT cell side.
In summary, microscopical analyses strengthen the evidence for a possible role of S100A4
in the MAIT phenotype. Proteomic data already showed a high upregulation of S100A4 in
MAIT cells, implying an importance of this protein in the phenotype of MAIT cells. Now it
could be shown that indeed S100A4 localizes at the immunological synapse of MAIT cells
after activation with target cells, in time dependent manner.
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Figure 37 | S100A4 localizes at the MAIT immunological synapse. Sorted MAIT cells were co-incubated with
THP-1 cells that had been fed with fixed E. coli before. Cells were then fixed, permeabilized and stained with
DAPI and monoclonal antibodies against IS marker perforin and S100A4. Images were acquired by wide-field
fluorescence microscopy. (A) A MAIT cell that is not in contact with a target cell. Although perforin appears to
be localized in one spot, the distribution of S100A4 is spread through the whole cell. (B) MAIT cells in contact
with a target cell (T) after five minutes of incubation. Lytic granules and high amounts of S100A are located
at the interface between MAIT cell and target cell. (C & D) Intensity Surface Plot of the S100A4 channel (A)
and (B), respectively. The higher the intensity of the detected S100A4, the higher elevation of the surface plot.
Again, high abundance of S100A4 can be detected at the MAIT-target cell interface. (E) Development of S100A4
localization is displayed over the course of 30 minutes of IS formation. S100A4 intensity was measured on one
line diametrical towards the immunological synapse, as displayed in the schematic. The intensity of S100A4 at
the synapse at roughly 5-6 µm after the start of the measurement increases after IS formation, and peaks at 5
minutes. Afterwards, it decreases again. Scales in the microscopic images display 5 µm. Graph contains data
from 33 cells and cell:cell conjugates.
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4.1 Chemical inhibition of NK cell effector functions
4.1.1 Specificity of used kinase inhibitors
The first part of this thesis showed the modulation of innate immune functions of NK cells
with small chemicals (3.1.1, 3.1.2).135 It could be shown that used inhibitors significantly
reduced NK cell effector functions degranulation and cytokine release. However, although
kinase inhibitors have been established as valid tools for enzyme inhibition in particular at
the level of primary human immune cells,154 their specificity, and thus their suitability to
investigate the role of the target kinases has to be taken into account to interpret the results.
Dasatinib inhibits not only the activity of Src-family kinases (SFKs) but also interferes with
activity of kinases like BCR-ABL1, and is a valuable drug in leukemia therapy.155 Dasatinib
is indeed a proper tool for proof-of-conept experiments, as its targets, SFKs, are putative
signaling components in NK cell activation.21,25 This could already been shown in previous
studies, where application of Dasatinib diminished NK cell effector functions.156–158 The
results generated in this thesis were not only in full accordance with the former studies, but
also showed a strong impact of Dasatinib treatment on NK cells degranulation and TNF-α
release in PBMC and pure NK cell cultures. A study by Hassold and colleagues, however,
revealed that NK cells that were pretreated with Dasatinib for 24 hours showed increased
effector functions.159 This might be a mechanism of NK cells to adapt to Dasatinib exposure.
In contrast to Dasatinib, CK59, and CID755673 are considered as highly specific kinase
inhibitors. CK59 has a structure analogue to kinase inhibitor olomoucine, which was demon-
strated to specifically inhibit isoforms of CaMKII. Affinity studies revealed isoforms CaMKII-γ
and CaMKII-δ to bind to CK59 with the highest affinity.160 The same study also showed that
10 µM CK59 already diminish activity of CaMKII to 45 %. Additionally, Poggi and colleagues
demonstrated that inhibiting CaMKII activity reduces NK-cell killing of dendritic cells (DC),
as well as release of IFN-γ by NK cells upon contact with DCs.161 Additionally, Poggi and
colleagues did not observe decreased killing of K562 cells by NK cells that had been treated
with a CaMKII inhibitor. In this study, however, inhibition of CaMKII significantly decreased
effector functions of NK cells that had been stimulated with K562 target cells. However, it
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has to be taken into account that in the Poggi study specific lysis of target cells was studied,
while in this thesis degranulation and the release of cytokines was analyzed. Also in this
thesis, degranulation was assessed in CD3-CD56+ NK cells after 2 hours of incubation, while
Poggi and colleagues analyzed CD3-CD16+ NK cells after 4 hours and used a completely
different set of CaMKII inhibitors. It might therefore be possible, that CaMKII is coordinating
degranulation, but not involved in other processes that might lead to killing of target cells.
Kinase inhibitor CID755673 has been described to be specific for PKD kinase family members
PKD1, PKD2 and PKD3. With 200 other targets, it did not show any effect.162 It could also
been shown that CID755673 has no effect on the activity of protein kinase C (PKC), usually
lying upstream of PKD kinase in signaling networks, or CaMKII. This again proves high
specificity of CID755673 as these kinases are closely related to PKD.162,163 Interestingly, PKD2
is considered as a signaling component in NK cells although functional data underlying this
hypothesis are missing. However it has been shown that isoforms of PKD do not play a role
in integrin-mediated lymphocyte adhesion and homing to lymphoid tissues.164 In the present
study, application of CID755673 led to remarkable changes in NK cells degranulation and
cytokine release. These observations suggest that PKD family kinases are participating in the
signal network coordinating NK cell effector functions.
4.1.2 Role of PKD and CaMKII in NK cell activation
Experiments in pure NK cell cultures also revealed inhibitory effects of the three used inhibitors
in these pure cultures (3.1.2). Surprisingly, responses to inhibitor treatment in pure NK cells
were different from the responses that were detected in PBMC cultures. Not only displayed
the different donors remarkably variable response profiles in pure NK cells. It was also
observed that used inhibitors have the capability to enhance NK cell effector functions. This
observations suggest also possible roles for the analyzed kinases in inhibitory pathways. As
protein kinases are part of a multitude of different signaling pathways, this is very much
possible. Coordination of kinase activity and substrate binding, and therefore realization
of pathway-specific functions of kinases are most likely controlled by post-translational
modifications. It has already been shown that phosphorylation status of S876 directly
correlates with PKD2 activity.163 Activity of CaMKII relies on phosphorylation status of amino
acid Thr286.165 A study of König and colleagues could reveal additional phosphorylation
sites in these kinases that had not been described before, and were not functionally described
so far: engagements of NK cell receptors was shown to induce phosphorylation of PKD2 at
S214 and of CaMKII at S330.134 Although a number of different phosphorylation sites are
described for both kinases, no mechanistic model exists explaining their involvement in NK
cell activation.
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To better understand donor variations and the apparent conflicting results generated in
PBMC and pure NK cell cultures, the expression of kinase isoforms has to be considered. For
example, protein kinase C isoforms (PKCδ, ε, θ, and η) act as upstream signal components
of PKD family kinase isoforms (PKD1, PKD2, and PKD3).166–168 Protein kinase C isoform
PKCδ has been described to phosphorylate PKD1 and PKD2, while PKCε and PKCη activate
PKD1.168–170 Unfortunately, there is no data available regarding isoforms phosphorylating
PKCθ and PKD3. Importantly, PKCθ plays a pivotal role for ITAM-mediated release of IFN-γ
and TNF-α, but not for NK cell-mediated cytotoxicity or cytokine release induced by IL-12 and
IL-18.171 Interestingly, a different study reported a reduced IL-12-induced IFN-γ response of
NK cells in PKCθ knock out mice (PKCθ−/−).172 In the same study however, a reduction of
cytotoxic potential of NK cells against YAC-1 target cells could not be detected. Additionally,
NK cells of PKCθ−/− mice were reported to display a reduced capacity to degranulate when
triggered with RMA-S tumor cells.173 Taken together, when comparing these results with the
data generated in the present work, it becomes apparent that an isoform-specific knock-out
of upstream kinase PKCθ leads to a less pronounced inhibition of NK cell effector functions
than chemical inhibition of PKD, a signaling component downstream of PKC. It is therefore
possible, that the signaling pathway leading to NK cell activation depends not solely on PKCθ,
but also involves other isoforms of PKC that phosphorylate one or more PKD isoforms (Fig.
38).
In conclusion, chemical inhibition of either CaMKII or PKD family kinases limits NK cell
effector functions. Results from natural cytotoxicity further substantiated the role of these
kinases in NK cell signaling. However, the results with pure NK cells also indicate the
importance to further investigate the molecular basis of donor variations, which may be caused
either by differential pre-activation of kinases at the level of post-translational modifications
or simply by differential expression of kinase isoforms.
4.1.3 Perspectives for kinase inhibitors in cancer and NK cell therapy
In cancer therapy, the application of small molecular kinase inhibitors has been a valuable
tool for years.174 However, results from this this study provide novel insights into the effects
of donor variability and chemically-mediated NK inhibition, and its potential use.
First, this study reveals potentially dangerous side effects of kinase inhibitors. Especially
dasatinib, which is already used as a tool in cancer therapy against chronic myelogenous
leukemia (CML) and acute lymphoblastic leukemia (ALL)155,175 has drastic effects on the
effector functions of NK cells (3.1.1, 3.1.2). But also CID755673, which as well inhibits NK cell
activity, has already been suggested as an therapeutic drug in prostate cancer.162,176 Although
these compounds exert anti-tumor properties, this thesis shows that their application poses
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Figure 38 | Schematic representation of known and potential interactions between PKC and PKD family
kinase isoforms. Continuous lines indicate known interactions between specific PKC and PKD family kinase
isoforms leading to activation through phosphorylation of the latter. Potential interactions of specific PKDs with
PKCθ isoforms, to this date not experimentally validated, are shown as dashed lines.
certain risks. Both compounds have in general a negative effect on the immune response
against tumor cells, and might also diminish other activities from other immune cells. For
dasatinib, it has also been shown that application decreases T cell activity.177 Therefor,
application of these compounds might lead to increased susceptibility for opportunistic
infections, formation of new tumors or the original tumor itself and the capability of kinase
inhibitors to modulate immune cells has to be evaluated when considering them as anti-cancer
drugs. Also, during the course of this thesis it has become apparent that cells from different
humans react differently to inhibitor treatment. Not only the inhibitory effect was different
from donor to donor, some even reacted with increased responses. Consequently, in cancer
therapy it would make sense to check the sensitivity of the patient against the applied drug
before starting the treatment. This would not only help against wrong dosing of the respective
drug, but also prevent over-reactions of the immune system.
Second, kinase inhibitors are a promising tool to treat diseases that are mediated by NK
cell hyperactivity. However, very little is known about pathogenic conditions that are caused
by NK cell activity. The number and activity of NK cell is reduced in most diseases cause
by autoimmune reactions. However, some studies speculate about disease-promoting role
of NK cells in these cases.178,179 Also, NK cells can undergo malignant transformation and
actually become cancer cells. This rare type of large granular lymphocyte (LGL) can be
chronic or aggressive.180–182 In its chronic state, therapy is relatively simple and patients
have a positive prognosis. The rare aggressive form, however, is classified as one of the most
aggressive tumors encountered and resistant to various therapeutic agents. Patients are left
with a very poor prognosis and usually die within a few months, due to disseminated disease
with associated coagulopathy and multiple organ failure. In cases like this it is logical, that
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treatment with kinase inhibitors that are not only effective against leukemia, but can also
diminish overly active NK cells, could help in treating this dangerous disease. However, data
in actual patients or even animal models is missing.
4.2 Novel mechanisms of innate immunity in MAIT cells
4.2.1 Proteomic analysis of low-abundant primary immune cells
A challenge in the present thesis was to establish a proteomic workflow that would be suitable
to comparatively analyze the proteome of small cell numbers. Screening of healthy donors
had revealed MAIT cell numbers that were below 1 % of total T cell count for some donors
(3.2). This resulted in amounts of sorted cells of less than 1·106 cells per buffy coat in some
donors, that were then used for test experiments (Fig. 16). To cope with these possibly
small cell numbers and to maximize the yield of the resulting low amounts of protein, a lysis
protocol with a minimum of sample loss was chosen (see 2.7.1). The protocol is based on
lysis with urea and does not contain any protein extraction steps before tryptic digest that
could decrease the protein yield. With this protocol, and subsequent SCX subfractionation
with a 15 minute long gradient of increasing salt concentration, it was decided to set the
run length of the LC preceding the MS measurements to the maximal 120 minutes for every
SCX-generated fraction. This approach made it possible to identify 2260 proteins out of
250 000 PBMCs (3.4), and it was therefor decided to keep this protocol unchanged also for
the comparative MAIT cell experiments. Here, MS analyses led to the identification of 3700
to 4300 proteins per donor (Tab. 11), albeit the cell numbers varying from 1.7·106 to 9.8·106
cells per donor. This might be due to the rather short SCX gradient used. The use of a longer
gradient could have led to a larger number of proteins identified. However, this workflow
was highly reproducible and led to a robust modification of a large number of proteins over
several experiments, and was therefor suitable for the experiments conducted during this
thesis.
4.2.2 Proteomic results are in accordance with current knowledge
This study provides the first proteomic overview of the protein abundance in MAIT, NK and
cCD8+ T cells. However, flow cytometric analyses of selected effector molecule expression in
MAIT cells have been published,80,117 as well as a recent transcriptomic study comparing
CD8+CD161++ and CD8+CD161- cells.146
In 2011, flow cytometric analyses revealed multidrug resistance protein 1 (MDR1) to be
prominently expressed on MAIT cells, and already reported as high, MAIT-specific expression
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of CD26,80 who has recently be suggested as a specific marker for MAIT cells.82 Also, low
expression of CD62L in MAIT was reported, which is consistent with their classification as
effector cells. These observations could be repeated in this study (3.5.3.2, Tab. 14), showing
the reliability of the generated data. The same study also summarized cytokine secretion
profiles of MAIT cells after stimulation. However, none of these secreted cytokines, e.g.
IL-17 or IFN-γ, could be identified in the proteomic data set. Granzyme B (GzmB) was
reported to be released in same amounts by MAIT and cCD8+ T cells after stimulation with
PMA/ionomycin and CD3/CD28 antibody stimulation, respectively. Accordingly, proteomic
data showed abundance of GzmB in MAIT and cCD8+ T cells to be equal (3.5.4.1, Tab. 15).
A recent study by Kurioka and colleagues focused on quantification of granzyme expression
in MAIT cells by flow cytometry.117 Granzyme A (GzmA) and granzyme K (GzmK) were
identified to be highly expressed in MAIT cells. This could be confirmed by proteomic
analysis (3.5.4.1, Tab. 15), with log2RF MAIT:cCD8
+ of 1.60 and 1.91 for GzmA and GzmK,
respectively. In the Kurioka study, however, expression levels of pore-forming protein perforin,
granulysin and GzmB were reported to be lower in resting MAIT cells than in cCD8+ T
cells, whereas previous studies have shown them to be secreted in prominent amounts upon
stimulation.80,94 Also, proteomic data showed perforin, granulysin and GzmB to be present in
equal amounts in MAIT and cCD8+ T cells (3.5.3.2, 3.5.4.1, Tab. 14 & 15). Furthermore, flow
cytometric data showed that only 20 % of all CD8+ T cells are positive for GzmB, all of them
defined as conventional CD8+ T cells due to their low or intermediate expression of CD161.
Also, only 25 % of the CD8+CD161-/CD161+ T cells were positive for perforin, while 10 % of
CD8+CD161++ MAIT cells were detected to express perforin. Only 10 % of non-MAIT CD8+ T
cells were positive for granulysin.117 Thus, the difference between antibody based detection
that indicated lower GzmB, perforin and granulysin expression in MAITs, and proteomic
analysis which could not detect any difference, might be due to the fact that indeed only a
small set of cCD8+ T cells expresses these proteins.
Also in 2014, an extensive study was published, where the authors systematical analyzed
the difference between CD8+CD161++ and CD8+CD161- T cells on the level of mRNA.146 As
almost all CD8+CD161++ T cells are MAIT cells in the transcriptomic study, and the majority
of MAIT cells is CD8+ in the proteome analysis, this study can be compared with the proteomic
analysis. Interestingly, only a relatively small amount of regulated genes or corresponding
proteins overlapped in both studies, although no extreme differences in terms of regulation
factors were present (3.5.3.2, Tab. 13). No downregulated gene was to be found upregulated
as protein and vice versa. Among the genes and proteins that were consistently identified as
regulated in both studies is effector molecule GzmA. The transcriptomic analysis, however,
identified 544 regulated genes. Out of those, 384 of the regulated genes weren’t identified on
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the the protein level at all. Out of the overlapping 160 proteins, 141 genes were identified as
regulated that were not found to be regulated on the protein level. Also, by coincidence the
same number, 141 proteins that were found to be regulated were described as not regulated
by the transcriptomic data. This discrepancy might be explained by the stringent conditions
applied to identify regulated proteins in the proteomic set. It might also be a result of post-
translational regulations of protein levels, that would lead to a different protein abundance as
the one that was indicated by the mRNA amounts. Finally, the compared cell subsets are not
identical with the ones in the present study, which might also lead to falsification of results.
Interestingly, transcriptomic comparison of CD8+CD161++ and CD8+CD161- T cells also did
not detect different expression of GzmB, perforin or granulysin,146 although the compared
cell types were completely identical to the ones used in the Kurioka study in which different
expression levels of these proteins could be detected.117
Taken together, flow cytometric studies mostly reflect the regulation that was determined
by mass spectrometry, and also identify GzmA and GzmK as key proteins for MAIT cell effector
functions, with increased abundance when compared with conventional cytotoxic T cells. The
comparison with transcriptomic data however requires further careful validation, although
now major contrasts could be detected.
4.2.3 Is the definition of a “typical” MAIT cell possible with proteomics?
Studies with material from human donors are always subjected to the individual geno- and
phenotype of humans. Therefor, it had to be ruled out that individual variations would
influence the outcome of the study, and donor variability had to be taken into account.
Labeling with iTRAQ reagent and detection of the intensities of the different markers
allowed to quantify protein abundance in the different donors (3.5.3.2). The difference in
abundance between the three investigated cell types can be displayed as regulation factors
(RF), that are equal to the fold change of abundance. Alternatively, the logarithm to the base
of 2 of the fold change (log2 RF) can be used. This ensues in a log2 RF of 0 for proteins
with the same abundance. A log2 RF value of 1 indicates a two-fold abundance increase,
while log2 RF -1 shows that the respective protein is half as abundant in one cell type when
being compared to the reference. When investigating the distribution of log2 RF it became
apparent, that almost all donors showed a similar general distribution of values (Fig. 30).
Additionally data also demonstrated regulation factors for every single protein that were
more or less coherent over every donor (Fig. 31). Donor 2, however, is an exception from
the else consistently looking data. The regulation factors of donor 2 are spread significantly
further than the log2 RFs of the other four donors (Fig. 30). Also, donor 2 showed a different
pattern of distribution of the log2 RF, which can be seen in Fig 31. Yet, this donor-dependent
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variation is nothing out of the ordinary. Primary cells are known for showing donor-dependent
variations, and were also observed to display huge differences in percentages of the different
cell types (3.5.1, Tab. 10). Similar observations about human donors showed large variation
of immune cell responses to infection, again indicating the variability of primary material.183
Additionally, in the part of this thesis analyzing NK effector functions donors showed variation
when reacting to treatment with kinase inhibitors (3.1.2, Fig. 14). Also in proteomic studies,
similar donor variations could be observed.19,184 The reason for donor 2 to show this distinct
distribution of regulation factors remains open to speculation. Donor 2 was a 36-year old
healthy male and had the largest number of MAIT cells. The number of initially isolated
PBMCs was high, but not abnormally increased (data not shown). Also with regard to
lymphocyte numbers, or percentages of T cells and MAIT cells no significant deviation of a
single factor was detected (data not shown). However, all these factors in combination finally
resulted in a total of almost 10·106 MAIT cells isolated. Although this donor was also classified
as healthy and tested negatively for HIV, HBV and HCV, it can of course not be excluded that
he suffered or recovered from a not-detected infection. Nonetheless, infections and even
auto-inflammatory diseases are usually accompanied by a decrease of MAIT cell numbers
in peripheral blood.77,113,115,125,128,129,131 The increased number of MAIT cells might have
been an effect of overcompensation when restoring their numbers after an recently-cleared
infection. It is then also possible, that the amount of stronger or differently regulated protein
might then be due to this infection, that had not be detected. It might be imaginable that cells
acquire a more diverse proteomic phenotype when exerting their different effector functions
during and after the course of an infection. If this is the case, it opens up the possibility to
use MAIT cell numbers as a marker for disease progression.
However, as donor 2 was, with respect to the data available, completely healthy and did
not show any anomalies in cell numbers or percentages, it was decided to keep the data
as unbiased as possible and not remove the donor from the analysis. Interestingly, it was
nevertheless possible to define a large number of proteins that were regulated in all five
donors, revealing sets of proteins that are indeed regulated donor-independently in MAIT
cells, and therefore define the typical MAIT cell.
4.2.4 Best of both worlds: Typical MAIT cells between NK cells and CD8
T cells
As MAIT cells are usually described to be “innate-like T cells”, an aim of this thesis was
to assess how “innate-like” MAIT cells actually are. The study was therefore designed to
compare MAIT cells with both adaptive and innate immune cells, in this case conventional
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CD8-positive T cells, that are not MAITs (cCD8+ T cells), and NK cells, respectively. It is an
advantage of systematic analyses containing quantitative data, that these kind of data usually
allow general statistical comparison of different analytes, in this case cell types.
Statistical analyses like principal component analysis or multidimensional scaling make it
possible to visualize the level of similarity of individual cases of a dataset. It was therefore tried
to calculate the similarity or distance between MAITs, NK cells and cCD8+ T cells. Available
data however, did not lead to satisfying results, as it was not possible to normalize quantitative
data sufficiently. This approach resulted in a clustering of the different experiments rather
than in clustering of different cell types (MAITs, NK, cCD8+, data not shown). This indicates
that the technical variance of mass spectrometry makes it difficult to impossible to compare
different experiments with systematic approaches, even with various methods of normalization
applied. This leaves the number of proteins regulated between the cell types as a method
to assess the similarity between different cells. In five donors, 135 proteins were identified
with significantly different regulation factors between MAIT and NK cells (see 3.5.3.2, Tab.
12). When comparing MAIT and cCD8+ T cells, 160 proteins were significantly regulated
while the number of regulated proteins between NK and cCD8+ T cells was 231. When
assuming that cell types are more different if more proteins are differentially express, these
numbers might indeed give a rough estimate about how similar the cell types are. Numbers
then indicate that NK and cCD8+ T cells are the most different. Surprisingly, the difference
between innate NK cells and MAIT cells would then be lower than the difference between
MAIT and adaptive cCD8+ T cells. This would indeed indicate a more innate-like phenotype
of MAIT cells, which would then be phenotypically located between NK and cCD8+ T cells,
with displaying surprising phenotypical similarity to NK cells (Fig. 39).
4.2.5 Defining the typical MAIT cell phenotype with proteomics
4.2.5.1 A new set of markers for human MAIT cells
MAIT cells are usually defined as T cells, that express the invariant Vα7.2 TCR chain, and high
amounts of CD161.94 Recently, also other markers for MAIT cells have emerged, like IL-18
receptor,80 MDR-180 or CD26.82 However, distinct intracellular marker is missing. Proteomic
data also could identify a number of proteins, that are exclusive for MAIT cells (Tab. 18) and
can serve as distinct MAIT markers. Importantly, this list also includes CD26 as the highest
regulated protein between MAIT and cCD8 T cells, and can serve as a proof for the validity of
the identified markers. Interestingly, among this putative marker molecules are also surface
markers that have never been described in the context of MAIT cells before. CD98 transporter
for large amino acids, like tryptophane,185 and CD48 is a activation marker for B cells and the
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Figure 39 | Similarity between human NK, MAIT and cCD8+ T cells. Proteomic data indicated a more similar
phenotype of MAIT cells to NK cells then to cCD8+ T cells, as less proteins were found to be significantly regulated
betwen MAIT and NK cells as between MAIT and cCD8+ T cells.
ligand for CD2.186 Both of this molecules could be confirmed to be increased on MAIT cells in
the course of this study (3.5.3.3, Fig. 32). Intracellular markers for T cell subpopulations are
usually transcription factors, like FoxP3 for regulatory T cells. However, these are often low
abundant and detection is therefore difficult. For example, typical MAIT cell transcription
factors like RORγt or PLZF could not be identified in this highly sensitive proteomic approach.
Intracellular proteins like L-amino-acid oxidase or secernin-1 however, were found to be
highly abundant, and can therefore serve as marker for MAIT cells.
4.2.5.2 The arsenal of MAIT cells - innate immunity requires a specific pattern of
effector molecules
MAIT cells have already been subject to investigations aiming to define their exact effector
function and also the effector molecules that allow them to exert these functions. However,
proteomic studies allow the systematic identification of differentially regulated proteins, and
generated data are furthermore not restricted to molecules that are detectable by antibodies
like in Western Blot or flow cytometric applications. Additionally, with an unbiased method
like mass spectrometry, it is not necessary to decide what proteins would be of interest before
conducting experiments. It was therefore possible, to identify effector molecules that are
typical for MAIT cells, when compared with NK and conventional, CD8-positive T cells (cCD8+
T cells), respectively (3.5.4.1, Tab. 15). Among these were all human granzymes, important
effector molecules in immunity.64,187–189 All known granzymes are serine proteases and
usually associated with the induction of target cell death.
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Granzyme A (GzmA) showed a similar abundance in MAIT and NK cells, and was found to be
less abundant in cCD8+ T cells. It has been shown to be expressed in higher levels in MAIT cells,
and colocalizes with granzyme K and CD107a.117 Current knowledge implicates that GzmA
uses a different, caspase-independent pathway than other granzymes to induce apoptosis. It
has been shown that GzmA enters the matrix of mitochondria and mediates the generation
of mitochondrial super oxide, dissipating the membrane potential.190 Additionally, oxidative
stress leads to relocalization of the redox-sensitive SET complex to the nucleas, where GzmA
can enter, liberating nucleases and in this way inducing DNA damage.191,192 Interestingly,
the cytotoxic potential of human GzmA is lower than the one of murine GzmA,193 and the
efficiency of hGzmA to induce cell death has been discussed. Instead, extracellular GzmA has
been shown to trigger the release of IL-1β, TNF-α, IL-6 and IL-8 in human monocytes,194,195
and of IL-6 and IL-8 of fibroblast and epithelial cell lines.196 Furthermore, GzmA multiplies
the lipopolysaccharide (LPS)-induced cytokine release by human monocytes.197 Also, GzmA-
release by γδ T cells induces TNF-α secretion in human macrophages infected by mycobacteria,
thereby inhibiting the growth of the microorganisms.198
Granzyme B (GzmB) was detected with the highest abundance in NK cells, with MAITs and
cCD8+ T cells showing significantly lower abundance. Until now, GzmB has been described
to be not expressed at all in MAIT cells117 and rapidly induces apoptosis, usually using a
mechanism that is dependent on caspases.199 As all members of the granzyme family, GzmB
also exerts proteolytic functions and is able to cleave its target proteins after aspartic acid
residues.200 It can for example cleave caspase 3,201 which however doesn’t result in its full
activation.202,203 Additionally, GzmB also shows strong preference to proteolytically activate
Bcl-2 family member Bid,202 initiating the relocalization of Bid to the mitochondria and
subsequent permeabilization of the outer membrane. This leads to the release of mitochondrial
intermembrane molecule Smac/Diablo and cytochrome C.203 The interactions of the latter
with Apaf-1 facilitate aptoptsome formation and activation of caspase 9, while Smac/Diablo
relieves inhibition of caspase 3 activity by inhibitor of apoptosis protein 3 (IAP3). All these
processes allow caspase 3 to become fully active and effectively induce target cell apoptosis.
Apart from its cytotoxic capacity, GzmB has also been shown to synergistically increase the
secretion of TNF-α from primary human monocytes, similar to effects of GzmA or GzmK.197
Also, GzmB is able to process cytokines, like pro-IL18 or the precursor of IL-1α, enhancing
increasing its biological activity.
Granyzme H (GzmH) was found to be higher abundant in NK cells than in cCD8+ T cells,
and displayed the lowest abundance in MAIT cells. The precise mechanism of GzmH-mediated
apoptosis is still under debate, and pathways independent204 and dependent,205 respectively,
of cleavage of Bid, ICAD (inhibitor of caspase-activated DNAse)/DFF45 (DNA Fragmentation
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Factor 45) and caspase-3 have been suggested for GzmH-mediated apoptosis. The most recent
work on GzmH functionality suggest that the enzyme indeed cleaves and activates DFF45,
but is independent of Bid activation.206 Nevertheless, GzmH disrupts the outer mitochondrial
membrane and releases cytochrome C and Smac/Diablo, much like GzmB. The neutralization
of IAPs and the generation of an apoptosome, however, are not required to induce GzmH-
mediated cell death. No immune-modulatory functions of GzmH have been described so far.
There is however evidence for anti-viral functions of GzmH, as it can proteolytically inactivate
virus-derived inhibitors of GzmB207 or different viral proteins.208
Granzyme K’s (GzmK) increased abundance in MAIT cells in comparison with both NK and
cCD8+ T cells has already been suggested by flow cytometric data.117 Granzymes A and K
are closely related,192 and similar to GzmA, GzmK also cleaves the SET complex, leading to
apoptotic processes.209 It has also been reported, that GzmK can cleave p53 to proapoptotic
forms, indicating a unique mechanism for GzmK-mediated killing.210 However, also the killing
efficiency of GzmK has been questioned, and other functions were suggested. Similar to
GzmA, GzmK can trigger the secretion of IL-6 and IL-8 from human fibroblasts.211 Strikingly,
GzmK can also interact with bacteria and LPS, and in combination with LPS increases the
release of TNF-α, IL-6 and IL-8 in vivo and in vitro.197 Furthermore, GzmK has been shown to
cleave β-tubulin.212
Granzyme M (GzmM) showed the lowest abundance in cCD8+ T cells, and the highest
in NK cells. It has been described that GzmM is highly expressed in NK and NKT cells,
and expressed in a third of all CD8+ T cells.213 It was therefore been attributed a role in
innate immunity,214 although more recent studies have revealed high expression of GzmM
in differentiated effector T cells.215 Interestingly, GzmM could also be detected in cCD8+ T
cells in this thesis, and showed significantly higher abundance in MAIT cells. The function of
GzmM however and physiological releveance, is not yet completely understood, also because
of contradictory data.216 Different mechanisms about GzmM inducing cell death have been
reported. One study characterized the cell death induced by GzmM as accompanied by
chromatine condensation and rapid lysis, but not cytochrome C release, caspase 3-activation,
loss of membrane potential or DNA fragmentation.217 Different studies have shown that
GzmM indeed does lead to DNA fragmentation, mitochondrial damage and caspasce activa-
tion.218,219 The differences in result may be due to varying experimental procedures as it has
been suggested by de Poot and Bovenschen.216 Additionally, GzmM has been shown to cleave
α-tubulin, thereby destabilizing the microtubule network of the cell.220 There is also data
available for human GzmM to promote inflammatory processes. Nevertheless, in mice it could
be shown that also mGzmM seems to synergistically enhance the inflammatory response
to LPS challenging,221 and furthermore promotes secretion of macrophage inflammatory
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protein-1 alpha (MIP-1α) from NK cells.222
Granulysin could be detected with the highest abundance in NK cells, with MAIT and cCD8+
T cell showing a lower similar abundance. Granulysin is a cytotoxic protein65,223 that is
usually expressed in NK cells and T cells.224 Granulysin is synthesized as a molecule of 15 kDa,
and later cleaved into a 9 kDa form.225 While the 15 kDa form is secreted constitutively, the
9 kDA form is located in cytolytic granules and shows antimicrobial and tumoricidal activity
if recombinantly expressed.224 The 9 kDa form of granulysin can bind to the membrane of
the target cell and breach it, thereby entering the cell and causing calcium influx.226,227 This
also leads to subsequent decrease of intracellular potassium, all this causing mitochondrial
damage, releasing cytochrome c and apoptosis-inducing factor into the cytoplasm, triggering
a caspase-dependent mechanism that leads to apoptosis.228 Interestingly it has also recently
been shown that granulysin also plays a vital role in the direct killing of mycobacteria by NK
cells.229
Perforin was found to be extremely high expressed in NK cells, and in similar amounts in
MAIT and cCD8+ T cells (Tab. 14). Perforin is a pore-forming protein, that plays a pivotal role
of delivering granzymes into the target cell cytoplasm.63,230,231 Its function is absolutely vital
for the immune system, humans and mice that suffer from perforin-deficiency have to deal
with increased susceptibility to infections or cancer.232,233 The exact mechanism of perforin
to deliver granzymes into the target cell is not completely understood.234 Two models have
been suggested, one proposing that perforin forms pores in the plasma membrane, through
which the granzymes are delivered.235 More recent studies however indicate a two-step
process, where first indeed pores in the plasma membrane are formed through which the
granules enter. Subsequently, perforin also forms pores in the membrane of endocytosed
endosomes, releasing the cytotoxic granzymes into the cytosol.236
Interestingly, quantification of effector molecules revealed a pattern of expression that
is typical for MAIT cells, not only when being compared with NK cells. Also, MAIT cells
express a profile of granzymes that is distinct from cCD8+ T cells (Fig. 40). While the
differential expression of perforin, granulysin, GzmA, GzmB and GzmB in MAIT and cCD8+
T cells has already been discussed on the base of flow cytometric analysis by Kurioka and
colleagues,117 new data in this study indicate also a specific expression pattern for GzmH
and GzmM. Apart from that, proteomic data clearly indicates that NK cells express the most
complete granzyme panel when being compared with the other investigated cell types, with
high amounts of GzmB, granulysin and perforin, which all exert pronounced cytolytic activity.
The only exception is GzmK that is abundant in lesser amounts than in MAIT cells, which
show the highest abundance of all cell types. Previous studies have also described GzmK as
highly prevalent in MAIT cells,117 so proteomic data further underlines a possible pivotal
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Figure 40 | Differential abundance of effector molecules in cCD8+ T, MAIT and NK cells. Relative protein
abundance of effector molecules in the different cell types was determined by mass spectrometry (3.5.4.1, Tab.
15), and is display schematically. The circle size displays the relative regulation for the respective protein, with
increased and decreased size pointing out increased and decreased abundance, respectively. Circles of the same
size indicate no regulation. NK cells possess an almost complete arsenal of granzymes when compared with the
other cell types, with the exception of GzmK, which is highly upregulated in MAIT cells. MAIT cells also express
GzmA in high amounts, while cCD8+ T cells express the lowest amounts of effector molecules.
role of GzmK in the MAIT phenotype. MAIT cells also express GzmA and GzmM in high and
intermediate amounts, respectively. Interestingly, cCD8+ T cells show the lowest abundance
of all effector proteins when compared with the other cell types, with the exception of GzmH
that is higher expressed than in MAIT cells. abundance of GzmM has never been described in
MAIT cells before, and interestingly also showed an increased expression when compared
with cCD8+ T cells, indicating a more pronounced role of this effector molecule in MAIT cells
than in cCD8+ T cells.
Also based on proteomic data, the effector phenotype of resting MAIT cells is dominated by
GzmA and GzmK (Fig. 40), which have recently emerged as exerting rather pro-inflammatory
than cytotoxic functions.194–196 Strikingly, both proteins have also been shown to specifically
interact with LPS and target intracellular bacteria,197 which is in accordance with the anti-
bacterial functions of MAIT cells. The high abundance of GzmM also discriminates MAIT
from other cytotoxic T cells, and has not been discussed before. Also GzmM is only mildly
cytotoxic, but also shows LPS-dependent proinflammatory potential in mice.221 Interestingly,
abundance of GzmM increases during T cell differentiation from naïve to effector T cells,215
indicating the phenotype of MAIT cells that resembles the one of antigen-experienced CD8+
T cells. GzmH was the only granzyme significantly downregulated in MAIT cells, but its
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pro-apoptocic and anti-viral functions are still under debate. In summary, the granzyme
expression profile of resting MAITs indicate a more pro-inflammatory then cytotoxic phenotype
when compared with conventional cCD8+ T cells, with higher expression of granzymes A, M
and K. Interestingly, all these granzymes have been shown to exert specific, anti-bacterial
functions which are in accordance with the anti-bacterial phenotype of MAIT cells. It also
shows, that MAIT cells can react quicker than conventional T cells, as the already have a
panel of granzymes ready to secrete. However, the dedicated pro-inflammatory function of
these highly abundant proteins can potentially lead to problems if MAIT cells contribute to
auto-immune inflammations, a problem that has been discussed already.237 Their role in
auto-immune diseases like inflammatory bowel disease is not yet clear, and it might be that
their ability to infiltrate the sites of inflammation and their high amounts of pro-inflammatory
cytokines and granzymes might influence the course of the inflammatory response negatively.
This, together with the rather unspecific type of antigen MAITs recognize leads to the question
on how tightly MAIT activity is actually regulated. This has especially be considered in the
gut, where the commensal flora is very much present and can produce MR1 ligands that can
lead to MAIT activation, and potentially lead to excessive reactions and cytokine release. In
contrast to NK cells, however, resting MAITs express less cytotoxic proteins, with decreased
abundance of perforin, granulysin and the highly cytotoxic granzyme B. When triggered,
MAITs cells rapidly start expressing these proteins,80,117 rendering them able to lyse target
cells even more efficiently. So the way to prevent MAIT cell over-activation in the first hours
of infection might be the low abundance of cytotoxic granzyme B in resting cells and the
general low responsiveness to TCR-dependent stimulation.76,80,85 Later, when MAIT cells are
highly cytotoxic, stimuli independent from TCR-signaling and therefore cell-to-cell contacts
become even more important.110 All these factors might hinder MAIT cells from reacting
excessively to stimuli provided to their rather unspecific TCR, and cause damage through
cytotoxic effectors.
4.2.5.3 Increased capacity for exocytosis in typical human MAIT cells
In general, MAIT cells are considered part of the innate, or innate-like immune response.
As innate immune cells are almost the first line of defense against pathogens, they have to
react quickly. In the proteomic data, evidence was found that indeed MAIT cells possess the
capability for a quicker, more pronounced exocytotic response.
A significantly regulated protein was LFA-1. Expression of LFA-1 is increased on effector T
cells, and rises the affinity of T cells for target cells.55 Accordingly, proteomic data revealed
MAIT cells to show mildly increased expression of LFA-1 (log2 RF MAIT:cCD8
+ 0.63, regulated
in three of five donors), which again substantiates the fact that MAIT cells have an effector
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phenotype.
Systematic analysis of significanlty upregulated pathways with MetaCore GeneGo showed
that the most upregulated pathways can be associated with exocytosis and secretion (3.5.4.2,
Fig. 33). Furthermore, closer analysis of the upregulated single proteins (Tab. 16), that are
part of these pathways revealed that all of them are indeed rather promoting exocytosis or
processes associated with immunological synapse formation, like cytoskeletal remodeling.
Most of them are increased similarly in MAIT and NK cells, when being compared with
conventional CD8+ T cells.
Alpha-actinin 4 is a non-muscular isoform of alpha-actinin, like alpha-actinin 1.238 Ac-
cordingly, only these two members of the alpha-actinin family were identified in the MAIT
proteome. The alpha-actinin family is in general associated with linking actin filaments to the
plasma membrane, and cytoskeletal remodeling148,239 which is a vital part in immune cell
polarization and activation. Also, the ability of alpha-actinin 4 to bind actin is dependent on
calcium,240 whose influx upon T cell activation plays a vital part in triggering T cell effector
functions. Interestingly, isoform alpha actinin 1, which has high structural and sequential
homology, has been shown to link LFA-1 to the actin cytoskeleton.241
Annexin IV is a calcium-dependent phospholipid binding protein, that has been suggested to
play a role in synaptic exocytosis as it is located on synaptic membranes and forms a complex
with rabphilin and synaptotagmin 1.149 Also, annexin IV localizes towards the membrane
after calcium influx.242
Unconventional myosin-1f is closely related to actin motor protein myosin 1 and highly
expressed in immune cells. Knowledge about its specific function is very fragmentary. How-
ever, like all myosins, isoform 1f also possesses a motor domain,243 and might therefore be
also implicated in transport towards the immunological synapse like other myosin class I
isoforms.150
Synaptotagmin-like protein 2 (Slp2) has already been shown to interact with Rab27a in
cytotoxic lymphocytes, localizes at the immunological synapse and significantly contributes
to secretory lysosome exocytosis from CTL.151 It has also reported that Slp2 is responsible for
inducing polarity in epithelial cells.244
Secernin-1 is especially interesting, as it is not only upregulated when compared with cCD8+
T cells, like the others, but also when compared with NK cells (Tab. 16). Therefore, it might
be vital for MAIT cell function. Secernin-1 has been shown to promote exocytosis in mast
cells in a calcium-dependent manner,147 and could also realize the same function in MAIT
cells. If it does, then the pronounced abundance of secernin-1 could further substantiate the
fact that exocytosis is positively regulated in MAIT cells. This is further underlined by the
fact that among the top twenty proteins positively regulated between MAIT and cCD8+ cells,
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five are directly associated with exocytotic processes (Tab. 17). Among those are the already
described myosin-1f, secernin-1 and alpha-actinin 4.
But also S100A4, a calcium binding protein, that is highly expressed in cytotoxic CD56dim NK
cells19 is highly abundant in MAIT cells. In NK cells it locates to the immunological synapse19
and has a role in coordinating granule exocytosis in NK cells (M. Heyner, in preparation).
Annexin 1 binds phospholipids in the presence of calcium, and assemblies at the membrane.245
T cells that are deficient of annexin 1 show decreased activation..246 Numerous of these
proteins are also present in the list of proteins whose expression is upregulated in MAIT cells,
when compared to both NK cells and cCD8+ T cells, and are therefore typical for MAIT cells
(Tab. 18).
Taken together, several proteins that are associated with the positive regulation of exocytosis
or immune cell activation show high abundance in MAIT cells, and are typical for the MAIT
cell phenotype. However, due to the heterogeneity of the exact functions of these proteins, the
implications of their upregulation are not obvious. One possibility would be that exocytosis
in MAIT cell is differently regulated and executed than in NK and cCD8+ T cells. When
taking into account that MAIT cells display an innate-like phenotype and are therefore part
of one of the first lines of defense against microorganisms, it is possible that they need to
release their granules quicker and in larger amounts. Increased abundance of proteins like
secernin-1, myosin-1f or Spl2 would enable them to do so, if their unresponsiveness towards
TCR-dependent stimuli is overcome.
4.2.5.4 Controlling the killer: MAIT cells display a unique set of proteins that
regulate proliferation
One of the most interesting questions in MAIT cell research is how their activity is controlled.
MAIT cells react against a broad range of bacteria, of which some are part of the commensal
flora.79,94 How their activity is controlled or regulated is so far unknown. Although MAIT
cells proliferate upon activation, they display an exhausted phenotype in chronic infections,
together with decreased numbers. It is possible that this is one method to prevent over-
activation and autoimmunity. What mechanisms exactly control these processes however, is
so far unknown.
Among the proteins typical for MAIT cells were molecules that are associated with the
regulation of proliferation. It has already been reported that MAIT cells are prone to apoptosis
through elevated levels of caspases-3 and -7,247 which might be a method to regulated their
pro-inflammatory function. Accordingly it was suggested that MAIT cells die in chronic HIV
infection, due to activation induced cell death.129 Proteomic data showed that proteins
L-amino-acid oxidase, galectin-3 and both parts of the CD98 heterodimer are upregulated in
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MAIT cells (Tab. 18).
L-amino-acid oxidase (LAAO) is encoded by the IL-4-induced gene 1 (IL4I1) and has been
shown to be highly expressed in Th17 cells and even higher in CD4+CD161+ T cells.248 There,
it was also reported that its expression decreases IL-2 production and proliferation, and
knock-down of IL4I1-mRNA accordingly increased the proliferative capacity. Additionally, its
expression is controlled by transcription factor RORγt.248 In a different study, it was observed
that high expression of IL4I1 leads to increased abundance of protein Tob1, that directly
inhibits proliferation.249 In MAIT cells, the pronounced abundance of this protein has not
been discussed yet. However, it is logical that the high expression of RORγt in MAIT cells
would also result in high expression of LAAO. Also in MAIT cells, this protein will most likely
inhibit proliferation, and lead to a similar phenotype as in Th17 cells.
Galectin-3 is usually present in the cytoplasm but can be secreted.250 Interestingly, intra-
cellular galectin-3 prevents apoptosis, while extracellular galectin-3 can induce cell death
specifically in T cells.251 Although the concentration needed for apoptosis induction is rela-
tively high, it has been suggested that galectin-3 might increase its apoptotic capacity when
expressed on the cell surface, similar to galectin-1.252 Proteomic studies revealed high abun-
dance of galectin-3 in MAIT cells for the first time. However, the localization could not be
determined. It is possible that galectin-3 is relocated to the surface after certain stimuli or
activation and there induces cell death in either target cells, or even other MAIT cells. The
latter might be another method of a negative feedback mechanism to regulate MAIT cell
activity in vivo. Nevertheless, the functions of galectin-3 are diverse,250 so there also can be
functions that are realized by this protein in MAIT cells.
CD98, or LAT1, is a heterodimer, that forms a transporter for large amino acids, like
tryptophane.185 It has been reported that CD98 plays an important role in activated T cells
by catalyzing the influx of amino acids that serve as nutrients.253 Such high abundance of
CD98 on MAIT cells implicates a state of readiness, that makes instant influx of nutrients
possible, if needed. The possibility to react quickly makes sense for an innate-like cell type,
and goes hand in hand with the observed upregulation of exocytotic pathways. Furthermore,
a recent study has associated defects in the tryptophane metabolism in HIV patients with the
depletion of MAIT cells.254 Authors observed a negative correlation of MAIT cell numbers
and the amount of tryptophane in patient blood. However, they did not state if the loss of
MAIT cells caused the depletion of tryptophane, or vice versa. Proteomic data suggest an
increased need for tryptophane in MAIT cells, especially under the stress of a chronic HIV
infection. This might result in a vicious circle, where activated MAIT cells use up the present
tryptophane quickly, and start do die due to lack of nutrients afterwards.
Overall, MAIT cells showed unique expression of proteins associated with proliferation
104
4.2 Novel mechanisms of innate immunity in MAIT cells
iTCR
iVαh7.2-Jα33
iVαm19-Jα33
CD161
ABCB1 (MDR)
CD26
Vβh2/1322
Vβm6/8
CD98
CD48
Granzyme K
Granzyme A
Granzyme M
Galectin-3?
▲ exocytosis
Figure 41 | Proteomic definition of a typical primary human MAIT cell. In this study, the proteome primary
human MAIT cells was analyzed for the first time. Data revealed a strong upregulation of proteins associated
with exocytosis, like secernin-1. High abundance of Granzymes A, K and M suggests a more pro-inflammatory
than cytotoxic phenotype of resting MAIT cells. The regulation and control of proliferation seems to be controlled
differently as in conventional CD8+ T cells, as proteins like L-amino-acid oxidase (LAAO) or CD98 showed an
increased presence. Also, makers like CD48 were found to be upregulated and can be used to distinguish MAIT
cells from conventional T cells. Galectin-3 has been found to be highly abundant as well, but so far it is not clear
if it is located on the surface or intracellular.
and apoptosis, that differentiate their phenotype even further from conventional CD8+ T
cells. These factors can influence the proliferation of MAIT cells themselves, but also of other
surrounding cells and might therefore be a method to regulate MAIT cell activity and prevent
auto-immune responses. Furthermore, high abundance of transporters for amino acids might
also add to their capability to react quickly upon activation.
In total, this unique proteomic profiles underlines the uniqueness and complexity of MAIT
cells, and further underline that they indeed are fundamentally different from conventional
cCD8+ T cells (Fig. 41). A number of proteins are highly upregulated, that don’t play an
important role in cCD8+ T cells (like Granzyme M) or have never been described in that
context (secernin-1, S100A4).
4.2.6 First insights into the molecular mechanisms of MAIT cytotoxicity
Although MAIT cells are functionally described, molecular mechanisms coordinating their
effector functions are currently unkown. Also, the interface between MAIT cell and target
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cell has never been shown before.
This study presents the first glimpse on the formation of the MAIT immunological synapse
(3.6). After activation of primary human MAIT cells with monocytic cell line THP-1 that were
fed with bacteria, MAIT cells showed typical polarization and localization of granules towards
the interface between MAIT cell and target cell (Fig. 34). This process is typical for T cells
or lymphocytes in general.45,57,58 Additionally, localization of the microtubule-organizing
center towards the IS could be observed (Fig. 36), which is also a common process during IS
formation.45,57,58 These first data suggest formation of a synapse, that is not too different
from the one of conventional CD8+ T cells.
Proteomic data had also revealed increased abundance of calcium-binding protein S100A4
in MAIT cells (Tab. 15). In previous work from our group it could be shown that S100A4 is
not only highly expressed in the cytotoxic CD56dim NK cells subset and localizes at the NK
cell IS,19 but also coordinates the directed release of cytolytic granules in NK cells (Heyner
M., in preparation). Additionally, S100A4 has been suggested to colocalize with microtubuli
in antibody-stimulated primary human T cells (N. Amsberg, personal communication). In
MAIT cells, no direct colocalization of S100A4 and microtubules could be observed (Fig. 35).
Nevertheless, in immunofluorescent pictures, structures formed by microtubuli and S100A4
became apparent, and close associations of the two proteins. As the closely related S100
proteins have been reported to interact with microtubules already,255,256 it is possible that it
is a simple interaction that is observed here, and that could not be detected as colocalization,
possibly due to sterical hindering of the used antibodies. However, these pictures nevertheless
show that highly upregulated S100A4 is a structural component in MAIT cells, and might
have a pivotal role in organizing the cytoskeleton.
Furthermore, in activated MAIT cells, overlap of both S100A4 and microtubules was still
visible (Fig. 36). Interestingly, S100A4 also localized towards the MAIT IS in a time dependent
manner upon MAIT cell stimulation with THP-1 target cells (Fig. 37). After a timespan of
thirty minutes, S100A4 was distributed equally in the cell again. These data suggest a role of
S100A4 in IS formation in MAIT cells. Interestingly, MAIT cells express far more S100A4 than
NK cells, although the amount of cytolytic granulyes, granzymes and perforin is significantly
lower in MAITs (Tab. 15). Therefore, amounts of S100A4 do not correlate with the number
of granules, suggesting an additional role for S100A4 besides possible granule coordination.
In summary, the MAIT cell IS has been shown for the first time, and it displays properties
that are similar to the IS of conventional CD8+ T cells. Although first light has been shed on
the role of S100A4 in synapse formation, and it indeed has been shown to localize to the
MAIT:THP-1 interface, its exact role in MAIT cells remains to be elucidated.
In total, proteomic data allows a first glimpse on the novel mechanisms of innate immunity
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in MAIT cells, and the generation of a hypothetical step-by-step model on how MAIT activity
can be exerted and controlled (Fig. 42). While high abundance of CD98, and the resulting
availability of nutrients can already keep MAITs in a state of readiness, their effector molecule
profile is dominated by granzymes A, K and M. Upon target cell contact, and recognition of
the antigen:MR-1 complex, proteins like secernin-1, Slp2 and S100A4 can promote synapse
formation and quick and massive exocytosis of granules. Also, granules converge to the
interface between MAIT and target cells, where S100A4 accumulates. After delivery of the
cytolytic granules into the target cell, and its subsequent cell death, MAIT activity has to be
controlled. MAITs are sensitive to stimulation by cytokines, so especially in a pro-inflammatory
environment, overactivity needs to be prevented. Factors like galectin-3 that, upon secretion,
induces apoptosis in T cells, or LAAO, which prevents T cell proliferation, can be factors to
keep MAIT cells from damaging healthy cells.
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Figure 42 | A first view on MAIT cell IS formation and proliferation control. Although knowledge is still
fragmentary, proteomic data from this study allows glimpses on novel mechanisms in MAIT cells, and the
generation of a preliminary step-by-step model of MAIT activation. (A) Resting MAIT cells already express high
amounts of CD98, that allow high nutrient intake and can keep them in a state allowing quick reaction to stimuli.
Also, MAIT cells primarily express granzymes A, K and M. (B) Upon recognition of the target cell, MAIT cells
release the granzymes, and additionally cytokines like IFN-γ and IL-17. A pronounced exocytotic response upon
stimulation can be supported by the presence of promoting factors like S100A4, secernin-1 and Spl2. Also, the
MTOC and the cytolytic granules converge to the target cell. At the interface, S100A4 accumulation can be
observed. (C) After the killing of the target cell, MAIT proliferation and activity has to be tightly to controlled to
prevent overactivation, especially in a pro-inflammatory environment. Galectin-3 can be a factor that, if secreted,
kills active MAIT cells and therefore prevent damage of healthy tissue. This would also explain low numbers of
MAIT cells in chronic infections.
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5.1 Coordination of NK effector function by kinases Fyn,
CaMKII and PKD
In the first part of the present work, NK cell effector functions were inhibited by chemical
perturbation of kinases SFK, CaMKII and PKD2, that had been suggested in a previous
study as NK cell signaling components.43 By stimulating primary human NK cells with K562
target cells in PBMC cultures after inhibitor treatment, it could be demonstrated that NK
cell degranulation and release of cytokines TNF-α and IFN-γ was indeed reduced (3.1.1,
Fig. 13).135 Already low amounts of SFK-inhibitor Dasatinib significantly reduced surface
expression of CD107a and cytokine secretion. The effect of CaMKII inhibitor CK59 was
less pronounced, but also reproducibly decreased effector functions was seen, although the
observed effect was more dose-dependent and gradual. Inhibition with CID755673, that
is directed against PKD kinases, had the strongest effect on TNF-α-release, but also dose-
dependently decreased the number of CD107a+ and IFN-γ+ cells. The inhibitor experiments
were repeated in cultures of purified NK cells, to reveal effects from other cell types (3.1.2,
Fig. 14). In general, results generated in pure NK cells were in accordance with data
received in PBMC cultures. For all inhibitors, a dose-dependent decrease of NK cell effector
functions was observed. However, it also became apparent that donor variation can have
an substantial impact on the results obtained from primary cells, as some donors showed
remarkably different reactions on the inhibitor treatment. Taken together, all results further
implicate pivotal roles for SFK kinases, CaMKII and PKD kinases in NK cells activation.
However, further investigation of the role of these kinases in NK cell function is of great
interest, as the understanding of NK cell signaling is far from complete. Other methods, like
RNA interference or CRISPR/Cas-mediated gene editing, might yield useful complementary
data on NK cell activity. These methods could be used to specifically silence or delete genes of
the investigated kinases, and therefore rule out any side-effects by the highly specific inhibitors.
Another possibility to shed further light on the role of the described kinases SFK/Fyn, CaMKII
and PKD is the overexpression of mutants. For example, point mutation variants that can
not be phosphorylated at the described sites, or mutants that are constitutively active by
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mutations that mimic constant phosphoryalation. However, the application of methods that
directly manipulate genetic material in primary cells, has proven to be difficult. It is of course
possible to conduct experiments like this with NK cell lines like NK92, but the situation in
immortalized cell lines doesn’t always reflect the situation in primary cell material or even in
vivo.
For a possible clinical application against leukemia or autoimmune-diseases, as discussed
in 4.1.3, the effect of the used kinase inhibitors could be investigated in animal models for
NK-LGL.257 Also, the NK cell line NKL is derived from NK-LGL258 and its reaction to treatment
with inhibitors could also yield primary results for a possible use of the chemicals in therapy.
5.2 Proteomic analysis reveals novel mechanisms of innate
immunity in MAIT cells
In the second part, mass spectrometry was used to comparatively analyze the proteome
of primary human MAIT, NK and conventional, non-MAIT CD8+ (cCD8+) T cells and the
proteome for primary human MAIT cells was defined for the very first time. Also, proteomic
workflows were establish to successfully handle low amounts of cells that can be expected
when isolating cell subsets from human buffy coats (3.4). In total, over 5500 proteins could
be identified from five different healthy human donors, with 2600 being commonly identified
in all experiments (3.5.2, Fig. 27). For these 5500 proteins, regulation factors could be
calculated. The proteins that were identified in all donors that showed similar distribution,
although also donor variation became apparent (3.5.3.1, Fig. 30 and 31), that might be a
result of infection (4.2.3). Different numbers where found to be robustly regulated between
the analyzed cell subsets (3.5.3.2, Tab. 12). From these data, it is possible to state that
surprisingly on the level of proteins, MAIT cells are not as closely related to cCD8+ T cells
as to NK cells (4.2.3). This suggests a phenotype for MAIT cells that is also dominated by
proteins that are important for prototypic innate effectors like NK cells. Also, data confirmed
a unique set of effector molecules for MAIT cells, with pronounced abundance of granzymes
(Gzm) A and K, as well as GzmM (3.5.4.1, Tab. 15). This suggests that resting MAITs
are rather pro-inflammatory than cytotoxic and this set of effector molecules can provide
a regulatory mechanism to prevent cytotoxicity against unspecific targets (4.2.5.2). Also,
systematic analyses of regulated proteins revealed pronounced abundance of proteins that
regulate or promote exocytosis (3.5.4.2), and could indicate that MAIT cells themselves
possess pronounced mechanisms of exocytosis, enabling them to react more quickly and
fiercely upon activation (4.2.5.3). Another mechanism of regulating MAIT activity is most
likely their proneness to apoptosis. Systematic analysis showed high abundance of proteins
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that are associated with regulation of proliferation (4.2.5.4). These factors might also play a
part in restricting MAIT cell responses, even kill adjacent immune cells or enable them to act
quickly upon stimulation (4.2.5.4).
Taken together, these data add vital knowledge to further understand the fascinating cell
subset of MAIT cells. They show distinct features from conventional cCD8+ T cells and that
core mechanisms like exocytosis and proliferation are differently regulated. However, our
knowledge about the activation, function and phenotype of MAIT cells is far from complete.
However, this thesis has laid important foundations for proteomic analysis of small immune
cell numbers, and established reproducible experimental set-ups. Now, on the basis of the
established protocols, it would be easy to further refine data acquisition. Recently, and during
the course of this thesis, technologies with enhanced sample preparation methods were
developed, to further increase the sensitivity of proteomics.142 This might even allow access
to low abundant transcription factors that are vital for the MAIT cell phenotype (RORγt,
PLZF), interleukins (IL-17, IL-2) or other cytokines (TNF-α, IFN-γ) that could not be identified
or quantified in the conservative but robust approach of this study.
The situation is similar regarding the quantification method. For this study, the well-
defined and robust quantification method iTRAQ was chosen, to establish a completely new
protocol. Also here, a most recently developed technique has been suggested to increase
the dynamic range of quantification.259 This could help to further differentiate the already
defined regulation factors, or identify regulations that were rejected in this study.
It will also be of great interest to examine the novel players and mechanisms in more
detail. Do MAIT cells exocytose faster than conventional cells once they are activated? Does
secernin-1 really promote exocytosis? What is the exact function of proteins like galectin-3
that are highly upregulated and can potentially induce death in other T cells? However,
as in NK cells, genetic manipulation of primary human MAIT cells is not possible. Also,
cell lines exists that express the MAIT cell TCR,105 and so do mouse models with increased
numbers of MAITs.76,113,260 Both would potentially allow to generate knock-out mutants
of these proteins, but if the effect would be comparable to primary human cells is obscure.
Nevertheless, experiments to analyze if e. g. MAIT cells really express galectin-3 on the
surface upon activation, or if secernin-1 or Spl2 do co-localize with the synapse or granules,
can be done in human material by flow cytometry or fluorescence microscopy.
This thesis and former studies have proven that proteomics are a valuable tool to charac-
terize primary human immune cells. It is therefore also a possibility to analyze the difference
of MAIT cells to even closer related cell types, like NKT cells, or both CD8+CD161+ and
CD8+CD161- cells. Furthermore, it might be worth considering to additionally analyze subsets
of MAIT cells themselves, like the DN and CD8+ MAITs, or the ones differentiated by different
111
5 Summary and outlook
combination of CD8 chains.95
Also, following experiments that will be conducted will deal with the exhaustion and
depletion of MAIT cells in chronic infections.77,128,129 The reason why MAIT cells are
depleted in the blood of chronic HIV patients is still under debate, and proteomic comparison
of the still present cells and the cells from healthy donors will give insights into the reasons
for this depletion (cooperation with J. Sandberg, Karolinska Stockholm and M. Eller, MHRP
Bethesda). These data will be complemented by data from chronic HCV patients (coop. H.
Wedemeyer, MHH Hannover). This thesis has laid a solid basis to understand the changes
that can become apparent when comparing exhausted and resting MAIT cells.
Another field of research that is highly interesting is MAIT behavior in Clostridium difficile
infection (CDI). Clostridium difficile is a new emerging pathogen with increasing relevance,
especially in nocosomial infections. Although the pathogen is prevalent in the gut, surprisingly
the interactions between MAIT cells and C. difficile have not been investigated until now. To
investigate this connection, it was planned to investigate the C. difficile-specific activation of
primary human MAIT cells. Although this activation is possible as C. difficile is present in the
gut and possesses the ability to produce riboflavin,261 it has just been suggested70 but never
shown. Also, it will be analyzed which MR1-binding metabolites are produced by Clostridium
difficile. Even if the bacteria surprisingly do not induce activation in MAIT cells, it might be
possible that they produce inhibiting ligands. Furthermore, and complementary to the data
of exhausted MAIT cells in viral infections, it is planned to characterize the phenotype of
MAITs and other innate cells in C. difficile-infected patients. With the help of transgenic mice,
that only express the MAIT-TCR it will also be possible to investigate the impact of MAIT cells
on C. difficile infection in vivo.
5.3 First-time characterization of the MAIT cell immunological
synapse
In this thesis, the first observation of the MAIT immunological synapse (IS) was presented.
For this, an assay was developed to visualize the interaction between MAIT cell and target cell.
This experimental setup led to direct observation of cytotoxic activity, and the identification
of novel components of the MAIT IS. Indeed, granules containing perforin localize to the IS
(3.6.1, Fig. 34), while the cell polarizes and the MTOC relocates (Fig. 36). Upon activation,
calcium-dependent protein S100A4 partly associates with the microtubule skeleton. Also,
time-dependent accumulation of S1000A4 could be observed at the MAIT IS (3.6.3, Fig. 37).
However, the knowledge about MAIT cell IS formation is still scarce. It might of interest to
analyze if the formation is differently regulated or executed, when compared to conventional
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T cells - kinetically or mechanistically. The method established in this work to analyze the
MAIT IS with fluorescence microscopy will allow the analysis of different factors like secernin-
1 or Spl2, and if they are recruited to the synapse. Also, the colocalization status of S100A4
and microtubules could be investigated further, and if S100A4 localizes at microtubules and
under which circumstances.
Additionally, it is of interest to investigate why S100A4 is so prominently expressed in MAIT
cells. It is also highly expressed in extremely cytotoxic CD56dim NK cells19 and is suggested
to coordinate granule release. So, further colocalization experiments of S100A4 and markers
for granules like CD107a might increase our knowledge about the function of this protein.
This would also be true for genetically manipulated cells, but as stated in the chapter before,
this is not a trivial experiment and might even be hard to accomplish in primary cells.
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UniProt Accession Description Unique Peptides Unique spectra MAIT:NK MAIT/CD8 NK/CD8 MAIT:NK MAIT:cCD8 NK:cCD8
O14874 [3-methyl-2-oxobutanoate dehydrogenase] kinase, mitochondrial 1 1 NA NA NA
P54922 [Protein ADP-ribosylarginine] hydrolase 1 1 NA NA NA
Q15118 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1 3 8 0.18 -0.63 -0.61
Q15120 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3 6 22 0.63 0.56 -0.33 5 5
Q9P0J1 [Pyruvate dehydrogenase]-phosphatase 1, mitochondrial 7 13 0.05 0.08 0.00
Q04446 1,4-alpha-glucan-branching enzyme 7 27 0.02 0.03 0.02
P61604 10 kDa heat shock protein, mitochondrial 13 236 0.27 -0.33 -0.52
Q15029 116 kDa U5 small nuclear ribonucleoprotein component 31 194 0.01 -0.10 -0.04
Q9NRX4 14 kDa phosphohistidine phosphatase 2 18 -0.57 -0.18 -0.02
P31946 14-3-3 protein beta/alpha 9 411 -0.12 -0.17 -0.26
P62258 14-3-3 protein epsilon 12 251 -0.11 -0.10 -0.03
Q04917 14-3-3 protein eta 9 261 0.43 0.64 0.17 4
P61981 14-3-3 protein gamma 7 319 0.38 0.10 -0.18
P31947 14-3-3 protein sigma 1 180 5.01 3.30 -1.70
P27348 14-3-3 protein theta 13 369 0.39 0.59 0.19 4
P63104 14-3-3 protein zeta/delta 17 736 -0.14 0.10 0.06
O60613 15 kDa selenoprotein 4 9 -0.14 0.16 0.23
Q9C0C2 182 kDa tankyrase-1-binding protein 1 3 0.30 -0.23 -0.53
Q99943 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha 2 3 -0.26 -0.35 -0.09
Q9NUQ2 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon 4 14 0.45 0.08 -0.28
Q9NRZ7 1-acyl-sn-glycerol-3-phosphate acyltransferase gamma 1 1 -0.23 -0.20 0.04
Q9Y2I7 1-phosphatidylinositol 3-phosphate 5-kinase 1 7 NA NA NA
Q00722 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 7 24 -0.30 0.03 0.40
Q01970 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 1 3 0.26 0.61 0.36
P51178 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 1 1 0.16 0.13 -0.03
Q4KWH8 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1 1 13 0.12 0.37 0.23
P19174 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 11 22 0.84 0.22 -0.55 3 4
P16885 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 9 32 -2.00 0.13 1.99 4 4
P09543 2',3'-cyclic-nucleotide 3'-phosphodiesterase 6 24 -0.18 0.15 0.32
Q16698 2,4-dienoyl-CoA reductase, mitochondrial 17 169 0.08 0.15 0.04
Q6L8Q7 2',5'-phosphodiesterase 12 8 34 0.10 -0.11 -0.29
Q05823 2-5A-dependent ribonuclease 3 4 -0.12 -0.08 0.29
P00973 2'-5'-oligoadenylate synthase 1 1 1 -0.18 0.20 0.38
P29728 2'-5'-oligoadenylate synthase 2 6 20 -0.01 0.14 0.12
Q9Y6K5 2'-5'-oligoadenylate synthase 3 5 17 0.30 0.16 -0.14
Q15646 2'-5'-oligoadenylate synthase-like protein 4 8 -0.23 0.32 0.49
P62333 26S protease regulatory subunit 10B 16 86 0.15 0.03 -0.10
P62191 26S protease regulatory subunit 4 18 119 0.10 -0.09 -0.15
P17980 26S protease regulatory subunit 6A 24 144 0.02 -0.11 -0.14
P43686 26S protease regulatory subunit 6B 11 46 0.18 0.03 -0.08
P35998 26S protease regulatory subunit 7 22 132 0.08 -0.04 -0.19
P62195 26S protease regulatory subunit 8 12 100 0.04 -0.02 -0.06
Q99460 26S proteasome non-ATPase regulatory subunit 1 17 70 0.06 0.06 0.01
O75832 26S proteasome non-ATPase regulatory subunit 10 8 53 0.25 0.05 -0.16
O00231 26S proteasome non-ATPase regulatory subunit 11 13 72 0.10 -0.03 -0.18
O00232 26S proteasome non-ATPase regulatory subunit 12 10 49 0.11 -0.07 -0.24
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13 7 27 0.12 0.07 -0.09
O00487 26S proteasome non-ATPase regulatory subunit 14 5 35 0.19 -0.02 -0.19
Q13200 26S proteasome non-ATPase regulatory subunit 2 19 65 0.22 0.07 -0.14
O43242 26S proteasome non-ATPase regulatory subunit 3 13 41 0.16 0.18 -0.11
P55036 26S proteasome non-ATPase regulatory subunit 4 11 75 0.06 -0.04 -0.03
Q16401 26S proteasome non-ATPase regulatory subunit 5 9 48 0.10 -0.04 -0.16
Q15008 26S proteasome non-ATPase regulatory subunit 6 8 44 0.12 0.09 -0.03
P51665 26S proteasome non-ATPase regulatory subunit 7 6 26 0.28 -0.10 -0.13
P48556 26S proteasome non-ATPase regulatory subunit 8 3 4 0.26 0.05 -0.26
O00233 26S proteasome non-ATPase regulatory subunit 9 8 53 -0.05 0.00 0.15
Q13442 28 kDa heat- and acid-stable phosphoprotein 11 68 0.01 0.08 0.08
P82912 28S ribosomal protein S11, mitochondrial 1 1 0.33 0.20 -0.13
O15235 28S ribosomal protein S12, mitochondrial 1 1 0.00 0.18 0.18
O60783 28S ribosomal protein S14, mitochondrial 1 3 -0.04 -0.40 -0.37
P82914 28S ribosomal protein S15, mitochondrial 2 22 0.63 -0.03 -0.23 3
Q9Y3D3 28S ribosomal protein S16, mitochondrial 1 3 -0.30 0.16 0.40
Q9Y2R5 28S ribosomal protein S17, mitochondrial 2 14 0.25 0.12 -0.48
Q9NVS2 28S ribosomal protein S18a, mitochondrial 3 5 0.18 -0.08 -0.13
Q9Y676 28S ribosomal protein S18b, mitochondrial 1 1 -0.10 -0.08 0.02
P82921 28S ribosomal protein S21, mitochondrial 3 9 -0.17 -0.13 0.11
P82650 28S ribosomal protein S22, mitochondrial 3 11 0.12 -0.08 -0.21
Q9Y3D9 28S ribosomal protein S23, mitochondrial 5 8 -0.01 0.03 0.04
P82663 28S ribosomal protein S25, mitochondrial 1 4 0.27 0.07 -0.06
Q9BYN8 28S ribosomal protein S26, mitochondrial 2 3 NA NA NA
Q92552 28S ribosomal protein S27, mitochondrial 5 6 0.36 0.09 -0.27
Q9Y2Q9 28S ribosomal protein S28, mitochondrial 2 2 -0.12 -0.11 0.02
P51398 28S ribosomal protein S29, mitochondrial 3 11 0.03 0.02 0.00
Q9NP92 28S ribosomal protein S30, mitochondrial 1 1 0.16 -0.22 -0.39
Q92665 28S ribosomal protein S31, mitochondrial 6 18 0.11 -0.02 -0.07
Q9Y291 28S ribosomal protein S33, mitochondrial 1 5 -0.23 -0.09 0.08
P82930 28S ribosomal protein S34, mitochondrial 3 6 0.10 -0.59 -0.70
P82673 28S ribosomal protein S35, mitochondrial 2 4 0.27 0.16 -0.20
P82909 28S ribosomal protein S36, mitochondrial 7 37 0.00 -0.03 -0.04
P82675 28S ribosomal protein S5, mitochondrial 2 10 0.06 -0.18 -0.11
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Q9Y2R9 28S ribosomal protein S7, mitochondrial 3 3 -0.01 0.02 0.02
P82933 28S ribosomal protein S9, mitochondrial 4 7 -0.02 0.07 0.05
Q96SZ5 2-aminoethanethiol dioxygenase 5 12 -0.30 0.02 0.20
O43598 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 4 13 0.43 -0.52 -0.94 3
Q02218 2-oxoglutarate dehydrogenase, mitochondrial 25 160 0.58 0.35 -0.14 5
P12694 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial 7 30 0.25 0.10 -0.19
O95861 3'(2'),5'-bisphosphate nucleotidase 1 14 51 0.11 -0.01 -0.06
Q8IV48 3'-5' exoribonuclease 1 1 1 0.13 0.06 -0.07
Q9BYD6 39S ribosomal protein L1, mitochondrial 5 7 0.39 -0.06 -0.40
Q9Y3B7 39S ribosomal protein L11, mitochondrial 8 29 0.09 -0.06 -0.19
P52815 39S ribosomal protein L12, mitochondrial 9 49 0.11 0.00 -0.12
Q9BYD1 39S ribosomal protein L13, mitochondrial 2 4 -0.21 -0.52 -0.32
Q6P1L8 39S ribosomal protein L14, mitochondrial 4 10 0.06 -0.01 -0.01
Q9P015 39S ribosomal protein L15, mitochondrial 1 1 0.33 -0.23 -0.55
Q9NX20 39S ribosomal protein L16, mitochondrial 3 7 0.06 -0.37 -0.54
Q9NRX2 39S ribosomal protein L17, mitochondrial 2 5 0.00 -0.38 -0.37
Q9H0U6 39S ribosomal protein L18, mitochondrial 1 2 0.41 0.06 -0.36
P49406 39S ribosomal protein L19, mitochondrial 3 5 0.25 0.02 -0.13
Q5T653 39S ribosomal protein L2, mitochondrial 3 9 -0.20 0.17 0.31
Q7Z2W9 39S ribosomal protein L21, mitochondrial 1 1 NA NA NA
Q9NWU5 39S ribosomal protein L22, mitochondrial 3 12 0.17 0.13 -0.03
Q16540 39S ribosomal protein L23, mitochondrial 2 8 0.16 0.12 -0.05
Q96A35 39S ribosomal protein L24, mitochondrial 1 3 0.24 0.02 -0.26
Q9P0M9 39S ribosomal protein L27, mitochondrial 3 10 0.27 0.09 -0.18
P09001 39S ribosomal protein L3, mitochondrial 1 1 0.50 0.22 -0.28
Q8TCC3 39S ribosomal protein L30, mitochondrial 1 3 0.14 -0.10 -0.24
O75394 39S ribosomal protein L33, mitochondrial 1 5 -0.72 -0.19 0.54
Q9BQ48 39S ribosomal protein L34, mitochondrial 1 1 -0.07 -0.36 -0.30
Q9BZE1 39S ribosomal protein L37, mitochondrial 4 8 0.38 0.03 -0.39
Q96DV4 39S ribosomal protein L38, mitochondrial 5 8 0.03 -0.22 -0.17
Q9NYK5 39S ribosomal protein L39, mitochondrial 3 8 0.21 -0.05 -0.21
Q9BYD3 39S ribosomal protein L4, mitochondrial 3 11 0.08 0.06 -0.07
Q9NQ50 39S ribosomal protein L40, mitochondrial 3 9 -0.04 -0.21 -0.24
Q8IXM3 39S ribosomal protein L41, mitochondrial 1 3 0.56 0.11 -0.45
Q9Y6G3 39S ribosomal protein L42, mitochondrial 2 2 -0.38 0.32 0.71
Q8N983 39S ribosomal protein L43, mitochondrial 3 9 0.36 0.12 -0.11
Q9H9J2 39S ribosomal protein L44, mitochondrial 3 9 0.30 0.09 -0.30
Q9BRJ2 39S ribosomal protein L45, mitochondrial 3 7 -0.35 -0.63 -0.27
Q9H2W6 39S ribosomal protein L46, mitochondrial 3 10 0.08 -0.04 -0.13
Q9HD33 39S ribosomal protein L47, mitochondrial 1 4 NA NA NA
Q96GC5 39S ribosomal protein L48, mitochondrial 2 7 0.16 -0.10 -0.32
Q13405 39S ribosomal protein L49, mitochondrial 4 14 0.45 0.09 -0.31
Q8N5N7 39S ribosomal protein L50, mitochondrial 2 7 0.37 -0.06 -0.43
Q96EL3 39S ribosomal protein L53, mitochondrial 2 4 -0.02 -0.18 -0.16
Q6P161 39S ribosomal protein L54, mitochondrial 1 1 -1.80 -0.90 0.92
Q7Z7F7 39S ribosomal protein L55, mitochondrial 2 7 0.16 0.02 -0.20
Q9BYD2 39S ribosomal protein L9, mitochondrial 4 7 0.20 -0.15 -0.12
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 15 297 0.12 0.01 -0.11
Q9BUT1 3-hydroxybutyrate dehydrogenase type 2 5 32 0.16 -0.31 -0.44
P31937 3-hydroxyisobutyrate dehydrogenase, mitochondrial 8 72 0.27 -0.08 -0.42
Q6NVY1 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial 6 25 0.10 0.10 0.01
P42765 3-ketoacyl-CoA thiolase, mitochondrial 28 307 0.25 0.81 0.53 5 4
P09110 3-ketoacyl-CoA thiolase, peroxisomal 6 10 -0.19 -0.12 -0.01
Q06136 3-ketodihydrosphingosine reductase 1 4 0.97 0.62 -0.34
P25325 3-mercaptopyruvate sulfurtransferase 6 20 -0.55 0.31 0.71 4 5
Q9NWU1 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial 4 16 0.11 0.00 -0.38
O15530 3-phosphoinositide-dependent protein kinase 1 5 17 -0.04 -0.03 0.17
P46783 40S ribosomal protein S10 8 130 0.37 0.02 -0.37
P62280 40S ribosomal protein S11 18 166 0.44 0.05 -0.47 5
P25398 40S ribosomal protein S12 11 86 0.40 -0.02 -0.48
P62277 40S ribosomal protein S13 13 98 0.45 -0.07 -0.47 5
P62263 40S ribosomal protein S14 8 183 0.18 -0.01 -0.22
P62841 40S ribosomal protein S15 3 7 0.53 0.00 -0.59
P62244 40S ribosomal protein S15a 12 95 0.28 0.05 -0.36
P62249 40S ribosomal protein S16 12 287 0.40 -0.05 -0.58 5
P0CW22 40S ribosomal protein S17-like 9 125 0.27 0.01 -0.27
P62269 40S ribosomal protein S18 12 199 0.48 0.04 -0.41
P39019 40S ribosomal protein S19 15 277 0.29 -0.09 -0.58
P15880 40S ribosomal protein S2 20 207 0.54 -0.09 -0.55 5
P60866 40S ribosomal protein S20 6 55 0.30 -0.04 -0.42
P63220 40S ribosomal protein S21 8 126 0.16 -0.11 -0.24
P62266 40S ribosomal protein S23 7 118 0.48 -0.08 -0.50
P62847 40S ribosomal protein S24 6 80 0.19 -0.12 -0.20
P62851 40S ribosomal protein S25 9 90 0.29 -0.18 -0.44
P62854 40S ribosomal protein S26 2 51 0.71 0.07 -0.49 4
P42677 40S ribosomal protein S27 1 54 0.41 0.13 -0.15
Q71UM5 40S ribosomal protein S27-like 1 52 0.01 -0.28 -0.28
P62857 40S ribosomal protein S28 5 161 0.63 0.02 -0.33 3
P62273 40S ribosomal protein S29 2 3 -0.04 -0.85 -0.82
P23396 40S ribosomal protein S3 22 261 0.72 0.05 -0.52 3 5
P62861 40S ribosomal protein S30 2 58 0.14 -0.07 -0.20
P61247 40S ribosomal protein S3a 24 312 0.57 -0.03 -0.57 5 5
P62701 40S ribosomal protein S4, X isoform 14 228 0.41 -0.09 -0.48
P22090 40S ribosomal protein S4, Y isoform 1 5 34 -0.24 -0.42 -0.19
P46782 40S ribosomal protein S5 12 77 0.61 -0.14 -0.60 5
P62753 40S ribosomal protein S6 13 114 0.53 0.01 -0.44 4
P62081 40S ribosomal protein S7 11 129 0.45 -0.05 -0.44 5
P62241 40S ribosomal protein S8 11 141 0.30 0.12 -0.45
P46781 40S ribosomal protein S9 13 105 0.65 0.12 -0.44 3
P08865 40S ribosomal protein SA 12 183 0.42 0.10 -0.47
P80404 4-aminobutyrate aminotransferase, mitochondrial 4 6 0.34 0.71 0.37
P08195 4F2 cell-surface antigen heavy chain 9 47 1.06 1.14 -0.03 5 5
P49189 4-trimethylaminobutyraldehyde dehydrogenase 20 167 0.38 -0.10 -0.40 5
Q8TCD5 5'(3')-deoxyribonucleotidase, cytosolic type 1 1 0.65 0.26 -0.38
O43422 52 kDa repressor of the inhibitor of the protein kinase 1 1 1.29 0.75 -0.53
Q8IZH2 5'-3' exoribonuclease 1 8 13 -0.14 -0.14 0.15
Q9H0D6 5'-3' exoribonuclease 2 18 83 -0.01 -0.18 -0.11
Q00013 55 kDa erythrocyte membrane protein 2 2 -0.03 -0.34 -0.32
Q13131 5'-AMP-activated protein kinase catalytic subunit alpha-1 4 17 -0.06 0.20 0.29
P54619 5'-AMP-activated protein kinase subunit gamma-1 4 11 0.05 0.34 0.30
P49914 5-formyltetrahydrofolate cyclo-ligase 2 5 -0.05 -0.61 -0.37
Q96CB9 5-methylcytosine rRNA methyltransferase NSUN4 1 1 NA NA NA
P21589 5'-nucleotidase 5 13 0.58 -0.36 -0.88 4 5
Q5TFE4 5'-nucleotidase domain-containing protein 1 6 18 0.41 0.05 -0.43
Q8IUZ5 5-phosphohydroxy-L-lysine phospho-lyase 4 6 0.20 -0.16 -0.37
P10809 60 kDa heat shock protein, mitochondrial 45 909 0.27 -0.19 -0.56 5
P10155 60 kDa SS-A/Ro ribonucleoprotein 11 36 -0.02 0.28 0.25
P05388 60S acidic ribosomal protein P0 15 199 0.58 0.01 -0.58 5 5
P05386 60S acidic ribosomal protein P1 2 55 0.50 -0.18 -0.50
P05387 60S acidic ribosomal protein P2 6 114 0.49 0.14 -0.15
Q96D46 60S ribosomal export protein NMD3 1 8 0.21 0.05 -0.34
P27635 60S ribosomal protein L10 10 152 0.52 0.12 -0.39
P62906 60S ribosomal protein L10a 11 177 0.52 -0.02 -0.56 5 5
P62913 60S ribosomal protein L11 7 113 0.46 0.07 -0.48 5
P30050 60S ribosomal protein L12 11 167 0.37 -0.02 -0.46 5
P26373 60S ribosomal protein L13 17 185 0.31 0.00 -0.33
P40429 60S ribosomal protein L13a 12 113 0.44 -0.07 -0.42 5
P50914 60S ribosomal protein L14 11 141 0.45 0.03 -0.54 5
P61313 60S ribosomal protein L15 6 47 0.70 0.10 -0.66 5 5
P18621 60S ribosomal protein L17 9 136 0.49 -0.07 -0.47
Q07020 60S ribosomal protein L18 9 100 0.64 0.08 -0.56 5 5
Q02543 60S ribosomal protein L18a 11 106 0.51 0.21 -0.38
P84098 60S ribosomal protein L19 7 80 0.59 0.11 -0.45 4
P46778 60S ribosomal protein L21 3 58 0.20 -0.01 -0.12
P35268 60S ribosomal protein L22 7 77 0.54 0.09 -0.47 4
P62829 60S ribosomal protein L23 10 191 0.26 -0.03 -0.32
P62750 60S ribosomal protein L23a 11 138 0.60 0.06 -0.45
P83731 60S ribosomal protein L24 11 169 0.24 -0.16 -0.38
P61254 60S ribosomal protein L26 7 85 0.24 -0.13 -0.33
P61353 60S ribosomal protein L27 8 89 0.44 0.07 -0.37
P46776 60S ribosomal protein L27a 9 130 0.61 0.05 -0.53
P46779 60S ribosomal protein L28 9 111 0.31 -0.21 -0.43 5
P47914 60S ribosomal protein L29 5 44 0.29 -0.22 -0.57
P39023 60S ribosomal protein L3 31 226 0.44 0.20 -0.48 5
P62888 60S ribosomal protein L30 10 155 0.48 -0.03 -0.52
P62899 60S ribosomal protein L31 6 59 0.35 -0.01 -0.41
P62910 60S ribosomal protein L32 6 90 0.35 0.02 -0.36
P49207 60S ribosomal protein L34 9 124 0.48 0.04 -0.56 5
P42766 60S ribosomal protein L35 5 53 0.17 -0.07 -0.45
P18077 60S ribosomal protein L35a 5 18 0.36 0.22 -0.51
Q9Y3U8 60S ribosomal protein L36 6 81 0.58 -0.03 -0.46
P83881 60S ribosomal protein L36a 2 18 0.36 -0.74 -0.97 3 3
Q969Q0 60S ribosomal protein L36a-like 2 15 0.91 0.49 -0.42
P61927 60S ribosomal protein L37 2 4 0.18 -0.19 -0.40
P61513 60S ribosomal protein L37a 6 43 0.38 0.06 -0.21
P63173 60S ribosomal protein L38 5 146 0.15 -0.02 -0.21
P36578 60S ribosomal protein L4 26 356 0.51 0.01 -0.49 5 5
P46777 60S ribosomal protein L5 21 181 0.42 -0.07 -0.52 5
Q02878 60S ribosomal protein L6 16 163 0.64 -0.07 -0.52 4 5
P18124 60S ribosomal protein L7 15 99 0.58 0.17 -0.46 5 5
P62424 60S ribosomal protein L7a 17 284 0.47 -0.05 -0.43 5 5
Q6DKI1 60S ribosomal protein L7-like 1 5 16 0.34 -0.04 -0.27
P62917 60S ribosomal protein L8 10 140 0.30 -0.12 -0.44
P32969 60S ribosomal protein L9 9 69 0.47 -0.01 -0.26
Q9Y221 60S ribosome subunit biogenesis protein NIP7 homolog 3 3 -0.11 -0.32 -0.22
Q16875 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 5 12 0.23 0.92 0.40 3
Q01813 6-phosphofructokinase type C 17 70 0.14 -0.03 -0.13
P17858 6-phosphofructokinase, liver type 13 67 -0.01 -0.01 -0.08
P08237 6-phosphofructokinase, muscle type 2 6 0.12 -0.41 -0.52
P52209 6-phosphogluconate dehydrogenase, decarboxylating 13 103 0.04 -0.23 -0.21
O95336 6-phosphogluconolactonase 12 161 -0.37 -0.06 0.30
P36639 7,8-dihydro-8-oxoguanine triphosphatase 1 2 -0.28 -0.19 0.08
P11021 78 kDa glucose-regulated protein 43 755 -0.10 0.34 0.36
Q7L2J0 7SK snRNA methylphosphate capping enzyme 6 27 -0.31 -0.45 -0.07
Q6ZVK8 8-oxo-dGDP phosphatase NUDT18 1 4 NA NA NA
Q9P2A4 ABI gene family member 3 8 37 -0.42 0.35 0.80 5 5
Q8IZP0 Abl interactor 1 4 19 0.47 0.30 -0.17 5
Q9Y4K1 Absent in melanoma 1 protein 14 24 0.63 0.12 -0.40 4
A1L0T0 Acetolactate synthase-like protein 4 5 -0.10 -0.20 -0.02
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic 11 16 -0.06 -0.27 -0.37
P24752 Acetyl-CoA acetyltransferase, mitochondrial 21 114 0.78 0.12 -0.47 4
Q13085 Acetyl-CoA carboxylase 1 1 1 -0.35 0.21 0.57
Q9NUB1 Acetyl-coenzyme A synthetase 2-like, mitochondrial 7 18 -0.16 0.24 0.26
Q13510 Acid ceramidase 6 31 -0.46 0.41 0.83 4
Q32M88 Acid trehalase-like protein 1 6 24 -0.24 -0.07 0.28
O43427 Acidic fibroblast growth factor intracellular-binding protein 1 1 0.03 0.17 0.12
P39687 Acidic leucine-rich nuclear phosphoprotein 32 family member A 8 147 -0.02 -0.25 -0.16
Q92688 Acidic leucine-rich nuclear phosphoprotein 32 family member B 6 74 0.24 -0.29 -0.61 4
Q9BTT0 Acidic leucine-rich nuclear phosphoprotein 32 family member E 9 84 0.39 0.17 -0.14
Q99798 Aconitate hydratase, mitochondrial 29 263 0.13 -0.02 -0.13
P68032 Actin, alpha cardiac muscle 1 2 2409 -0.23 -0.04 0.18
P68133 Actin, alpha skeletal muscle 1 2405 NA NA NA
P60709 Actin, cytoplasmic 1 13 4816 -0.10 0.04 0.14
O14639 Actin-binding LIM protein 1 10 37 0.24 -0.99 -1.08 5 4
O96019 Actin-like protein 6A 11 47 0.12 -0.04 -0.05
Q9NZ32 Actin-related protein 10 4 15 0.11 -0.07 -0.12
P61160 Actin-related protein 2 18 221 -0.19 0.11 0.34
Q92747 Actin-related protein 2/3 complex subunit 1A 4 6 -0.37 0.03 0.40
O15143 Actin-related protein 2/3 complex subunit 1B 17 246 -0.08 0.03 0.21
O15144 Actin-related protein 2/3 complex subunit 2 17 164 0.08 0.14 0.32
O15145 Actin-related protein 2/3 complex subunit 3 9 106 -0.18 0.02 0.04
P59998 Actin-related protein 2/3 complex subunit 4 9 101 -0.24 0.14 0.39
O15511 Actin-related protein 2/3 complex subunit 5 11 201 -0.40 -0.23 0.13
Q9BPX5 Actin-related protein 2/3 complex subunit 5-like protein 5 63 -0.70 0.66 1.47 5 5 5
P61158 Actin-related protein 3 20 400 -0.26 0.12 0.34
Q9P1U1 Actin-related protein 3B 1 52 -0.51 -0.47 0.03
Q9H9F9 Actin-related protein 5 3 9 0.04 -0.09 0.02
Q9GZN1 Actin-related protein 6 1 1 -0.32 -0.04 0.29
Q9H981 Actin-related protein 8 3 3 -0.03 0.03 -0.01
Q07912 Activated CDC42 kinase 1 1 1 -0.43 0.30 0.74
P53999 Activated RNA polymerase II transcriptional coactivator p15 10 102 -0.08 -0.22 -0.26
Q15650 Activating signal cointegrator 1 1 2 0.23 0.34 0.10
Q8N9N2 Activating signal cointegrator 1 complex subunit 1 1 1 -0.15 0.02 0.17
Q9H1I8 Activating signal cointegrator 1 complex subunit 2 1 1 -1.11 -0.19 0.93
Q8N3C0 Activating signal cointegrator 1 complex subunit 3 5 5 0.04 0.34 0.28
Q6VMQ6 Activating transcription factor 7-interacting protein 1 2 9 -0.29 -0.02 0.39
O95433 Activator of 90 kDa heat shock protein ATPase homolog 1 11 34 0.23 -0.07 -0.17
Q9ULW3 Activator of basal transcription 1 5 8 0.25 -0.08 -0.37
Q12979 Active breakpoint cluster region-related protein 2 8 0.12 0.20 0.08
Q86WX3 Active regulator of SIRT1 3 10 -0.10 -0.10 -0.07
Q9H2P0 Activity-dependent neuroprotector homeobox protein 12 32 -0.19 -0.27 -0.12
O14561 Acyl carrier protein, mitochondrial 2 35 0.25 0.10 -0.22
P13798 Acylamino-acid-releasing enzyme 13 94 -0.07 -0.03 -0.03
Q6JQN1 Acyl-CoA dehydrogenase family member 10 1 2 0.40 -0.21 -0.60
Q9H845 Acyl-CoA dehydrogenase family member 9, mitochondrial 2 7 0.46 0.34 -0.11
Q96CM8 Acyl-CoA synthetase family member 2, mitochondrial 3 8 -0.06 -0.12 0.08
Q4G176 Acyl-CoA synthetase family member 3, mitochondrial 9 14 0.33 0.18 -0.37
Q92604 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 1 1 -1.03 0.58 1.61
Q9BR61 Acyl-CoA-binding domain-containing protein 6 1 1 0.04 0.05 0.02
P07108 Acyl-CoA-binding protein 4 28 -0.12 0.24 0.65 3
Q86TX2 Acyl-coenzyme A thioesterase 1 8 42 -0.13 -0.12 0.01
Q9NPJ3 Acyl-coenzyme A thioesterase 13 5 45 0.29 -0.01 -0.25
O14734 Acyl-coenzyme A thioesterase 8 1 1 -0.55 -0.36 0.19
Q9Y305 Acyl-coenzyme A thioesterase 9, mitochondrial 4 16 0.35 0.66 0.26 3
Q5T1C6 Acyl-coenzyme A thioesterase THEM4 2 6 0.42 0.12 -0.46
Q53H12 Acylglycerol kinase, mitochondrial 8 29 -0.40 0.32 0.58 4
P28039 Acyloxyacyl hydrolase 1 1 -0.52 0.21 0.73
P07311 Acylphosphatase-1 1 5 0.06 -0.09 0.01
P14621 Acylphosphatase-2 2 10 -0.26 -0.04 0.18
O75608 Acyl-protein thioesterase 1 5 28 -0.04 0.34 0.47
O95372 Acyl-protein thioesterase 2 8 41 0.23 -0.08 -0.28
Q6P587 Acylpyruvase FAHD1, mitochondrial 5 17 -0.25 0.01 -0.02
P82987 ADAMTS-like protein 3 1 1 2.05 2.80 0.76
Q6UY14 ADAMTS-like protein 4 1 1 -0.08 -0.02 0.07
P46108 Adapter molecule crk 1 1 -1.10 -0.38 0.73
Q8NC96 Adaptin ear-binding coat-associated protein 1 1 5 0.12 -0.07 -0.18
Q9NVZ3 Adaptin ear-binding coat-associated protein 2 9 41 -0.16 -0.05 0.01
P07741 Adenine phosphoribosyltransferase 7 85 0.68 -0.05 -0.73 4 5
P00813 Adenosine deaminase 18 74 -0.29 0.31 0.64 4
Q9NZK5 Adenosine deaminase CECR1 7 17 0.18 0.33 0.23
P55263 Adenosine kinase 6 25 0.54 -0.19 -0.73 5
P23526 Adenosylhomocysteinase 16 96 0.21 -0.69 -0.79 3 5
P51828 Adenylate cyclase type 7 1 1 -0.33 0.19 0.51
P54819 Adenylate kinase 2, mitochondrial 16 232 -0.07 -0.11 0.01
Q9Y6K8 Adenylate kinase isoenzyme 5 2 5 -0.42 -1.13 -0.72
P30566 Adenylosuccinate lyase 10 36 0.27 -0.27 -0.43 5
P30520 Adenylosuccinate synthetase isozyme 2 15 71 -0.19 0.03 0.29
Q01518 Adenylyl cyclase-associated protein 1 33 454 -0.07 0.01 0.10
O95396 Adenylyltransferase and sulfurtransferase MOCS3 4 6 -0.14 -0.19 -0.05
Q9HDC9 Adipocyte plasma membrane-associated protein 12 89 -0.69 0.75 1.28 3 5 4
P12235 ADP/ATP translocase 1 2 51 0.19 0.12 0.12
P05141 ADP/ATP translocase 2 3 104 -0.20 0.00 0.12
P12236 ADP/ATP translocase 3 2 89 0.38 0.16 -0.14
Q9BRR6 ADP-dependent glucokinase 3 18 -0.18 0.28 0.06
Q9BW91 ADP-ribose pyrophosphatase, mitochondrial 1 1 0.12 -0.17 -0.28
P28907 ADP-ribosyl cyclase 1 3 5 -1.93 -0.22 1.70
P61204 ADP-ribosylation factor 3 4 35 0.04 0.28 0.31
P18085 ADP-ribosylation factor 4 1 19 0.14 0.36 -0.04
P84085 ADP-ribosylation factor 5 1 33 -0.07 0.11 0.02
P62330 ADP-ribosylation factor 6 5 25 0.03 1.02 0.56 3
Q8N6T3 ADP-ribosylation factor GTPase-activating protein 1 6 16 0.06 0.23 0.18
Q8N6H7 ADP-ribosylation factor GTPase-activating protein 2 13 67 -0.16 0.00 0.18
Q9NP61 ADP-ribosylation factor GTPase-activating protein 3 6 18 -0.09 0.65 0.57 5 5
Q9UJY5 ADP-ribosylation factor-binding protein GGA1 3 8 -0.14 -0.01 0.30
Q9UJY4 ADP-ribosylation factor-binding protein GGA2 4 14 0.04 0.29 0.08
Q9NZ52 ADP-ribosylation factor-binding protein GGA3 3 11 0.10 0.19 0.10
Q9NXU5 ADP-ribosylation factor-like protein 15 1 3 -0.07 0.27 0.41
P36404 ADP-ribosylation factor-like protein 2 2 9 0.34 -0.33 -0.63
Q9Y2Y0 ADP-ribosylation factor-like protein 2-binding protein 1 1 1.43 0.68 -0.73
P36405 ADP-ribosylation factor-like protein 3 3 21 0.77 0.70 -0.30 5 5
Q66PJ3 ADP-ribosylation factor-like protein 6-interacting protein 4 6 20 -0.04 -0.48 -0.45
Q96BM9 ADP-ribosylation factor-like protein 8A 1 3 -0.76 0.25 1.01
Q9NVJ2 ADP-ribosylation factor-like protein 8B 3 19 -0.23 0.22 0.51
Q13795 ADP-ribosylation factor-related protein 1 2 2 -0.39 -0.02 0.36
Q9UKK9 ADP-sugar pyrophosphatase 7 78 0.09 -0.09 -0.23
Q96AP0 Adrenocortical dysplasia protein homolog 2 7 -0.10 0.03 0.18
P10109 Adrenodoxin, mitochondrial 1 8 0.91 0.12 -0.78
Q9UHB7 AF4/FMR2 family member 4 2 4 0.03 -0.08 -0.07
P43652 Afamin 1 5 1.16 1.28 0.13
Q9Y4W6 AFG3-like protein 2 20 75 0.16 -0.06 -0.27
O43488 Aflatoxin B1 aldehyde reductase member 2 8 97 0.00 0.06 0.03
Q6ULP2 Aftiphilin 4 6 -0.03 0.00 0.04
O00170 AH receptor-interacting protein 14 91 0.13 0.03 -0.21
O43572 A-kinase anchor protein 10, mitochondrial 1 3 -0.25 -0.03 -0.04
Q9UKA4 A-kinase anchor protein 11 1 1 -0.37 -0.09 0.26
Q12802 A-kinase anchor protein 13 33 103 -0.09 0.01 0.10
Q02040 A-kinase anchor protein 17A 2 3 0.11 0.18 0.07
Q9P0M2 A-kinase anchor protein 7 isoform gamma 1 2 -0.19 -0.27 -0.09
O43823 A-kinase anchor protein 8 6 18 -0.28 -0.06 0.17
Q9ULX6 A-kinase anchor protein 8-like 8 36 -0.17 -0.08 0.05
Q99996 A-kinase anchor protein 9 14 36 0.14 0.05 -0.09
Q9NRG9 Aladin 5 6 -0.24 0.14 0.16
P49588 Alanine--tRNA ligase, cytoplasmic 29 98 0.09 -0.18 -0.17
Q5JTZ9 Alanine--tRNA ligase, mitochondrial 10 24 0.12 -0.09 -0.04
Q9BTE6 Alanyl-tRNA editing protein Aarsd1 4 12 -0.10 -0.31 -0.22
P14550 Alcohol dehydrogenase 13 114 0.36 0.07 -0.27
P11766 Alcohol dehydrogenase class-3 13 77 0.21 -0.18 -0.24
Q8IZ83 Aldehyde dehydrogenase family 16 member A1 11 57 -0.12 -0.15 -0.02
P30837 Aldehyde dehydrogenase X, mitochondrial 6 7 0.48 0.15 -0.35
P42330 Aldo-keto reductase family 1 member C3 11 92 -1.62 -0.04 1.51 5 5
Q96C23 Aldose 1-epimerase 7 27 1.40 0.90 -0.40 5 5
P15121 Aldose reductase 14 147 0.07 -0.20 -0.56
Q96BT7 Alkylated DNA repair protein alkB homolog 8 1 1 0.40 0.31 -0.11
O00116 Alkyldihydroxyacetonephosphate synthase, peroxisomal 2 4 0.06 0.24 -0.01
P55008 Allograft inflammatory factor 1 1 1 -0.61 -0.36 0.27
Q8NFV4 Alpha/beta hydrolase domain-containing protein 11 3 7 0.11 -0.10 -0.20
Q96IU4 Alpha/beta hydrolase domain-containing protein 14B 8 148 0.52 0.15 -0.43 4
Q96GS6 Alpha/beta hydrolase domain-containing protein 17A 1 1 -0.50 0.44 0.93
Q9H553 Alpha-1,3/1,6-mannosyltransferase ALG2 1 2 0.47 0.41 -0.06
P26572 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase 2 3 0.01 0.21 0.19
P01011 Alpha-1-antichymotrypsin 7 10 -1.40 0.04 1.47
P01009 Alpha-1-antitrypsin 6 19 -0.55 0.36 1.04 5
P02765 Alpha-2-HS-glycoprotein 2 106 0.89 0.14 -0.04 3
P01023 Alpha-2-macroglobulin 3 7 1.03 1.21 0.12
P30533 Alpha-2-macroglobulin receptor-associated protein 2 2 -0.69 -0.17 0.52
P12814 Alpha-actinin-1 24 438 0.05 -1.32 -1.54 5 5
O43707 Alpha-actinin-4 41 645 -0.27 1.03 1.29 5 4
P35611 Alpha-adducin 19 102 -0.10 -0.29 -0.21
Q9UDR5 Alpha-aminoadipic semialdehyde synthase, mitochondrial 1 1 0.05 -0.30 -0.35
P61163 Alpha-centractin 5 63 0.08 -0.07 -0.13
O43768 Alpha-endosulfine 5 48 -0.28 -0.69 -0.25
P06733 Alpha-enolase 39 1256 0.23 -0.18 -0.41
P02771 Alpha-fetoprotein 3 6 1.01 1.53 -0.09
Q9NZD4 Alpha-hemoglobin-stabilizing protein 2 2 -0.76 -0.29 0.49
Q9C0B1 Alpha-ketoglutarate-dependent dioxygenase FTO 2 3 0.70 0.00 -0.69
P35475 Alpha-L-iduronidase 7 48 -0.57 0.23 0.78 5
Q9NTJ4 Alpha-mannosidase 2C1 2 2 0.13 0.14 0.02
P17050 Alpha-N-acetylgalactosaminidase 3 5 -0.45 -0.06 0.39
P54802 Alpha-N-acetylglucosaminidase 4 8 -0.59 0.28 0.94 4
P54920 Alpha-soluble NSF attachment protein 14 57 0.11 0.08 0.07
P37840 Alpha-synuclein 10 34 -0.63 -0.29 0.26 4
P40222 Alpha-taxilin 5 13 -0.11 0.21 0.29
Q8TCU4 Alstrom syndrome protein 1 1 1 0.41 0.60 0.20
Q06203 Amidophosphoribosyltransferase 7 18 0.09 -0.40 -0.49
Q12904 Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 10 49 0.11 0.09 -0.10
Q13155 Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 6 34 0.19 0.08 -0.12
Q03154 Aminoacylase-1 2 2 -0.33 0.04 0.37
Q9H4A4 Aminopeptidase B 14 54 -0.05 0.10 0.10
P15144 Aminopeptidase N 2 3 0.79 0.71 -0.08
Q08117 Amino-terminal enhancer of split 2 2 -0.17 0.02 0.18
Q01433 AMP deaminase 2 10 31 0.22 -0.11 -0.26
Q01432 AMP deaminase 3 3 9 0.92 0.27 -0.65 5 5
Q96FJ0 AMSH-like protease 1 1 0.09 0.24 0.15
Q99767 Amyloid beta A4 precursor protein-binding family A member 2 1 5 -2.15 -2.67 -0.52
O00213 Amyloid beta A4 precursor protein-binding family B member 1 1 4 0.01 -0.80 -0.82
Q7Z5R6 Amyloid beta A4 precursor protein-binding family B member 1-interacting protein 14 76 -0.12 -0.18 -0.15
Q8TCF1 AN1-type zinc finger protein 1 1 2 -0.01 0.04 0.04
Q8WV99 AN1-type zinc finger protein 2B 1 2 0.09 0.05 -0.04
Q6FIF0 AN1-type zinc finger protein 6 2 5 -0.66 -0.06 0.61 3
Q6FI81 Anamorsin 7 23 -0.15 -0.19 -0.11
Q9H1A4 Anaphase-promoting complex subunit 1 2 2 0.42 -0.23 -0.65
Q96DE5 Anaphase-promoting complex subunit 16 1 7 -0.11 0.03 0.10
Q9UJX4 Anaphase-promoting complex subunit 5 1 1 NA NA NA
Q9UJX3 Anaphase-promoting complex subunit 7 3 8 -0.12 -0.08 0.27
Q8NHZ8 Anaphase-promoting complex subunit CDC26 1 1 -0.07 -0.37 -0.32
Q9Y679 Ancient ubiquitous protein 1 3 3 -0.43 -0.80 -0.36
Q8N7X0 Androglobin 1 1 -1.81 -0.78 1.04
P04920 Anion exchange protein 2 5 10 0.33 0.29 -0.31
A6QL63 Ankyrin repeat and BTB/POZ domain-containing protein BTBD11 5 8 0.56 0.22 -0.34
Q9P2R3 Ankyrin repeat and FYVE domain-containing protein 1 10 29 0.03 0.19 0.15
Q8IWZ3 Ankyrin repeat and KH domain-containing protein 1 8 28 -0.09 -0.02 0.14
Q86XL3 Ankyrin repeat and LEM domain-containing protein 2 2 4 -0.27 0.26 0.53
Q9NXR5 Ankyrin repeat domain-containing protein 10 1 1 0.39 0.48 0.09
Q6UB99 Ankyrin repeat domain-containing protein 11 1 1 -0.91 -1.23 -0.32
Q8IZ07 Ankyrin repeat domain-containing protein 13A 3 5 0.13 0.05 -0.07
Q6ZTN6 Ankyrin repeat domain-containing protein 13D 2 3 -0.14 -0.05 0.09
O75179 Ankyrin repeat domain-containing protein 17 2 12 -0.20 -0.16 0.05
Q96NW4 Ankyrin repeat domain-containing protein 27 2 4 -0.27 0.22 0.58
P16157 Ankyrin-1 2 2 -0.87 -0.87 0.01
Q12955 Ankyrin-3 2 2 0.52 -0.16 -0.68
P04083 Annexin A1 30 780 0.63 1.22 0.61 5 5 3
P50995 Annexin A11 22 222 0.04 -0.27 -0.33
P07355 Annexin A2 31 508 0.75 1.32 0.59 5 5
P12429 Annexin A3 1 3 0.04 -0.77 -0.80
P09525 Annexin A4 14 108 -0.31 0.81 1.25 5 5
P08758 Annexin A5 19 139 1.92 0.85 -0.93 5 5 5
P08133 Annexin A6 64 1162 -0.28 -0.16 0.13
P20073 Annexin A7 14 124 0.35 -0.10 -0.49 5
Q9NW15 Anoctamin-10 1 2 -0.13 0.21 0.34
Q4KMQ2 Anoctamin-6 1 3 NA NA NA
Q03518 Antigen peptide transporter 1 9 116 -0.20 0.16 0.28
Q03519 Antigen peptide transporter 2 7 54 0.06 0.23 0.17
Q10567 AP-1 complex subunit beta-1 8 96 -0.06 0.22 0.19
O43747 AP-1 complex subunit gamma-1 7 17 -0.07 0.30 0.21
O75843 AP-1 complex subunit gamma-like 2 4 12 -0.13 0.26 0.41
Q9BXS5 AP-1 complex subunit mu-1 5 24 -0.09 0.14 0.17
P61966 AP-1 complex subunit sigma-1A 2 15 0.17 -0.14 -0.15
P56377 AP-1 complex subunit sigma-2 3 20 -0.30 0.21 0.56
O95782 AP-2 complex subunit alpha-1 16 98 -0.36 0.11 0.40
O94973 AP-2 complex subunit alpha-2 7 50 0.15 0.08 -0.11
P63010 AP-2 complex subunit beta 12 111 -0.19 0.12 0.21
Q96CW1 AP-2 complex subunit mu 11 29 0.02 0.26 0.21
P53680 AP-2 complex subunit sigma 1 4 -0.14 0.05 0.17
Q2M2I8 AP2-associated protein kinase 1 16 74 0.19 0.07 -0.21
O00203 AP-3 complex subunit beta-1 15 36 0.22 0.20 -0.03
O14617 AP-3 complex subunit delta-1 4 6 0.11 0.16 -0.04
Q9Y2T2 AP-3 complex subunit mu-1 6 17 -0.14 0.19 0.22
Q92572 AP-3 complex subunit sigma-1 3 14 0.28 0.48 0.20 4
P59780 AP-3 complex subunit sigma-2 1 1 NA NA NA
Q2VPB7 AP-5 complex subunit beta-1 1 1 -0.29 0.03 0.33
O43299 AP-5 complex subunit zeta-1 2 5 -0.08 -0.06 0.02
Q0VD83 Apolipoprotein B receptor 29 162 -0.73 0.65 1.42 5 3 5
P04114 Apolipoprotein B-100 1 4 0.02 -0.12 -0.11
P02655 Apolipoprotein C-II 1 3 1.50 1.60 0.10
P02656 Apolipoprotein C-III 2 54 0.21 0.17 -0.04
P02649 Apolipoprotein E 3 5 1.41 1.72 0.33
Q9BQE5 Apolipoprotein L2 6 42 -0.30 0.78 1.12 4 4
O95236 Apolipoprotein L3 5 5 0.79 0.51 -0.27
Q9BUR5 Apolipoprotein O 2 6 0.28 0.15 -0.08
Q6UXV4 Apolipoprotein O-like 5 9 0.02 -0.24 -0.34
Q9BZZ5 Apoptosis inhibitor 5 13 70 -0.01 -0.15 -0.16
Q07812 Apoptosis regulator BAX 8 95 -0.21 -0.02 0.03
P10415 Apoptosis regulator Bcl-2 2 8 0.31 -0.35 -0.74 3
Q9ULZ3 Apoptosis-associated speck-like protein containing a CARD 5 24 -0.46 0.43 0.37
O95831 Apoptosis-inducing factor 1, mitochondrial 21 135 0.11 0.01 -0.16
Q9UKV3 Apoptotic chromatin condensation inducer in the nucleus 33 202 -0.25 -0.25 0.02
O14727 Apoptotic protease-activating factor 1 2 2 0.04 0.15 0.10
Q7Z2E3 Aprataxin 3 4 -0.21 -0.12 0.10
P20292 Arachidonate 5-lipoxygenase-activating protein 1 14 NA NA NA
Q9Y2X7 ARF GTPase-activating protein GIT1 6 21 0.09 0.01 -0.09
Q14161 ARF GTPase-activating protein GIT2 8 31 0.02 0.14 0.20
P53367 Arfaptin-1 6 11 -0.51 0.24 0.69 4 5
P52594 Arf-GAP domain and FG repeat-containing protein 1 6 29 0.09 0.00 -0.06
O95081 Arf-GAP domain and FG repeat-containing protein 2 4 9 0.07 0.17 0.24
Q15027 Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1 20 84 0.22 -0.04 -0.14
Q15057 Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 16 29 0.02 0.14 0.22
O75689 Arf-GAP with dual PH domain-containing protein 1 3 6 -0.55 0.42 0.97
Q99490 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2 7 24 0.24 0.29 0.05
Q96P47 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3 1 3 -0.55 -0.12 0.57
Q96P48 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 8 19 -0.59 0.14 0.64 4 3
Q8WWN8 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3 1 1 -0.32 -0.13 0.17
Q9ULH1 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 4 11 -0.22 -0.42 0.19
P05089 Arginase-1 4 7 0.99 0.79 -0.36
Q9NWB6 Arginine and glutamate-rich protein 1 6 28 -0.20 -0.29 0.05
Q7L4I2 Arginine/serine-rich coiled-coil protein 2 6 58 -0.18 -0.08 0.12
Q8TF01 Arginine/serine-rich protein PNISR 3 8 -0.06 -0.59 -0.65 3 3
Q9P2R6 Arginine-glutamic acid dipeptide repeats protein 2 2 0.11 -0.33 -0.45
P54136 Arginine--tRNA ligase, cytoplasmic 17 81 0.42 0.09 -0.29
P04424 Argininosuccinate lyase 5 16 -0.52 0.30 0.84 4
O95260 Arginyl-tRNA--protein transferase 1 5 6 0.11 -0.18 -0.24
Q9NVT9 Armadillo repeat-containing protein 1 1 1 -0.65 -0.06 0.58
Q8N2F6 Armadillo repeat-containing protein 10 2 5 0.42 0.22 -0.17
Q6NXE6 Armadillo repeat-containing protein 6 2 2 -0.41 0.16 0.54
Q8IUR7 Armadillo repeat-containing protein 8 2 3 0.20 0.33 0.13
Q7L311 Armadillo repeat-containing X-linked protein 2 1 1 -0.16 -0.36 -0.20
Q9UH62 Armadillo repeat-containing X-linked protein 3 3 6 0.02 0.61 0.62
Q8N5I2 Arrestin domain-containing protein 1 2 2 -0.26 0.02 0.27
P15289 Arylsulfatase A 5 37 -0.15 0.06 0.28
P15848 Arylsulfatase B 2 2 0.10 0.57 0.47
Q9BVC5 Ashwin 4 7 -0.14 -0.05 -0.06
P08243 Asparagine synthetase 1 1 0.05 -0.05 -0.09
O43776 Asparagine--tRNA ligase, cytoplasmic 8 34 0.24 -0.02 -0.09
P17174 Aspartate aminotransferase, cytoplasmic 11 78 0.08 -0.02 -0.09
P00505 Aspartate aminotransferase, mitochondrial 18 134 0.46 -0.05 -0.37
P14868 Aspartate--tRNA ligase, cytoplasmic 22 89 0.39 0.12 -0.33
Q6PI48 Aspartate--tRNA ligase, mitochondrial 7 30 0.25 0.16 -0.18
Q9ULA0 Aspartyl aminopeptidase 11 59 0.38 -0.28 -0.66 5
Q12797 Aspartyl/asparaginyl beta-hydroxylase 1 9 -1.96 -2.79 -0.82
Q15121 Astrocytic phosphoprotein PEA-15 4 17 -0.34 0.10 0.31
P54253 Ataxin-1 2 2 -0.78 0.13 0.92
Q9UBB4 Ataxin-10 4 20 0.02 0.22 0.10
P0C7T5 Ataxin-1-like 4 6 -0.21 -0.16 0.27
Q8WWM7 Ataxin-2-like protein 17 49 -0.21 0.07 0.21
P54252 Ataxin-3 7 33 -0.05 -0.13 -0.12
O15265 Ataxin-7 2 3 0.05 -0.19 -0.23
Q6SPF0 Atherin 9 31 -0.28 -0.39 0.08
Q5TGY3 AT-hook DNA-binding motif-containing protein 1 1 1 -0.56 -0.09 0.48
Q7Z591 AT-hook-containing transcription factor 19 57 0.05 0.36 0.37
Q8NHH9 Atlastin-2 2 3 0.08 0.65 0.55
Q6DD88 Atlastin-3 5 17 0.19 0.41 0.26
O43313 ATM interactor 1 11 -0.46 0.18 0.60 3
P24539 ATP synthase F(0) complex subunit B1, mitochondrial 8 37 0.18 0.13 0.01
P00846 ATP synthase subunit a 1 2 0.07 -0.11 -0.18
P25705 ATP synthase subunit alpha, mitochondrial 42 875 0.01 0.05 0.02
P06576 ATP synthase subunit beta, mitochondrial 30 1198 -0.01 0.02 -0.01
O75947 ATP synthase subunit d, mitochondrial 9 75 -0.01 -0.06 0.24
P30049 ATP synthase subunit delta, mitochondrial 4 60 -0.02 -0.05 0.21
P56385 ATP synthase subunit e, mitochondrial 5 105 -0.06 0.09 -0.02
P56381 ATP synthase subunit epsilon, mitochondrial 2 9 0.23 -0.01 -0.03
P56134 ATP synthase subunit f, mitochondrial 2 6 0.64 0.44 -0.19
O75964 ATP synthase subunit g, mitochondrial 7 95 0.08 0.05 -0.08
P36542 ATP synthase subunit gamma, mitochondrial 12 73 0.22 0.13 -0.16
P48047 ATP synthase subunit O, mitochondrial 17 172 -0.03 0.02 -0.02
Q99766 ATP synthase subunit s, mitochondrial 1 2 0.25 0.05 -0.19
P18859 ATP synthase-coupling factor 6, mitochondrial 5 50 -0.05 0.09 0.20
O43681 ATPase ASNA1 9 39 -0.11 0.04 0.09
Q8NBU5 ATPase family AAA domain-containing protein 1 4 9 -0.12 -0.26 -0.01
Q9ULI0 ATPase family AAA domain-containing protein 2B 1 2 -1.08 -0.22 0.87
Q9NVI7 ATPase family AAA domain-containing protein 3A 7 52 0.15 0.19 0.21
Q5T9A4 ATPase family AAA domain-containing protein 3B 1 17 -0.34 -0.05 0.30
Q5T2N8 ATPase family AAA domain-containing protein 3C 1 22 -0.03 0.07 0.11
Q9UII2 ATPase inhibitor, mitochondrial 6 42 0.04 -0.03 -0.15
Q96S55 ATPase WRNIP1 3 12 -0.14 -0.37 -0.21
Q8IZY2 ATP-binding cassette sub-family A member 7 1 1 0.29 0.20 -0.08
O75027 ATP-binding cassette sub-family B member 7, mitochondrial 1 4 -0.13 -0.02 -0.17
Q9NUT2 ATP-binding cassette sub-family B member 8, mitochondrial 2 22 0.11 0.15 0.18
P33897 ATP-binding cassette sub-family D member 1 1 5 0.33 0.61 0.31 4
Q9UBJ2 ATP-binding cassette sub-family D member 2 1 1 NA NA NA
P61221 ATP-binding cassette sub-family E member 1 17 79 0.50 -0.18 -0.50 5
Q8NE71 ATP-binding cassette sub-family F member 1 26 119 0.04 -0.21 -0.21
Q9UG63 ATP-binding cassette sub-family F member 2 9 22 0.52 0.14 -0.39
Q9NUQ8 ATP-binding cassette sub-family F member 3 8 32 0.18 0.04 -0.24
P53396 ATP-citrate synthase 29 163 -0.07 0.26 0.19
Q8IW45 ATP-dependent (S)-NAD(P)H-hydrate dehydratase 7 13 0.21 -0.23 -0.43
O76031 ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial 5 10 0.12 -0.02 -0.10
P46063 ATP-dependent DNA helicase Q1 20 113 -0.08 0.13 0.26
Q08211 ATP-dependent RNA helicase A 44 310 0.06 -0.08 -0.16
Q92499 ATP-dependent RNA helicase DDX1 20 91 0.22 -0.22 -0.44
Q9NVP1 ATP-dependent RNA helicase DDX18 14 36 0.45 -0.17 -0.53 5
Q9UMR2 ATP-dependent RNA helicase DDX19B 13 84 -0.16 -0.09 0.01
Q9GZR7 ATP-dependent RNA helicase DDX24 22 111 -0.06 -0.44 -0.40 5 5
O00148 ATP-dependent RNA helicase DDX39A 3 113 -0.29 -0.11 0.06
O00571 ATP-dependent RNA helicase DDX3X 7 205 -0.08 0.04 0.04
O15523 ATP-dependent RNA helicase DDX3Y 1 160 -0.13 0.08 0.18
Q86XP3 ATP-dependent RNA helicase DDX42 21 85 0.04 -0.15 -0.14
Q9BQ39 ATP-dependent RNA helicase DDX50 5 19 0.15 -0.24 -0.23
Q8N8A6 ATP-dependent RNA helicase DDX51 7 13 0.27 0.13 -0.11
Q8TDD1 ATP-dependent RNA helicase DDX54 7 17 0.27 -0.12 -0.29
Q8NHQ9 ATP-dependent RNA helicase DDX55 4 8 0.04 -0.14 -0.18
Q7Z478 ATP-dependent RNA helicase DHX29 3 7 0.33 0.25 -0.11
Q14562 ATP-dependent RNA helicase DHX8 6 18 0.09 -0.07 -0.14
Q8IYB8 ATP-dependent RNA helicase SUPV3L1, mitochondrial 6 28 0.26 0.06 0.01
Q96TA2 ATP-dependent zinc metalloprotease YME1L1 4 8 0.10 0.09 0.06
O14497 AT-rich interactive domain-containing protein 1A 28 105 -0.21 -0.06 0.19
Q8NFD5 AT-rich interactive domain-containing protein 1B 8 33 -0.14 -0.03 0.04
Q68CP9 AT-rich interactive domain-containing protein 2 2 4 -0.19 -0.08 0.08
Q99856 AT-rich interactive domain-containing protein 3A 1 2 -1.55 -0.18 1.36
Q8IVW6 AT-rich interactive domain-containing protein 3B 3 3 -1.05 -0.69 0.37
P29374 AT-rich interactive domain-containing protein 4A 5 10 0.05 0.01 -0.06
Q4LE39 AT-rich interactive domain-containing protein 4B 6 9 -0.02 0.09 0.07
Q8WXX7 Autism susceptibility gene 2 protein 1 1 NA NA NA
Q9H1Y0 Autophagy protein 5 2 3 0.20 -0.07 -0.44
O75143 Autophagy-related protein 13 1 1 0.20 0.42 0.22
Q676U5 Autophagy-related protein 16-1 2 8 0.20 0.32 0.11
Q2TAZ0 Autophagy-related protein 2 homolog A 1 3 0.03 0.08 0.05
Q96BY7 Autophagy-related protein 2 homolog B 1 2 0.14 0.24 0.11
Q7Z3C6 Autophagy-related protein 9A 1 1 -0.69 -0.69 0.01
Q96BJ3 Axin interactor, dorsalization-associated protein 1 1 0.43 0.40 -0.05
O15169 Axin-1 1 2 -0.24 0.07 0.31
P20160 Azurocidin 1 4 0.07 0.05 -0.01
Q13490 Baculoviral IAP repeat-containing protein 2 3 3 -0.40 -0.13 0.32
Q9NR09 Baculoviral IAP repeat-containing protein 6 3 4 0.03 0.12 0.04
Q99933 BAG family molecular chaperone regulator 1 5 6 -0.13 -0.09 -0.10
O95816 BAG family molecular chaperone regulator 2 2 3 -0.45 -0.84 -0.38
O95817 BAG family molecular chaperone regulator 3 2 5 0.01 -0.23 -0.17
O95429 BAG family molecular chaperone regulator 4 2 4 -0.93 -0.39 0.54
Q9UL15 BAG family molecular chaperone regulator 5 3 9 -0.09 -0.12 0.01
P02730 Band 3 anion transport protein 4 10 -0.87 -0.93 -0.15 3 3
O43491 Band 4.1-like protein 2 4 9 0.28 0.20 -0.06
Q9Y2J2 Band 4.1-like protein 3 1 5 -0.03 0.33 0.36
O75531 Barrier-to-autointegration factor 6 58 -0.73 -0.50 0.21 3 4
Q7L1Q6 Basic leucine zipper and W2 domain-containing protein 1 8 28 0.25 0.36 -0.03
Q9Y6E2 Basic leucine zipper and W2 domain-containing protein 2 1 5 0.35 0.12 -0.22
P35613 Basigin 3 10 -0.12 0.25 0.39
Q8WUZ0 B-cell CLL/lymphoma 7 protein family member C 2 3 -0.16 -0.01 0.34
Q86UU0 B-cell CLL/lymphoma 9-like protein 8 16 -0.13 -0.12 -0.01
P20749 B-cell lymphoma 3 protein 1 6 -0.01 -0.01 -0.03
O95999 B-cell lymphoma/leukemia 10 5 6 -0.40 -0.50 -0.03
Q9C0K0 B-cell lymphoma/leukemia 11B 18 65 0.57 -0.42 -0.71 4 5
Q9UHQ4 B-cell receptor-associated protein 29 1 3 -0.44 0.24 0.68
P51572 B-cell receptor-associated protein 31 9 62 0.32 0.32 -0.15
Q92934 Bcl2 antagonist of cell death 2 8 -0.10 0.58 0.57 4
Q16611 Bcl-2 homologous antagonist/killer 1 1 -0.35 0.05 0.41
Q9NYF8 Bcl-2-associated transcription factor 1 21 123 0.04 -0.16 -0.03
Q9BXH1 Bcl-2-binding component 3 1 2 NA NA NA
Q14457 Beclin-1 2 5 -0.39 -0.04 0.30
O15155 BET1 homolog 2 2 0.27 0.42 0.15
Q9P109 Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 1 2 0.27 -0.27 -0.54
Q6Y288 Beta-1,3-glucosyltransferase 1 1 -0.41 -0.18 0.23
Q9UBV7 Beta-1,4-galactosyltransferase 7 1 1 NA NA NA
Q13884 Beta-1-syntrophin 3 13 -0.59 -0.11 0.60
P02749 Beta-2-glycoprotein 1 1 2 2.42 2.76 0.35
P61769 Beta-2-microglobulin 4 16 0.01 0.27 0.27
Q13425 Beta-2-syntrophin 4 13 -0.32 0.67 0.63 4
Q562R1 Beta-actin-like protein 2 1 918 -0.29 -0.04 0.25
P25098 Beta-adrenergic receptor kinase 1 14 45 -0.11 0.10 0.07
P49407 Beta-arrestin-1 9 38 -0.81 -0.51 0.59 4 4
P32121 Beta-arrestin-2 6 24 0.13 0.08 -0.35
Q8WYA6 Beta-catenin-like protein 1 4 9 -0.05 0.05 0.04
P42025 Beta-centractin 2 48 0.20 -0.11 -0.31
P13929 Beta-enolase 1 158 -0.25 -0.45 -0.20
P16278 Beta-galactosidase 6 32 0.10 0.68 0.47 5
P08236 Beta-glucuronidase 1 3 0.19 0.02 -0.15
P06865 Beta-hexosaminidase subunit alpha 4 20 -0.27 0.40 0.64
P07686 Beta-hexosaminidase subunit beta 18 69 0.01 0.79 0.58 5
Q53H82 Beta-lactamase-like protein 2 2 2 0.41 0.09 -0.33
O00462 Beta-mannosidase 2 8 -0.31 0.47 0.73
Q9HBI1 Beta-parvin 2 3 -0.08 -0.15 -0.07
P55957 BH3-interacting domain death agonist 5 29 0.33 -0.17 -0.18
O43252 Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 4 5 0.05 0.06 0.57
Q3LXA3 Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing) 16 120 -0.08 -0.07 0.01
Q13057 Bifunctional coenzyme A synthase 5 18 0.07 -0.08 -0.35
P34913 Bifunctional epoxide hydrolase 2 8 41 0.16 -1.42 -1.64 5 5
P07814 Bifunctional glutamate/proline--tRNA ligase 45 244 0.31 0.11 -0.14
Q8IUF8 Bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA 3 6 0.38 -0.18 -0.55
Q9H6W3 Bifunctional lysine-specific demethylase and histidyl-hydroxylase NO66 8 15 0.52 0.17 -0.28
Q96T60 Bifunctional polynucleotide phosphatase/kinase 12 37 -0.07 0.34 0.38
O60502 Bifunctional protein NCOAT 8 14 0.05 0.40 0.32
P31939 Bifunctional purine biosynthesis protein PURH 35 315 0.54 -0.13 -0.64 5 5
Q9Y223 Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase 3 6 -0.14 -0.04 0.10
P53004 Biliverdin reductase A 9 34 -0.23 -0.14 0.12
P78537 Biogenesis of lysosome-related organelles complex 1 subunit 1 2 8 -0.39 -0.09 0.21
Q6QNY1 Biogenesis of lysosome-related organelles complex 1 subunit 2 1 1 -0.69 -0.36 0.34
Q6QNY0 Biogenesis of lysosome-related organelles complex 1 subunit 3 3 17 -0.01 0.08 0.22
Q9NUP1 Biogenesis of lysosome-related organelles complex 1 subunit 4 3 7 -0.07 0.04 -0.13
Q8TDH9 Biogenesis of lysosome-related organelles complex 1 subunit 5 3 6 -0.39 -0.20 0.24
Q8NFC6 Biorientation of chromosomes in cell division protein 1-like 1 24 73 -0.24 -0.19 0.02
P50747 Biotin--protein ligase 1 1 -0.32 -0.25 0.06
P49789 Bis(5'-adenosyl)-triphosphatase 1 1 -0.33 -0.57 -0.22
Q9Y6X5 Bis(5'-adenosyl)-triphosphatase ENPP4 7 18 -0.84 0.09 0.92 4 4
P50583 Bis(5'-nucleosyl)-tetraphosphatase 1 1 0.40 0.18 -0.21
P07738 Bisphosphoglycerate mutase 4 12 -0.47 -0.20 0.13
Q13867 Bleomycin hydrolase 7 19 0.32 0.18 0.03
P54132 Bloom syndrome protein 1 5 1.20 0.31 -0.89
Q9H3K6 BolA-like protein 2 6 69 0.10 -0.11 -0.17
Q10589 Bone marrow stromal antigen 2 2 5 -0.50 0.38 0.89
P80723 Brain acid soluble protein 1 5 15 0.09 0.17 0.09
O15382 Branched-chain-amino-acid aminotransferase, mitochondrial 4 10 0.20 0.08 -0.14
Q6UWZ7 BRCA1-A complex subunit Abraxas 3 6 0.22 -0.05 -0.20
Q9NXR7 BRCA1-A complex subunit BRE 2 2 0.24 0.17 -0.06
Q96RL1 BRCA1-A complex subunit RAP80 4 12 0.01 -0.14 -0.15
Q6PJG6 BRCA1-associated ATM activator 1 1 2 -0.36 -0.19 0.16
Q7Z569 BRCA1-associated protein 1 1 -1.29 -1.70 -0.39
Q9P287 BRCA2 and CDKN1A-interacting protein 5 6 -0.14 -0.20 -0.12
P11274 Breakpoint cluster region protein 10 29 -0.33 -0.14 0.28
Q9HCU9 Breast cancer metastasis-suppressor 1 1 1 -0.30 -0.08 0.22
Q9H6U6 Breast carcinoma-amplified sequence 3 6 18 0.00 0.20 0.19
Q9Y6D6 Brefeldin A-inhibited guanine nucleotide-exchange protein 1 4 12 0.00 0.05 0.13
Q9Y6D5 Brefeldin A-inhibited guanine nucleotide-exchange protein 2 2 6 0.47 0.32 -0.23
Q9UBW5 Bridging integrator 2 28 189 -0.52 0.12 0.60 4 5
Q9NQY0 Bridging integrator 3 1 1 0.06 0.12 0.06
Q9NWV8 BRISC and BRCA1-A complex member 1 9 52 -0.09 -0.20 -0.08
Q15018 BRISC complex subunit Abro1 14 35 0.09 0.05 -0.04
Q5VW32 BRO1 domain-containing protein BROX 4 9 -0.10 0.16 0.25
Q8TBE0 Bromo adjacent homology domain-containing 1 protein 1 1 NA NA NA
Q9NRL2 Bromodomain adjacent to zinc finger domain protein 1A 6 10 -0.38 -0.33 -0.01
Q9UIF9 Bromodomain adjacent to zinc finger domain protein 2A 4 6 -0.19 -0.17 0.11
Q9ULD4 Bromodomain and PHD finger-containing protein 3 1 2 NA NA NA
O95696 Bromodomain-containing protein 1 4 7 0.40 0.22 -0.30
P25440 Bromodomain-containing protein 2 3 8 -0.28 -0.17 0.12
Q15059 Bromodomain-containing protein 3 5 24 -0.15 -0.14 0.05
O60885 Bromodomain-containing protein 4 10 44 -0.02 -0.02 -0.02
Q9NPI1 Bromodomain-containing protein 7 2 3 -0.54 -0.20 0.33
Q9H0E9 Bromodomain-containing protein 8 4 5 0.05 -0.08 -0.04
Q9NW68 BSD domain-containing protein 1 1 1 0.33 0.28 -0.07
Q96CX2 BTB/POZ domain-containing protein KCTD12 5 9 -0.09 -0.47 -0.40
Q96SI1 BTB/POZ domain-containing protein KCTD15 1 1 NA NA NA
Q6PI47 BTB/POZ domain-containing protein KCTD18 1 1 -0.40 -0.20 0.18
Q9BRD0 BUD13 homolog 4 6 -0.82 -0.08 0.73
O00481 Butyrophilin subfamily 3 member A1 1 11 -0.12 0.08 0.30
P78410 Butyrophilin subfamily 3 member A2 1 11 0.15 0.26 0.11
O00478 Butyrophilin subfamily 3 member A3 4 16 0.05 0.12 -0.02
Q6UXG8 Butyrophilin-like protein 9 1 1 -0.84 -1.23 -0.38
Q13895 Bystin 5 25 0.01 -0.02 -0.09
P11586 C-1-tetrahydrofolate synthase, cytoplasmic 34 159 0.12 -0.03 -0.14
O14523 C2 domain-containing protein 2-like 1 1 -1.02 -0.87 0.16
Q4AC94 C2 domain-containing protein 3 1 3 0.68 0.98 0.31
Q86YS7 C2 domain-containing protein 5 7 14 0.13 0.01 -0.05
P21730 C5a anaphylatoxin chemotactic receptor 1 2 2 0.23 -0.02 -0.25
O75844 CAAX prenyl protease 1 homolog 5 14 0.04 0.17 0.24
Q8WUQ7 Cactin 6 12 -0.04 0.08 -0.07
P27708 CAD protein 31 96 0.41 0.02 -0.34
Q6ZTQ4 Cadherin-related family member 3 1 2 NA NA NA
Q99653 Calcineurin B homologous protein 1 2 2 0.41 0.32 -0.09
Q9Y6J0 Calcineurin-binding protein cabin-1 5 9 -0.08 -0.01 -0.04
Q99828 Calcium and integrin-binding protein 1 4 19 -0.24 0.44 0.63 4
Q8IWX8 Calcium homeostasis endoplasmic reticulum protein 9 14 0.06 0.14 0.01
Q96D31 Calcium release-activated calcium channel protein 1 1 2 0.21 0.43 0.22
P49069 Calcium signal-modulating cyclophilin ligand 2 2 -0.08 -0.04 0.05
Q8NE86 Calcium uniporter protein, mitochondrial 1 1 0.18 -1.19 -1.35
Q9BPX6 Calcium uptake protein 1, mitochondrial 1 3 0.31 0.11 -0.20
Q8IU85 Calcium/calmodulin-dependent protein kinase type 1D 7 12 0.19 0.30 0.09
Q13557 Calcium/calmodulin-dependent protein kinase type II subunit delta 8 55 0.42 0.52 0.06 5
Q13555 Calcium/calmodulin-dependent protein kinase type II subunit gamma 6 29 -0.09 -0.11 0.02
Q16566 Calcium/calmodulin-dependent protein kinase type IV 14 43 0.96 -0.23 -1.03 4 5
Q9P1Z2 Calcium-binding and coiled-coil domain-containing protein 1 2 2 -0.26 0.03 0.29
O75746 Calcium-binding mitochondrial carrier protein Aralar1 10 38 0.18 0.08 -0.15
Q6NUK1 Calcium-binding mitochondrial carrier protein SCaMC-1 15 72 0.83 0.56 -0.22 4 4
Q9Y376 Calcium-binding protein 39 7 16 0.39 -0.09 -0.49
Q9NP80 Calcium-independent phospholipase A2-gamma 1 2 NA NA NA
Q9Y2V2 Calcium-regulated heat stable protein 1 2 13 -1.18 -0.35 1.01 4 4
Q9HB71 Calcyclin-binding protein 9 21 0.47 -0.12 -0.35
Q9BXY5 Calcyphosin-2 1 1 0.49 0.00 -0.51
Q05682 Caldesmon 7 14 -0.18 -0.19 -0.10
P62158 Calmodulin 8 201 0.00 -0.06 0.09
Q9NZT1 Calmodulin-like protein 5 2 2 1.28 1.29 0.01
Q7Z624 Calmodulin-lysine N-methyltransferase 1 1 0.21 -0.23 -0.44
Q9P1Y5 Calmodulin-regulated spectrin-associated protein 3 1 1 -0.29 -0.20 0.08
P27824 Calnexin 12 69 0.17 0.61 0.51 3 5
P04632 Calpain small subunit 1 9 59 0.25 0.41 0.05
P07384 Calpain-1 catalytic subunit 11 55 -0.28 0.08 0.35
O75808 Calpain-15 2 5 -0.62 0.03 0.66 4
P17655 Calpain-2 catalytic subunit 17 99 0.64 0.63 0.21 3 5
Q9Y6W3 Calpain-7 4 8 0.17 -0.01 -0.10
P20810 Calpastatin 24 144 0.08 0.60 0.64 3 3
Q99439 Calponin-2 16 332 0.42 0.04 -0.45
Q15417 Calponin-3 3 20 -0.41 -0.87 -0.46
P27797 Calreticulin 16 123 -0.02 0.16 0.26
P17612 cAMP-dependent protein kinase catalytic subunit alpha 2 22 -0.35 -0.32 -0.10
P22694 cAMP-dependent protein kinase catalytic subunit beta 2 23 -0.53 -0.82 -0.08 3
P61925 cAMP-dependent protein kinase inhibitor alpha 1 1 -0.09 -1.27 -1.20
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit 16 108 -0.57 -0.75 -0.21 4 5
P31321 cAMP-dependent protein kinase type I-beta regulatory subunit 2 32 -0.19 -0.99 -0.75 4 4
P13861 cAMP-dependent protein kinase type II-alpha regulatory subunit 17 92 0.06 0.00 -0.09
P56211 cAMP-regulated phosphoprotein 19 1 38 0.49 0.15 -0.26
Q03060 cAMP-responsive element modulator 1 1 0.65 0.62 -0.02
O60519 cAMP-responsive element-binding protein-like 2 1 1 0.28 -0.36 -0.64
Q9BSD7 Cancer-related nucleoside-triphosphatase 7 47 0.00 -0.38 -0.37
P30622 CAP-Gly domain-containing linker protein 1 18 42 0.00 0.17 0.18
Q9UDT6 CAP-Gly domain-containing linker protein 2 2 3 -0.14 0.44 0.32
Q14444 Caprin-1 9 42 0.03 0.07 0.12
Q8N1G2 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 5 11 -0.29 0.02 0.31
Q8IYT2 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2 1 1 -0.23 -0.15 0.09
Q6JBY9 CapZ-interacting protein 17 118 0.00 -0.04 0.02
Q8IV04 Carabin 8 37 -0.62 -0.15 0.47
P31327 Carbamoyl-phosphate synthase, mitochondrial 2 5 NA 0.46 NA
P00915 Carbonic anhydrase 1 7 40 -0.45 -0.41 -0.14
P00918 Carbonic anhydrase 2 8 29 1.16 1.08 -0.19 5 5
Q9Y2D0 Carbonic anhydrase 5B, mitochondrial 4 6 -0.31 -0.37 -0.06
P16152 Carbonyl reductase 1 15 149 -0.17 -0.56 -0.36 5
O75828 Carbonyl reductase 3 8 68 -0.36 -2.23 -1.88 5 5
Q8N4T8 Carbonyl reductase family member 4 5 18 0.40 -0.23 -0.59
P48052 Carboxypeptidase A2 1 1 -0.92 -0.10 0.80
P43155 Carnitine O-acetyltransferase 9 24 0.42 0.37 0.00
P50416 Carnitine O-palmitoyltransferase 1, liver isoform 4 32 -0.51 0.34 0.87 3
P23786 Carnitine O-palmitoyltransferase 2, mitochondrial 6 15 -0.11 -0.09 0.13
A5YM72 Carnosine synthase 1 1 1 -1.01 -0.63 0.38
P49747 Cartilage oligomeric matrix protein 1 2 0.96 1.07 0.12
P48729 Casein kinase I isoform alpha 2 8 -0.14 0.03 0.18
P48730 Casein kinase I isoform delta 2 2 0.01 0.44 0.42
P49674 Casein kinase I isoform epsilon 1 2 0.11 0.14 0.03
P78368 Casein kinase I isoform gamma-2 1 2 -0.17 -0.09 0.09
P68400 Casein kinase II subunit alpha 9 41 0.08 0.03 -0.06
P19784 Casein kinase II subunit alpha' 5 12 -0.16 0.15 0.31
P67870 Casein kinase II subunit beta 5 24 0.08 0.01 -0.04
Q9H078 Caseinolytic peptidase B protein homolog 2 5 0.07 0.18 0.11
Q9H8G2 Caspase activity and apoptosis inhibitor 1 1 2 -0.82 -0.28 0.55
Q9BXL7 Caspase recruitment domain-containing protein 11 15 41 0.06 0.26 0.17
Q5EG05 Caspase recruitment domain-containing protein 16 1 29 -0.24 0.28 0.32
Q9Y2G2 Caspase recruitment domain-containing protein 8 5 11 0.13 0.27 0.25
P29466 Caspase-1 10 65 1.17 1.04 0.15 5 5
Q92851 Caspase-10 4 7 -0.89 -0.08 0.55 3
P31944 Caspase-14 6 7 0.33 0.83 -0.04 3
P42574 Caspase-3 2 22 -0.77 0.20 0.75 5 5
P49662 Caspase-4 3 14 0.05 0.23 0.18
P55210 Caspase-7 2 10 -0.05 0.10 0.05
Q14790 Caspase-8 5 19 -0.21 0.26 0.45
P55211 Caspase-9 1 1 -0.72 0.07 0.78
Q9BXW7 Cat eye syndrome critical region protein 5 9 38 0.47 0.00 -0.51
P04040 Catalase 16 66 -0.20 -0.21 0.05
P21964 Catechol O-methyltransferase 2 10 -0.20 -0.08 0.18
P07858 Cathepsin B 3 13 0.60 -0.02 -0.47
P07339 Cathepsin D 18 223 -1.04 0.10 1.21 4 4
P08311 Cathepsin G 4 17 0.12 -0.02 -0.37
P25774 Cathepsin S 7 18 -0.13 0.53 0.46 4 5
P56202 Cathepsin W 4 24 -0.41 0.89 1.61 5 5
Q9UBR2 Cathepsin Z 3 27 -0.49 0.69 0.87 5 5
P20645 Cation-dependent mannose-6-phosphate receptor 4 11 0.00 -0.07 0.04
P11717 Cation-independent mannose-6-phosphate receptor 19 47 -0.71 0.37 1.01 4 5
P51681 C-C chemokine receptor type 5 1 1 1.45 1.80 0.33
P13501 C-C motif chemokine 5 6 12 -1.49 -0.44 1.27 4 4
Q96Q11 CCA tRNA nucleotidyltransferase 1, mitochondrial 10 26 -0.08 -0.38 -0.36
P17676 CCAAT/enhancer-binding protein beta 1 1 NA NA NA
Q03701 CCAAT/enhancer-binding protein zeta 2 3 0.53 0.31 -0.22
A5YKK6 CCR4-NOT transcription complex subunit 1 14 30 0.10 0.11 0.01
Q9H9A5 CCR4-NOT transcription complex subunit 10 2 3 -0.34 0.10 0.30
Q9UKZ1 CCR4-NOT transcription complex subunit 11 2 8 0.00 0.02 -0.05
Q9NZN8 CCR4-NOT transcription complex subunit 2 7 32 -0.13 -0.06 0.12
O75175 CCR4-NOT transcription complex subunit 3 6 18 -0.20 -0.28 -0.10
Q96LI5 CCR4-NOT transcription complex subunit 6-like 3 4 0.23 0.00 -0.23
Q9UIV1 CCR4-NOT transcription complex subunit 7 2 3 -0.16 -0.05 0.10
O95971 CD160 antigen 1 2 -1.27 0.15 1.42
O95400 CD2 antigen cytoplasmic tail-binding protein 2 7 18 -0.49 -0.20 0.19
Q9Y5K6 CD2-associated protein 19 61 0.16 0.00 -0.17
P16070 CD44 antigen 9 126 0.72 0.65 -0.18 4 5
P09326 CD48 antigen 6 39 0.76 0.78 0.06 5 5
P13987 CD59 glycoprotein 2 13 0.75 0.50 -0.23 5 5
P60033 CD81 antigen 1 4 0.47 0.45 -0.02
P27701 CD82 antigen 1 1 0.46 0.77 0.32
P21926 CD9 antigen 1 8 0.23 -0.31 -0.48
P48960 CD97 antigen 5 46 -0.47 0.49 0.92 5
P14209 CD99 antigen 4 28 -0.01 0.34 0.85
Q9NRR8 CDC42 small effector protein 1 1 1 -0.91 0.45 1.38
Q9NRR3 CDC42 small effector protein 2 3 24 0.22 0.07 -0.12
Q15642 Cdc42-interacting protein 4 1 1 -0.04 0.81 0.85
Q9NZ45 CDGSH iron-sulfur domain-containing protein 1 4 11 0.25 -0.12 -0.34
Q8N5K1 CDGSH iron-sulfur domain-containing protein 2 4 10 0.37 0.45 0.18
P0C7P0 CDGSH iron-sulfur domain-containing protein 3, mitochondrial 5 9 -0.44 0.46 0.77
Q96SZ6 CDK5 regulatory subunit-associated protein 1 1 2 NA NA NA
Q96SN8 CDK5 regulatory subunit-associated protein 2 1 5 -0.97 -1.17 -0.19
Q96JB5 CDK5 regulatory subunit-associated protein 3 7 36 0.53 0.08 -0.27
P51948 CDK-activating kinase assembly factor MAT1 1 1 -1.02 -0.88 0.16
Q9NXV6 CDKN2A-interacting protein 19 81 -0.16 -0.32 -0.16
Q96HQ2 CDKN2AIP N-terminal-like protein 2 4 -0.50 0.08 0.58
Q32NB8 CDP-diacylglycerol--glycerol-3-phosphate 3-phosphatidyltransferase, mitochondrial 1 1 -0.02 -0.02 0.01
O14735 CDP-diacylglycerol--inositol 3-phosphatidyltransferase 1 4 NA NA NA
Q8N163 Cell cycle and apoptosis regulator protein 2 26 158 -0.07 -0.13 -0.01
Q99638 Cell cycle checkpoint control protein RAD9A 1 1 -0.28 -0.22 0.06
Q9NV96 Cell cycle control protein 50A 1 5 -1.07 0.15 1.23
Q9NQS1 Cell death regulator Aven 1 2 -0.10 0.11 0.21
Q92600 Cell differentiation protein RCD1 homolog 4 14 -0.09 -0.05 0.03
P60953 Cell division control protein 42 homolog 9 108 0.04 0.15 0.27
Q99459 Cell division cycle 5-like protein 28 131 -0.11 -0.09 0.02
Q8IX12 Cell division cycle and apoptosis regulator protein 1 21 88 -0.07 -0.11 -0.03
P30260 Cell division cycle protein 27 homolog 3 4 -0.22 0.21 0.16
Q9NX58 Cell growth-regulating nucleolar protein 15 63 0.33 0.33 0.12
P62633 Cellular nucleic acid-binding protein 9 43 0.28 -0.07 -0.30
P41208 Centrin-2 5 10 -0.06 -0.45 -0.32
O15182 Centrin-3 2 4 -0.20 -0.71 -0.51
Q6IQ19 Centriole, cilia and spindle-associated protein 1 1 0.62 -0.08 -0.69
Q7Z7A1 Centriolin 8 19 0.08 -0.20 -0.21
Q8N137 Centrobin 2 4 -0.12 -0.22 -0.09
Q03188 Centromere protein C 11 32 -0.37 -0.05 0.33
Q7Z7K6 Centromere protein V 6 21 0.10 -0.28 -0.40
O43264 Centromere/kinetochore protein zw10 homolog 1 1 1.56 -0.29 -1.84
Q02224 Centromere-associated protein E 1 7 0.64 0.19 -0.41
Q8N960 Centrosomal protein of 120 kDa 4 5 0.00 -0.08 -0.08
Q66GS9 Centrosomal protein of 135 kDa 3 6 -0.19 -0.15 0.04
Q5SW79 Centrosomal protein of 170 kDa 4 10 0.09 -0.30 -0.20
Q9BYV8 Centrosomal protein of 41 kDa 1 4 -0.24 -0.17 0.09
Q86XR8 Centrosomal protein of 57 kDa 4 11 0.12 -0.20 -0.22
Q8NA72 Centrosomal protein POC5 2 2 -1.18 -0.90 0.28
Q5VT06 Centrosome-associated protein 350 3 3 -0.08 0.08 0.17
Q9BV73 Centrosome-associated protein CEP250 19 33 -0.12 -0.12 0.00
Q9NWW5 Ceroid-lipofuscinosis neuronal protein 6 2 2 -0.13 -0.09 0.05
Q9UFW8 CGG triplet repeat-binding protein 1 9 38 0.02 0.01 0.13
Q13370 cGMP-inhibited 3',5'-cyclic phosphodiesterase B 2 2 0.65 0.49 -0.16
Q8NI60 Chaperone activity of bc1 complex-like, mitochondrial 4 9 -0.04 -0.49 -0.21
Q9HD42 Charged multivesicular body protein 1a 4 26 -0.07 0.09 0.27
Q7LBR1 Charged multivesicular body protein 1b 4 21 -0.32 -0.22 0.18
O43633 Charged multivesicular body protein 2a 7 51 -0.21 -0.06 0.09
Q9UQN3 Charged multivesicular body protein 2b 5 24 0.36 0.00 -0.33
Q9Y3E7 Charged multivesicular body protein 3 2 2 -0.06 -0.24 -0.18
Q9BY43 Charged multivesicular body protein 4a 8 46 -0.07 0.06 0.12
Q9H444 Charged multivesicular body protein 4b 10 77 -0.20 -0.19 0.04
Q9NZZ3 Charged multivesicular body protein 5 6 23 -0.26 -0.31 0.20
Q96FZ7 Charged multivesicular body protein 6 4 18 -0.17 0.38 0.50
Q8WUX9 Charged multivesicular body protein 7 5 12 0.06 -1.07 -1.14 3 3
Q9BWS9 Chitinase domain-containing protein 1 4 7 0.12 0.04 -0.07
Q9BT22 Chitobiosyldiphosphodolichol beta-mannosyltransferase 2 7 -0.07 0.09 0.16
Q96S66 Chloride channel CLIC-like protein 1 2 4 0.12 -0.36 -0.35
O00299 Chloride intracellular channel protein 1 18 289 -0.44 0.84 0.96 4 4
O95833 Chloride intracellular channel protein 3 12 60 -1.89 0.36 1.93 5 5
Q9Y696 Chloride intracellular channel protein 4 1 11 -0.78 -0.12 0.66
Q9NZA1 Chloride intracellular channel protein 5 2 11 1.43 0.61 -0.82
Q9Y259 Choline/ethanolamine kinase 4 12 0.01 0.14 -0.02
P49585 Choline-phosphate cytidylyltransferase A 7 24 -0.06 0.27 0.49 4
Q9NRG0 Chromatin accessibility complex protein 1 2 7 -0.18 -0.18 -0.01
Q8IXM2 Chromatin complexes subunit BAP18 9 92 -0.98 -0.09 0.82 5 5
Q9HAF1 Chromatin modification-related protein MEAF6 3 10 -0.04 -0.08 0.00
Q9Y3Y2 Chromatin target of PRMT1 protein 5 77 -0.16 -0.24 0.00
P83916 Chromobox protein homolog 1 7 113 0.03 0.13 0.01
Q13185 Chromobox protein homolog 3 11 137 -0.44 -0.27 0.19
P45973 Chromobox protein homolog 5 9 47 -0.14 -0.29 -0.19
O95503 Chromobox protein homolog 6 2 4 -0.13 0.21 0.19
Q9HC52 Chromobox protein homolog 8 2 5 -0.27 -0.08 0.20
Q9Y232 Chromodomain Y-like protein 2 7 -0.26 -0.01 0.26
O14647 Chromodomain-helicase-DNA-binding protein 2 4 4 -0.02 -0.07 -0.07
Q12873 Chromodomain-helicase-DNA-binding protein 3 7 32 -0.19 -0.35 -0.18
Q14839 Chromodomain-helicase-DNA-binding protein 4 20 72 -0.13 -0.04 0.14
Q9HCK8 Chromodomain-helicase-DNA-binding protein 8 3 23 -0.18 -0.10 0.06
Q96JM3 Chromosome alignment-maintaining phosphoprotein 1 12 30 -0.11 -0.22 -0.17
Q8WVB6 Chromosome transmission fidelity protein 18 homolog 1 1 0.07 0.10 0.03
P0CG12 Chromosome transmission fidelity protein 8 homolog isoform 2 7 53 -0.40 -0.17 0.22
Q9ULV3 Cip1-interacting zinc finger protein 6 9 -0.28 -0.19 0.25
Q8N0X4 Citrate lyase subunit beta-like protein, mitochondrial 8 18 0.27 -0.17 -0.43
O75390 Citrate synthase, mitochondrial 13 161 0.26 0.13 -0.14
O60271 C-Jun-amino-terminal kinase-interacting protein 4 10 12 -0.06 -0.02 0.11
Q9NX76 CKLF-like MARVEL transmembrane domain-containing protein 6 1 1 0.74 0.68 -0.06
Q00610 Clathrin heavy chain 1 52 293 -0.17 0.25 0.35
Q8NHS4 Clathrin heavy chain linker domain-containing protein 1 1 1 0.42 0.13 -0.27
Q14677 Clathrin interactor 1 10 32 -0.29 0.17 0.28
P09496 Clathrin light chain A 6 22 -0.67 0.35 1.03
P09497 Clathrin light chain B 5 32 -0.28 0.11 0.43
Q10570 Cleavage and polyadenylation specificity factor subunit 1 14 26 0.04 -0.17 -0.11
Q9P2I0 Cleavage and polyadenylation specificity factor subunit 2 8 17 -0.15 -0.17 -0.03
Q9UKF6 Cleavage and polyadenylation specificity factor subunit 3 7 19 -0.04 -0.15 -0.12
O95639 Cleavage and polyadenylation specificity factor subunit 4 4 6 0.00 -0.04 0.04
O43809 Cleavage and polyadenylation specificity factor subunit 5 11 49 -0.17 -0.18 -0.21
Q16630 Cleavage and polyadenylation specificity factor subunit 6 6 36 0.01 -0.03 -0.06
Q8N684 Cleavage and polyadenylation specificity factor subunit 7 11 80 -0.17 -0.19 -0.02
Q05048 Cleavage stimulation factor subunit 1 9 28 -0.03 -0.07 -0.07
P33240 Cleavage stimulation factor subunit 2 6 71 -0.16 -0.17 -0.01
Q9H0L4 Cleavage stimulation factor subunit 2 tau variant 9 53 -0.20 -0.25 0.00
Q12996 Cleavage stimulation factor subunit 3 6 9 0.10 -0.39 -0.32
O96005 Cleft lip and palate transmembrane protein 1 3 3 0.17 0.27 0.10
Q7Z460 CLIP-associating protein 1 10 24 0.06 0.13 0.42
O75122 CLIP-associating protein 2 10 28 -0.14 0.13 0.34
P10909 Clusterin 3 3 0.07 -0.48 -0.57
Q9UGN4 CMRF35-like molecule 8 3 3 -1.81 -0.57 1.25
Q7Z401 C-myc promoter-binding protein 1 3 -0.28 -0.28 0.01
Q99417 C-Myc-binding protein 4 21 -0.19 0.01 0.19
Q14019 Coactosin-like protein 13 156 -0.24 -1.53 -1.79 5 5
P12259 Coagulation factor V 2 2 0.94 1.07 0.13
P00488 Coagulation factor XIII A chain 9 28 -0.13 -0.28 -0.02
P53621 Coatomer subunit alpha 29 139 0.17 0.28 0.16
P53618 Coatomer subunit beta 16 86 0.10 0.27 0.19
P35606 Coatomer subunit beta' 16 48 0.13 0.34 0.08
P48444 Coatomer subunit delta 23 107 0.08 0.23 0.20
O14579 Coatomer subunit epsilon 10 38 0.25 0.20 0.10
Q9Y678 Coatomer subunit gamma-1 19 110 0.10 0.47 0.40 5
Q9UBF2 Coatomer subunit gamma-2 4 18 0.01 -0.12 -0.04
P61923 Coatomer subunit zeta-1 3 41 0.05 0.10 0.11
Q96EY8 Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial 1 3 -0.97 -0.46 0.51
O00748 Cocaine esterase 1 2 -3.43 0.18 3.63
Q8IWY9 Codanin-1 1 1 0.36 0.13 -0.23
P23528 Cofilin-1 15 605 -0.49 -0.24 0.37 5
Q9Y281 Cofilin-2 2 206 -0.12 0.10 0.22
Q8WVM7 Cohesin subunit SA-1 5 12 -0.04 -0.11 0.14
Q8N3U4 Cohesin subunit SA-2 5 20 -0.09 0.04 0.21
Q6P1N0 Coiled-coil and C2 domain-containing protein 1A 9 13 -0.26 0.14 0.44
Q5T0F9 Coiled-coil and C2 domain-containing protein 1B 7 18 -0.27 -0.09 0.31
Q96A19 Coiled-coil domain-containing protein 102A 3 6 -0.32 0.03 0.48
Q96NT0 Coiled-coil domain-containing protein 115 1 1 -0.13 -0.09 0.02
Q8IWD4 Coiled-coil domain-containing protein 117 1 2 -1.36 -0.38 0.98
Q8WUD4 Coiled-coil domain-containing protein 12 5 30 -0.23 -0.17 0.18
Q96CT7 Coiled-coil domain-containing protein 124 6 21 0.22 -0.09 -0.21
Q96BQ5 Coiled-coil domain-containing protein 127 1 2 -0.10 -0.11 -0.01
Q96JG6 Coiled-coil domain-containing protein 132 4 4 -0.11 0.05 0.08
Q9H6E4 Coiled-coil domain-containing protein 134 2 2 -0.01 0.17 0.17
Q6PK04 Coiled-coil domain-containing protein 137 3 8 -0.15 0.00 0.08
Q8NCX0 Coiled-coil domain-containing protein 150 1 5 -0.19 -0.35 -0.15
Q6TFL3 Coiled-coil domain-containing protein 171 1 1 0.16 0.33 0.17
Q9P1Z9 Coiled-coil domain-containing protein 180 1 7 NA NA NA
O60826 Coiled-coil domain-containing protein 22 7 12 -0.13 -0.02 0.20
Q86WR0 Coiled-coil domain-containing protein 25 2 3 0.23 -0.06 -0.31
Q8IWP9 Coiled-coil domain-containing protein 28A 1 4 -0.03 -0.06 -0.02
Q96M95 Coiled-coil domain-containing protein 42A 1 1 0.32 -0.47 -0.79
Q96MW1 Coiled-coil domain-containing protein 43 2 14 0.03 0.05 -0.05
Q96A33 Coiled-coil domain-containing protein 47 4 5 0.18 0.21 0.10
Q8IVM0 Coiled-coil domain-containing protein 50 1 4 -1.19 -0.09 1.09 4 4
Q96ER9 Coiled-coil domain-containing protein 51 1 7 0.22 0.02 -0.20
Q4VC31 Coiled-coil domain-containing protein 58 4 16 0.17 -0.07 -0.39
Q16204 Coiled-coil domain-containing protein 6 9 23 -0.14 0.15 0.25
A2IDD5 Coiled-coil domain-containing protein 78 1 1 NA NA NA
Q8N4S0 Coiled-coil domain-containing protein 82 1 1 -1.96 -1.39 0.58
Q9H6F5 Coiled-coil domain-containing protein 86 9 26 0.30 -0.10 -0.39
A6NC98 Coiled-coil domain-containing protein 88B 34 88 -0.41 0.09 0.71 5
Q9Y3X0 Coiled-coil domain-containing protein 9 6 28 -0.05 -0.03 0.04
Q9GZT6 Coiled-coil domain-containing protein 90B, mitochondrial 3 5 0.03 -0.10 -0.24
Q7Z6B0 Coiled-coil domain-containing protein 91 3 5 0.32 -0.01 -0.32
Q567U6 Coiled-coil domain-containing protein 93 6 9 -0.01 0.07 0.20
Q9BW85 Coiled-coil domain-containing protein 94 3 9 -0.06 -0.01 0.13
Q96F63 Coiled-coil domain-containing protein 97 1 2 0.18 0.14 -0.03
Q96BP2 Coiled-coil-helix-coiled-coil-helix domain-containing protein 1 1 1 0.10 0.03 -0.09
Q9NX63 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial 13 57 0.04 0.04 -0.01
Q9BRQ6 Coiled-coil-helix-coiled-coil-helix domain-containing protein 6, mitochondrial 3 7 0.32 -0.16 -0.59
Q9BUK0 Coiled-coil-helix-coiled-coil-helix domain-containing protein 7 1 1 0.63 0.56 -0.06
P38432 Coilin 1 1 -0.11 0.06 0.18
O75534 Cold shock domain-containing protein E1 10 30 0.04 0.01 -0.09
Q14011 Cold-inducible RNA-binding protein 5 32 -0.26 -0.07 0.27
P12109 Collagen alpha-1(VI) chain 1 1 0.80 0.50 -0.29
P39060 Collagen alpha-1(XVIII) chain 1 3 NA NA NA
P08123 Collagen alpha-2(I) chain 1 2 NA NA NA
Q9Y5P4 Collagen type IV alpha-3-binding protein 1 3 -0.09 0.07 0.19
P23508 Colorectal mutant cancer protein 1 2 NA NA NA
Q8N668 COMM domain-containing protein 1 1 3 -0.28 0.40 0.68
Q9UBI1 COMM domain-containing protein 3 2 4 -0.09 -0.07 0.06
Q7Z4G1 COMM domain-containing protein 6 2 2 -0.71 -0.23 0.49
Q9NX08 COMM domain-containing protein 8 2 5 -0.19 0.06 0.21
Q9P000 COMM domain-containing protein 9 2 3 -0.12 -0.77 -0.13
P01024 Complement C3 1 6 0.96 1.19 0.23
P0C0L4 Complement C4-A 1 2 -0.41 0.27 0.67
Q07021 Complement component 1 Q subcomponent-binding protein, mitochondrial 6 24 0.52 0.05 -0.36
P02748 Complement component C9 1 2 NA NA NA
Q9NPL8 Complex I assembly factor TIMMDC1, mitochondrial 1 2 -0.07 -0.46 -0.38
Q8IUX1 Complex I assembly factor TMEM126B, mitochondrial 1 1 -0.02 -0.17 -0.15
Q5U5X0 Complex III assembly factor LYRM7 1 4 0.01 -0.22 0.07
Q8WTW3 Conserved oligomeric Golgi complex subunit 1 4 5 0.04 0.06 -0.01
Q14746 Conserved oligomeric Golgi complex subunit 2 3 5 0.01 0.19 0.22
Q96JB2 Conserved oligomeric Golgi complex subunit 3 1 1 0.25 0.31 0.07
Q9H9E3 Conserved oligomeric Golgi complex subunit 4 2 2 0.03 0.12 0.09
Q9UP83 Conserved oligomeric Golgi complex subunit 5 1 2 NA NA NA
Q9Y2V7 Conserved oligomeric Golgi complex subunit 6 2 2 0.01 0.08 0.07
P83436 Conserved oligomeric Golgi complex subunit 7 2 4 -0.11 0.07 0.18
Q6PJW8 Consortin 1 1 -0.16 -0.06 0.08
Q96EK7 Constitutive coactivator of peroxisome proliferator-activated receptor gamma 3 10 -0.09 -0.11 -0.10
Q9NZB2 Constitutive coactivator of PPAR-gamma-like protein 1 24 61 0.07 0.15 0.16
Q13098 COP9 signalosome complex subunit 1 7 25 0.17 -0.06 -0.19
P61201 COP9 signalosome complex subunit 2 6 9 0.28 0.01 -0.30
Q9UNS2 COP9 signalosome complex subunit 3 10 32 0.24 -0.15 -0.17
Q9BT78 COP9 signalosome complex subunit 4 12 77 0.28 0.01 -0.24
Q92905 COP9 signalosome complex subunit 5 4 26 0.43 0.17 -0.32
Q7L5N1 COP9 signalosome complex subunit 6 6 28 0.20 -0.04 -0.27
Q9UBW8 COP9 signalosome complex subunit 7a 3 4 0.32 0.04 -0.27
Q9H9Q2 COP9 signalosome complex subunit 7b 3 20 -0.07 -0.12 0.05
Q99627 COP9 signalosome complex subunit 8 4 27 0.20 0.04 -0.09
Q99829 Copine-1 13 83 0.14 0.24 0.08
O75131 Copine-3 12 58 0.17 0.13 -0.03
O14618 Copper chaperone for superoxide dismutase 6 31 -0.24 -0.34 -0.14
Q9NTM9 Copper homeostasis protein cutC homolog 7 31 0.04 -0.35 -0.26
O00244 Copper transport protein ATOX1 5 18 -0.64 0.30 0.84 3 4
Q04656 Copper-transporting ATPase 1 1 2 NA NA NA
P36551 Coproporphyrinogen-III oxidase, mitochondrial 5 17 0.06 0.11 0.07
O75367 Core histone macro-H2A.1 20 597 0.03 -0.12 -0.11
Q9P0M6 Core histone macro-H2A.2 1 70 -0.07 -0.01 0.04
Q13951 Core-binding factor subunit beta 6 39 -0.27 -0.13 0.20
Q15517 Corneodesmosin 2 2 -0.15 -1.87 -1.74
P31146 Coronin-1A 24 786 0.01 -0.03 -0.06
Q9BR76 Coronin-1B 2 3 -0.69 -0.24 0.46
Q9ULV4 Coronin-1C 6 15 -0.86 -0.06 0.64 5 5
Q92828 Coronin-2A 3 3 0.11 -0.12 -0.30
P57737 Coronin-7 23 146 0.27 0.25 0.06
Q9P1F3 Costars family protein ABRACL 1 7 NA NA NA
Q9NRP2 COX assembly mitochondrial protein 2 homolog 1 3 -1.01 -0.26 0.74
Q7Z7K0 COX assembly mitochondrial protein homolog 1 2 0.21 0.28 0.07
Q9P0U4 CpG-binding protein 2 5 -0.09 -0.26 -0.17
Q9UEE9 Craniofacial development protein 1 2 6 0.16 -0.18 -0.34
Q8IUR6 CREB3 regulatory factor 1 1 0.13 -0.31 -0.42
Q92793 CREB-binding protein 9 20 -0.10 -0.04 0.14
Q6UUV9 CREB-regulated transcription coactivator 1 3 3 -1.31 -0.46 0.76
Q53ET0 CREB-regulated transcription coactivator 2 3 7 -0.07 0.17 0.21
Q6UUV7 CREB-regulated transcription coactivator 3 4 11 -0.45 -0.40 0.12
P46109 Crk-like protein 10 66 -0.02 0.19 0.23
Q9BZJ0 Crooked neck-like protein 1 7 15 -0.04 0.13 0.04
Q9H668 CST complex subunit STN1 1 1 -0.08 -0.07 0.02
O15320 cTAGE family member 5 5 8 -0.36 -0.13 -0.03
Q05D32 CTD small phosphatase-like protein 2 5 19 -0.09 -0.02 0.09
Q13363 C-terminal-binding protein 1 8 83 -0.28 0.11 0.35
P56545 C-terminal-binding protein 2 4 29 -1.34 0.05 1.25 3 3
P17812 CTP synthase 1 4 13 -0.29 -0.19 0.07
Q9NRF8 CTP synthase 2 1 3 0.04 -0.64 -0.69
Q9Y240 C-type lectin domain family 11 member A 1 1 0.49 0.63 0.14
Q92478 C-type lectin domain family 2 member B 1 3 -0.59 0.51 1.03 3
Q92879 CUGBP Elav-like family member 1 1 9 0.23 0.04 -0.21
O95319 CUGBP Elav-like family member 2 10 68 -0.15 -0.06 0.19
Q13616 Cullin-1 5 7 -0.11 0.05 0.05
Q13617 Cullin-2 6 22 0.16 -0.09 -0.18
Q13618 Cullin-3 8 28 0.19 -0.01 -0.28
Q13619 Cullin-4A 3 16 0.27 0.18 -0.09
Q13620 Cullin-4B 5 26 0.28 -0.05 -0.34
Q93034 Cullin-5 3 6 0.32 0.07 -0.15
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 32 127 0.22 -0.02 -0.28
Q69YN2 CWF19-like protein 1 8 14 0.19 -0.16 -0.20
Q2TBE0 CWF19-like protein 2 2 3 -0.05 0.25 0.31
Q7LFL8 CXXC-type zinc finger protein 5 1 1 -1.24 0.47 1.72
P18846 Cyclic AMP-dependent transcription factor ATF-1 1 28 -0.69 -0.16 0.52
P15336 Cyclic AMP-dependent transcription factor ATF-2 1 6 -0.40 0.02 0.43
P17544 Cyclic AMP-dependent transcription factor ATF-7 1 1 -1.70 0.10 1.81
P16220 Cyclic AMP-responsive element-binding protein 1 4 54 -0.26 -0.07 0.00
Q9UQ88 Cyclin-dependent kinase 11A 6 17 0.11 -0.28 -0.15
Q9NYV4 Cyclin-dependent kinase 12 5 7 -0.14 -0.29 -0.04
Q14004 Cyclin-dependent kinase 13 2 3 -0.27 -0.01 0.27
Q00537 Cyclin-dependent kinase 17 2 3 0.09 0.49 0.50
Q9BWU1 Cyclin-dependent kinase 19 1 4 -0.32 0.21 0.40
P24941 Cyclin-dependent kinase 2 4 9 -0.52 -0.29 0.23
P42773 Cyclin-dependent kinase 4 inhibitor C 4 9 -0.55 0.27 0.51
Q00535 Cyclin-dependent kinase 5 2 9 -0.22 0.03 0.19
Q00534 Cyclin-dependent kinase 6 3 16 0.13 0.52 0.52 3 4
P50750 Cyclin-dependent kinase 9 3 21 -0.28 -0.14 0.01
P46527 Cyclin-dependent kinase inhibitor 1B 7 32 0.11 0.01 -0.03
O14976 Cyclin-G-associated kinase 17 56 -0.11 0.18 0.26
O75909 Cyclin-K 1 1 0.30 0.03 -0.26
Q96S94 Cyclin-L2 1 4 -0.25 -0.16 0.04
O60563 Cyclin-T1 4 6 -0.41 -0.35 0.06
Q8ND76 Cyclin-Y 2 10 0.02 0.03 0.01
P01040 Cystatin-A 1 1 -0.19 -2.45 -2.27
P04080 Cystatin-B 5 66 -0.22 -0.02 -0.17
O76096 Cystatin-F 3 22 -0.63 1.33 1.93 4 5 5
Q15828 Cystatin-M 1 1 0.01 -1.07 -1.10
P21291 Cysteine and glycine-rich protein 1 7 33 -0.10 0.26 0.17
Q9UHD1 Cysteine and histidine-rich domain-containing protein 1 8 21 -0.01 -0.25 -0.18
Q9Y697 Cysteine desulfurase, mitochondrial 8 15 0.20 -0.34 -0.46
Q9Y4P1 Cysteine protease ATG4B 1 1 -0.13 0.03 0.17
Q9P021 Cysteine-rich PDZ-binding protein 1 1 0.47 1.15 0.69
P50238 Cysteine-rich protein 1 4 29 0.47 0.52 -0.02 3
P52943 Cysteine-rich protein 2 1 13 0.54 0.28 -0.26
Q6UXH1 Cysteine-rich with EGF-like domain protein 2 1 1 -0.03 0.07 0.11
P49589 Cysteine--tRNA ligase, cytoplasmic 13 48 0.30 0.18 -0.01
Q53TN4 Cytochrome b reductase 1 1 2 -1.52 -0.16 1.37
P04839 Cytochrome b-245 heavy chain 2 4 0.22 0.01 -0.21
P13498 Cytochrome b-245 light chain 1 2 0.26 0.66 0.40
P00167 Cytochrome b5 4 22 0.54 0.23 -0.22
Q7L1T6 Cytochrome b5 reductase 4 1 1 0.03 0.24 0.21
O43169 Cytochrome b5 type B 1 2 -0.16 0.07 0.23
O14569 Cytochrome b561 domain-containing protein 2 1 1 0.92 0.93 0.02
P31930 Cytochrome b-c1 complex subunit 1, mitochondrial 14 139 0.29 0.11 0.09
P22695 Cytochrome b-c1 complex subunit 2, mitochondrial 22 219 0.07 0.10 0.04
P07919 Cytochrome b-c1 complex subunit 6, mitochondrial 5 7 -0.71 -0.26 0.12
P14927 Cytochrome b-c1 complex subunit 7 6 22 -0.12 0.08 0.35
O14949 Cytochrome b-c1 complex subunit 8 4 21 -0.06 0.02 0.12
Q9UDW1 Cytochrome b-c1 complex subunit 9 1 3 0.36 0.23 -0.13
P47985 Cytochrome b-c1 complex subunit Rieske, mitochondrial 9 72 -0.14 0.04 0.17
P99999 Cytochrome c 10 127 0.10 0.25 0.00
Q9NYJ1 Cytochrome c oxidase assembly factor 4 homolog, mitochondrial 1 2 0.09 -0.14 -0.24
Q5JTJ3 Cytochrome c oxidase assembly factor 6 homolog 1 1 -0.12 0.11 0.22
Q9Y2R0 Cytochrome c oxidase assembly protein 3 homolog, mitochondrial 2 3 0.55 0.29 -0.27
Q49B96 Cytochrome c oxidase assembly protein COX19 1 4 0.13 0.00 0.00
Q14061 Cytochrome c oxidase copper chaperone 1 5 0.02 -0.02 0.36
Q5RI15 Cytochrome c oxidase protein 20 homolog 1 1 0.54 0.35 -0.18
P00403 Cytochrome c oxidase subunit 2 5 50 0.51 0.29 -0.25
P13073 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 6 80 0.33 0.23 -0.09
P20674 Cytochrome c oxidase subunit 5A, mitochondrial 6 102 -0.08 -0.08 0.11
P10606 Cytochrome c oxidase subunit 5B, mitochondrial 6 61 0.07 -0.11 -0.10
P14854 Cytochrome c oxidase subunit 6B1 5 19 0.60 0.27 -0.25
P09669 Cytochrome c oxidase subunit 6C 2 26 -0.07 -0.13 -0.21
P14406 Cytochrome c oxidase subunit 7A2, mitochondrial 3 31 0.22 0.01 -0.19
O14548 Cytochrome c oxidase subunit 7A-related protein, mitochondrial 4 13 -0.02 0.45 0.43
P15954 Cytochrome c oxidase subunit 7C, mitochondrial 3 28 0.41 0.00 -0.23
P10176 Cytochrome c oxidase subunit 8A, mitochondrial 1 5 -0.15 -0.39 -0.08
P08574 Cytochrome c1, heme protein, mitochondrial 3 8 -0.02 -0.12 -0.01
Q6UW02 Cytochrome P450 20A1 3 7 0.49 0.16 -0.20
Q15438 Cytohesin-1 4 22 0.23 -0.14 -0.59
O43739 Cytohesin-3 1 15 0.48 0.72 0.19 3
Q9UIA0 Cytohesin-4 3 4 -0.02 -0.36 -0.32
O60759 Cytohesin-interacting protein 2 19 0.12 -0.32 -0.41 5
P31785 Cytokine receptor common subunit gamma 1 5 -0.36 0.03 0.42
Q8IUI8 Cytokine receptor-like factor 3 11 75 -0.03 -0.47 -0.48 5
P21399 Cytoplasmic aconitate hydratase 8 35 -0.02 -0.23 -0.34
Q14204 Cytoplasmic dynein 1 heavy chain 1 85 306 0.12 0.29 0.06
Q13409 Cytoplasmic dynein 1 intermediate chain 2 9 50 0.00 -0.01 0.10
Q9Y6G9 Cytoplasmic dynein 1 light intermediate chain 1 8 27 -0.10 -0.09 0.05
O43237 Cytoplasmic dynein 1 light intermediate chain 2 5 18 0.18 -0.12 -0.13
Q7L576 Cytoplasmic FMR1-interacting protein 1 2 49 -0.39 0.04 0.39
Q96F07 Cytoplasmic FMR1-interacting protein 2 8 62 -0.02 0.30 0.28
Q9UKF7 Cytoplasmic phosphatidylinositol transfer protein 1 2 10 -0.35 0.00 0.25
P16333 Cytoplasmic protein NCK1 5 17 -0.28 -0.01 0.36
O43639 Cytoplasmic protein NCK2 2 9 -0.10 -0.25 -0.14
Q7Z7A3 Cytoplasmic tRNA 2-thiolation protein 1 3 3 -0.17 -0.19 -0.03
Q2VPK5 Cytoplasmic tRNA 2-thiolation protein 2 1 1 -0.15 -0.14 0.01
Q07065 Cytoskeleton-associated protein 4 7 20 0.52 0.18 -0.45
Q14008 Cytoskeleton-associated protein 5 22 65 -0.05 -0.04 0.07
P28838 Cytosol aminopeptidase 21 162 -0.24 0.21 0.47
Q9H0P0 Cytosolic 5'-nucleotidase 3A 1 1 -0.26 0.11 0.37
O00154 Cytosolic acyl coenzyme A thioester hydrolase 3 5 -0.95 -0.32 0.63 3
Q9UPW5 Cytosolic carboxypeptidase 1 3 7 -0.17 0.25 0.53
Q8NFI3 Cytosolic endo-beta-N-acetylglucosaminidase 6 18 -0.19 -0.46 -0.44 4
Q9H6Q4 Cytosolic Fe-S cluster assembly factor NARFL 2 2 0.10 0.07 -0.04
P53384 Cytosolic Fe-S cluster assembly factor NUBP1 5 11 0.02 -0.12 -0.09
Q9Y5Y2 Cytosolic Fe-S cluster assembly factor NUBP2 6 30 -0.15 0.04 0.06
Q96KP4 Cytosolic non-specific dipeptidase 24 238 0.03 0.17 0.09
P49902 Cytosolic purine 5'-nucleotidase 1 6 0.04 -0.09 -0.02
Q69YQ0 Cytospin-A 2 3 -0.52 -0.14 0.39
Q5M775 Cytospin-B 5 10 -0.80 0.18 1.24 3 5
O43175 D-3-phosphoglycerate dehydrogenase 10 37 -0.09 -1.19 -1.66 5 5
Q96EP5 DAZ-associated protein 1 6 28 -0.30 0.05 0.21
Q15038 DAZ-associated protein 2 1 1 0.04 -0.16 -0.20
Q02338 D-beta-hydroxybutyrate dehydrogenase, mitochondrial 4 9 0.79 0.06 -0.64 3
Q5BKZ1 DBIRD complex subunit ZNF326 3 9 -0.76 -0.14 0.73 4 4
Q9UKG1 DCC-interacting protein 13-alpha 9 46 -0.03 0.21 0.27
Q96GG9 DCN1-like protein 1 3 3 -0.51 -0.11 0.39
Q8IWE4 DCN1-like protein 3 1 1 0.56 0.68 0.13
Q9H773 dCTP pyrophosphatase 1 3 14 0.35 -0.32 -0.85 3
Q8TEB1 DDB1- and CUL4-associated factor 11 2 4 -0.53 -0.70 -0.17
Q9NV06 DDB1- and CUL4-associated factor 13 4 7 0.18 -0.08 -0.24
Q96JK2 DDB1- and CUL4-associated factor 5 1 2 -0.25 0.23 0.48
P61962 DDB1- and CUL4-associated factor 7 5 22 -0.25 0.12 0.31
Q5TAQ9 DDB1- and CUL4-associated factor 8 1 1 -0.18 0.13 0.31
P30046 D-dopachrome decarboxylase 2 16 0.07 -0.02 -0.15
Q96HY6 DDRGK domain-containing protein 1 6 34 0.25 0.04 -0.15
Q9UER7 Death domain-associated protein 6 5 6 -0.10 -0.19 0.07
Q9BTC0 Death-inducer obliterator 1 23 49 -0.09 -0.10 0.00
Q96BY6 Dedicator of cytokinesis protein 10 31 86 -0.10 -0.28 -0.18
Q5JSL3 Dedicator of cytokinesis protein 11 22 62 -0.08 -0.08 -0.02
Q92608 Dedicator of cytokinesis protein 2 29 107 0.17 0.23 0.00
Q8NF50 Dedicator of cytokinesis protein 8 30 105 0.00 -0.04 0.03
Q9BZ29 Dedicator of cytokinesis protein 9 4 7 0.55 0.19 -0.35
Q9BTZ2 Dehydrogenase/reductase SDR family member 4 7 47 0.02 -0.06 -0.09
Q9Y394 Dehydrogenase/reductase SDR family member 7 6 29 0.16 0.73 0.48 5 4
Q8N5I4 Dehydrogenase/reductase SDR family member on chromosome X 1 1 0.02 0.27 0.25
Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 17 173 -0.01 0.06 0.13
P30038 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 3 5 -0.41 0.07 0.49
P54886 Delta-1-pyrroline-5-carboxylate synthase 12 33 0.25 0.04 -0.33
P13716 Delta-aminolevulinic acid dehydratase 8 33 -0.06 -0.41 -0.29 4
Q08495 Dematin 3 7 -0.14 -0.23 0.01
Q8TEH3 DENN domain-containing protein 1A 2 4 -0.66 0.04 0.70
Q8IV53 DENN domain-containing protein 1C 6 14 -0.08 0.08 0.14
Q9H6A0 DENN domain-containing protein 2D 6 14 -0.11 -0.32 -0.35
O75064 DENN domain-containing protein 4B 4 7 0.19 0.28 0.32
Q5VZ89 DENN domain-containing protein 4C 9 16 0.20 0.41 0.20
O43583 Density-regulated protein 6 29 0.01 -0.07 -0.14
P27707 Deoxycytidine kinase 8 45 -0.17 -0.10 -0.06
P32321 Deoxycytidylate deaminase 2 3 0.00 0.16 0.10
Q9BU89 Deoxyhypusine hydroxylase 1 1 -0.10 -0.07 0.05
P49366 Deoxyhypusine synthase 1 5 -0.01 -0.09 -0.11
Q9Y3Z3 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 36 372 -0.20 -0.08 0.10
Q9H147 Deoxynucleotidyltransferase terminal-interacting protein 1 6 12 0.16 0.11 0.06
Q5QJE6 Deoxynucleotidyltransferase terminal-interacting protein 2 12 50 0.24 0.02 -0.16
O00115 Deoxyribonuclease-2-alpha 1 13 -1.42 0.39 1.93 5 5
P33316 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 9 38 -0.07 -0.24 -0.16
O75140 DEP domain-containing protein 5 2 2 0.09 -0.15 -0.24
Q9GZP9 Derlin-2 1 1 0.17 0.23 0.04
P81605 Dermcidin 6 75 0.23 -0.24 -0.42
Q6E0U4 Dermokine 2 5 0.04 0.34 0.30
P17661 Desmin 1 180 1.18 0.49 -0.68
Q08554 Desmocollin-1 3 5 0.02 -1.54 -1.46
Q14574 Desmocollin-3 1 1 0.18 -1.72 -1.92
Q02413 Desmoglein-1 7 22 -0.04 0.58 -0.06 3
P15924 Desmoplakin 7 12 0.79 0.86 0.08
P60981 Destrin 7 93 -0.31 0.08 0.37
Q9BW61 DET1- and DDB1-associated protein 1 3 6 0.02 0.13 0.10
Q96JH7 Deubiquitinating protein VCIP135 20 50 -0.18 0.13 0.32
Q9Y295 Developmentally-regulated GTP-binding protein 1 12 59 0.35 -0.09 -0.42
P55039 Developmentally-regulated GTP-binding protein 2 5 15 0.20 0.01 -0.12
Q9NR28 Diablo homolog, mitochondrial 7 34 -0.03 0.21 0.15
P23743 Diacylglycerol kinase alpha 23 126 0.54 -0.86 -1.45 4 5 5
Q86XP1 Diacylglycerol kinase eta 1 2 -0.20 -0.17 0.03
P52824 Diacylglycerol kinase theta 4 8 -0.90 0.12 0.96 5 5
Q13574 Diacylglycerol kinase zeta 7 25 -0.12 -0.41 -0.18
Q9H4E7 Differentially expressed in FDCP 6 homolog 15 154 -0.15 0.04 0.16
Q68CQ4 Digestive organ expansion factor homolog 1 1 0.73 -0.08 -0.83
P09622 Dihydrolipoyl dehydrogenase, mitochondrial 15 132 0.26 0.09 -0.13
P10515 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex12 73 0.52 0.07 -0.40
P36957 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex13 137 0.42 0.03 -0.18
Q02127 Dihydroorotate dehydrogenase (quinone), mitochondrial 4 5 0.54 -0.16 -0.53
P09417 Dihydropteridine reductase 6 39 0.55 -0.08 -0.70 5 5
Q16555 Dihydropyrimidinase-related protein 2 18 137 -0.74 0.05 0.62 4 4
O14531 Dihydropyrimidinase-related protein 4 1 1 -1.36 -0.27 1.09
Q9BPU6 Dihydropyrimidinase-related protein 5 1 20 -0.75 0.11 0.49
Q12882 Dihydropyrimidine dehydrogenase 16 55 0.28 0.04 -0.21
Q01459 Di-N-acetylchitobiase 4 9 -0.16 0.41 0.72 4 3
P53634 Dipeptidyl peptidase 1 6 60 -1.33 0.41 1.60 5 5
Q9UHL4 Dipeptidyl peptidase 2 8 61 0.22 0.33 0.06 5
Q9NY33 Dipeptidyl peptidase 3 15 64 -0.37 0.12 0.48
P27487 Dipeptidyl peptidase 4 10 49 2.61 2.39 -0.25 5 5
Q86TI2 Dipeptidyl peptidase 9 4 9 -0.33 0.41 0.52
O95989 Diphosphoinositol polyphosphate phosphohydrolase 1 2 10 0.03 0.07 -0.18
Q9NZJ9 Diphosphoinositol polyphosphate phosphohydrolase 2 3 13 -0.05 -0.33 -0.21
P53602 Diphosphomevalonate decarboxylase 7 33 -0.67 0.04 0.74 4 3
Q9BQC3 Diphthamide biosynthesis protein 2 2 3 0.15 0.20 0.05
Q8IYB7 DIS3-like exonuclease 2 3 4 -0.06 -0.02 -0.13
Q14689 Disco-interacting protein 2 homolog A 1 1 -0.14 -0.07 0.08
Q9P265 Disco-interacting protein 2 homolog B 1 2 -0.19 0.06 0.25
O14672 Disintegrin and metalloproteinase domain-containing protein 10 5 16 0.02 0.71 0.82 5 5
P78536 Disintegrin and metalloproteinase domain-containing protein 17 1 1 0.17 0.35 0.19
Q12959 Disks large homolog 1 3 8 0.26 0.18 -0.23
Q92796 Disks large homolog 3 2 3 -0.14 -0.07 0.34
Q9Y2H0 Disks large-associated protein 4 8 10 -0.17 -0.04 0.12
P26358 DNA (cytosine-5)-methyltransferase 1 12 28 -0.07 0.08 0.09
Q9Y6K1 DNA (cytosine-5)-methyltransferase 3A 2 8 -0.01 -0.19 0.06
Q16531 DNA damage-binding protein 1 24 63 0.01 0.19 0.06
Q92466 DNA damage-binding protein 2 3 7 0.07 -0.03 -0.07
Q9NRW3 DNA dC->dU-editing enzyme APOBEC-3C 1 1 -0.10 0.39 0.49
Q8IUX4 DNA dC->dU-editing enzyme APOBEC-3F 1 1 -0.14 0.02 0.14
Q9HC16 DNA dC->dU-editing enzyme APOBEC-3G 2 14 -1.15 0.64 1.42 5 4 5
Q03468 DNA excision repair protein ERCC-6 2 3 -0.69 -0.18 0.52
O00273 DNA fragmentation factor subunit alpha 9 52 0.07 -0.01 -0.20
Q9ULG1 DNA helicase INO80 3 3 -0.15 0.06 0.21
P49916 DNA ligase 3 12 44 -0.17 0.04 0.14
Q9NPF5 DNA methyltransferase 1-associated protein 1 7 17 -0.19 -0.14 -0.03
P40692 DNA mismatch repair protein Mlh1 1 1 0.03 0.03 -0.01
P43246 DNA mismatch repair protein Msh2 12 19 0.00 -0.19 -0.11
P52701 DNA mismatch repair protein Msh6 9 23 -0.14 -0.22 -0.07
P06746 DNA polymerase beta 6 15 -0.51 -0.52 -0.03
P28340 DNA polymerase delta catalytic subunit 1 3 0.10 -0.09 -0.19
P49005 DNA polymerase delta subunit 2 1 2 -0.26 -0.41 -0.17
Q15054 DNA polymerase delta subunit 3 2 2 -0.21 -0.13 0.09
Q9NRF9 DNA polymerase epsilon subunit 3 3 5 -0.48 -0.31 0.32
Q9NR33 DNA polymerase epsilon subunit 4 1 1 0.40 -0.05 -0.45
P54098 DNA polymerase subunit gamma-1 2 3 0.58 0.30 -0.27
Q9UHN1 DNA polymerase subunit gamma-2, mitochondrial 1 1 NA NA NA
Q92889 DNA repair endonuclease XPF 2 4 0.11 -0.43 -0.11
P23025 DNA repair protein complementing XP-A cells 1 9 -0.05 -0.05 0.03
Q01831 DNA repair protein complementing XP-C cells 7 30 0.09 -0.23 -0.38
P28715 DNA repair protein complementing XP-G cells 3 5 0.06 -0.25 -0.18
Q92878 DNA repair protein RAD50 25 64 -0.19 -0.09 0.11
P18887 DNA repair protein XRCC1 10 41 -0.25 -0.04 0.28
Q13426 DNA repair protein XRCC4 2 4 -0.65 -0.33 0.31
P49736 DNA replication licensing factor MCM2 6 9 -0.77 -0.42 0.27
P25205 DNA replication licensing factor MCM3 6 8 -0.95 -0.65 0.37 4 5
P33991 DNA replication licensing factor MCM4 2 7 -0.90 -0.54 0.53 3
P33992 DNA replication licensing factor MCM5 4 5 -1.38 -0.87 0.50 3 3
Q14566 DNA replication licensing factor MCM6 3 6 -0.96 -0.29 0.61 3
P33993 DNA replication licensing factor MCM7 5 8 -1.34 -0.75 0.49 4 4
P11387 DNA topoisomerase 1 17 56 0.15 -0.21 -0.15
Q02880 DNA topoisomerase 2-beta 34 107 -0.12 -0.08 0.19
O95985 DNA topoisomerase 3-beta-1 1 1 -0.21 0.10 0.32
P27695 DNA-(apurinic or apyrimidinic site) lyase 13 128 0.31 -0.54 -0.84 4 5
O60870 DNA/RNA-binding protein KIN17 5 7 -0.09 -0.15 -0.06
P29372 DNA-3-methyladenine glycosylase 7 19 -0.36 -0.13 0.25
Q13422 DNA-binding protein Ikaros 9 53 -0.22 -0.22 -0.03
P48382 DNA-binding protein RFX5 10 24 -0.22 -0.05 0.08
Q01826 DNA-binding protein SATB1 9 34 0.38 0.05 -0.29
P38935 DNA-binding protein SMUBP-2 3 8 0.05 0.15 0.10
P78527 DNA-dependent protein kinase catalytic subunit 69 312 -0.02 -0.06 -0.06
Q96LW4 DNA-directed primase/polymerase protein 1 2 NA NA NA
O95602 DNA-directed RNA polymerase I subunit RPA1 9 21 0.15 -0.15 -0.29
Q9H9Y6 DNA-directed RNA polymerase I subunit RPA2 3 4 0.44 0.20 -0.23
O15446 DNA-directed RNA polymerase I subunit RPA34 5 11 0.04 -0.21 -0.22
Q3B726 DNA-directed RNA polymerase I subunit RPA43 1 1 0.24 -0.18 -0.42
P0CAP2 DNA-directed RNA polymerase II subunit GRINL1A 5 14 -0.02 0.02 -0.07
Q6EEV4 DNA-directed RNA polymerase II subunit GRINL1A, isoforms 4/5 2 11 -0.02 -0.34 -0.31
P24928 DNA-directed RNA polymerase II subunit RPB1 26 89 -0.05 -0.09 -0.11
P30876 DNA-directed RNA polymerase II subunit RPB2 22 103 0.15 -0.05 -0.10
P19387 DNA-directed RNA polymerase II subunit RPB3 5 29 0.07 -0.05 -0.20
O15514 DNA-directed RNA polymerase II subunit RPB4 2 10 -0.23 -0.41 0.11
P62487 DNA-directed RNA polymerase II subunit RPB7 2 5 -0.06 -0.15 -0.05
P36954 DNA-directed RNA polymerase II subunit RPB9 2 2 -0.01 0.01 0.03
Q9Y2Y1 DNA-directed RNA polymerase III subunit RPC10 1 2 -0.43 -0.12 0.32
Q9NW08 DNA-directed RNA polymerase III subunit RPC2 1 3 0.02 -0.13 -0.39
Q9BUI4 DNA-directed RNA polymerase III subunit RPC3 2 4 -0.21 -0.07 -0.05
Q9NVU0 DNA-directed RNA polymerase III subunit RPC5 1 1 0.07 -0.59 -0.68
Q9H1D9 DNA-directed RNA polymerase III subunit RPC6 1 2 0.10 0.10 0.01
Q9BT43 DNA-directed RNA polymerase III subunit RPC7-like 1 4 -0.12 -0.35 -0.20
O00411 DNA-directed RNA polymerase, mitochondrial 1 1 -0.96 -0.74 0.24
O15160 DNA-directed RNA polymerases I and III subunit RPAC1 5 19 -0.07 -0.18 -0.19
Q9Y2S0 DNA-directed RNA polymerases I and III subunit RPAC2 3 18 0.20 -0.09 0.01
P19388 DNA-directed RNA polymerases I, II, and III subunit RPABC1 6 23 -0.04 -0.16 -0.18
P61218 DNA-directed RNA polymerases I, II, and III subunit RPABC2 2 12 -0.08 -0.29 -0.19
P52434 DNA-directed RNA polymerases I, II, and III subunit RPABC3 4 25 0.07 -0.27 -0.23
P53803 DNA-directed RNA polymerases I, II, and III subunit RPABC4 1 1 0.05 -0.08 -0.12
P62875 DNA-directed RNA polymerases I, II, and III subunit RPABC5 2 4 0.06 -0.02 -0.15
P31689 DnaJ homolog subfamily A member 1 7 41 -0.04 -0.10 -0.04
O60884 DnaJ homolog subfamily A member 2 9 12 -0.07 -0.36 -0.26
Q96EY1 DnaJ homolog subfamily A member 3, mitochondrial 5 20 0.37 -0.16 -0.55
P25685 DnaJ homolog subfamily B member 1 15 66 0.20 -0.23 -0.58
Q9UBS4 DnaJ homolog subfamily B member 11 6 23 -0.45 0.17 0.74 5
P25686 DnaJ homolog subfamily B member 2 4 19 0.63 0.15 0.17 3
O75190 DnaJ homolog subfamily B member 6 4 14 0.14 0.30 0.23
Q96KC8 DnaJ homolog subfamily C member 1 1 1 0.10 0.71 0.62
Q8IXB1 DnaJ homolog subfamily C member 10 3 4 -0.14 0.04 0.18
Q9NVH1 DnaJ homolog subfamily C member 11 5 12 0.07 -0.04 -0.17
O75165 DnaJ homolog subfamily C member 13 11 26 -0.12 0.01 -0.02
Q9NVM6 DnaJ homolog subfamily C member 17 6 13 -0.66 -0.15 0.26
Q99543 DnaJ homolog subfamily C member 2 8 17 0.14 -0.13 -0.20
Q5F1R6 DnaJ homolog subfamily C member 21 2 2 0.20 -0.16 -0.36
Q13217 DnaJ homolog subfamily C member 3 1 4 -0.12 0.50 0.62
Q99615 DnaJ homolog subfamily C member 7 10 36 -0.24 0.03 0.37
O75937 DnaJ homolog subfamily C member 8 14 84 -0.20 -0.19 0.00
Q8WXX5 DnaJ homolog subfamily C member 9 12 50 0.14 -0.21 -0.17
Q5SXM8 DNL-type zinc finger protein 1 8 0.12 0.06 -0.26
Q99704 Docking protein 1 4 7 -0.29 -0.01 0.28
O60496 Docking protein 2 10 76 -0.95 0.44 1.43 5 5
Q7L591 Docking protein 3 1 1 NA NA NA
O60762 Dolichol-phosphate mannosyltransferase 4 6 -0.17 0.12 0.22
Q9P2X0 Dolichol-phosphate mannosyltransferase subunit 3 1 6 0.49 0.91 0.41
P39656 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 8 46 0.41 0.49 -0.01 5
P04843 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 27 142 0.27 0.34 -0.01
P04844 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 7 29 0.38 0.32 0.03
P46977 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A 3 16 0.66 0.68 0.20 4 4
Q8TCJ2 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B 2 3 0.43 0.21 -0.14
Q9Y673 Dolichyl-phosphate beta-glucosyltransferase 3 7 0.12 0.31 0.19
P49959 Double-strand break repair protein MRE11A 14 47 -0.35 -0.15 0.19
O60216 Double-strand-break repair protein rad21 homolog 19 103 -0.15 -0.17 -0.01
O95793 Double-stranded RNA-binding protein Staufen homolog 1 5 8 -0.20 0.00 0.20
Q9NUL3 Double-stranded RNA-binding protein Staufen homolog 2 5 11 -0.32 -0.06 0.32
P55265 Double-stranded RNA-specific adenosine deaminase 37 170 -0.01 -0.14 -0.03
P78563 Double-stranded RNA-specific editase 1 1 2 0.36 0.09 -0.27
Q9NS39 Double-stranded RNA-specific editase B2 1 1 NA NA NA
O14972 Down syndrome critical region protein 3 1 1 -0.26 0.03 0.29
Q14919 Dr1-associated corepressor 5 36 -0.52 -0.31 0.06
Q16643 Drebrin 10 41 1.15 0.51 -0.61 5 4 3
Q9UJU6 Drebrin-like protein 25 275 -0.22 0.22 0.36
Q8TEA8 D-tyrosyl-tRNA(Tyr) deacylase 1 2 13 0.02 0.21 0.25
Q02750 Dual specificity mitogen-activated protein kinase kinase 1 7 40 0.10 -0.09 -0.15
P36507 Dual specificity mitogen-activated protein kinase kinase 2 6 28 -0.30 0.08 0.35
P46734 Dual specificity mitogen-activated protein kinase kinase 3 6 22 -0.04 0.39 0.24
P45985 Dual specificity mitogen-activated protein kinase kinase 4 4 15 -0.17 -0.03 0.17
P52564 Dual specificity mitogen-activated protein kinase kinase 6 4 23 0.19 0.16 -0.05
P49759 Dual specificity protein kinase CLK1 2 3 0.25 0.17 -0.09
P28562 Dual specificity protein phosphatase 1 1 1 -0.24 0.09 0.34
Q9UNI6 Dual specificity protein phosphatase 12 2 6 -0.16 0.31 0.48
Q9BVJ7 Dual specificity protein phosphatase 23 5 17 -0.66 -0.15 0.60 5 3
P51452 Dual specificity protein phosphatase 3 5 11 0.00 0.01 0.14
Q13627 Dual specificity tyrosine-phosphorylation-regulated kinase 1A 2 2 -0.25 -0.14 0.11
Q14203 Dynactin subunit 1 26 126 0.12 -0.02 -0.04
Q13561 Dynactin subunit 2 20 109 -0.14 -0.05 -0.05
O75935 Dynactin subunit 3 6 18 0.26 0.08 -0.13
Q9UJW0 Dynactin subunit 4 6 17 0.07 -0.03 -0.09
Q9BTE1 Dynactin subunit 5 1 3 -0.45 -0.08 0.00
O00399 Dynactin subunit 6 3 8 -0.22 -0.32 -0.10
O00429 Dynamin-1-like protein 10 37 -0.03 -0.04 0.01
P50570 Dynamin-2 27 165 -0.20 0.14 0.39
O60313 Dynamin-like 120 kDa protein, mitochondrial 28 93 0.05 -0.15 -0.16
Q9C0G6 Dynein heavy chain 6, axonemal 1 10 0.07 0.07 -0.25
Q96JB1 Dynein heavy chain 8, axonemal 2 3 0.11 -0.27 -0.38
P63167 Dynein light chain 1, cytoplasmic 2 26 -0.44 0.16 0.28
Q96FJ2 Dynein light chain 2, cytoplasmic 4 61 0.24 0.16 -0.01
Q9NP97 Dynein light chain roadblock-type 1 3 18 0.08 -0.03 0.05
P51808 Dynein light chain Tctex-type 3 1 3 -0.04 0.08 0.26
Q96EV8 Dysbindin 3 15 -0.33 -0.21 0.13
Q96L91 E1A-binding protein p400 18 51 -0.18 -0.06 0.05
Q9UII4 E3 ISG15--protein ligase HERC5 1 1 -0.20 -0.02 0.18
O00257 E3 SUMO-protein ligase CBX4 3 3 0.16 0.02 -0.14
Q96MF7 E3 SUMO-protein ligase NSE2 1 1 -0.52 -0.59 -0.07
O75925 E3 SUMO-protein ligase PIAS1 2 4 -0.03 0.09 0.13
Q8N2W9 E3 SUMO-protein ligase PIAS4 1 1 -0.27 -0.12 0.15
P49792 E3 SUMO-protein ligase RanBP2 50 182 -0.08 0.07 0.08
Q14258 E3 ubiquitin/ISG15 ligase TRIM25 11 52 -0.07 0.14 0.17
Q9UKV5 E3 ubiquitin-protein ligase AMFR 2 2 0.47 0.44 -0.01
Q9Y4X5 E3 ubiquitin-protein ligase ARIH1 1 8 0.09 0.18 0.09
O95376 E3 ubiquitin-protein ligase ARIH2 2 4 0.03 0.00 -0.03
Q5VTR2 E3 ubiquitin-protein ligase BRE1A 12 29 -0.23 -0.20 0.13
O75150 E3 ubiquitin-protein ligase BRE1B 9 25 -0.31 -0.09 0.25
P22681 E3 ubiquitin-protein ligase CBL 6 10 -0.07 -0.11 -0.17
Q13191 E3 ubiquitin-protein ligase CBL-B 4 6 -0.65 0.23 0.85
Q96EP1 E3 ubiquitin-protein ligase CHFR 1 1 -0.21 0.35 0.57
Q9UNE7 E3 ubiquitin-protein ligase CHIP 2 5 0.07 -0.17 -0.16
Q8TDB6 E3 ubiquitin-protein ligase DTX3L 10 22 0.22 0.17 0.18
Q75N03 E3 ubiquitin-protein ligase Hakai 2 6 -0.05 0.06 -0.12
Q9ULT8 E3 ubiquitin-protein ligase HECTD1 6 10 -0.19 -0.04 0.11
Q5T447 E3 ubiquitin-protein ligase HECTD3 5 25 -0.09 0.23 0.24
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1 30 134 0.14 0.13 0.00
Q96J02 E3 ubiquitin-protein ligase Itchy homolog 3 8 0.25 0.58 0.38
Q9P0J7 E3 ubiquitin-protein ligase KCMF1 1 1 -0.14 0.04 0.18
Q6UWE0 E3 ubiquitin-protein ligase LRSAM1 3 7 0.58 0.70 -0.10
Q86YT6 E3 ubiquitin-protein ligase MIB1 1 1 -0.30 0.02 0.30
Q9HCI7 E3 ubiquitin-protein ligase MSL2 4 4 -0.12 -0.01 0.16
O43164 E3 ubiquitin-protein ligase Praja-2 1 1 -0.95 -0.77 0.19
Q7Z6E9 E3 ubiquitin-protein ligase RBBP6 10 24 -0.41 -0.11 0.16
Q06587 E3 ubiquitin-protein ligase RING1 4 13 -0.06 -0.04 0.09
Q99496 E3 ubiquitin-protein ligase RING2 2 11 0.08 0.02 -0.01
Q9BV68 E3 ubiquitin-protein ligase RNF126 2 4 -0.03 0.05 0.37
O43567 E3 ubiquitin-protein ligase RNF13 2 8 -0.52 0.60 1.13 3
Q86XS8 E3 ubiquitin-protein ligase RNF130 1 9 0.38 0.79 0.43
Q9H6Y7 E3 ubiquitin-protein ligase RNF167 1 1 -3.68 -2.16 1.54
Q8NCN4 E3 ubiquitin-protein ligase RNF169 5 8 -0.67 0.01 0.68
Q9P0P0 E3 ubiquitin-protein ligase RNF181 1 1 NA NA NA
Q63HN8 E3 ubiquitin-protein ligase RNF213 65 246 0.05 0.22 0.21
Q9NWF9 E3 ubiquitin-protein ligase RNF216 1 1 -0.58 0.06 0.62
Q96BH1 E3 ubiquitin-protein ligase RNF25 1 1 -0.74 -0.61 0.14
Q96EP0 E3 ubiquitin-protein ligase RNF31 8 27 0.14 0.20 0.16
Q969K3 E3 ubiquitin-protein ligase RNF34 1 1 0.59 0.45 -0.13
P19474 E3 ubiquitin-protein ligase TRIM21 4 18 0.00 0.24 0.24
Q8IYM9 E3 ubiquitin-protein ligase TRIM22 4 9 -0.30 0.04 0.24
Q13049 E3 ubiquitin-protein ligase TRIM32 3 5 0.06 0.03 -0.04
Q9UPN9 E3 ubiquitin-protein ligase TRIM33 5 8 -0.46 -0.11 0.35
Q8WV44 E3 ubiquitin-protein ligase TRIM41 2 5 -0.16 -0.29 -0.15
Q9BRZ2 E3 ubiquitin-protein ligase TRIM56 7 23 -0.17 0.01 0.16
Q14669 E3 ubiquitin-protein ligase TRIP12 15 70 -0.38 -0.06 0.42
Q8IWV7 E3 ubiquitin-protein ligase UBR1 5 9 0.03 0.22 0.18
Q8IWV8 E3 ubiquitin-protein ligase UBR2 1 1 -0.08 0.69 0.77
Q5T4S7 E3 ubiquitin-protein ligase UBR4 26 58 -0.05 0.06 -0.07
O95071 E3 ubiquitin-protein ligase UBR5 5 7 0.09 -0.07 -0.19
Q96PU4 E3 ubiquitin-protein ligase UHRF2 3 4 0.75 0.29 -0.52
P98170 E3 ubiquitin-protein ligase XIAP 4 15 -0.14 0.00 0.16
Q96JP5 E3 ubiquitin-protein ligase ZFP91 4 26 -0.41 0.01 0.24
Q8NHG8 E3 ubiquitin-protein ligase ZNRF2 1 1 0.02 0.68 0.64
O94874 E3 UFM1-protein ligase 1 12 48 0.31 0.12 -0.31
Q07108 Early activation antigen CD69 1 2 0.58 1.64 1.06
Q15075 Early endosome antigen 1 27 72 -0.18 0.00 0.20
O95834 Echinoderm microtubule-associated protein-like 2 12 54 0.13 0.28 0.14
Q32P44 Echinoderm microtubule-associated protein-like 3 18 106 -0.01 -0.01 -0.03
Q9HC35 Echinoderm microtubule-associated protein-like 4 22 94 0.97 0.68 -0.43 5 5
Q6ZMW3 Echinoderm microtubule-associated protein-like 6 1 2 -0.88 -1.39 -0.50
Q9BSW2 EF-hand calcium-binding domain-containing protein 4B 3 5 -0.45 0.00 0.45
Q96C19 EF-hand domain-containing protein D2 21 404 -1.26 0.67 1.62 5 5 5
O43854 EGF-like repeat and discoidin I-like domain-containing protein 3 1 1 -0.03 -0.56 -0.52
Q9GZT9 Egl nine homolog 1 2 15 0.00 0.10 0.08
Q8N3D4 EH domain-binding protein 1-like protein 1 9 22 -0.13 0.02 0.21
Q9H4M9 EH domain-containing protein 1 18 283 0.12 0.59 0.35 5
Q9NZN3 EH domain-containing protein 3 1 58 -0.25 -0.09 0.16
Q9H223 EH domain-containing protein 4 7 25 -0.01 0.40 0.42
Q14657 EKC/KEOPS complex subunit LAGE3 5 20 -0.01 -0.15 0.01
Q9Y3C4 EKC/KEOPS complex subunit TPRKB 2 12 0.15 -0.27 -0.25
Q15717 ELAV-like protein 1 13 93 -0.26 -0.27 0.11
P13804 Electron transfer flavoprotein subunit alpha, mitochondrial 14 142 0.35 -0.16 -0.47 5
P38117 Electron transfer flavoprotein subunit beta 18 216 0.30 -0.21 -0.55
Q16134 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial 7 16 0.03 0.15 0.11
Q8IUD2 ELKS/Rab6-interacting/CAST family member 1 3 6 -0.02 -0.01 0.02
Q6PJG2 ELM2 and SANT domain-containing protein 1 8 14 -0.14 -0.03 0.13
Q8IZ81 ELMO domain-containing protein 2 1 1 0.09 0.03 -0.08
P68104 Elongation factor 1-alpha 1 23 1732 0.15 0.17 -0.18
P24534 Elongation factor 1-beta 10 70 0.21 -0.01 -0.10
P29692 Elongation factor 1-delta 10 178 0.16 0.03 0.05
P26641 Elongation factor 1-gamma 15 124 0.29 0.17 -0.28
P13639 Elongation factor 2 40 568 0.24 0.06 -0.25
Q96RP9 Elongation factor G, mitochondrial 11 27 0.43 0.14 -0.28
P43897 Elongation factor Ts, mitochondrial 4 15 0.30 0.07 -0.10
Q7Z2Z2 Elongation factor Tu GTP-binding domain-containing protein 1 7 13 0.19 0.14 0.01
P49411 Elongation factor Tu, mitochondrial 27 379 0.46 0.19 -0.13
O95163 Elongator complex protein 1 7 13 0.12 0.20 0.07
Q6IA86 Elongator complex protein 2 1 1 -0.59 -0.30 0.29
Q9H9T3 Elongator complex protein 3 2 9 0.03 0.10 0.07
Q96EB1 Elongator complex protein 4 1 1 -0.25 -0.32 -0.07
Q8TE02 Elongator complex protein 5 1 1 -0.19 -0.01 0.17
Q0PNE2 Elongator complex protein 6 2 2 0.10 -0.21 -0.31
Q6PCB8 Embigin 1 2 0.74 1.22 0.49
Q96FZ2 Embryonic stem cell-specific 5-hydroxymethylcytosine-binding protein 1 1 NA NA NA
P50402 Emerin 5 41 0.25 0.05 -0.24
Q9Y6C2 EMILIN-1 1 1 NA NA NA
Q9UI08 Ena/VASP-like protein 25 344 -0.44 -0.44 0.20
Q969S2 Endonuclease 8-like 2 1 1 NA NA NA
O94919 Endonuclease domain-containing 1 protein 2 5 -0.34 0.09 0.43
Q14249 Endonuclease G, mitochondrial 2 5 -0.09 0.31 0.36
P78549 Endonuclease III-like protein 1 3 4 -0.24 -0.11 0.04
Q99961 Endophilin-A2 10 39 -0.29 0.19 0.56 4
Q9Y371 Endophilin-B1 10 52 -0.44 0.23 0.53 4
Q9NR46 Endophilin-B2 7 47 0.16 0.01 0.06
Q9NZ08 Endoplasmic reticulum aminopeptidase 1 17 69 0.20 0.34 0.37
Q6P179 Endoplasmic reticulum aminopeptidase 2 8 27 -0.30 -0.01 0.23
Q96DZ1 Endoplasmic reticulum lectin 1 2 2 -0.14 0.31 0.45
Q7Z2K6 Endoplasmic reticulum metallopeptidase 1 7 18 0.20 0.95 0.56 5
P30040 Endoplasmic reticulum resident protein 29 8 107 0.08 0.05 0.01
Q9BS26 Endoplasmic reticulum resident protein 44 5 11 -0.47 0.33 0.91 4
Q969X5 Endoplasmic reticulum-Golgi intermediate compartment protein 1 6 20 0.28 0.71 0.31 5
P14625 Endoplasmin 36 304 0.21 0.47 0.28 5
Q9UPY3 Endoribonuclease Dicer 1 1 0.28 0.32 0.04
O60869 Endothelial differentiation-related factor 1 6 57 -0.08 -0.14 0.01
Q92556 Engulfment and cell motility protein 1 15 63 -0.15 -0.03 -0.10
Q96JJ3 Engulfment and cell motility protein 2 10 54 -0.02 0.27 0.27
Q14511 Enhancer of filamentation 1 4 5 -0.59 0.35 0.93
Q96F86 Enhancer of mRNA-decapping protein 3 5 15 0.01 -0.09 -0.21
Q6P2E9 Enhancer of mRNA-decapping protein 4 20 91 0.08 0.00 -0.10
Q52LR7 Enhancer of polycomb homolog 2 1 1 0.17 0.15 -0.02
P84090 Enhancer of rudimentary homolog 3 19 0.04 0.04 -0.12
Q9UHY7 Enolase-phosphatase E1 4 15 0.30 -0.19 -0.27
P42126 Enoyl-CoA delta isomerase 1, mitochondrial 3 22 0.13 0.18 0.10
O75521 Enoyl-CoA delta isomerase 2, mitochondrial 7 29 0.39 -0.10 -0.37 5
Q86YB7 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial 1 9 0.15 -0.07 -0.27
P30084 Enoyl-CoA hydratase, mitochondrial 15 147 0.22 -0.05 -0.23
Q92817 Envoplakin 1 1 NA NA NA
O95936 Eomesodermin homolog 5 7 -0.36 0.38 0.71
Q8N6I1 EP300-interacting inhibitor of differentiation 2 1 1 0.22 -0.01 -0.23
P42566 Epidermal growth factor receptor substrate 15 14 44 0.10 0.30 0.29
Q9UBC2 Epidermal growth factor receptor substrate 15-like 1 14 37 -0.56 0.13 0.52 5 5
P61916 Epididymal secretory protein E1 6 21 -0.42 0.78 1.26 4 5
Q9Y2E5 Epididymis-specific alpha-mannosidase 2 2 -0.71 -0.16 0.56
Q9NRG7 Epimerase family protein SDR39U1 2 3 -0.06 0.23 0.28
P58107 Epiplakin 9 38 0.18 -0.76 -0.87
Q96J88 Epithelial-stromal interaction protein 1 3 3 -0.22 0.21 0.44
Q9Y6I3 Epsin-1 3 9 -0.24 0.08 0.52
Q8N766 ER membrane protein complex subunit 1 5 11 0.07 0.29 0.37
Q5UCC4 ER membrane protein complex subunit 10 2 2 0.13 0.35 0.23
Q15006 ER membrane protein complex subunit 2 3 10 -0.28 0.01 0.29
Q9P0I2 ER membrane protein complex subunit 3 1 2 0.10 0.47 0.37
Q5J8M3 ER membrane protein complex subunit 4 1 1 -0.11 -0.07 0.04
Q9NPA0 ER membrane protein complex subunit 7 1 1 0.05 -0.04 -0.09
O43402 ER membrane protein complex subunit 8 1 3 NA NA NA
O94905 Erlin-2 3 5 -0.20 -0.08 0.14
Q96HE7 ERO1-like protein alpha 2 7 0.86 0.76 -0.21 4 3
P27105 Erythrocyte band 7 integral membrane protein 8 111 -0.77 0.60 1.25 4 5 5
P30042 ES1 protein homolog, mitochondrial 14 128 -0.07 -0.17 -0.22
Q9H501 ESF1 homolog 3 4 0.04 -0.43 -0.12
Q9H4I9 Essential MCU regulator, mitochondrial 1 2 0.09 0.27 0.19
Q9H0W9 Ester hydrolase C11orf54 4 14 -0.10 -0.35 -0.32
Q8NBQ5 Estradiol 17-beta-dehydrogenase 11 2 3 0.48 0.43 -0.04
Q53GQ0 Estradiol 17-beta-dehydrogenase 12 4 18 0.16 0.12 -0.07
Q92506 Estradiol 17-beta-dehydrogenase 8 8 50 0.19 -0.23 -0.39
Q99447 Ethanolamine-phosphate cytidylyltransferase 9 26 -0.47 0.07 0.42
Q9NTX5 Ethylmalonyl-CoA decarboxylase 10 41 0.08 -0.22 -0.65 3
P19419 ETS domain-containing protein Elk-1 1 1 0.20 -0.56 -0.75
P50548 ETS domain-containing transcription factor ERF 2 2 -0.53 -0.12 0.42
P32519 ETS-related transcription factor Elf-1 9 55 -0.15 -0.07 0.09
Q15723 ETS-related transcription factor Elf-2 6 11 -0.35 -0.06 0.26
O00418 Eukaryotic elongation factor 2 kinase 1 1 NA NA NA
P60842 Eukaryotic initiation factor 4A-I 9 275 0.36 0.36 0.12
Q14240 Eukaryotic initiation factor 4A-II 3 203 0.44 0.08 -0.31
P38919 Eukaryotic initiation factor 4A-III 16 135 0.08 -0.07 -0.12
P15170 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A 13 58 0.44 -0.08 -0.54
P62495 Eukaryotic peptide chain release factor subunit 1 5 27 0.46 0.22 -0.25
O43324 Eukaryotic translation elongation factor 1 epsilon-1 1 2 -0.05 -0.05 0.01
P47813 Eukaryotic translation initiation factor 1A, X-chromosomal 7 32 0.43 -0.07 -0.62 3
O60739 Eukaryotic translation initiation factor 1b 3 11 -0.01 0.03 0.04
P05198 Eukaryotic translation initiation factor 2 subunit 1 15 92 0.21 0.11 -0.11
P20042 Eukaryotic translation initiation factor 2 subunit 2 12 31 0.22 0.27 -0.14
P41091 Eukaryotic translation initiation factor 2 subunit 3 15 71 0.29 0.14 -0.07
Q9BY44 Eukaryotic translation initiation factor 2A 12 29 0.13 0.09 -0.09
Q9BQI3 Eukaryotic translation initiation factor 2-alpha kinase 1 1 1 0.32 0.00 -0.32
P41214 Eukaryotic translation initiation factor 2D 5 10 0.26 -0.29 -0.59
Q14152 Eukaryotic translation initiation factor 3 subunit A 36 182 0.37 0.29 -0.10
P55884 Eukaryotic translation initiation factor 3 subunit B 18 94 0.41 0.28 -0.18
Q99613 Eukaryotic translation initiation factor 3 subunit C 28 161 0.32 0.20 -0.26
O15371 Eukaryotic translation initiation factor 3 subunit D 11 33 0.29 0.28 -0.13
P60228 Eukaryotic translation initiation factor 3 subunit E 13 88 0.27 0.28 -0.12
O00303 Eukaryotic translation initiation factor 3 subunit F 8 59 0.30 0.20 -0.20
O75821 Eukaryotic translation initiation factor 3 subunit G 6 14 -0.78 -0.46 0.39
O15372 Eukaryotic translation initiation factor 3 subunit H 12 65 0.37 0.19 -0.19
Q13347 Eukaryotic translation initiation factor 3 subunit I 12 80 0.16 0.12 -0.12
O75822 Eukaryotic translation initiation factor 3 subunit J 9 18 0.03 0.01 -0.04
Q9UBQ5 Eukaryotic translation initiation factor 3 subunit K 6 22 0.55 0.23 -0.28
Q9Y262 Eukaryotic translation initiation factor 3 subunit L 15 73 0.47 0.37 -0.08
Q7L2H7 Eukaryotic translation initiation factor 3 subunit M 4 19 0.33 0.26 -0.07
Q04637 Eukaryotic translation initiation factor 4 gamma 1 19 82 0.12 0.09 -0.05
P78344 Eukaryotic translation initiation factor 4 gamma 2 10 26 0.14 0.07 0.16
O43432 Eukaryotic translation initiation factor 4 gamma 3 3 11 -0.37 0.07 0.53
P23588 Eukaryotic translation initiation factor 4B 12 78 0.14 0.01 -0.20
P06730 Eukaryotic translation initiation factor 4E 5 32 -0.09 -0.32 -0.23
Q9NRA8 Eukaryotic translation initiation factor 4E transporter 2 2 -0.61 -0.12 0.49
Q8N5X7 Eukaryotic translation initiation factor 4E type 3 1 2 0.21 -0.04 -0.26
Q13541 Eukaryotic translation initiation factor 4E-binding protein 1 2 7 0.01 -0.19 0.20
Q13542 Eukaryotic translation initiation factor 4E-binding protein 2 2 13 -0.13 0.08 0.16
Q15056 Eukaryotic translation initiation factor 4H 6 29 -0.18 -0.11 0.19
P55010 Eukaryotic translation initiation factor 5 12 44 0.10 0.09 0.07
P63241 Eukaryotic translation initiation factor 5A-1 8 187 0.19 -0.12 -0.19
O60841 Eukaryotic translation initiation factor 5B 21 55 0.20 -0.02 -0.16
P56537 Eukaryotic translation initiation factor 6 6 49 -0.11 0.00 0.01
Q9NV70 Exocyst complex component 1 2 4 0.13 0.34 0.18
Q96KP1 Exocyst complex component 2 6 8 -0.04 0.07 0.02
O60645 Exocyst complex component 3 2 2 -0.09 0.11 0.20
Q96A65 Exocyst complex component 4 5 15 0.18 0.26 0.17
O00471 Exocyst complex component 5 1 1 -0.28 0.05 0.33
Q8TAG9 Exocyst complex component 6 1 4 -0.18 0.10 0.28
Q9Y2D4 Exocyst complex component 6B 3 4 0.07 0.03 0.04
Q9UPT5 Exocyst complex component 7 1 1 -0.02 -0.08 -0.06
Q8IYI6 Exocyst complex component 8 4 6 -0.52 -0.20 0.46
Q9Y3B2 Exosome complex component CSL4 2 4 -0.03 0.09 0.09
Q5RKV6 Exosome complex component MTR3 7 40 -0.05 -0.24 -0.20
Q13868 Exosome complex component RRP4 7 28 0.08 -0.23 -0.25
Q9NQT5 Exosome complex component RRP40 4 7 0.71 0.01 -0.42
Q9NPD3 Exosome complex component RRP41 5 23 0.12 0.05 -0.06
Q15024 Exosome complex component RRP42 3 6 0.11 -0.12 -0.34
Q96B26 Exosome complex component RRP43 3 11 0.13 -0.16 -0.27
Q06265 Exosome complex component RRP45 2 4 0.17 0.12 -0.05
Q9NQT4 Exosome complex component RRP46 5 19 0.02 -0.30 -0.36
Q9Y2L1 Exosome complex exonuclease RRP44 8 28 0.12 -0.03 -0.29
Q01780 Exosome component 10 13 40 -0.08 -0.15 -0.08
O14980 Exportin-1 10 26 0.15 0.18 -0.04
P55060 Exportin-2 11 46 0.15 -0.17 -0.14
Q9C0E2 Exportin-4 2 7 0.37 0.29 -0.08
Q9HAV4 Exportin-5 4 13 0.21 0.07 -0.16
Q9UIA9 Exportin-7 8 26 0.17 0.16 -0.04
O43592 Exportin-T 1 2 0.49 0.19 -0.30
Q9BSJ8 Extended synaptotagmin-1 25 186 0.24 -0.05 -0.18
A0FGR8 Extended synaptotagmin-2 15 80 -0.31 -0.18 0.21
P15311 Ezrin 25 577 0.55 0.29 -0.08
Q9Y5B9 FACT complex subunit SPT16 24 70 0.19 0.08 -0.12
Q08945 FACT complex subunit SSRP1 15 86 0.20 0.08 -0.07
P52907 F-actin-capping protein subunit alpha-1 14 261 0.29 0.20 -0.01
P47755 F-actin-capping protein subunit alpha-2 7 100 -0.14 -0.07 -0.05
P47756 F-actin-capping protein subunit beta 16 188 0.09 0.17 0.01
P23610 Factor VIII intron 22 protein 2 3 0.20 0.15 -0.03
Q8NFF5 FAD synthase 1 1 NA NA NA
Q96CU9 FAD-dependent oxidoreductase domain-containing protein 1 1 1 0.25 -0.27 -0.52
P55789 FAD-linked sulfhydryl oxidase ALR 3 24 0.12 0.41 0.27 5
Q96AE4 Far upstream element-binding protein 1 30 355 -0.10 -0.08 0.03
Q92945 Far upstream element-binding protein 2 36 339 -0.25 -0.24 0.07
Q96I24 Far upstream element-binding protein 3 16 127 -0.22 -0.14 0.14
P14324 Farnesyl pyrophosphate synthase 5 34 -0.22 0.12 0.31
Q9UNN5 FAS-associated factor 1 4 10 -0.02 0.00 -0.07
Q96CS3 FAS-associated factor 2 5 10 0.28 0.21 -0.32
Q8TES7 Fas-binding factor 1 1 4 NA NA NA
Q7L8L6 FAST kinase domain-containing protein 5 1 1 0.52 0.33 -0.20
P49327 Fatty acid synthase 17 46 -0.32 0.04 0.38
Q01469 Fatty acid-binding protein, epidermal 4 11 -0.01 -0.59 -0.20
P51648 Fatty aldehyde dehydrogenase 1 2 -0.58 -0.19 0.39
Q9UK22 F-box only protein 2 1 1 NA NA NA
Q9NVF7 F-box only protein 28 2 7 -0.18 -0.35 -0.05
Q9UK99 F-box only protein 3 4 5 -0.08 0.14 0.22
Q6PIJ6 F-box only protein 38 2 3 0.97 0.28 -0.69
Q9NRD1 F-box only protein 6 2 3 -0.47 0.41 0.65
Q9Y3I1 F-box only protein 7 1 7 -0.20 0.08 0.31
P0C2W1 F-box/SPRY domain-containing protein 1 1 2 0.40 0.35 -0.04
Q9BZK7 F-box-like/WD repeat-containing protein TBL1XR1 8 29 -0.01 -0.14 -0.26
Q86WN1 FCH and double SH3 domains protein 1 7 24 -0.15 0.02 0.02
O94868 FCH and double SH3 domains protein 2 1 1 -0.08 -0.12 -0.05
O14526 FCH domain only protein 1 4 9 0.27 -0.15 -0.37
Q9BZ67 FERM domain-containing protein 8 1 1 -0.26 0.51 0.77
Q86UX7 Fermitin family homolog 3 20 146 0.08 0.40 0.26
P02794 Ferritin heavy chain 6 19 0.85 0.80 0.16 4 4
P02792 Ferritin light chain 4 12 0.52 1.05 0.41 4
P22830 Ferrochelatase, mitochondrial 8 13 -0.16 0.07 0.31
O95684 FGFR1 oncogene partner 2 2 -0.43 -0.04 0.40
Q9NVK5 FGFR1 oncogene partner 2 5 32 -0.36 0.09 0.28
Q9Y613 FH1/FH2 domain-containing protein 1 5 8 0.08 0.14 0.16
P02671 Fibrinogen alpha chain 11 27 -0.24 -0.16 0.11
P02675 Fibrinogen beta chain 4 5 -0.26 -0.04 0.22
P02679 Fibrinogen gamma chain 5 18 -0.15 -0.11 0.02
P22607 Fibroblast growth factor receptor 3 1 1 0.21 0.42 0.19
P02751 Fibronectin 1 1 1.02 1.28 0.27
Q9BTV5 Fibronectin type III and SPRY domain-containing protein 1 2 4 -0.75 0.30 1.03
Q9Y2H6 Fibronectin type-III domain-containing protein 3A 3 5 0.25 0.12 -0.04
P20930 Filaggrin 9 19 0.04 -0.45 -0.58
Q5D862 Filaggrin-2 5 8 0.24 -1.31 -1.38
P21333 Filamin-A 144 2187 -0.23 0.43 0.74 4
O75369 Filamin-B 67 321 0.31 -0.33 -0.47 5
Q5T1M5 FK506-binding protein 15 14 47 -0.20 0.11 0.27
P39748 Flap endonuclease 1 12 51 -0.43 -0.10 0.56
P30043 Flavin reductase (NADPH) 7 64 -0.19 0.06 0.26
O75955 Flotillin-1 23 98 -0.33 0.06 0.39
Q14254 Flotillin-2 21 96 -0.32 0.05 0.25
Q96SL8 Flt3-interacting zinc finger protein 1 1 1 -0.64 -0.09 0.56
Q96CP2 FLYWCH family member 2 9 32 -0.24 -0.50 -0.29 4
Q9P0K8 Forkhead box protein J2 1 2 NA NA NA
P85037 Forkhead box protein K1 8 25 0.12 -0.19 -0.31
Q01167 Forkhead box protein K2 1 3 -0.16 0.13 0.28
O43524 Forkhead box protein O3 1 1 -0.22 0.17 0.39
Q9H334 Forkhead box protein P1 2 8 -0.13 -1.00 -0.80 4 4
Q96RU3 Formin-binding protein 1 22 119 0.35 0.27 -0.08
Q8N3X1 Formin-binding protein 4 7 26 -0.17 -0.14 -0.11
O95466 Formin-like protein 1 30 117 0.16 0.50 0.45 4
P15408 Fos-related antigen 2 5 8 0.22 0.79 0.76
Q13642 Four and a half LIM domains protein 1 1 5 1.03 0.90 -0.39 3
Q13643 Four and a half LIM domains protein 3 2 16 -0.47 0.61 0.77 3 5
Q06787 Fragile X mental retardation protein 1 10 19 -0.33 0.23 0.47 4
P51114 Fragile X mental retardation syndrome-related protein 1 5 24 0.00 0.01 -0.18
P51116 Fragile X mental retardation syndrome-related protein 2 4 8 -0.37 -0.01 0.36
Q16595 Frataxin, mitochondrial 2 4 -0.25 -0.37 -0.14
Q01543 Friend leukemia integration 1 transcription factor 6 20 0.04 0.05 0.16
Q9H479 Fructosamine-3-kinase 3 4 -0.15 -0.57 -0.42
P09467 Fructose-1,6-bisphosphatase 1 10 49 -0.09 -0.19 -0.22
Q9NQ88 Fructose-2,6-bisphosphatase TIGAR 6 17 -0.24 0.02 0.21
P04075 Fructose-bisphosphate aldolase A 27 735 -0.07 -0.24 -0.20
P09972 Fructose-bisphosphate aldolase C 21 310 0.01 -0.30 -0.20
Q8N612 FTS and Hook-interacting protein 1 1 -0.29 0.28 0.55
A2VDF0 Fucose mutarotase 1 1 0.17 0.39 0.20
P07954 Fumarate hydratase, mitochondrial 20 86 0.00 -0.16 -0.02
P16930 Fumarylacetoacetase 4 11 -0.19 0.11 0.25
Q96GK7 Fumarylacetoacetate hydrolase domain-containing protein 2A 6 20 0.02 -0.06 -0.09
Q9BWH2 FUN14 domain-containing protein 2 4 13 -0.02 0.17 0.04
O15117 FYN-binding protein 22 188 -0.55 -1.04 -0.54 5
Q9BQS8 FYVE and coiled-coil domain-containing protein 1 8 15 0.09 0.14 0.08
P98174 FYVE, RhoGEF and PH domain-containing protein 1 1 12 1.31 2.10 0.80
Q5JSP0 FYVE, RhoGEF and PH domain-containing protein 3 13 51 -0.02 -0.23 -0.04
Q92917 G patch domain and KOW motifs-containing protein 6 16 -0.02 -0.02 0.07
Q9BRR8 G patch domain-containing protein 1 2 8 -0.18 -0.25 -0.19
Q8N954 G patch domain-containing protein 11 3 10 -0.20 0.03 0.23
Q9UKJ3 G patch domain-containing protein 8 12 20 -0.19 -0.07 0.20
P43250 G protein-coupled receptor kinase 6 5 16 -0.17 0.02 0.02
Q6ZVF9 G protein-regulated inducer of neurite outgrowth 3 12 33 0.45 1.03 0.39 5
Q06546 GA-binding protein alpha chain 3 7 0.00 0.13 0.11
Q06547 GA-binding protein subunit beta-1 3 4 -1.52 -1.03 0.44
Q8TAK5 GA-binding protein subunit beta-2 3 5 -0.13 -0.44 -0.31
P54803 Galactocerebrosidase 4 7 -0.14 0.35 0.62
P51570 Galactokinase 10 46 0.00 0.08 0.03
P07902 Galactose-1-phosphate uridylyltransferase 6 21 -0.05 0.14 0.17
P09382 Galectin-1 10 113 -1.25 -0.22 1.29 5 4
Q05315 Galectin-10 1 1 -1.27 0.02 1.30
P17931 Galectin-3 5 27 1.19 1.49 0.05 5 5
Q08380 Galectin-3-binding protein 3 3 0.80 -0.31 -1.10
P47929 Galectin-7 1 5 0.95 0.81 -0.14
O00214 Galectin-8 2 5 0.68 0.62 -0.05
O00182 Galectin-9 2 4 -1.05 -0.03 1.02
Q9UEY8 Gamma-adducin 11 28 -0.08 -0.03 -0.23
P09104 Gamma-enolase 12 154 0.82 -0.17 -0.92 5 5
Q92820 Gamma-glutamyl hydrolase 5 12 -0.61 0.04 0.45
Q9BVM4 Gamma-glutamylaminecyclotransferase 1 14 -0.40 -0.03 0.35
O75223 Gamma-glutamylcyclotransferase 8 23 0.02 -0.04 -0.06
P13284 Gamma-interferon-inducible lysosomal thiol reductase 1 5 -1.02 0.37 1.28
Q16666 Gamma-interferon-inducible protein 16 37 189 -0.17 0.22 0.34
Q9HBI0 Gamma-parvin 3 16 -0.08 0.44 0.51
Q99747 Gamma-soluble NSF attachment protein 9 23 0.00 0.03 0.13
Q9NUQ3 Gamma-taxilin 3 10 0.47 -0.08 -0.47
Q9BSJ2 Gamma-tubulin complex component 2 3 4 -0.13 0.03 -0.15
Q96CW5 Gamma-tubulin complex component 3 5 10 0.05 -0.24 -0.15
Q96RT7 Gamma-tubulin complex component 6 3 9 -0.18 -0.16 0.15
P17900 Ganglioside GM2 activator 2 3 -0.10 -0.01 0.09
Q96QA5 Gasdermin-A 3 4 0.13 0.08 -0.32
P57764 Gasdermin-D 4 9 -0.21 0.03 0.22
P16383 GC-rich sequence DNA-binding factor 2 2 2 -0.42 -0.56 -0.13
O95479 GDH/6PGL endoplasmic bifunctional protein 5 11 -0.34 0.11 0.38
Q13630 GDP-L-fucose synthase 6 33 0.02 0.19 0.09
O60547 GDP-mannose 4,6 dehydratase 3 3 -0.03 0.04 0.06
P06396 Gelsolin 26 151 -1.98 -0.11 1.96 5 5
O14893 Gem-associated protein 2 1 2 0.21 0.07 -0.14
P57678 Gem-associated protein 4 2 7 0.17 -0.29 -0.45
Q8TEQ6 Gem-associated protein 5 5 18 0.27 -0.12 -0.44
Q9P107 GEM-interacting protein 18 56 0.04 0.11 0.14
Q12789 General transcription factor 3C polypeptide 1 4 4 -0.09 0.04 0.15
Q8WUA4 General transcription factor 3C polypeptide 2 1 4 -0.31 -0.09 0.22
Q9Y5Q9 General transcription factor 3C polypeptide 3 2 7 -0.37 -0.14 -0.15
Q9UKN8 General transcription factor 3C polypeptide 4 4 10 -0.20 -0.05 0.31
Q9Y5Q8 General transcription factor 3C polypeptide 5 5 11 -0.31 0.05 0.32
P29083 General transcription factor IIE subunit 1 2 3 -0.01 -0.09 -0.06
P35269 General transcription factor IIF subunit 1 8 27 0.08 0.13 0.00
P13984 General transcription factor IIF subunit 2 3 7 -0.37 0.06 0.49
Q13888 General transcription factor IIH subunit 2 2 2 0.54 -0.18 -0.71
Q13889 General transcription factor IIH subunit 3 1 1 -0.17 -0.52 -0.36
Q92759 General transcription factor IIH subunit 4 1 1 -0.49 -0.04 0.43
P78347 General transcription factor II-I 20 81 -0.07 -0.07 -0.06
O60763 General vesicular transport factor p115 25 137 0.05 0.31 0.28
Q14687 Genetic suppressor element 1 1 4 -0.51 0.01 0.28
Q9NQX3 Gephyrin 1 6 0.45 0.08 -0.34
P53609 Geranylgeranyl transferase type-1 subunit beta 1 1 NA NA NA
Q92696 Geranylgeranyl transferase type-2 subunit alpha 5 12 0.01 0.23 0.23
P53611 Geranylgeranyl transferase type-2 subunit beta 1 1 0.18 -0.29 -0.47
O60318 Germinal-center associated nuclear protein 5 8 -0.09 0.05 0.15
Q8N2G8 GH3 domain-containing protein 2 3 -0.25 -0.34 -0.07
P60983 Glia maturation factor beta 5 51 -0.27 0.11 0.29
O60234 Glia maturation factor gamma 8 126 -0.02 -0.11 -0.13
Q9NZM4 Glioma tumor suppressor candidate region gene 1 protein 2 3 -0.76 -0.17 0.60
Q9NZM5 Glioma tumor suppressor candidate region gene 2 protein 2 4 0.67 0.18 -0.48
Q92990 Glomulin 1 3 0.08 0.22 0.12
Q9Y692 Glucocorticoid modulatory element-binding protein 1 3 6 -1.21 -0.61 0.61
Q9UKD1 Glucocorticoid modulatory element-binding protein 2 3 9 -0.05 -0.08 -0.02
P04150 Glucocorticoid receptor 7 23 -0.22 0.08 0.45
Q86VQ1 Glucocorticoid-induced transcript 1 protein 2 3 -0.67 0.28 0.96
Q96EK6 Glucosamine 6-phosphate N-acetyltransferase 1 2 -0.36 -0.17 0.18
P46926 Glucosamine-6-phosphate isomerase 1 6 84 0.98 0.48 -0.23 3
Q8TDQ7 Glucosamine-6-phosphate isomerase 2 2 45 0.34 0.07 -0.27
Q6PCE3 Glucose 1,6-bisphosphate synthase 1 1 0.20 0.16 -0.04
P11413 Glucose-6-phosphate 1-dehydrogenase 22 191 -0.69 0.35 0.90 3 4
P06744 Glucose-6-phosphate isomerase 18 209 0.45 0.14 -0.48
P14314 Glucosidase 2 subunit beta 16 162 -0.42 0.13 0.44
Q6ZQY3 Glutamate decarboxylase-like protein 1 1 2 NA NA NA
P00367 Glutamate dehydrogenase 1, mitochondrial 28 274 0.19 0.19 0.05
P48506 Glutamate--cysteine ligase catalytic subunit 7 18 0.07 0.03 -0.01
P48507 Glutamate--cysteine ligase regulatory subunit 2 11 0.01 0.31 0.49
Q9BQ67 Glutamate-rich WD repeat-containing protein 1 3 12 0.10 -0.14 -0.21
O94925 Glutaminase kidney isoform, mitochondrial 12 54 0.40 0.18 -0.25
P15104 Glutamine synthetase 1 1 1.35 1.28 -0.06
Q6IA69 Glutamine-dependent NAD(+) synthetase 3 3 0.20 0.37 0.18
Q06210 Glutamine--fructose-6-phosphate aminotransferase 1 9 35 0.22 0.22 -0.03
Q2TAL8 Glutamine-rich protein 1 5 10 0.02 0.04 0.04
P47897 Glutamine--tRNA ligase 8 20 -0.12 0.12 0.24
Q9NXS2 Glutaminyl-peptide cyclotransferase-like protein 1 1 -0.50 -0.10 0.41
O43716 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial 1 5 0.19 -0.01 -0.37
P35754 Glutaredoxin-1 6 80 0.26 0.25 0.27
O76003 Glutaredoxin-3 4 14 0.29 0.08 -0.09
Q86SX6 Glutaredoxin-related protein 5, mitochondrial 4 21 -0.24 0.09 0.15
Q92947 Glutaryl-CoA dehydrogenase, mitochondrial 8 56 0.27 0.06 -0.12
P07203 Glutathione peroxidase 1 7 21 0.38 -0.31 -0.78 4
Q96SL4 Glutathione peroxidase 7 1 7 NA NA NA
P00390 Glutathione reductase, mitochondrial 20 122 0.06 0.28 0.15
Q9Y2Q3 Glutathione S-transferase kappa 1 13 104 0.45 0.11 -0.41
P09488 Glutathione S-transferase Mu 1 3 20 0.51 -0.55 -1.06
P28161 Glutathione S-transferase Mu 2 2 26 -1.10 -1.11 -0.01
P78417 Glutathione S-transferase omega-1 11 109 0.39 0.20 -0.12
P09211 Glutathione S-transferase P 10 169 -1.51 -0.39 0.94 4 4
P30711 Glutathione S-transferase theta-1 3 4 0.08 -0.44 -0.53
P48637 Glutathione synthetase 17 64 -0.05 -0.14 -0.19
P04406 Glyceraldehyde-3-phosphate dehydrogenase 30 1622 0.12 -0.04 -0.22
P32189 Glycerol kinase 2 2 -0.02 0.00 0.02
Q8N335 Glycerol-3-phosphate dehydrogenase 1-like protein 7 15 1.07 1.14 -0.03 4 4
P43304 Glycerol-3-phosphate dehydrogenase, mitochondrial 11 27 -0.16 0.07 0.34
Q9NPB8 Glycerophosphocholine phosphodiesterase GPCPD1 1 2 -0.26 0.22 0.48
P23434 Glycine cleavage system H protein, mitochondrial 1 3 -0.04 -0.14 -0.09
P41250 Glycine--tRNA ligase 15 42 -0.03 -0.01 -0.13
P35573 Glycogen debranching enzyme 18 47 0.01 -0.19 -0.30
P11216 Glycogen phosphorylase, brain form 20 80 -0.02 -0.38 -0.35
P11217 Glycogen phosphorylase, muscle form 1 9 0.03 -0.16 -0.19
P49840 Glycogen synthase kinase-3 alpha 4 21 -0.07 0.07 0.14
P49841 Glycogen synthase kinase-3 beta 1 2 NA NA NA
P13807 Glycogen synthase, muscle 2 6 0.41 0.54 0.13
P46976 Glycogenin-1 9 57 0.76 1.07 0.42 4 5
Q9NZD2 Glycolipid transfer protein 2 7 -0.28 0.28 0.42
P04921 Glycophorin-C 1 5 0.11 -0.12 -0.22
O43292 Glycosylphosphatidylinositol anchor attachment 1 protein 1 3 -0.16 0.02 0.18
P30419 Glycylpeptide N-tetradecanoyltransferase 1 7 77 0.36 -0.13 -0.45 4
O60551 Glycylpeptide N-tetradecanoyltransferase 2 7 38 0.66 0.06 -0.56 5 4
Q9HC38 Glyoxalase domain-containing protein 4 15 124 0.22 -0.08 -0.43
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase 12 97 0.02 -0.17 -0.28
Q9P2T1 GMP reductase 2 10 28 0.33 0.12 -0.16
P49915 GMP synthase 14 66 0.03 -0.10 0.05
Q92896 Golgi apparatus protein 1 4 5 -0.35 -0.26 0.27
O00461 Golgi integral membrane protein 4 1 1 -1.93 -0.92 1.02
Q9H4A6 Golgi phosphoprotein 3 4 7 0.11 -0.13 0.36
Q9H4A5 Golgi phosphoprotein 3-like 1 2 0.08 0.51 0.42
Q9H8Y8 Golgi reassembly-stacking protein 2 3 22 0.21 0.16 0.03
Q9H3P7 Golgi resident protein GCP60 6 22 0.05 0.20 0.12
O95249 Golgi SNAP receptor complex member 1 1 12 0.01 0.21 0.19
Q7L5D6 Golgi to ER traffic protein 4 homolog 1 1 -0.05 -0.38 -0.32
Q9HD26 Golgi-associated PDZ and coiled-coil motif-containing protein 1 3 -0.24 0.06 0.31
Q9H4G4 Golgi-associated plant pathogenesis-related protein 1 7 68 -0.85 0.56 1.39 5 5 5
Q08379 Golgin subfamily A member 2 8 16 -0.29 -0.02 0.34
Q08378 Golgin subfamily A member 3 28 87 -0.02 -0.18 -0.07
Q13439 Golgin subfamily A member 4 10 13 0.08 0.16 0.10
Q8TBA6 Golgin subfamily A member 5 6 9 -0.21 0.06 0.28
A6NP81 Golgin subfamily A member 8-like protein 2 4 4 -1.44 -0.01 1.44
Q14789 Golgin subfamily B member 1 11 15 0.28 0.16 0.01
Q92538 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 6 17 -0.05 0.18 0.15
Q8IXQ4 GPALPP motifs-containing protein 1 2 20 -0.23 -0.32 -0.22
Q8TEQ8 GPI ethanolamine phosphate transferase 3 1 1 0.01 0.10 0.09
Q96S52 GPI transamidase component PIG-S 1 3 -0.33 0.03 0.34
Q969N2 GPI transamidase component PIG-T 3 8 -0.17 0.35 0.59
Q92643 GPI-anchor transamidase 1 1 -0.19 0.01 0.20
Q9HCN4 GPN-loop GTPase 1 2 10 0.26 0.11 -0.10
Q9Y653 G-protein coupled receptor 56 3 13 -0.92 -0.18 0.63 5 5
P28676 Grancalcin 2 2 0.42 -0.86 -1.28
P28799 Granulins 1 1 -0.02 -0.03 -0.03
P22749 Granulysin 4 15 -1.82 0.28 2.13 4 4
P12544 Granzyme A 18 164 -0.08 1.60 1.78 5 4
P10144 Granzyme B 5 28 -2.08 0.05 1.82 5 5
P20718 Granzyme H 7 55 -2.44 -0.71 1.64 5 5 5
P49863 Granzyme K 14 126 1.66 1.91 0.29 5 5
P51124 Granzyme M 7 32 -0.84 0.92 1.90 4 5 4
Q13588 GRB2-related adapter protein 2 3 -0.06 -1.24 -1.17
O75791 GRB2-related adapter protein 2 9 69 0.38 0.01 -0.53 5
Q12849 G-rich sequence factor 1 4 17 0.04 -0.01 -0.06
Q96CN9 GRIP and coiled-coil domain-containing protein 1 5 6 0.14 0.14 0.01
Q8IWJ2 GRIP and coiled-coil domain-containing protein 2 6 16 -0.05 0.00 -0.04
Q4V328 GRIP1-associated protein 1 11 25 -0.26 -0.03 0.27
Q8TAE8 Growth arrest and DNA damage-inducible proteins-interacting protein 1 3 10 -0.47 -0.28 0.23
O60861 Growth arrest-specific protein 7 1 1 NA NA NA
P62993 Growth factor receptor-bound protein 2 11 52 0.08 -0.23 -0.44
Q9H3K2 Growth hormone-inducible transmembrane protein 2 3 0.55 0.31 -0.24
Q9HAV7 GrpE protein homolog 1, mitochondrial 11 25 0.13 -0.09 -0.14
Q9P0R6 GSK3-beta interaction protein 1 1 0.25 0.03 -0.21
P30047 GTP cyclohydrolase 1 feedback regulatory protein 2 19 -0.23 0.65 0.78 5 3
Q9UIJ7 GTP:AMP phosphotransferase AK3, mitochondrial 12 61 0.05 -0.21 -0.35
O75616 GTPase Era, mitochondrial 2 2 0.02 0.03 -0.01
Q8WWP7 GTPase IMAP family member 1 15 174 0.24 0.15 -0.11
Q9UG22 GTPase IMAP family member 2 3 10 0.06 0.42 0.36
Q9NUV9 GTPase IMAP family member 4 23 226 0.82 0.14 -0.69 5 5
Q96F15 GTPase IMAP family member 5 11 47 0.23 0.22 0.02
Q6P9H5 GTPase IMAP family member 6 1 26 0.09 0.07 -0.01
Q8NHV1 GTPase IMAP family member 7 8 59 0.16 -0.20 -0.38
Q8ND71 GTPase IMAP family member 8 17 86 0.13 -0.13 -0.28
P01116 GTPase KRas 1 44 -0.03 0.02 0.05
P01111 GTPase NRas 1 41 0.10 0.01 -0.08
Q14C86 GTPase-activating protein and VPS9 domain-containing protein 1 8 21 -0.02 0.03 0.06
P62826 GTP-binding nuclear protein Ran 12 172 0.37 -0.03 -0.40
O00178 GTP-binding protein 1 7 27 0.04 0.21 0.12
A4D1E9 GTP-binding protein 10 1 1 -0.38 -0.46 -0.07
Q15382 GTP-binding protein Rheb 3 3 0.07 0.25 0.31
Q9NR31 GTP-binding protein SAR1a 3 15 0.15 0.28 0.02
P47224 Guanine nucleotide exchange factor MSS4 1 3 NA NA NA
P04899 Guanine nucleotide-binding protein G(i) subunit alpha-2 9 145 0.11 0.34 0.03
P59768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 6 14 0.37 0.92 0.46 3
P63218 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 2 3 0.26 -0.01 -0.26
P62873 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 4 76 0.28 0.39 0.08
P62879 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 4 56 0.39 0.52 0.13 5
P08754 Guanine nucleotide-binding protein G(k) subunit alpha 5 88 0.47 0.58 0.10 4
P09471 Guanine nucleotide-binding protein G(o) subunit alpha 1 59 0.82 0.19 -0.62
P50148 Guanine nucleotide-binding protein G(q) subunit alpha 2 2 -0.30 -0.18 0.11
P63092 Guanine nucleotide-binding protein G(s) subunit alpha isoforms short 5 68 0.76 0.67 -0.09 5 5
Q14344 Guanine nucleotide-binding protein subunit alpha-13 7 88 0.08 0.64 0.60 4 4
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 16 115 0.37 0.28 -0.40
P36915 Guanine nucleotide-binding protein-like 1 12 57 0.67 0.16 -0.44 4
Q9BVP2 Guanine nucleotide-binding protein-like 3 13 53 0.52 -0.11 -0.53 5
Q8N4P3 Guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase MESH1 4 15 -0.18 -0.62 -0.26 4
Q16774 Guanylate kinase 5 36 -0.10 0.10 0.06
Q96PP9 Guanylate-binding protein 4 5 24 -0.12 -0.29 -0.16
Q96PP8 Guanylate-binding protein 5 9 57 0.03 0.77 0.66 5 5
Q8N8V2 Guanylate-binding protein 7 2 9 -0.59 -0.57 0.01
P51798 H(+)/Cl(-) exchange transporter 7 1 3 -0.59 0.18 0.78
Q9NY12 H/ACA ribonucleoprotein complex subunit 1 1 3 NA NA NA
Q9NX24 H/ACA ribonucleoprotein complex subunit 2 6 51 0.29 -0.05 -0.30
Q9NPE3 H/ACA ribonucleoprotein complex subunit 3 6 43 0.27 0.12 -0.20
O60832 H/ACA ribonucleoprotein complex subunit 4 20 106 0.39 -0.14 -0.54 5
Q9H0R4 Haloacid dehalogenase-like hydrolase domain-containing protein 2 6 38 0.04 -0.61 -0.58 4
Q9BSH5 Haloacid dehalogenase-like hydrolase domain-containing protein 3 6 21 0.27 -0.06 -0.22
Q92574 Hamartin 1 1 0.59 0.86 0.28
Q96CS2 HAUS augmin-like complex subunit 1 2 4 0.10 -0.23 -0.28
Q9H6D7 HAUS augmin-like complex subunit 4 1 1 -0.05 -0.13 -0.07
O94927 HAUS augmin-like complex subunit 5 1 1 0.83 0.30 -0.52
Q7Z4H7 HAUS augmin-like complex subunit 6 2 2 -0.25 -0.34 -0.11
Q99871 HAUS augmin-like complex subunit 7 1 2 0.17 -0.35 -0.51
Q9Y450 HBS1-like protein 6 9 0.10 -0.21 -0.25
Q53T59 HCLS1-binding protein 3 3 5 -0.29 0.01 0.35
Q7Z4H3 HD domain-containing protein 2 2 8 -0.86 -0.50 0.26 5 5
Q9UBI9 Headcase protein homolog 4 6 0.02 -0.35 -0.37
Q9H583 HEAT repeat-containing protein 1 2 3 0.46 -0.24 -0.69
Q86Y56 HEAT repeat-containing protein 2 1 2 NA NA NA
Q9P2D3 HEAT repeat-containing protein 5B 1 11 -0.15 -0.37 -0.22
Q6AI08 HEAT repeat-containing protein 6 1 1 -0.11 -0.25 -0.14
P48723 Heat shock 70 kDa protein 13 1 1 -0.09 0.40 0.49
Q0VDF9 Heat shock 70 kDa protein 14 5 11 0.05 -0.11 -0.23
P08107 Heat shock 70 kDa protein 1A/1B 24 431 -0.14 -0.10 0.02
P34932 Heat shock 70 kDa protein 4 32 153 0.17 0.03 -0.09
P11142 Heat shock cognate 71 kDa protein 34 1129 -0.05 -0.10 -0.08
Q00613 Heat shock factor protein 1 1 4 NA NA NA
Q92598 Heat shock protein 105 kDa 19 65 -0.01 -0.49 -0.45 5
Q12931 Heat shock protein 75 kDa, mitochondrial 11 93 0.41 -0.18 -0.66 5 5
P04792 Heat shock protein beta-1 8 24 -0.18 -0.36 -0.16
P07900 Heat shock protein HSP 90-alpha 26 870 0.23 0.17 -0.25
P08238 Heat shock protein HSP 90-beta 23 761 0.21 -0.01 -0.13
Q15477 Helicase SKI2W 12 27 0.26 0.05 -0.29
Q6ZRS2 Helicase SRCAP 10 14 -0.03 -0.01 -0.01
Q9BYK8 Helicase with zinc finger domain 2 4 10 -0.17 0.37 0.53
Q9UK76 Hematological and neurological expressed 1 protein 4 25 -0.78 -0.32 0.38 5
Q9H910 Hematological and neurological expressed 1-like protein 9 49 0.01 0.04 0.11
P14317 Hematopoietic lineage cell-specific protein 28 421 -0.10 0.09 0.19
P09601 Heme oxygenase 1 2 2 -0.97 0.22 1.19
P30519 Heme oxygenase 2 12 72 -0.09 -0.06 0.11
Q9NRV9 Heme-binding protein 1 5 6 -0.26 -0.19 0.12
Q9Y5Z4 Heme-binding protein 2 8 39 0.40 -0.17 -0.31
Q96RW7 Hemicentin-1 1 5 1.47 1.67 0.29
P69905 Hemoglobin subunit alpha 11 683 -0.55 -0.66 -0.25 5
P68871 Hemoglobin subunit beta 8 927 -0.74 -0.76 0.02 5 5
P02042 Hemoglobin subunit delta 8 463 -0.78 -0.59 0.01 5 5
P69891 Hemoglobin subunit gamma-1 2 33 -0.90 -0.62 0.09 3 3
Q9Y251 Heparanase 2 2 -0.45 -0.04 0.41
O14964 Hepatocyte growth factor-regulated tyrosine kinase substrate 5 16 -0.21 0.08 0.29
P51858 Hepatoma-derived growth factor 16 132 -0.05 -0.26 -0.24
Q7Z4V5 Hepatoma-derived growth factor-related protein 2 5 19 -0.04 -0.37 0.01
Q9NQG7 Hermansky-Pudlak syndrome 4 protein 1 1 -0.38 -0.06 0.32
Q86YV9 Hermansky-Pudlak syndrome 6 protein 3 5 -0.07 0.04 0.14
Q5SSJ5 Heterochromatin protein 1-binding protein 3 28 294 0.25 -0.33 -0.49
Q99729 Heterogeneous nuclear ribonucleoprotein A/B 10 148 -0.08 0.04 0.05
Q13151 Heterogeneous nuclear ribonucleoprotein A0 11 176 -0.40 -0.25 0.04
P09651 Heterogeneous nuclear ribonucleoprotein A1 14 387 -0.12 -0.14 0.06
P51991 Heterogeneous nuclear ribonucleoprotein A3 14 232 -0.14 -0.19 -0.02
Q14103 Heterogeneous nuclear ribonucleoprotein D0 15 353 -0.22 -0.22 0.06
O14979 Heterogeneous nuclear ribonucleoprotein D-like 10 200 -0.49 -0.37 0.02
P52597 Heterogeneous nuclear ribonucleoprotein F 16 204 -0.08 -0.20 -0.03
P31943 Heterogeneous nuclear ribonucleoprotein H 9 266 0.08 -0.19 -0.08
P55795 Heterogeneous nuclear ribonucleoprotein H2 9 188 -0.16 -0.05 0.00
P31942 Heterogeneous nuclear ribonucleoprotein H3 12 161 -0.06 -0.38 -0.31
P61978 Heterogeneous nuclear ribonucleoprotein K 28 735 -0.14 -0.24 -0.04
P14866 Heterogeneous nuclear ribonucleoprotein L 20 320 -0.01 -0.20 -0.02
Q8WVV9 Heterogeneous nuclear ribonucleoprotein L-like 4 16 0.59 0.52 -0.32
P52272 Heterogeneous nuclear ribonucleoprotein M 49 904 -0.17 -0.16 0.12
O60506 Heterogeneous nuclear ribonucleoprotein Q 17 194 0.06 0.00 -0.06
O43390 Heterogeneous nuclear ribonucleoprotein R 21 259 -0.08 -0.15 -0.05
Q00839 Heterogeneous nuclear ribonucleoprotein U 31 372 -0.12 -0.17 0.04
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 18 117 -0.02 0.07 -0.04
Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-like protein 2 33 247 -0.05 -0.10 -0.03
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 28 873 -0.33 -0.33 0.06
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 21 626 0.02 -0.17 -0.18
Q9NZJ6 Hexaprenyldihydroxybenzoate methyltransferase, mitochondrial 1 1 0.15 -0.07 -0.22
P19367 Hexokinase-1 35 292 0.72 0.27 -0.55 5 5
P52789 Hexokinase-2 2 64 0.53 0.07 -0.45
P52790 Hexokinase-3 3 12 -0.09 0.03 0.12
P30273 High affinity immunoglobulin epsilon receptor subunit gamma 4 15 -2.14 0.13 2.09 5 5
Q15651 High mobility group nucleosome-binding domain-containing protein 3 2 3 -2.52 -1.80 0.73
O00479 High mobility group nucleosome-binding domain-containing protein 4 4 33 0.27 -0.19 -0.46
P82970 High mobility group nucleosome-binding domain-containing protein 5 2 2 -0.34 0.25 0.60
Q9NP66 High mobility group protein 20A 2 5 0.05 0.16 0.12
P09429 High mobility group protein B1 8 108 -0.05 -0.19 -0.30
P26583 High mobility group protein B2 7 100 -0.07 0.05 0.22
O15347 High mobility group protein B3 2 3 -0.64 -0.12 0.53
P17096 High mobility group protein HMG-I/HMG-Y 3 18 0.31 -0.56 -0.45 3
P37235 Hippocalcin-like protein 1 2 17 0.38 0.19 -0.17
Q9BW71 HIRA-interacting protein 3 1 3 -0.03 -0.25 -0.28
O95568 Histidine protein methyltransferase 1 homolog 1 63 0.49 0.35 -0.12
P49773 Histidine triad nucleotide-binding protein 1 8 75 0.36 0.19 -0.59 4
Q9BX68 Histidine triad nucleotide-binding protein 2, mitochondrial 7 58 -0.21 0.09 0.31
P12081 Histidine--tRNA ligase, cytoplasmic 13 67 -0.08 -0.04 -0.09
Q92831 Histone acetyltransferase KAT2B 1 2 -0.16 0.01 0.18
Q92993 Histone acetyltransferase KAT5 1 2 NA NA NA
Q92794 Histone acetyltransferase KAT6A 5 6 -0.08 -0.23 -0.12
O95251 Histone acetyltransferase KAT7 6 16 0.18 0.05 -0.13
Q9H7Z6 Histone acetyltransferase KAT8 2 5 -0.14 -0.24 -0.10
Q09472 Histone acetyltransferase p300 3 8 -0.22 0.02 0.19
O14929 Histone acetyltransferase type B catalytic subunit 2 18 -0.33 0.05 0.34
Q9Y294 Histone chaperone ASF1A 2 7 0.25 0.09 -0.35
Q13547 Histone deacetylase 1 6 38 0.05 -0.11 -0.21
Q92769 Histone deacetylase 2 3 22 -0.33 -0.42 -0.09
O15379 Histone deacetylase 3 1 3 -0.02 -0.02 -0.02
P56524 Histone deacetylase 4 1 3 -0.25 -0.14 0.12
Q9UQL6 Histone deacetylase 5 1 3 -0.13 0.00 0.13
Q9UBN7 Histone deacetylase 6 2 3 0.21 0.17 0.00
Q8WUI4 Histone deacetylase 7 4 8 -0.59 -0.42 0.63
Q9H0E3 Histone deacetylase complex subunit SAP130 8 29 -0.24 -0.11 0.05
O00422 Histone deacetylase complex subunit SAP18 8 21 -0.14 -0.53 -0.06 3
O75446 Histone deacetylase complex subunit SAP30 1 1 0.51 1.01 0.52
Q9HAJ7 Histone deacetylase complex subunit SAP30L 1 3 0.12 -0.27 -0.42
P07305 Histone H1.0 7 58 -0.22 -2.15 -1.79 5 5
Q02539 Histone H1.1 3 884 -0.49 -0.29 0.28
P16403 Histone H1.2 8 2638 -0.03 -0.11 0.08
P16402 Histone H1.3 9 2613 -0.20 -0.70 -0.52 5
P10412 Histone H1.4 6 2655 -0.10 0.14 0.55
P16401 Histone H1.5 11 814 -1.37 -0.16 1.32 5 5
Q92522 Histone H1x 13 205 -0.01 -0.42 -0.46 5
P04908 Histone H2A type 1-B/E 1 1180 0.12 0.07 -0.11
Q96KK5 Histone H2A type 1-H 2 1250 -0.41 0.16 0.45
P0C0S5 Histone H2A.Z 3 425 0.20 -0.06 -0.31
P16104 Histone H2AX 5 333 -0.98 -0.20 0.82 4 3
Q96A08 Histone H2B type 1-A 1 1817 0.54 0.90 0.37
P33778 Histone H2B type 1-B 1 2863 -0.10 -0.82 -0.28 5
P58876 Histone H2B type 1-D 1 2954 -1.02 -0.77 0.34
P06899 Histone H2B type 1-J 2 2897 0.20 -0.88 -0.42 3
Q99879 Histone H2B type 1-M 1 2950 -1.20 -0.66 1.11 3
Q5QNW6 Histone H2B type 2-F 2 2957 -0.88 -1.10 -0.06 3
Q8N257 Histone H2B type 3-B 2 2758 -0.74 0.09 0.84
P68431 Histone H3.1 3 797 -2.29 -0.87 1.31 5 4 5
P84243 Histone H3.3 3 798 -0.42 -0.62 -0.22
P62805 Histone H4 15 3544 0.21 0.08 0.04
Q9UPP1 Histone lysine demethylase PHF8 3 8 -0.18 -0.06 0.07
Q86X55 Histone-arginine methyltransferase CARM1 1 1 0.14 0.02 -0.14
Q09028 Histone-binding protein RBBP4 4 65 -0.19 -0.09 0.15
Q16576 Histone-binding protein RBBP7 5 59 -0.15 -0.10 0.09
Q03164 Histone-lysine N-methyltransferase 2A 20 35 0.15 -0.14 -0.31
Q9UMN6 Histone-lysine N-methyltransferase 2B 2 2 0.07 -0.22 -0.30
Q8NEZ4 Histone-lysine N-methyltransferase 2C 2 2 -0.52 -0.13 0.40
O14686 Histone-lysine N-methyltransferase 2D 1 1 -0.33 -0.14 0.20
Q8IZD2 Histone-lysine N-methyltransferase 2E 2 4 -0.24 0.02 0.33
Q9H9B1 Histone-lysine N-methyltransferase EHMT1 2 4 -0.95 -0.26 0.69
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 2 2 0.03 -0.39 -0.41
Q92800 Histone-lysine N-methyltransferase EZH1 1 2 -0.23 -0.22 0.01
O15047 Histone-lysine N-methyltransferase SETD1A 12 40 -0.05 -0.16 0.02
Q9UPS6 Histone-lysine N-methyltransferase SETD1B 2 7 0.08 -0.08 -0.21
Q9BYW2 Histone-lysine N-methyltransferase SETD2 1 2 -0.49 -0.08 0.42
Q86TU7 Histone-lysine N-methyltransferase setd3 5 14 -0.33 0.30 0.61 5
Q15047 Histone-lysine N-methyltransferase SETDB1 3 4 0.04 0.27 0.23
Q53H47 Histone-lysine N-methyltransferase SETMAR 5 6 0.13 -0.05 -0.05
O43719 HIV Tat-specific factor 1 6 19 0.10 -0.10 -0.18
P30443 HLA class I histocompatibility antigen, A-1 alpha chain 5 150 -0.21 -0.37 -0.09
P13746 HLA class I histocompatibility antigen, A-11 alpha chain 1 152 0.47 1.17 0.69
P05534 HLA class I histocompatibility antigen, A-24 alpha chain 1 145 0.72 0.99 0.27
P16190 HLA class I histocompatibility antigen, A-33 alpha chain 6 172 0.19 0.36 0.10 5
P13747 HLA class I histocompatibility antigen, alpha chain E 6 59 0.07 0.07 -0.09
P30511 HLA class I histocompatibility antigen, alpha chain F 2 6 -0.61 -0.32 0.23
P30464 HLA class I histocompatibility antigen, B-15 alpha chain 0 175 NA NA NA
P18463 HLA class I histocompatibility antigen, B-37 alpha chain 0 93 NA NA NA
P30481 HLA class I histocompatibility antigen, B-44 alpha chain 3 72 0.40 1.01 0.58
P30490 HLA class I histocompatibility antigen, B-52 alpha chain 0 149 NA NA NA
P30492 HLA class I histocompatibility antigen, B-54 alpha chain 0 146 NA NA NA
P30493 HLA class I histocompatibility antigen, B-55 alpha chain 0 148 NA NA NA
P01889 HLA class I histocompatibility antigen, B-7 alpha chain 1 104 0.53 0.33 -0.20
Q31612 HLA class I histocompatibility antigen, B-73 alpha chain 0 76 NA NA NA
Q29718 HLA class I histocompatibility antigen, B-82 alpha chain 0 92 NA NA NA
P30499 HLA class I histocompatibility antigen, Cw-1 alpha chain 0 77 NA NA NA
P30501 HLA class I histocompatibility antigen, Cw-2 alpha chain 1 113 0.18 0.44 0.17
P04222 HLA class I histocompatibility antigen, Cw-3 alpha chain 0 108 NA NA NA
P30504 HLA class I histocompatibility antigen, Cw-4 alpha chain 1 166 1.37 -0.12 -1.48
P10321 HLA class I histocompatibility antigen, Cw-7 alpha chain 1 108 -0.12 0.29 0.41
P04233 HLA class II histocompatibility antigen gamma chain 3 3 -0.42 0.14 0.55
P04440 HLA class II histocompatibility antigen, DP beta 1 chain 3 3 -0.85 -0.61 0.25
Q8WY36 HMG box transcription factor BBX 2 2 -0.12 -0.20 -0.09
Q9UGU5 HMG domain-containing protein 4 1 1 -0.77 -0.10 0.68
Q9BPY8 Homeodomain-only protein 2 2 -0.08 0.88 0.96
Q86YZ3 Hornerin 13 38 -0.13 -0.59 -0.22 3
P51610 Host cell factor 1 33 240 -0.19 -0.07 0.09
Q9Y5Z7 Host cell factor 2 1 8 0.19 0.10 -0.09
P50502 Hsc70-interacting protein 15 126 0.13 -0.35 -0.51
Q9NZL4 Hsp70-binding protein 1 1 1 NA NA NA
Q16543 Hsp90 co-chaperone Cdc37 14 75 0.13 0.06 -0.10
Q7L3B6 Hsp90 co-chaperone Cdc37-like 1 1 2 -0.06 -0.11 -0.05
P42858 Huntingtin 6 12 -0.06 0.14 0.27
O00291 Huntingtin-interacting protein 1 3 3 -0.51 0.08 0.60
O75146 Huntingtin-interacting protein 1-related protein 11 27 -0.34 -0.30 -0.13
Q9NX55 Huntingtin-interacting protein K 3 4 -1.21 -0.68 0.49
Q92839 Hyaluronan synthase 1 1 1 NA NA NA
Q16836 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 13 46 0.17 -0.28 -0.09
Q16775 Hydroxyacylglutathione hydrolase, mitochondrial 7 21 0.07 -0.05 -0.29
P35914 Hydroxymethylglutaryl-CoA lyase, mitochondrial 7 28 0.16 -0.04 -0.02
Q01581 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 1 1 -0.38 0.13 0.51
Q6YN16 Hydroxysteroid dehydrogenase-like protein 2 8 18 0.29 0.19 -0.15
Q14526 Hypermethylated in cancer 1 protein 1 1 -0.02 0.20 0.22
P00492 Hypoxanthine-guanine phosphoribosyltransferase 8 48 0.41 -0.04 -0.26
Q9Y4L1 Hypoxia up-regulated protein 1 24 99 0.14 0.74 0.55 5
Q9NWT6 Hypoxia-inducible factor 1-alpha inhibitor 1 1 -0.96 -0.57 0.40
P22304 Iduronate 2-sulfatase 2 5 -1.04 -0.02 0.89 3 3
P01876 Ig alpha-1 chain C region 2 2 0.27 0.26 0.00
P01857 Ig gamma-1 chain C region 4 21 -0.93 0.62 1.81 3 5 5
P01859 Ig gamma-2 chain C region 3 4 0.00 0.47 0.12
P01777 Ig heavy chain V-III region TEI 1 2 -0.26 0.27 0.53
P01765 Ig heavy chain V-III region TIL 1 3 -0.77 -0.06 0.76
P01834 Ig kappa chain C region 4 29 -1.12 0.19 1.15 5 5
P01593 Ig kappa chain V-I region AG 1 7 -2.19 0.14 2.34
P01606 Ig kappa chain V-I region OU 2 7 -0.22 0.31 0.53
P01619 Ig kappa chain V-III region B6 1 5 NA NA NA
P04433 Ig kappa chain V-III region VG (Fragment) 1 1 -1.61 0.37 1.97
P01625 Ig kappa chain V-IV region Len 2 6 -0.87 0.48 1.40 4 4
P0CG05 Ig lambda-2 chain C regions 4 11 -0.91 0.22 1.10 5 5
Q8WZA9 Immunity-related GTPase family Q protein 7 16 -0.28 -0.16 0.10
P01591 Immunoglobulin J chain 1 1 -0.04 -0.79 -0.75
Q93033 Immunoglobulin superfamily member 2 2 5 0.58 -0.36 -0.94 3
Q969P0 Immunoglobulin superfamily member 8 3 5 0.08 -0.29 -0.37
P78318 Immunoglobulin-binding protein 1 6 32 0.09 -0.02 0.03
O00629 Importin subunit alpha-3 5 18 -0.05 0.10 -0.08
O00505 Importin subunit alpha-4 2 20 0.10 0.30 0.15
P52294 Importin subunit alpha-5 3 18 -0.18 -0.03 0.24
O60684 Importin subunit alpha-7 4 6 -0.03 0.29 0.29
Q14974 Importin subunit beta-1 12 119 0.01 0.02 -0.01
Q9UI26 Importin-11 1 1 -0.07 -0.06 0.02
Q8TEX9 Importin-4 2 4 0.46 0.09 -0.38
O00410 Importin-5 14 29 0.09 0.10 -0.07
O95373 Importin-7 1 1 0.41 0.16 -0.25
Q96P70 Importin-9 3 5 0.03 -0.13 -0.17
Q3SXM5 Inactive hydroxysteroid dehydrogenase-like protein 1 1 1 -0.39 -0.16 0.23
Q15111 Inactive phospholipase C-like protein 1 1 1 0.37 0.19 -0.17
Q9UPR0 Inactive phospholipase C-like protein 2 8 12 -0.23 0.02 0.25
Q8IV63 Inactive serine/threonine-protein kinase VRK3 5 13 -0.23 -0.09 0.05
Q8NI35 InaD-like protein 1 17 0.86 0.91 0.16 3 3
Q07820 Induced myeloid leukemia cell differentiation protein Mcl-1 1 6 -0.25 0.06 0.26
Q9Y6Y0 Influenza virus NS1A-binding protein 1 1 -0.31 0.46 0.75
Q9UK53 Inhibitor of growth protein 1 2 7 -0.27 -0.22 0.07
Q9NXR8 Inhibitor of growth protein 3 1 2 -0.12 -0.15 -0.03
O15111 Inhibitor of nuclear factor kappa-B kinase subunit alpha 1 3 NA NA NA
O14920 Inhibitor of nuclear factor kappa-B kinase subunit beta 9 23 -0.02 -0.07 0.06
Q14164 Inhibitor of nuclear factor kappa-B kinase subunit epsilon 1 2 0.35 0.23 -0.12
Q9Y2U8 Inner nuclear membrane protein Man1 6 21 -0.09 0.18 0.27
Q8NBZ0 INO80 complex subunit E 2 8 -0.11 0.06 0.22
Q15181 Inorganic pyrophosphatase 7 54 0.83 0.19 -0.53 5 5
Q9H2U2 Inorganic pyrophosphatase 2, mitochondrial 8 63 0.53 -0.14 -0.58 5
Q9BY32 Inosine triphosphate pyrophosphatase 5 30 -0.19 -0.12 0.17
P20839 Inosine-5'-monophosphate dehydrogenase 1 7 26 0.08 0.19 -0.04
P12268 Inosine-5'-monophosphate dehydrogenase 2 20 108 0.18 -0.12 -0.28
Q14643 Inositol 1,4,5-trisphosphate receptor type 1 2 7 0.07 -0.21 -0.10
Q14571 Inositol 1,4,5-trisphosphate receptor type 2 7 17 -0.01 -0.03 -0.08
Q14573 Inositol 1,4,5-trisphosphate receptor type 3 3 8 0.90 0.68 -0.02 3 3
Q8IWB1 Inositol 1,4,5-trisphosphate receptor-interacting protein 1 1 -0.05 0.59 0.65
Q3MIP1 Inositol 1,4,5-trisphosphate receptor-interacting protein-like 2 1 1 NA NA NA
O43314 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2 5 8 -0.13 0.25 0.29
P29218 Inositol monophosphatase 1 10 59 -0.18 -0.10 0.00
O14732 Inositol monophosphatase 2 1 1 1.36 1.10 -0.25
P49441 Inositol polyphosphate 1-phosphatase 2 4 -0.49 0.39 0.89
Q9BT40 Inositol polyphosphate 5-phosphatase K 1 1 -1.09 -0.47 0.63
Q9NPH2 Inositol-3-phosphate synthase 1 3 4 -0.30 -0.77 -0.46 3
Q13572 Inositol-tetrakisphosphate 1-kinase 1 2 -0.28 0.20 0.49
P27987 Inositol-trisphosphate 3-kinase B 11 24 -0.23 -0.27 -0.13
Q96DU7 Inositol-trisphosphate 3-kinase C 1 2 -0.51 0.22 0.73
Q9Y4H2 Insulin receptor substrate 2 2 7 -0.47 -0.01 0.38
Q9Y5U4 Insulin-induced gene 2 protein 1 1 -0.43 -0.05 0.38
O00425 Insulin-like growth factor 2 mRNA-binding protein 3 1 2 NA NA NA
P18065 Insulin-like growth factor-binding protein 2 1 1 NA NA NA
Q86V85 Integral membrane protein GPR180 1 1 -0.25 -0.11 0.15
Q8N201 Integrator complex subunit 1 6 15 -0.26 -0.13 0.14
Q9NVR2 Integrator complex subunit 10 3 5 0.06 -0.15 -0.21
Q5TA45 Integrator complex subunit 11 1 2 NA NA NA
Q96CB8 Integrator complex subunit 12 4 6 -0.34 -0.08 0.30
Q9H0H0 Integrator complex subunit 2 1 1 0.24 -0.06 -0.30
Q68E01 Integrator complex subunit 3 3 17 -0.44 0.06 0.46
Q96HW7 Integrator complex subunit 4 5 9 0.02 0.03 -0.02
Q6P9B9 Integrator complex subunit 5 3 7 -0.02 -0.02 -0.13
Q9UL03 Integrator complex subunit 6 2 3 -0.18 -0.04 0.13
Q9NVH2 Integrator complex subunit 7 2 4 -0.04 -0.16 -0.08
Q75QN2 Integrator complex subunit 8 1 3 0.04 -0.02 -0.06
Q9UKX5 Integrin alpha-11 1 1 0.04 -0.12 -0.15
P13612 Integrin alpha-4 2 17 -0.01 0.53 0.32 3
P08648 Integrin alpha-5 3 5 -0.34 0.40 0.65 3
P23229 Integrin alpha-6 4 4 -0.53 -0.12 0.41
P08514 Integrin alpha-IIb 13 59 -0.10 -0.20 0.02
P20701 Integrin alpha-L 23 120 -0.31 0.63 0.82 3 4
P11215 Integrin alpha-M 24 124 -2.03 -0.08 1.66 5 5
P20702 Integrin alpha-X 5 16 -1.64 0.12 1.56 3 3
P05556 Integrin beta-1 11 59 -0.31 0.28 0.30
P05107 Integrin beta-2 25 203 -1.19 0.47 1.54 5 5
P05106 Integrin beta-3 8 25 -0.07 -0.03 -0.06
P26010 Integrin beta-7 2 7 0.39 0.03 -0.31
Q969R8 Integrin-alpha FG-GAP repeat-containing protein 2 2 2 0.20 -0.37 -0.57
Q9H0C8 Integrin-linked kinase-associated serine/threonine phosphatase 2C 10 66 -0.49 -0.28 0.19
Q13418 Integrin-linked protein kinase 11 59 -0.04 0.35 0.38
Q8WWN9 Interactor protein for cytohesin exchange factors 1 3 17 0.40 0.02 -0.44
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 1 1 -0.03 -0.15 -0.14
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 6 18 0.97 1.07 0.12 3
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 1 1 1.52 1.99 0.47
P05362 Intercellular adhesion molecule 1 3 9 -0.62 0.67 1.13 3 5
P13598 Intercellular adhesion molecule 2 2 12 -0.28 0.28 0.50 4
P32942 Intercellular adhesion molecule 3 12 97 -0.14 0.72 0.91 4 5
P14316 Interferon regulatory factor 2 1 3 NA NA NA
Q8IU81 Interferon regulatory factor 2-binding protein 1 4 7 -0.07 0.02 0.06
Q7Z5L9 Interferon regulatory factor 2-binding protein 2 3 11 -0.08 0.07 0.24
Q9H1B7 Interferon regulatory factor 2-binding protein-like 7 25 -0.54 -0.10 0.33
Q14653 Interferon regulatory factor 3 5 5 -0.01 -0.14 -0.13
Q92985 Interferon regulatory factor 7 3 10 -0.42 -0.02 0.58
Q00978 Interferon regulatory factor 9 4 11 -0.47 -0.03 0.44
P80217 Interferon-induced 35 kDa protein 2 2 0.58 0.04 -0.53
P20591 Interferon-induced GTP-binding protein Mx1 14 131 0.04 0.21 0.21
P20592 Interferon-induced GTP-binding protein Mx2 13 119 0.53 0.26 -0.19
P32455 Interferon-induced guanylate-binding protein 1 12 90 0.61 -0.01 -0.75 4 5
P32456 Interferon-induced guanylate-binding protein 2 13 67 0.73 0.34 -0.41 5
Q9BYX4 Interferon-induced helicase C domain-containing protein 1 3 5 0.01 0.19 0.18
P09914 Interferon-induced protein with tetratricopeptide repeats 1 4 20 -0.66 0.23 0.82
O14879 Interferon-induced protein with tetratricopeptide repeats 3 7 30 -0.74 -0.12 0.66 4 5
Q13325 Interferon-induced protein with tetratricopeptide repeats 5 4 12 -0.16 -0.04 0.14
P19525 Interferon-induced, double-stranded RNA-activated protein kinase 13 38 0.06 0.18 0.17
O75569 Interferon-inducible double-stranded RNA-dependent protein kinase activator A 7 22 0.31 -0.18 -0.54 5
O00458 Interferon-related developmental regulator 1 1 5 0.07 -0.03 -0.09
Q9H9L3 Interferon-stimulated 20 kDa exonuclease-like 2 3 5 0.00 -0.05 0.01
Q96AZ6 Interferon-stimulated gene 20 kDa protein 7 55 0.02 0.05 0.02
Q12905 Interleukin enhancer-binding factor 2 13 185 0.07 -0.03 -0.17
Q12906 Interleukin enhancer-binding factor 3 33 284 -0.02 -0.05 -0.13
P01584 Interleukin-1 beta 2 3 0.20 0.48 0.28
Q9NWZ3 Interleukin-1 receptor-associated kinase 4 12 44 -0.09 0.10 0.23
P20809 Interleukin-11 1 1 NA NA NA
Q13478 Interleukin-18 receptor 1 2 2 0.41 0.82 0.41
P14784 Interleukin-2 receptor subunit beta 1 2 -2.23 0.21 2.45
Q6UWB1 Interleukin-27 receptor subunit alpha 1 1 NA NA NA
P16871 Interleukin-7 receptor subunit alpha 2 6 2.10 0.93 -1.09 4 4 4
P10145 Interleukin-8 1 1 -1.72 0.00 1.72
Q15811 Intersectin-1 1 1 -0.45 0.33 0.79
Q9NZM3 Intersectin-2 13 34 -0.07 0.02 0.22
Q5JVS0 Intracellular hyaluronan-binding protein 4 2 3 -0.22 -0.54 -0.32
Q9BW83 Intraflagellar transport protein 27 homolog 4 5 -0.32 0.07 0.38
O60306 Intron-binding protein aquarius 7 21 -0.12 -0.11 0.11
Q27J81 Inverted formin-2 3 3 0.16 -0.41 -0.57
Q6DN90 IQ motif and SEC7 domain-containing protein 1 2 3 -0.32 0.34 0.66
Q9BUE6 Iron-sulfur cluster assembly 1 homolog, mitochondrial 2 3 0.12 0.19 -0.08
Q86U28 Iron-sulfur cluster assembly 2 homolog, mitochondrial 5 17 0.42 -0.29 -0.70 5
Q9H1K1 Iron-sulfur cluster assembly enzyme ISCU, mitochondrial 7 22 0.21 -0.16 -0.36
Q8IWL3 Iron-sulfur cluster co-chaperone protein HscB, mitochondrial 1 2 -0.16 -0.10 0.06
Q8TB37 Iron-sulfur protein NUBPL 4 7 0.54 0.20 -0.38
Q2TAA2 Isoamyl acetate-hydrolyzing esterase 1 homolog 6 16 0.25 -0.16 -0.36
Q9UKU7 Isobutyryl-CoA dehydrogenase, mitochondrial 9 31 0.15 -0.06 -0.18
Q96CN7 Isochorismatase domain-containing protein 1 7 23 0.14 0.05 -0.11
Q96AB3 Isochorismatase domain-containing protein 2, mitochondrial 3 3 0.52 0.18 -0.35
O75874 Isocitrate dehydrogenase cytoplasmic 15 60 0.09 0.23 0.24
P50213 Isocitrate dehydrogenase subunit alpha, mitochondrial 12 38 0.24 -0.04 -0.41
O43837 Isocitrate dehydrogenase subunit beta, mitochondrial 11 53 0.32 -0.07 -0.32
P51553 Isocitrate dehydrogenase subunit gamma, mitochondrial 6 23 0.32 0.06 -0.15
P48735 Isocitrate dehydrogenase, mitochondrial 27 256 -0.41 0.11 0.40
P41252 Isoleucine--tRNA ligase, cytoplasmic 11 39 0.16 0.03 0.03
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial 22 121 0.35 0.13 -0.30
Q13907 Isopentenyl-diphosphate Delta-isomerase 1 1 1 -0.59 0.15 0.72
P26440 Isovaleryl-CoA dehydrogenase, mitochondrial 8 42 -0.03 -0.41 -0.47 5 4
P53990 IST1 homolog 6 48 0.02 0.07 -0.08
Q96N16 Janus kinase and microtubule-interacting protein 1 1 1 0.02 0.28 0.26
P0C870 JmjC domain-containing protein 7 1 1 NA NA NA
P14923 Junction plakoglobin 3 7 1.01 -0.43 -1.35
Q9Y624 Junctional adhesion molecule A 4 7 -0.38 -0.21 0.17
O60229 Kalirin 1 1 0.03 -0.27 -0.32
Q9BWU0 Kanadaptin 3 8 -0.15 -0.10 0.05
Q7Z3B3 KAT8 regulatory NSL complex subunit 1 1 1 0.05 0.06 0.02
Q9H9L4 KAT8 regulatory NSL complex subunit 2 3 5 0.15 -0.03 -0.17
Q9P2N6 KAT8 regulatory NSL complex subunit 3 1 1 -0.31 0.35 0.68
Q7Z4H8 KDEL motif-containing protein 2 2 5 -0.23 -0.01 0.18
Q8TBB5 Kelch domain-containing protein 4 5 7 -0.24 0.11 0.28
O94819 Kelch repeat and BTB domain-containing protein 11 1 1 NA NA NA
Q8N4N3 Kelch-like protein 36 3 4 -0.10 -0.42 -0.31
Q92764 Keratin, type I cuticular Ha5 1 6 0.02 0.03 0.01
P13645 Keratin, type I cytoskeletal 10 21 286 -0.03 -0.06 -0.09
P13646 Keratin, type I cytoskeletal 13 1 22 0.42 0.57 0.15
P02533 Keratin, type I cytoskeletal 14 4 90 0.57 0.39 -0.09
P19012 Keratin, type I cytoskeletal 15 1 36 NA NA NA
P08779 Keratin, type I cytoskeletal 16 9 89 1.54 0.93 -0.02 3
Q04695 Keratin, type I cytoskeletal 17 8 54 1.15 1.10 -0.14
P05783 Keratin, type I cytoskeletal 18 1 5 NA NA NA
P35527 Keratin, type I cytoskeletal 9 26 435 0.17 -0.09 -0.13
P04264 Keratin, type II cytoskeletal 1 35 514 0.05 0.27 0.04
P35908 Keratin, type II cytoskeletal 2 epidermal 31 330 -0.06 0.00 -0.27
P12035 Keratin, type II cytoskeletal 3 0 29 NA NA NA
P19013 Keratin, type II cytoskeletal 4 0 29 NA NA NA
P13647 Keratin, type II cytoskeletal 5 17 136 -0.09 -0.23 -0.03
P02538 Keratin, type II cytoskeletal 6A 5 138 0.58 0.25 0.04
P04259 Keratin, type II cytoskeletal 6B 2 136 1.38 1.07 -0.35
Q7RTS7 Keratin, type II cytoskeletal 74 1 21 1.57 1.62 -0.13
Q8N1N4 Keratin, type II cytoskeletal 78 0 16 NA NA NA
Q5XKE5 Keratin, type II cytoskeletal 79 1 59 2.24 1.32 -0.91
P05787 Keratin, type II cytoskeletal 8 2 82 NA NA NA
Q6KB66 Keratin, type II cytoskeletal 80 1 4 1.23 0.97 -0.25
Q5T749 Keratinocyte proline-rich protein 1 1 -1.11 -0.85 0.24
Q9HA64 Ketosamine-3-kinase 8 19 -0.03 -0.21 -0.13
Q07666 KH domain-containing, RNA-binding, signal transduction-associated protein 1 14 143 -0.23 -0.17 0.09
P43631 Killer cell immunoglobulin-like receptor 2DS2 1 3 -1.51 0.07 1.59
Q9NZS2 Killer cell lectin-like receptor subfamily F member 1 1 1 -0.34 0.06 0.41
Q86UP2 Kinectin 34 132 0.07 0.08 -0.11
O60282 Kinesin heavy chain isoform 5C 4 29 1.78 1.37 -0.41 3 3
Q07866 Kinesin light chain 1 8 32 0.16 0.43 0.15
Q9H0B6 Kinesin light chain 2 3 17 -0.52 0.34 0.49
Q9NSK0 Kinesin light chain 4 3 16 -0.14 0.04 0.28
P33176 Kinesin-1 heavy chain 17 75 -0.20 -0.05 0.25
Q9NQT8 Kinesin-like protein KIF13B 6 16 -0.37 0.16 0.57
Q15058 Kinesin-like protein KIF14 1 1 -1.85 1.01 2.87
Q12756 Kinesin-like protein KIF1A 2 3 0.62 0.44 -0.18
Q7Z4S6 Kinesin-like protein KIF21A 3 7 -0.12 0.14 0.17
O75037 Kinesin-like protein KIF21B 1 4 -0.60 0.24 0.84
O00139 Kinesin-like protein KIF2A 16 54 0.12 -0.08 -0.19
Q9Y496 Kinesin-like protein KIF3A 2 2 -0.07 0.05 0.13
O15066 Kinesin-like protein KIF3B 5 6 0.36 0.33 -0.17
Q9H410 Kinetochore-associated protein DSN1 homolog 2 5 -0.48 -0.25 0.24
Q96IY1 Kinetochore-associated protein NSL1 homolog 3 4 0.74 -0.10 -0.85
P01042 Kininogen-1 1 2 1.46 1.67 0.21
Q6NY19 KN motif and ankyrin repeat domain-containing protein 3 5 10 -0.94 0.29 1.33 4 4
O00522 Krev interaction trapped protein 1 2 4 0.14 0.35 0.21
Q13601 KRR1 small subunit processome component homolog 5 9 0.32 -0.13 -0.28
Q9Y4X4 Krueppel-like factor 12 4 7 -0.19 -0.02 0.17
Q9Y2Y9 Krueppel-like factor 13 2 5 -0.06 0.08 0.14
Q9BXK1 Krueppel-like factor 16 1 2 0.32 0.03 -0.29
Q9Y5W3 Krueppel-like factor 2 1 1 -0.14 -0.81 -0.66
Q16773 Kynurenine--oxoglutarate transaminase 1 1 7 0.11 -0.25 -0.32
Q6YP21 Kynurenine--oxoglutarate transaminase 3 5 29 0.38 0.06 -0.28
Q9H9P8 L-2-hydroxyglutarate dehydrogenase, mitochondrial 3 5 0.36 -0.10 -0.46
Q8WV93 Lactation elevated protein 1 1 1 0.14 -0.20 -0.34
P02788 Lactotransferrin 12 22 0.34 0.20 -0.25
Q04760 Lactoylglutathione lyase 4 51 0.38 0.35 -0.13
Q9Y2S2 Lambda-crystallin homolog 3 6 0.50 -0.11 -0.60
P42166 Lamina-associated polypeptide 2, isoform alpha 12 277 -0.21 -0.37 0.02
P42167 Lamina-associated polypeptide 2, isoforms beta/gamma 12 431 -0.13 -0.44 -0.30
Q14739 Lamin-B receptor 6 25 -0.42 -0.18 0.15
P20700 Lamin-B1 51 804 -0.35 -0.50 -0.26 5
Q03252 Lamin-B2 51 601 0.12 -0.09 -0.18
Q96RQ9 L-amino-acid oxidase 16 115 1.82 2.00 0.02 5 5
Q9NRN7 L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 3 4 0.00 -0.07 -0.07
O43813 LanC-like protein 1 2 20 0.32 -0.12 -0.58
Q9NS86 LanC-like protein 2 1 4 -0.11 0.12 0.22
P48449 Lanosterol synthase 1 1 -0.43 -0.27 0.16
Q6PKG0 La-related protein 1 11 22 0.09 -0.09 -0.08
Q92615 La-related protein 4B 4 5 -0.24 -0.25 0.34
Q4G0J3 La-related protein 7 9 39 -0.19 -0.18 0.11
Q01650 Large neutral amino acids transporter small subunit 1 2 7 2.01 2.38 0.37 5 5
P46379 Large proline-rich protein BAG6 7 22 0.27 -0.06 -0.21
Q9H089 Large subunit GTPase 1 homolog 4 7 0.05 -0.38 -0.48
Q9UK59 Lariat debranching enzyme 5 19 0.07 -0.18 -0.22
Q8NBF6 Late secretory pathway protein AVL9 homolog 2 2 -0.23 -0.45 -0.23
Q14766 Latent-transforming growth factor beta-binding protein 1 1 1 0.17 -0.24 -0.43
Q9BS40 Latexin 3 8 -0.28 -0.19 -0.02
Q9H400 Lck-interacting transmembrane adapter 1 4 15 0.42 -0.01 -0.44
Q14696 LDLR chaperone MESD 3 9 0.12 0.09 -0.06
Q99538 Legumain 1 1 -1.97 -0.26 1.72
Q8NC56 LEM domain-containing protein 2 3 17 -0.03 0.07 0.14
Q15334 Lethal(2) giant larvae protein homolog 1 2 3 -0.35 0.22 0.62
Q6P1M3 Lethal(2) giant larvae protein homolog 2 1 2 -0.60 0.20 0.80
Q96JM7 Lethal(3)malignant brain tumor-like protein 3 5 16 0.09 -0.29 -0.54
O95202 LETM1 and EF-hand domain-containing protein 1, mitochondrial 9 26 0.01 0.18 0.29
Q9UIC8 Leucine carboxyl methyltransferase 1 1 3 0.05 0.28 0.12
Q86V48 Leucine zipper protein 1 8 19 0.37 0.76 0.47 4 4
Q9Y250 Leucine zipper putative tumor suppressor 1 1 2 0.14 -0.05 -0.18
Q9NQ48 Leucine zipper transcription factor-like protein 1 6 8 0.02 -0.05 -0.02
P02750 Leucine-rich alpha-2-glycoprotein 1 1 -1.32 -0.74 0.60
P42704 Leucine-rich PPR motif-containing protein, mitochondrial 27 106 0.46 0.16 -0.43 5
Q9Y2L9 Leucine-rich repeat and calponin homology domain-containing protein 1 1 9 -0.25 0.02 0.41
Q96II8 Leucine-rich repeat and calponin homology domain-containing protein 3 4 20 -0.07 0.01 0.09
O75427 Leucine-rich repeat and calponin homology domain-containing protein 4 12 50 0.02 -0.17 -0.16
Q9UFC0 Leucine-rich repeat and WD repeat-containing protein 1 3 5 -0.22 -0.11 0.14
Q32MZ4 Leucine-rich repeat flightless-interacting protein 1 23 129 0.04 0.04 0.05
Q9Y608 Leucine-rich repeat flightless-interacting protein 2 4 14 0.24 0.08 0.06
Q9UQ13 Leucine-rich repeat protein SHOC-2 3 13 -0.10 -0.07 0.07
Q5S007 Leucine-rich repeat serine/threonine-protein kinase 2 1 5 0.12 -0.10 -0.22
Q6F5E8 Leucine-rich repeat-containing protein 16C 11 41 0.65 0.12 -0.54 5 4
Q8TCA0 Leucine-rich repeat-containing protein 20 1 1 NA NA NA
Q9H9A6 Leucine-rich repeat-containing protein 40 9 14 -0.02 0.11 0.05
Q15345 Leucine-rich repeat-containing protein 41 3 5 -0.14 -0.07 0.17
Q8N1G4 Leucine-rich repeat-containing protein 47 22 151 0.05 -0.13 -0.31
Q8N9N7 Leucine-rich repeat-containing protein 57 1 5 0.03 0.29 0.18
Q96AG4 Leucine-rich repeat-containing protein 59 4 8 -0.10 0.48 0.17
Q96NW7 Leucine-rich repeat-containing protein 7 1 8 -0.45 0.62 1.07
Q9P2J5 Leucine--tRNA ligase, cytoplasmic 15 35 0.30 -0.06 -0.26
Q9UIQ6 Leucyl-cystinyl aminopeptidase 4 22 -0.42 -0.12 0.23
P30740 Leukocyte elastase inhibitor 24 232 -0.54 -0.21 0.23
Q8NHL6 Leukocyte immunoglobulin-like receptor subfamily B member 1 2 2 0.23 0.04 -0.19
Q96BZ8 Leukocyte receptor cluster member 1 5 13 0.01 -0.30 -0.16
Q96B70 Leukocyte receptor cluster member 9 1 1 -0.46 0.20 0.64
Q08722 Leukocyte surface antigen CD47 4 50 0.32 0.79 0.43 5
P19397 Leukocyte surface antigen CD53 2 3 0.49 0.46 -0.02
Q6GTX8 Leukocyte-associated immunoglobulin-like receptor 1 3 14 -0.78 0.00 0.61 4 3
P16150 Leukosialin 5 55 -0.38 0.35 0.67 4
P09960 Leukotriene A-4 hydrolase 23 144 0.13 -0.06 -0.35
O60711 Leupaxin 9 70 0.41 0.13 -0.05
Q9UNZ5 Leydig cell tumor 10 kDa protein homolog 4 14 -0.03 -0.28 -0.11
Q8N0W3 L-fucose kinase 2 4 0.17 -0.03 -0.19
Q8N3X6 Ligand-dependent nuclear receptor corepressor-like protein 1 1 -0.31 1.46 1.79
Q5T3J3 Ligand-dependent nuclear receptor-interacting factor 1 1 2 -0.20 0.25 0.46
P48059 LIM and senescent cell antigen-like-containing domain protein 1 2 7 0.11 0.37 0.27
Q14847 LIM and SH3 domain protein 1 15 348 -0.99 0.13 1.01 5 5
Q9UHB6 LIM domain and actin-binding protein 1 8 16 -0.38 -0.34 0.21
Q8WWI1 LIM domain only protein 7 4 66 0.15 -0.95 -1.08 3
Q86U70 LIM domain-binding protein 1 2 6 -0.60 -0.16 0.30
Q9UGP4 LIM domain-containing protein 1 4 15 -0.80 0.12 0.96 5 5
Q9BT23 LIM domain-containing protein 2 3 18 -0.35 -0.32 0.18
O43561 Linker for activation of T-cells family member 1 3 10 0.70 0.14 -0.50 4
Q9GZY6 Linker for activation of T-cells family member 2 1 1 -1.42 0.19 1.61
Q9BU23 Lipase maturation factor 2 3 12 0.14 0.51 0.30
P11182 Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex9 26 0.20 -0.01 -0.19
Q86X29 Lipolysis-stimulated lipoprotein receptor 1 3 0.75 -0.17 -0.93 3 3
Q93052 Lipoma-preferred partner 8 13 -0.38 0.32 0.79 5
Q99732 Lipopolysaccharide-induced tumor necrosis factor-alpha factor 1 6 -0.52 0.21 0.58 5
P50851 Lipopolysaccharide-responsive and beige-like anchor protein 18 43 0.14 0.16 -0.06
Q13136 Liprin-alpha-1 4 9 -0.15 0.01 0.08
Q8ND30 Liprin-beta-2 1 1 -0.66 -0.64 0.02
P23141 Liver carboxylesterase 1 3 3 0.06 -0.06 0.06
Q8IVB5 LIX1-like protein 2 2 0.15 -0.21 -0.35
P00338 L-lactate dehydrogenase A chain 16 214 0.56 0.07 -0.47 4
P07195 L-lactate dehydrogenase B chain 17 303 0.59 -1.22 -1.79 5 5 5
P36776 Lon protease homolog, mitochondrial 26 87 0.43 0.00 -0.49 5
Q6PCB7 Long-chain fatty acid transport protein 1 2 2 1.94 0.32 -1.61
Q5K4L6 Long-chain fatty acid transport protein 3 2 6 -0.46 0.09 0.35
Q6P1M0 Long-chain fatty acid transport protein 4 2 3 -0.18 0.10 0.21
O95573 Long-chain-fatty-acid--CoA ligase 3 3 22 -0.13 0.22 0.35
O60488 Long-chain-fatty-acid--CoA ligase 4 2 8 -0.18 0.08 0.26
Q9ULC5 Long-chain-fatty-acid--CoA ligase 5 6 11 -0.22 0.19 0.36
Q969J3 Loss of heterozygosity 12 chromosomal region 1 protein 5 16 0.15 0.09 0.06
P12318 Low affinity immunoglobulin gamma Fc region receptor II-a 1 2 -0.17 0.06 0.23
P08637 Low affinity immunoglobulin gamma Fc region receptor III-A 3 10 -2.88 -0.05 2.82 3 3
Q5SW96 Low density lipoprotein receptor adapter protein 1 2 8 -0.02 -0.78 -0.68 5 5
P24666 Low molecular weight phosphotyrosine protein phosphatase 6 33 -0.18 -0.08 0.26
P14151 L-selectin 2 4 -1.43 -2.34 -0.77 3
O95232 Luc7-like protein 3 9 15 0.01 -0.11 -0.09
P05455 Lupus La protein 20 189 0.29 0.05 -0.39
Q7Z4W1 L-xylulose reductase 10 71 -0.17 -0.48 -0.38
O95274 Ly6/PLAUR domain-containing protein 3 1 1 NA NA NA
O60449 Lymphocyte antigen 75 2 2 -0.12 0.07 0.20
Q13094 Lymphocyte cytosolic protein 2 13 75 0.04 0.17 0.07
P33241 Lymphocyte-specific protein 1 22 269 -0.53 0.00 0.42
Q9UJU2 Lymphoid enhancer-binding factor 1 3 15 -0.12 -2.09 -1.96 4 4
Q12912 Lymphoid-restricted membrane protein 3 4 -0.30 0.00 0.30
Q9NU23 LYR motif-containing protein 2 1 3 -0.03 0.06 0.10
Q9HD34 LYR motif-containing protein 4 1 2 0.39 0.09 -0.30
A8MSI8 LYR motif-containing protein 9 1 1 0.36 -0.49 -0.84
P46736 Lys-63-specific deubiquitinase BRCC36 5 13 0.76 -0.10 -0.80 3 3
Q9Y2K7 Lysine-specific demethylase 2A 7 20 -0.18 -0.02 0.04
Q8NHM5 Lysine-specific demethylase 2B 1 1 -0.27 0.19 0.46
Q9Y4C1 Lysine-specific demethylase 3A 4 5 -0.27 -0.42 -0.13
Q7LBC6 Lysine-specific demethylase 3B 9 9 -0.05 -0.18 0.01
O94953 Lysine-specific demethylase 4B 1 2 -0.88 -0.52 0.37
Q9H3R0 Lysine-specific demethylase 4C 1 1 -0.17 0.19 0.37
P29375 Lysine-specific demethylase 5A 6 9 0.11 0.00 0.01
O15550 Lysine-specific demethylase 6A 2 3 0.30 0.37 0.07
Q6ZMT4 Lysine-specific demethylase 7A 1 1 -0.23 0.09 0.33
O75151 Lysine-specific demethylase PHF2 3 10 0.19 0.21 0.03
O60341 Lysine-specific histone demethylase 1A 9 21 -0.29 -0.13 0.12
Q15046 Lysine--tRNA ligase 17 65 0.76 0.34 -0.28 5
Q8IV50 LysM and putative peptidoglycan-binding domain-containing protein 2 4 21 0.18 0.10 -0.10
Q8NF37 Lysophosphatidylcholine acyltransferase 1 4 12 -0.68 0.94 1.67 4 4
Q5VWZ2 Lysophospholipase-like protein 1 5 11 0.46 -0.14 -0.48
Q96N66 Lysophospholipid acyltransferase 7 2 2 0.14 0.22 0.07
Q643R3 Lysophospholipid acyltransferase LPCAT4 2 3 0.91 0.56 -0.11
P38571 Lysosomal acid lipase/cholesteryl ester hydrolase 1 1 -0.40 -0.46 -0.06
P11117 Lysosomal acid phosphatase 3 3 -0.25 0.28 0.54
P10253 Lysosomal alpha-glucosidase 4 23 -0.17 0.25 0.53 5
O00754 Lysosomal alpha-mannosidase 6 15 -0.33 0.14 0.53
P10619 Lysosomal protective protein 3 20 0.64 0.75 0.24 4 5
P42785 Lysosomal Pro-X carboxypeptidase 6 31 -1.09 0.16 1.25 3 5
Q99698 Lysosomal-trafficking regulator 2 4 0.05 0.34 0.44
P11279 Lysosome-associated membrane glycoprotein 1 5 29 -0.54 0.60 0.65 3 5
P13473 Lysosome-associated membrane glycoprotein 2 2 2 -1.76 -0.76 1.00
P61626 Lysozyme C 6 26 0.13 0.03 0.03
Q8IU60 m7GpppN-mRNA hydrolase 1 1 NA NA NA
Q96C86 m7GpppX diphosphatase 11 62 -0.13 0.22 0.32
Q8N5G2 Macoilin 1 1 0.20 0.19 -0.02
Q7L5Y9 Macrophage erythroblast attacher 2 3 0.06 0.41 0.12
P14174 Macrophage migration inhibitory factor 2 167 0.21 -0.03 -0.32
P40121 Macrophage-capping protein 12 54 -0.60 -0.34 0.38 5
Q8NDA8 Maestro heat-like repeat-containing protein family member 1 1 5 NA NA NA
Q68CQ1 Maestro heat-like repeat-containing protein family member 7 1 2 NA NA NA
Q9H0U3 Magnesium transporter protein 1 2 2 0.72 0.49 -0.24
Q86V88 Magnesium-dependent phosphatase 1 3 3 -0.39 -0.67 -0.27
Q9NZW5 MAGUK p55 subfamily member 6 1 1 0.22 -0.60 -0.82
Q5T2T1 MAGUK p55 subfamily member 7 2 3 0.33 -0.27 -0.59
P07199 Major centromere autoantigen B 4 14 -0.17 0.10 0.26
P04156 Major prion protein 1 10 1.04 0.96 -0.08
Q14764 Major vault protein 36 208 -0.53 -0.37 0.12 5
P40925 Malate dehydrogenase, cytoplasmic 17 207 0.27 -0.30 -0.63 5
P40926 Malate dehydrogenase, mitochondrial 29 689 0.07 -0.08 -0.04
Q9BSQ5 Malcavernin 1 4 -0.31 0.08 0.52
Q14165 Malectin 4 10 0.31 0.78 0.32 5
Q68DK7 Male-specific lethal 1 homolog 6 17 -0.05 0.11 0.12
O43708 Maleylacetoacetate isomerase 1 3 -0.09 -0.15 -0.12
Q9ULC4 Malignant T-cell-amplified sequence 1 5 26 0.27 0.11 -0.15
O95822 Malonyl-CoA decarboxylase, mitochondrial 4 9 -0.02 0.06 0.23
Q8IVS2 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial 1 1 -0.12 0.38 0.48
Q9UM22 Mammalian ependymin-related protein 1 1 1 -2.85 -0.97 1.88
Q96IJ6 Mannose-1-phosphate guanyltransferase alpha 7 26 0.26 0.42 0.34 5
Q9Y5P6 Mannose-1-phosphate guanyltransferase beta 5 25 0.38 0.55 0.28 5
P34949 Mannose-6-phosphate isomerase 7 25 0.42 -0.12 -0.49
Q13724 Mannosyl-oligosaccharide glucosidase 11 40 0.34 0.17 0.10
P49137 MAP kinase-activated protein kinase 2 8 24 0.04 0.40 0.53
Q16644 MAP kinase-activated protein kinase 3 2 9 -0.43 0.05 0.48
Q8WXG6 MAP kinase-activating death domain protein 2 4 -0.58 -0.06 0.53
P27448 MAP/microtubule affinity-regulating kinase 3 7 10 -0.18 0.17 0.16
Q3KQU3 MAP7 domain-containing protein 1 11 44 -0.26 -0.30 -0.08
Q8IWC1 MAP7 domain-containing protein 3 1 1 0.20 0.25 0.05
P49006 MARCKS-related protein 6 11 -0.99 -0.96 0.04 3 4
Q92585 Mastermind-like protein 1 2 2 -0.43 0.25 0.68
P43243 Matrin-3 24 164 -0.16 -0.20 -0.08
P14780 Matrix metalloproteinase-9 1 2 0.53 -0.50 -1.02
Q9NR99 Matrix-remodeling-associated protein 5 1 1 -0.57 -0.16 0.41
P84157 Matrix-remodeling-associated protein 7 3 7 0.17 0.79 0.66 3 4
Q8IWI9 MAX gene-associated protein 1 1 NA NA NA
Q99583 Max-binding protein MNT 1 1 -0.16 -0.27 -0.12
Q96DY7 Mdm2-binding protein 1 1 -0.40 -0.26 0.14
Q14676 Mediator of DNA damage checkpoint protein 1 11 39 -0.27 -0.15 0.12
Q15648 Mediator of RNA polymerase II transcription subunit 1 6 14 -0.26 -0.12 0.23
Q9BTT4 Mediator of RNA polymerase II transcription subunit 10 2 4 -0.08 -0.19 -0.22
Q93074 Mediator of RNA polymerase II transcription subunit 12 4 7 -0.39 -0.27 0.11
O60244 Mediator of RNA polymerase II transcription subunit 14 1 15 NA NA NA
Q96RN5 Mediator of RNA polymerase II transcription subunit 15 2 4 0.00 0.11 0.12
Q9Y2X0 Mediator of RNA polymerase II transcription subunit 16 1 1 -0.05 -0.06 -0.01
Q9NVC6 Mediator of RNA polymerase II transcription subunit 17 3 5 -0.10 -0.03 0.00
Q9H944 Mediator of RNA polymerase II transcription subunit 20 4 6 -0.38 -0.18 0.20
Q13503 Mediator of RNA polymerase II transcription subunit 21 1 1 -0.44 -0.46 -0.04
Q15528 Mediator of RNA polymerase II transcription subunit 22 2 11 -0.12 -0.11 0.05
Q9ULK4 Mediator of RNA polymerase II transcription subunit 23 1 1 -0.17 -0.13 0.05
Q71SY5 Mediator of RNA polymerase II transcription subunit 25 2 2 -0.16 -0.07 0.08
Q9H204 Mediator of RNA polymerase II transcription subunit 28 1 1 -0.86 -0.62 0.26
Q9NX70 Mediator of RNA polymerase II transcription subunit 29 2 3 0.10 0.01 -0.02
Q9NPJ6 Mediator of RNA polymerase II transcription subunit 4 1 1 NA NA NA
O75586 Mediator of RNA polymerase II transcription subunit 6 2 2 -1.99 -1.67 0.33
O43513 Mediator of RNA polymerase II transcription subunit 7 1 1 -0.32 -0.32 0.00
P11310 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 15 66 0.04 0.03 -0.02
P42679 Megakaryocyte-associated tyrosine-protein kinase 5 21 -0.70 0.51 1.11 4 5 4
Q5JRA6 Melanoma inhibitory activity protein 3 8 21 0.19 0.09 0.10
Q9UNF1 Melanoma-associated antigen D2 10 32 0.16 -0.33 -0.38
Q96MG7 Melanoma-associated antigen G1 3 7 -0.26 -0.44 0.17
P15529 Membrane cofactor protein 1 1 0.88 0.49 -0.38
Q8N4V1 Membrane magnesium transporter 1 1 6 -0.13 -0.06 0.09
Q5TCQ9 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 1 1 NA NA NA
O00562 Membrane-associated phosphatidylinositol transfer protein 1 7 12 0.39 0.17 -0.13
O00264 Membrane-associated progesterone receptor component 1 1 2 -0.02 0.05 0.07
O15173 Membrane-associated progesterone receptor component 2 4 16 -0.03 0.03 0.07
O00255 Menin 6 18 0.12 -0.06 -0.18
P35240 Merlin 3 7 -0.40 0.61 0.83 4
P55145 Mesencephalic astrocyte-derived neurotrophic factor 6 20 -0.12 0.18 0.37
Q8N108 Mesoderm induction early response protein 1 3 8 0.42 0.22 -0.19
Q68D91 Metallo-beta-lactamase domain-containing protein 2 2 3 -0.01 -0.13 -0.13
Q96E52 Metalloendopeptidase OMA1, mitochondrial 1 21 -0.40 -0.66 -0.25
P04732 Metallothionein-1E 1 1 0.14 -0.81 -0.97
P02795 Metallothionein-2 1 9 0.24 -0.36 -0.60
O43312 Metastasis suppressor protein 1 6 13 -1.49 -0.05 1.56 3 3
Q13330 Metastasis-associated protein MTA1 4 22 0.08 -0.26 -0.44
O94776 Metastasis-associated protein MTA2 21 94 -0.16 0.11 0.26
Q13505 Metaxin-1 2 9 0.12 -0.03 -0.12
O75431 Metaxin-2 1 6 0.25 -0.04 -0.21
Q2M296 Methenyltetrahydrofolate synthase domain-containing protein 1 1 -0.20 0.04 0.23
Q9NZL9 Methionine adenosyltransferase 2 subunit beta 9 53 -0.11 0.00 0.10
P53582 Methionine aminopeptidase 1 5 15 0.38 0.33 -0.05
P50579 Methionine aminopeptidase 2 9 47 0.36 -0.03 -0.37
Q99707 Methionine synthase 1 1 0.41 0.16 -0.24
P56192 Methionine--tRNA ligase, cytoplasmic 12 43 0.32 0.24 -0.15
Q96GW9 Methionine--tRNA ligase, mitochondrial 1 1 NA NA NA
Q96DP5 Methionyl-tRNA formyltransferase, mitochondrial 1 1 -0.10 -0.22 -0.11
P16455 Methylated-DNA--protein-cysteine methyltransferase 7 32 -0.16 -0.25 -0.13
Q9UIS9 Methyl-CpG-binding domain protein 1 5 27 -0.15 -0.07 0.15
Q9UBB5 Methyl-CpG-binding domain protein 2 8 27 -0.05 0.11 0.17
O95983 Methyl-CpG-binding domain protein 3 3 4 -0.42 -0.27 0.14
O95243 Methyl-CpG-binding domain protein 4 1 5 -0.03 -0.04 0.00
P51608 Methyl-CpG-binding protein 2 29 329 0.53 0.07 -0.38 4
Q9HCC0 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial 11 38 0.30 -0.24 -0.38
Q96RQ3 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 11 38 0.12 -0.16 -0.33
P42898 Methylenetetrahydrofolate reductase 1 5 -0.45 -0.09 0.37
Q13825 Methylglutaconyl-CoA hydratase, mitochondrial 7 17 0.12 0.12 -0.09
Q02252 Methylmalonate-semialdehyde dehydrogenase, mitochondrial 14 51 0.68 0.00 -0.67 5 4
Q8IVH4 Methylmalonic aciduria type A protein, mitochondrial 4 9 0.10 -0.16 -0.18
Q96PE7 Methylmalonyl-CoA epimerase, mitochondrial 5 14 0.19 0.10 -0.14
P22033 Methylmalonyl-CoA mutase, mitochondrial 12 31 0.10 -0.11 -0.17
Q9BQA1 Methylosome protein 50 2 15 0.34 0.07 -0.30
P54105 Methylosome subunit pICln 4 14 0.19 -0.31 -0.42
Q9BV20 Methylthioribose-1-phosphate isomerase 7 30 0.22 0.23 0.04
Q96GX9 Methylthioribulose-1-phosphate dehydratase 4 14 0.27 0.07 -0.16
Q8N6R0 Methyltransferase-like protein 13 4 7 0.09 -0.06 -0.18
Q9HCE5 Methyltransferase-like protein 14 2 6 -0.08 -0.15 -0.14
Q86W50 Methyltransferase-like protein 16 3 8 0.07 -0.16 -0.20
Q9H8H3 Methyltransferase-like protein 7A 2 3 -1.09 -0.01 1.09
P22670 MHC class II regulatory factor RFX1 8 18 0.01 -0.06 0.02
Q8N3F8 MICAL-like protein 1 1 1 -0.22 0.17 0.39
P55082 Microfibril-associated glycoprotein 3 1 1 NA NA NA
P55081 Microfibrillar-associated protein 1 7 31 -0.19 -0.15 0.07
Q99735 Microsomal glutathione S-transferase 2 1 1 -0.72 0.22 0.94
O14880 Microsomal glutathione S-transferase 3 1 2 -0.36 -0.28 0.09
Q9UPN3 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 39 102 -0.06 0.08 0.13
Q66K74 Microtubule-associated protein 1S 11 37 0.07 0.18 0.07
P27816 Microtubule-associated protein 4 37 199 -0.26 0.22 0.57
Q15691 Microtubule-associated protein RP/EB family member 1 10 67 -0.03 0.16 0.13
Q15555 Microtubule-associated protein RP/EB family member 2 8 23 -0.29 -0.02 0.36
O60307 Microtubule-associated serine/threonine-protein kinase 3 2 10 -0.25 -0.03 0.41
O15021 Microtubule-associated serine/threonine-protein kinase 4 1 7 0.82 -0.08 -0.90
Q9NU22 Midasin 1 1 NA NA NA
A9UHW6 MIF4G domain-containing protein 1 2 -0.36 0.15 0.50
Q8N183 Mimitin, mitochondrial 4 9 0.30 0.00 -0.18
Q9BTE3 Mini-chromosome maintenance complex-binding protein 4 13 0.20 0.33 -0.01
Q92619 Minor histocompatibility protein HA-1 31 214 0.06 -0.13 -0.17
Q9H5X1 MIP18 family protein FAM96A 2 5 0.23 0.12 -0.11
P54278 Mismatch repair endonuclease PMS2 1 1 -0.44 -0.25 0.17
Q8N4C8 Misshapen-like kinase 1 3 19 0.57 0.31 -0.30
Q02978 Mitochondrial 2-oxoglutarate/malate carrier protein 5 31 0.02 0.13 0.22
Q7Z434 Mitochondrial antiviral-signaling protein 7 22 0.29 0.30 0.04
O43772 Mitochondrial carnitine/acylcarnitine carrier protein 1 2 NA NA NA
Q9NZJ7 Mitochondrial carrier homolog 1 1 2 -0.49 -0.31 0.19
Q9Y6C9 Mitochondrial carrier homolog 2 4 21 -0.11 0.15 0.17
Q86VD7 Mitochondrial coenzyme A transporter SLC25A42 1 3 -0.41 -0.07 0.34
Q9UBX3 Mitochondrial dicarboxylate carrier 1 1 NA NA NA
Q9NQG6 Mitochondrial dynamics protein MID51 2 7 -0.08 -0.01 0.03
Q7L5Y1 Mitochondrial enolase superfamily member 1 1 1 NA NA NA
Q9Y3D6 Mitochondrial fission 1 protein 3 10 0.38 0.08 -0.26
Q9GZY8 Mitochondrial fission factor 3 12 -0.01 0.24 0.23
Q9UDX5 Mitochondrial fission process protein 1 1 4 0.44 0.04 -0.40
Q9H019 Mitochondrial fission regulator 1-like 2 5 0.19 -0.13 -0.35
Q9BQP7 Mitochondrial genome maintenance exonuclease 1 1 1 -0.16 -0.13 0.01
Q9H936 Mitochondrial glutamate carrier 1 8 29 -0.06 0.05 0.18
P62072 Mitochondrial import inner membrane translocase subunit Tim10 3 10 0.20 0.00 -0.24
Q9Y5J6 Mitochondrial import inner membrane translocase subunit Tim10 B 1 1 1.60 1.27 -0.32
Q9Y5L4 Mitochondrial import inner membrane translocase subunit Tim13 2 26 -0.09 0.00 0.01
Q96DA6 Mitochondrial import inner membrane translocase subunit TIM14 2 6 -0.15 -0.11 0.09
Q9Y3D7 Mitochondrial import inner membrane translocase subunit TIM16 3 9 0.20 -0.19 -0.15
Q9BVV7 Mitochondrial import inner membrane translocase subunit Tim21 1 1 -0.02 0.08 0.10
O43615 Mitochondrial import inner membrane translocase subunit TIM44 11 29 0.09 0.03 -0.08
Q3ZCQ8 Mitochondrial import inner membrane translocase subunit TIM50 7 18 0.08 0.04 0.03
O60220 Mitochondrial import inner membrane translocase subunit Tim8 A 1 7 0.43 -0.26 -0.49
Q9Y5J7 Mitochondrial import inner membrane translocase subunit Tim9 4 17 0.26 -0.20 -0.42
Q15388 Mitochondrial import receptor subunit TOM20 homolog 2 9 0.05 0.06 0.16
Q9NS69 Mitochondrial import receptor subunit TOM22 homolog 4 25 0.18 0.01 -0.17
Q15785 Mitochondrial import receptor subunit TOM34 3 12 -0.36 -0.17 0.21
O96008 Mitochondrial import receptor subunit TOM40 homolog 4 6 0.22 0.06 -0.16
Q969M1 Mitochondrial import receptor subunit TOM40B 1 1 0.01 0.01 0.00
Q8N4H5 Mitochondrial import receptor subunit TOM5 homolog 2 8 0.35 -0.24 -0.29
Q96B49 Mitochondrial import receptor subunit TOM6 homolog 1 7 -0.26 0.10 0.19
O94826 Mitochondrial import receptor subunit TOM70 11 41 0.01 -0.10 -0.16
Q16891 Mitochondrial inner membrane protein 38 235 0.15 0.07 -0.17
Q15070 Mitochondrial inner membrane protein OXA1L 2 7 0.14 0.11 -0.03
Q99797 Mitochondrial intermediate peptidase 1 2 0.63 0.26 -0.36
Q8N4Q1 Mitochondrial intermembrane space import and assembly protein 40 1 1 -0.89 -0.79 0.11
Q9UJ68 Mitochondrial peptide methionine sulfoxide reductase 5 10 0.07 -0.23 -0.33
Q8IXI2 Mitochondrial Rho GTPase 1 1 2 -0.19 -0.11 0.09
Q8IXI1 Mitochondrial Rho GTPase 2 4 14 -0.06 0.12 0.08
Q7L0Y3 Mitochondrial ribonuclease P protein 1 10 19 0.58 0.12 -0.64 4 4
Q86UD5 Mitochondrial sodium/hydrogen exchanger 9B2 1 3 0.59 1.11 0.52
Q9HC21 Mitochondrial thiamine pyrophosphate carrier 2 3 -0.14 0.06 0.21
Q96BW9 Mitochondrial translocator assembly and maintenance protein 41 homolog 2 2 0.05 -0.18 -0.23
Q10713 Mitochondrial-processing peptidase subunit alpha 5 17 0.10 0.16 -0.08
O75439 Mitochondrial-processing peptidase subunit beta 11 45 0.10 0.01 -0.06
Q8IWA4 Mitofusin-1 1 2 NA NA NA
O95140 Mitofusin-2 2 3 0.04 0.03 -0.02
P28482 Mitogen-activated protein kinase 1 9 112 -0.02 0.46 0.53 5
O15264 Mitogen-activated protein kinase 13 4 21 0.14 -0.14 -0.37
Q16539 Mitogen-activated protein kinase 14 7 18 -0.11 0.33 0.43
P27361 Mitogen-activated protein kinase 3 5 29 0.28 0.18 -0.23
Q13164 Mitogen-activated protein kinase 7 2 2 0.05 0.44 0.39
P45983 Mitogen-activated protein kinase 8 1 1 0.33 0.20 -0.14
Q9Y2U5 Mitogen-activated protein kinase kinase kinase 2 2 2 0.30 0.32 0.02
Q99759 Mitogen-activated protein kinase kinase kinase 3 2 2 0.19 0.31 0.12
Q9Y6R4 Mitogen-activated protein kinase kinase kinase 4 1 2 0.57 0.48 -0.09
Q99683 Mitogen-activated protein kinase kinase kinase 5 1 2 NA NA NA
O43318 Mitogen-activated protein kinase kinase kinase 7 3 10 -0.19 -0.22 -0.03
Q92918 Mitogen-activated protein kinase kinase kinase kinase 1 9 18 0.44 0.08 -0.38 5
Q12851 Mitogen-activated protein kinase kinase kinase kinase 2 6 14 0.37 -0.49 -0.66 5 5
O95819 Mitogen-activated protein kinase kinase kinase kinase 4 2 13 -0.01 -0.16 -0.15
Q9Y4K4 Mitogen-activated protein kinase kinase kinase kinase 5 1 2 -0.13 0.39 0.51
O43684 Mitotic checkpoint protein BUB3 14 92 -0.05 -0.07 -0.07
Q9Y6D9 Mitotic spindle assembly checkpoint protein MAD1 9 19 -0.10 -0.04 0.18
Q9Y3D0 Mitotic spindle-associated MMXD complex subunit MIP18 3 17 0.06 0.26 0.18
Q6NZ67 Mitotic-spindle organizing protein 2B 3 6 -0.23 -0.07 -0.14
Q8NB16 Mixed lineage kinase domain-like protein 3 3 -0.23 0.06 0.53
Q9BYG3 MKI67 FHA domain-interacting nucleolar phosphoprotein 5 11 0.25 -0.36 -0.58
Q969V6 MKL/myocardin-like protein 1 3 8 -0.01 -0.17 0.01
Q96T76 MMS19 nucleotide excision repair protein homolog 1 9 -0.43 0.09 0.52
Q7L9L4 MOB kinase activator 1B 6 27 -0.18 0.05 0.25
Q96BX8 MOB kinase activator 3A 4 22 -0.29 0.09 0.40
P26038 Moesin 45 1368 -0.54 0.16 0.90 5 5
Q8N2K0 Monoacylglycerol lipase ABHD12 3 10 -0.89 0.11 0.85
O60669 Monocarboxylate transporter 2 2 4 -1.75 -0.88 0.87
P08571 Monocyte differentiation antigen CD14 2 2 0.82 0.21 -0.60
Q6UB35 Monofunctional C1-tetrahydrofolate synthase, mitochondrial 1 1 0.37 0.35 -0.02
Q99685 Monoglyceride lipase 1 1 -0.35 -0.63 -0.29
Q9Y6X9 MORC family CW-type zinc finger protein 2 1 1 -0.17 0.45 0.60
Q14149 MORC family CW-type zinc finger protein 3 6 8 -0.30 -0.25 0.16
Q9Y605 MORF4 family-associated protein 1 1 8 0.03 0.10 0.00
Q9UBU8 Mortality factor 4-like protein 1 6 24 0.08 -0.26 -0.33
Q15014 Mortality factor 4-like protein 2 2 5 0.23 0.16 -0.11
Q15796 Mothers against decapentaplegic homolog 2 1 13 -0.29 -0.11 0.18
P84022 Mothers against decapentaplegic homolog 3 1 11 0.22 0.62 0.38
Q13485 Mothers against decapentaplegic homolog 4 2 7 -0.08 -0.13 -0.04
Q99547 M-phase phosphoprotein 6 2 3 0.11 -0.30 -0.49
Q99549 M-phase phosphoprotein 8 3 13 -0.09 0.12 0.14
Q8TAP9 M-phase-specific PLK1-interacting protein 1 5 0.02 -0.34 -0.36
Q9NV56 MRG/MORF4L-binding protein 2 7 -0.02 -0.15 0.18
O43148 mRNA cap guanine-N7 methyltransferase 10 36 0.06 -0.12 -0.20
P78406 mRNA export factor 13 55 -0.06 -0.06 0.15
Q9UKD2 mRNA turnover protein 4 homolog 4 11 0.35 -0.06 -0.44
O60942 mRNA-capping enzyme 3 3 1.02 0.01 -1.01
Q9NPI6 mRNA-decapping enzyme 1A 7 25 -0.03 0.01 -0.04
Q96T58 Msx2-interacting protein 12 21 -0.24 -0.16 0.06
Q9H7C9 Mth938 domain-containing protein 3 11 -0.26 -0.36 0.05
Q9UDY8 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 3 5 0.19 0.20 0.00
P08183 Multidrug resistance protein 1 9 16 0.55 1.07 0.42 4
P22234 Multifunctional protein ADE2 15 51 0.15 -0.35 -0.43
Q13201 Multimerin-1 7 9 0.01 -0.14 -0.22
Q9BU76 Multiple myeloma tumor-associated protein 2 2 15 -0.06 0.13 0.21
Q96EY5 Multivesicular body subunit 12A 4 8 -0.43 0.14 0.63 5
Q9NR56 Muscleblind-like protein 1 4 15 0.08 -0.12 -0.05
Q9BQG0 Myb-binding protein 1A 13 37 0.33 -0.09 -0.22
O00499 Myc box-dependent-interacting protein 1 16 109 -0.01 -0.15 -0.11
P56270 Myc-associated zinc finger protein 3 3 -0.23 0.00 0.16
Q8TBZ2 MYCBP-associated protein 1 2 -2.73 0.03 2.76
Q9NUJ1 Mycophenolic acid acyl-glucuronide esterase, mitochondrial 9 36 0.49 0.19 -0.31
P02686 Myelin basic protein 5 10 -1.16 0.12 1.40 4 4
Q9P2K5 Myelin expression factor 2 2 2 NA NA NA
P41218 Myeloid cell nuclear differentiation antigen 8 30 -0.04 -0.15 -0.11
Q99836 Myeloid differentiation primary response protein MyD88 3 7 -0.06 0.16 0.24
Q15773 Myeloid leukemia factor 2 2 8 0.24 0.03 -0.20
Q96S97 Myeloid-associated differentiation marker 1 5 -0.60 0.18 0.59
P05164 Myeloperoxidase 12 40 0.21 -0.04 -0.11
Q14814 Myocyte-specific enhancer factor 2D 3 4 -0.72 -0.06 0.66
Q5VU43 Myomegalin 1 1 NA NA NA
P14649 Myosin light chain 6B 1 168 -0.34 -0.15 0.20
P60660 Myosin light polypeptide 6 9 318 0.00 0.08 0.05
Q6WCQ1 Myosin phosphatase Rho-interacting protein 4 4 0.23 0.28 0.04
P19105 Myosin regulatory light chain 12A 6 103 0.49 0.17 -0.22
P24844 Myosin regulatory light polypeptide 9 1 46 -0.39 -0.27 0.12
P35579 Myosin-9 173 3283 0.14 0.08 -0.11
P58546 Myotrophin 3 36 -0.02 0.01 -0.01
Q13496 Myotubularin 1 1 1.17 0.16 -1.01
Q13613 Myotubularin-related protein 1 4 5 0.07 0.13 0.02
Q9C0I1 Myotubularin-related protein 12 2 6 -0.33 -0.16 0.16
Q8NCE2 Myotubularin-related protein 14 2 3 0.09 0.15 -0.10
Q13615 Myotubularin-related protein 3 1 1 -0.43 0.36 0.80
O95248 Myotubularin-related protein 5 24 67 0.17 0.06 -0.02
Q9Y217 Myotubularin-related protein 6 2 2 0.94 1.08 0.15
P29966 Myristoylated alanine-rich C-kinase substrate 2 2 -0.25 -0.22 0.04
P20933 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase 3 18 -0.33 0.68 1.06 3 5
O95865 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 10 56 -0.53 0.43 1.08 5 5
Q86U44 N6-adenosine-methyltransferase 70 kDa subunit 9 27 0.08 0.02 -0.14
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 22 190 -0.66 0.18 0.93 5 5
Q15599 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 1 1 -1.70 -0.51 1.20
Q9UJ70 N-acetyl-D-glucosamine kinase 10 46 0.11 0.13 0.13
Q01415 N-acetylgalactosamine kinase 3 4 0.14 0.23 0.10
P34059 N-acetylgalactosamine-6-sulfatase 2 2 -0.70 0.32 1.02
P15586 N-acetylglucosamine-6-sulfatase 8 32 -0.59 0.81 1.42 5 5
O95671 N-acetylserotonin O-methyltransferase-like protein 7 25 -0.39 0.11 0.45
Q9H0A0 N-acetyltransferase 10 18 66 0.43 0.02 -0.37
Q93015 N-acetyltransferase 6 1 1 0.23 -0.24 -0.49
Q5FWF5 N-acetyltransferase ESCO1 1 1 -1.20 -0.36 0.85
Q56NI9 N-acetyltransferase ESCO2 1 4 NA NA NA
Q9C000 NACHT, LRR and PYD domains-containing protein 1 4 6 0.06 -0.17 -0.18
Q02083 N-acylethanolamine-hydrolyzing acid amidase 3 15 -0.07 -0.44 -0.29
P51606 N-acylglucosamine 2-epimerase 2 12 -0.61 -0.40 0.21
Q8NFW8 N-acylneuraminate cytidylyltransferase 12 73 0.22 0.04 -0.27
Q4G0N4 NAD kinase 2, mitochondrial 11 26 0.03 0.09 -0.02
Q13423 NAD(P) transhydrogenase, mitochondrial 36 295 0.10 0.02 -0.01
Q8NCW5 NAD(P)H-hydrate epimerase 7 28 -0.13 0.00 -0.01
P23368 NAD-dependent malic enzyme, mitochondrial 12 66 -0.03 0.15 0.19
Q96EB6 NAD-dependent protein deacetylase sirtuin-1 2 5 0.05 -0.24 -0.28
Q8IXJ6 NAD-dependent protein deacetylase sirtuin-2 3 3 -0.28 0.32 0.60
Q9NTG7 NAD-dependent protein deacetylase sirtuin-3, mitochondrial 1 3 0.66 -0.20 -0.86
Q9NRC8 NAD-dependent protein deacetylase sirtuin-7 1 1 -0.12 0.08 0.21
Q9NXA8 NAD-dependent protein deacylase sirtuin-5, mitochondrial 3 4 0.04 0.11 0.20
Q9BU61 NADH dehydrogenase 1 alpha subcomplex assembly factor 3 3 17 -0.11 -0.38 -0.27
Q9P032 NADH dehydrogenase 1 alpha subcomplex assembly factor 4 4 5 -0.03 -0.50 -0.22
O95299 NADH dehydrogenase 1 alpha subcomplex subunit 10, mitochondrial 10 38 0.32 -0.08 -0.35
Q86Y39 NADH dehydrogenase 1 alpha subcomplex subunit 11 2 4 0.09 0.00 -0.15
Q9UI09 NADH dehydrogenase 1 alpha subcomplex subunit 12 3 16 0.20 0.14 -0.02
Q9P0J0 NADH dehydrogenase 1 alpha subcomplex subunit 13 4 7 0.32 -0.02 -0.30
O43678 NADH dehydrogenase 1 alpha subcomplex subunit 2 7 35 0.04 0.08 -0.08
O95167 NADH dehydrogenase 1 alpha subcomplex subunit 3 2 2 0.22 -0.41 -0.63
O00483 NADH dehydrogenase 1 alpha subcomplex subunit 4 6 42 0.29 0.07 -0.10
Q16718 NADH dehydrogenase 1 alpha subcomplex subunit 5 3 22 -0.06 -0.06 0.03
P56556 NADH dehydrogenase 1 alpha subcomplex subunit 6 7 45 0.04 0.05 -0.05
O95182 NADH dehydrogenase 1 alpha subcomplex subunit 7 9 50 0.05 -0.07 -0.09
P51970 NADH dehydrogenase 1 alpha subcomplex subunit 8 4 11 0.10 -0.05 -0.23
Q16795 NADH dehydrogenase 1 alpha subcomplex subunit 9, mitochondrial 6 21 0.36 0.20 -0.17
O75438 NADH dehydrogenase 1 beta subcomplex subunit 1 2 4 0.38 -0.36 -0.74
O96000 NADH dehydrogenase 1 beta subcomplex subunit 10 6 35 0.30 0.08 -0.12
Q9NX14 NADH dehydrogenase 1 beta subcomplex subunit 11, mitochondrial 1 9 0.25 0.00 -0.16
O43676 NADH dehydrogenase 1 beta subcomplex subunit 3 4 16 0.26 0.20 0.03
O95168 NADH dehydrogenase 1 beta subcomplex subunit 4 3 29 0.37 -0.04 -0.32
O43674 NADH dehydrogenase 1 beta subcomplex subunit 5, mitochondrial 2 11 0.31 0.03 -0.34
O95139 NADH dehydrogenase 1 beta subcomplex subunit 6 2 2 -1.34 -1.21 0.14
P17568 NADH dehydrogenase 1 beta subcomplex subunit 7 3 27 0.33 0.08 -0.20
O95169 NADH dehydrogenase 1 beta subcomplex subunit 8, mitochondrial 3 10 0.29 0.20 -0.15
Q9Y6M9 NADH dehydrogenase 1 beta subcomplex subunit 9 4 31 0.03 0.09 -0.06
O95298 NADH dehydrogenase 1 subunit C2 2 5 0.08 -0.51 -0.58
P49821 NADH dehydrogenase flavoprotein 1, mitochondrial 8 34 0.47 0.13 -0.32
P19404 NADH dehydrogenase flavoprotein 2, mitochondrial 8 73 0.10 0.08 -0.06
P56181 NADH dehydrogenase flavoprotein 3, mitochondrial 1 1 -0.59 0.25 0.85
O75306 NADH dehydrogenase iron-sulfur protein 2, mitochondrial 9 19 0.34 -0.05 -0.22
O75489 NADH dehydrogenase iron-sulfur protein 3, mitochondrial 9 62 0.38 -0.02 -0.30
O43181 NADH dehydrogenase iron-sulfur protein 4, mitochondrial 3 5 0.03 -0.10 0.52
O43920 NADH dehydrogenase iron-sulfur protein 5 2 4 0.05 0.00 -0.09
O75380 NADH dehydrogenase iron-sulfur protein 6, mitochondrial 6 21 -0.17 -0.05 0.11
O75251 NADH dehydrogenase iron-sulfur protein 7, mitochondrial 5 26 0.16 0.00 -0.20
O00217 NADH dehydrogenase iron-sulfur protein 8, mitochondrial 6 14 0.10 0.00 -0.19
Q9UHQ9 NADH-cytochrome b5 reductase 1 3 10 0.41 0.08 -0.47
P00387 NADH-cytochrome b5 reductase 3 6 56 -0.09 0.36 0.24
P28331 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 30 178 0.23 0.07 -0.20
P03915 NADH-ubiquinone oxidoreductase chain 5 1 1 0.29 -0.13 -0.42
P48163 NADP-dependent malic enzyme 3 4 2.86 1.97 -0.45 3 3
P22570 NADPH:adrenodoxin oxidoreductase, mitochondrial 8 26 0.01 0.21 0.12
P16435 NADPH--cytochrome P450 reductase 8 18 -0.26 0.01 0.29
P41227 N-alpha-acetyltransferase 10 9 36 0.31 -0.17 -0.48
Q9BXJ9 N-alpha-acetyltransferase 15, NatA auxiliary subunit 7 25 0.50 0.19 -0.24
Q6N069 N-alpha-acetyltransferase 16, NatA auxiliary subunit 1 7 0.00 -0.71 -0.71
Q147X3 N-alpha-acetyltransferase 30 2 6 0.01 0.08 0.09
Q5VZE5 N-alpha-acetyltransferase 35, NatC auxiliary subunit 3 4 0.04 0.29 0.25
O95777 N-alpha-acetyltransferase 38, NatC auxiliary subunit 5 42 0.02 -0.13 -0.19
Q86UY6 N-alpha-acetyltransferase 40 2 2 -0.47 -0.09 0.37
Q9GZZ1 N-alpha-acetyltransferase 50 5 8 0.21 0.19 -0.22
O43847 Nardilysin 3 4 0.38 -0.07 -0.44
Q13765 Nascent polypeptide-associated complex subunit alpha 6 76 0.28 0.07 -0.43
Q9BZW8 Natural killer cell receptor 2B4 1 1 -0.51 0.51 1.03
P55160 Nck-associated protein 1-like 9 33 0.08 0.36 0.24
Q9HCH0 Nck-associated protein 5-like 1 1 -0.57 -0.89 -0.32
O75113 NEDD4-binding protein 1 2 9 0.12 0.21 0.12
O15049 NEDD4-binding protein 3 2 2 -0.34 -0.13 0.22
Q9H0M0 NEDD4-like E3 ubiquitin-protein ligase WWP1 1 1 0.30 -0.05 -0.35
O00308 NEDD4-like E3 ubiquitin-protein ligase WWP2 1 4 -0.04 0.02 0.06
Q15843 NEDD8 6 22 -0.19 -0.15 0.01
Q9Y5A7 NEDD8 ultimate buster 1 8 15 -0.20 -0.07 0.07
Q8TBC4 NEDD8-activating enzyme E1 catalytic subunit 9 26 -0.21 -0.03 0.04
Q13564 NEDD8-activating enzyme E1 regulatory subunit 6 33 -0.14 -0.01 0.03
P61081 NEDD8-conjugating enzyme Ubc12 6 26 -0.15 0.13 0.17
Q969M7 NEDD8-conjugating enzyme UBE2F 1 4 -0.29 0.13 0.42
Q9H3P2 Negative elongation factor A 10 34 -0.08 0.05 0.01
Q8WX92 Negative elongation factor B 2 2 0.04 -0.04 -0.07
Q8IXH7 Negative elongation factor C/D 4 5 0.42 0.27 0.18
P18615 Negative elongation factor E 13 53 -0.14 -0.11 0.01
Q8NF91 Nesprin-1 45 99 0.07 0.24 0.30
Q8WXH0 Nesprin-2 60 138 0.40 0.61 0.25 5
Q6ZMZ3 Nesprin-3 4 14 -0.24 -0.03 -0.03
Q9UMX5 Neudesin 1 1 -0.01 -0.33 -0.31
Q96SB3 Neurabin-2 16 49 -0.29 0.11 0.45 5
P13591 Neural cell adhesion molecule 1 3 6 -0.51 0.44 1.51 3
Q6ZNJ1 Neurobeachin-like protein 2 10 14 -0.41 0.66 0.60
Q09666 Neuroblast differentiation-associated protein AHNAK 302 2300 0.49 0.99 0.56 3 4
A2RRP1 Neuroblastoma-amplified sequence 2 6 0.14 -0.11 -0.55
P61601 Neurocalcin-delta 1 15 0.04 0.46 0.43
Q9UBB6 Neurochondrin 1 5 1.04 0.97 -0.07
Q04721 Neurogenic locus notch homolog protein 2 1 1 -1.49 -0.26 1.25
Q9UM47 Neurogenic locus notch homolog protein 3 1 3 -0.02 0.11 0.09
Q92686 Neurogranin 2 3 -0.48 0.02 0.51
Q8NEJ9 Neuroguidin 4 8 0.34 -0.17 -0.52
Q8IY17 Neuropathy target esterase 6 18 0.24 0.24 0.04
Q9Y639 Neuroplastin 3 7 0.03 0.42 0.45
Q14697 Neutral alpha-glucosidase AB 30 194 -0.29 0.07 0.30
Q15758 Neutral amino acid transporter B(0) 1 2 0.14 0.27 0.14
Q6PIU2 Neutral cholesterol ester hydrolase 1 3 15 -0.41 0.20 0.17
P59665 Neutrophil defensin 1 1 3 NA NA NA
P08246 Neutrophil elastase 1 1 0.50 0.12 -0.37
Q0ZGT2 Nexilin 1 1 0.34 -0.40 -0.76
Q8NCF5 NFATC2-interacting protein 4 20 -0.30 0.02 0.32
Q9Y6K9 NF-kappa-B essential modulator 12 41 -0.33 -0.15 0.11
P25963 NF-kappa-B inhibitor alpha 2 2 -0.33 -0.36 -0.03
O00221 NF-kappa-B inhibitor epsilon 1 3 -0.58 -0.01 0.58
Q9NYR9 NF-kappa-B inhibitor-interacting Ras-like protein 2 1 4 0.02 0.08 0.06
Q8N5F7 NF-kappa-B-activating protein 2 2 -0.09 -0.34 -0.24
O15226 NF-kappa-B-repressing factor 3 6 0.10 -0.05 -0.10
Q6ZNB6 NF-X1-type zinc finger protein NFXL1 1 2 -0.19 0.25 0.43
Q9P2E3 NFX1-type zinc finger-containing protein 1 2 4 -0.05 -0.20 0.17
Q8NBF2 NHL repeat-containing protein 2 2 2 -0.29 0.42 0.71
Q5JS37 NHL repeat-containing protein 3 2 2 -0.62 0.06 0.67
P55769 NHP2-like protein 1 7 75 0.41 -0.12 -0.45
Q5HYW2 NHS-like protein 2 7 13 0.10 0.75 0.94 3 3
Q96TA1 Niban-like protein 1 2 6 0.89 0.38 -0.57 3
O60934 Nibrin 11 29 -0.40 -0.03 0.42
Q969V3 Nicalin 5 17 0.12 0.26 0.27
Q92542 Nicastrin 3 5 0.48 0.51 0.04
Q9HAN9 Nicotinamide mononucleotide adenylyltransferase 1 6 9 -0.36 -0.01 0.26
Q96T66 Nicotinamide mononucleotide adenylyltransferase 3 1 1 -0.17 -1.12 -0.94
P43490 Nicotinamide phosphoribosyltransferase 14 62 0.27 0.13 -0.29
Q9NWW6 Nicotinamide riboside kinase 1 1 5 0.24 0.22 0.07
Q6XQN6 Nicotinate phosphoribosyltransferase 7 27 0.21 -0.10 -0.41
O15118 Niemann-Pick C1 protein 1 1 -0.08 1.24 1.33
Q8N4C6 Ninein 5 6 -0.15 -0.36 -0.17
Q9Y2I6 Ninein-like protein 1 1 -0.01 0.17 0.18
Q6KC79 Nipped-B-like protein 20 37 -0.19 -0.15 0.02
Q9Y2I1 Nischarin 4 5 -0.25 -0.24 0.01
Q9Y314 Nitric oxide synthase-interacting protein 7 23 -0.08 -0.90 -0.76 5 4
Q86X76 Nitrilase homolog 1 2 4 0.48 -0.14 -0.60
Q12980 Nitrogen permease regulator 3-like protein 1 1 0.30 -0.28 -0.57
P30414 NK-tumor recognition protein 3 3 0.31 0.04 -0.25
Q86UT6 NLR family member X1 2 4 -0.64 -0.32 0.23
Q659A1 NMDA receptor-regulated protein 2 1 2 0.02 -0.12 -0.15
Q9HBL8 NmrA-like family domain-containing protein 1 3 6 -0.11 -0.10 -0.08
Q13287 N-myc-interactor 5 8 0.12 -0.13 -0.20
Q15155 Nodal modulator 1 1 32 -0.16 0.08 0.25
P69849 Nodal modulator 3 1 32 -0.12 -0.19 -0.07
P05114 Non-histone chromosomal protein HMG-14 7 42 0.38 -0.51 -1.05 4 3
P05204 Non-histone chromosomal protein HMG-17 3 27 -0.08 -1.13 -0.43 4
Q15233 Non-POU domain-containing octamer-binding protein 20 425 -0.20 -0.19 0.05
P29597 Non-receptor tyrosine-protein kinase TYK2 2 12 0.07 0.63 0.56
P22307 Non-specific lipid-transfer protein 10 56 -0.78 -0.04 0.69 5 3
Q8WV22 Non-structural maintenance of chromosomes element 1 homolog 1 1 NA NA NA
Q9NVX2 Notchless protein homolog 1 2 2 -0.04 -0.39 -0.35
Q9UNZ2 NSFL1 cofactor p47 18 107 0.08 -0.17 -0.24
P51688 N-sulphoglucosamine sulphohydrolase 5 30 0.32 -0.10 -0.45
Q96KG9 N-terminal kinase-like protein 3 4 0.04 -0.19 -0.22
Q9BV86 N-terminal Xaa-Pro-Lys N-methyltransferase 1 1 1 0.13 -0.18 -0.33
P23497 Nuclear autoantigen Sp-100 8 38 -0.08 0.00 -0.01
P49321 Nuclear autoantigenic sperm protein 11 96 -0.10 -0.16 -0.09
Q13342 Nuclear body protein SP140 1 2 0.18 0.24 0.07
Q9H930 Nuclear body protein SP140-like protein 1 3 0.59 0.19 -0.39
Q09161 Nuclear cap-binding protein subunit 1 5 11 -0.23 -0.20 -0.02
P52298 Nuclear cap-binding protein subunit 2 1 5 0.25 -0.05 -0.29
Q9NXR1 Nuclear distribution protein nudE homolog 1 5 22 -0.36 -0.08 0.29
Q9GZM8 Nuclear distribution protein nudE-like 1 1 10 -0.55 -0.27 0.30
A8CG34 Nuclear envelope pore membrane protein POM 121C 7 16 -0.17 -0.03 0.10
O60524 Nuclear export mediator factor NEMF 6 6 0.14 0.03 -0.11
O00712 Nuclear factor 1 B-type 1 1 0.37 0.05 -0.33
Q00653 Nuclear factor NF-kappa-B p100 subunit 18 57 0.37 0.03 -0.49
P19838 Nuclear factor NF-kappa-B p105 subunit 26 157 0.23 -0.33 -0.50
O95644 Nuclear factor of activated T-cells, cytoplasmic 1 2 11 0.52 -0.07 -0.59
Q13469 Nuclear factor of activated T-cells, cytoplasmic 2 21 144 -0.74 0.19 0.89 5 5
Q12968 Nuclear factor of activated T-cells, cytoplasmic 3 3 19 -0.60 -0.16 0.31
Q6P4R8 Nuclear factor related to kappa-B-binding protein 5 10 -0.01 0.01 -0.05
Q9UHK0 Nuclear fragile X mental retardation-interacting protein 1 1 1 0.14 0.15 0.02
Q7Z417 Nuclear fragile X mental retardation-interacting protein 2 4 8 -0.33 -0.07 0.24
Q12972 Nuclear inhibitor of protein phosphatase 1 10 41 -0.23 -0.22 -0.09
Q9Y266 Nuclear migration protein nudC 16 74 -0.06 -0.03 0.04
Q14980 Nuclear mitotic apparatus protein 1 114 664 -0.37 -0.28 0.08
Q13901 Nuclear nucleic acid-binding protein C1D 1 1 0.53 0.20 -0.33
P57740 Nuclear pore complex protein Nup107 5 18 -0.28 0.03 0.29
Q8WUM0 Nuclear pore complex protein Nup133 11 36 -0.02 0.13 0.25
P49790 Nuclear pore complex protein Nup153 29 91 -0.26 0.03 0.36
O75694 Nuclear pore complex protein Nup155 11 34 -0.16 0.07 0.31
Q12769 Nuclear pore complex protein Nup160 1 4 0.04 0.12 0.13
Q92621 Nuclear pore complex protein Nup205 9 27 0.06 0.14 0.12
P35658 Nuclear pore complex protein Nup214 26 96 -0.06 0.04 0.10
Q9UKX7 Nuclear pore complex protein Nup50 13 49 -0.21 -0.18 -0.04
Q9BW27 Nuclear pore complex protein Nup85 5 8 -0.05 0.08 0.13
Q99567 Nuclear pore complex protein Nup88 11 32 -0.08 -0.06 0.06
Q8N1F7 Nuclear pore complex protein Nup93 14 71 -0.23 0.04 0.26
P52948 Nuclear pore complex protein Nup98-Nup96 13 49 -0.14 0.11 0.22
P37198 Nuclear pore glycoprotein p62 6 9 -0.10 0.10 0.14
Q8TEM1 Nuclear pore membrane glycoprotein 210 26 88 0.01 0.27 0.24
Q8TAT6 Nuclear protein localization protein 4 homolog 6 11 -0.01 0.04 0.01
Q8TC05 Nuclear protein MDM1 4 7 -0.33 -0.23 0.13
Q86WQ0 Nuclear receptor 2C2-associated protein 3 5 0.35 -0.16 -0.36
Q15788 Nuclear receptor coactivator 1 1 2 -0.85 -0.62 0.21
Q15596 Nuclear receptor coactivator 2 5 8 -0.02 0.11 0.00
Q9Y6Q9 Nuclear receptor coactivator 3 3 5 -0.88 -0.48 0.26
Q9HCD5 Nuclear receptor coactivator 5 9 45 -0.06 0.01 0.15
Q14686 Nuclear receptor coactivator 6 4 8 -0.19 0.09 0.11
Q8NI08 Nuclear receptor coactivator 7 1 1 NA NA NA
O75376 Nuclear receptor corepressor 1 23 64 -0.14 -0.18 -0.07
Q9Y618 Nuclear receptor corepressor 2 5 10 -0.65 -0.10 0.07
P49116 Nuclear receptor subfamily 2 group C member 2 9 30 -0.15 -0.12 0.00
Q9UHY1 Nuclear receptor-binding protein 6 17 0.16 0.09 -0.04
Q16656 Nuclear respiratory factor 1 4 16 -0.18 -0.06 0.06
Q9UBU9 Nuclear RNA export factor 1 8 34 -0.15 -0.12 0.02
Q9H0G5 Nuclear speckle splicing regulatory protein 1 3 6 -0.18 -0.23 -0.04
P23511 Nuclear transcription factor Y subunit alpha 2 34 -0.21 -0.16 0.02
P25208 Nuclear transcription factor Y subunit beta 1 1 -1.12 -0.31 0.83
Q13952 Nuclear transcription factor Y subunit gamma 4 16 0.11 0.02 -0.03
P61970 Nuclear transport factor 2 4 49 0.39 -0.07 -0.25
Q9H1E3 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 9 74 -0.17 -0.28 -0.06
O15381 Nuclear valosin-containing protein-like 1 5 NA NA NA
Q86WB0 Nuclear-interacting partner of ALK 5 13 -0.37 -0.16 0.11
Q9Y2C4 Nuclease EXOG, mitochondrial 2 6 0.08 -0.19 -0.11
P67809 Nuclease-sensitive element-binding protein 1 5 70 0.17 0.14 0.09
Q02818 Nucleobindin-1 8 27 -0.41 0.44 0.65 5
P80303 Nucleobindin-2 5 9 -0.01 -0.19 -0.16
Q14978 Nucleolar and coiled-body phosphoprotein 1 16 73 0.53 0.10 -0.45
Q9Y3T9 Nucleolar complex protein 2 homolog 2 5 0.51 -0.31 -0.81
Q8WTT2 Nucleolar complex protein 3 homolog 3 8 0.34 -0.25 -0.51
Q9BVI4 Nucleolar complex protein 4 homolog 1 1 0.50 -0.05 -0.54
Q9BZE4 Nucleolar GTP-binding protein 1 11 32 0.19 -0.09 -0.29
Q13823 Nucleolar GTP-binding protein 2 3 7 -0.06 -0.17 -0.01
Q5C9Z4 Nucleolar MIF4G domain-containing protein 1 5 14 0.27 -0.15 -0.35
Q9BSC4 Nucleolar protein 10 2 6 0.58 -0.11 -0.64 3
Q9H8H0 Nucleolar protein 11 2 6 0.40 -0.02 -0.33
Q9UGY1 Nucleolar protein 12 1 1 -1.04 -0.65 0.41
P78316 Nucleolar protein 14 6 11 0.30 -0.23 -0.53
Q9Y3C1 Nucleolar protein 16 3 13 0.33 -0.19 -0.10
O00567 Nucleolar protein 56 33 217 0.57 0.05 -0.55 5 5
Q9Y2X3 Nucleolar protein 58 20 204 0.62 0.06 -0.65 5 5
Q9H6R4 Nucleolar protein 6 7 17 0.31 -0.09 -0.75 3
Q9UMY1 Nucleolar protein 7 4 22 0.02 -0.15 -0.37
Q76FK4 Nucleolar protein 8 2 10 0.87 -0.17 -0.89 3 3
Q86U38 Nucleolar protein 9 5 9 0.28 0.01 -0.21
Q9NP64 Nucleolar protein of 40 kDa 1 2 -0.58 -0.48 0.11
Q9NR30 Nucleolar RNA helicase 2 20 85 0.49 -0.13 -0.62 5 5
P17480 Nucleolar transcription factor 1 19 73 0.32 -0.06 -0.26
P19338 Nucleolin 54 671 0.13 -0.19 -0.20
P31483 Nucleolysin TIA-1 isoform p40 2 30 -0.38 -0.48 0.06
Q01085 Nucleolysin TIAR 5 35 0.01 -0.07 -0.09
P06748 Nucleophosmin 14 369 0.44 -0.14 -0.49
Q53GS7 Nucleoporin GLE1 4 7 0.03 0.05 -0.03
Q9BTX1 Nucleoporin NDC1 2 4 -0.02 0.04 0.06
Q5SRE5 Nucleoporin NUP188 homolog 1 1 -0.26 -0.22 0.04
Q8NFH4 Nucleoporin Nup37 3 3 -0.08 0.02 0.29
Q8NFH3 Nucleoporin Nup43 3 12 -0.31 -0.14 0.15
Q8NFH5 Nucleoporin NUP53 7 60 -0.18 0.04 0.20
Q7Z3B4 Nucleoporin p54 7 17 -0.01 0.14 0.08
Q9BVL2 Nucleoporin p58/p45 4 6 -0.47 0.00 0.48
Q96EE3 Nucleoporin SEH1 6 23 0.01 -0.11 -0.18
P12270 Nucleoprotein TPR 85 321 -0.23 -0.04 0.17
Q13232 Nucleoside diphosphate kinase 3 2 9 -0.52 -0.13 0.44
O75414 Nucleoside diphosphate kinase 6 1 2 -0.55 0.10 0.65
Q9Y5B8 Nucleoside diphosphate kinase 7 1 3 -0.29 -0.50 -0.22
P15531 Nucleoside diphosphate kinase A 1 70 -1.32 -1.77 -0.44
P22392 Nucleoside diphosphate kinase B 7 94 0.35 0.14 -0.19
A8MXV4 Nucleoside diphosphate-linked moiety X motif 19, mitochondrial 2 3 0.25 0.13 -0.08
P55209 Nucleosome assembly protein 1-like 1 5 67 0.21 -0.24 -0.48
Q99733 Nucleosome assembly protein 1-like 4 13 116 0.03 -0.75 -0.84 5 5
Q12830 Nucleosome-remodeling factor subunit BPTF 8 20 -0.11 0.01 0.13
Q96RE7 Nucleus accumbens-associated protein 1 2 3 -0.17 0.73 0.89
Q96RS6 NudC domain-containing protein 1 3 9 0.06 -0.09 -0.15
Q8WVJ2 NudC domain-containing protein 2 4 12 0.01 -0.14 -0.21
Q8IVD9 NudC domain-containing protein 3 2 5 -0.09 -0.24 -0.22
Q86Y26 NUT family member 1 1 1 0.01 0.31 0.31
Q9Y530 O-acetyl-ADP-ribose deacetylase 1 4 5 0.01 -0.40 -0.45
Q9BQ69 O-acetyl-ADP-ribose deacetylase MACROD1 2 4 0.29 0.13 -0.12
Q9NTK5 Obg-like ATPase 1 8 54 -0.09 0.04 0.07
Q9NX40 OCIA domain-containing protein 1 6 25 0.24 0.12 0.01
Q56VL3 OCIA domain-containing protein 2 1 2 0.23 -0.49 -0.72
Q8NGR8 Olfactory receptor 1L8 1 3 0.42 0.48 0.06
Q9Y3B8 Oligoribonuclease, mitochondrial 3 13 0.32 0.36 -0.84 3
Q9NQR4 Omega-amidase NIT2 12 55 0.11 -0.07 -0.40
Q9HD40 O-phosphoseryl-tRNA(Sec) selenium transferase 2 6 NA NA NA
Q9NZT2 Opioid growth factor receptor 17 86 -0.05 -0.07 0.01
Q9H6K4 Optic atrophy 3 protein 1 2 0.08 -0.08 -0.17
Q96CV9 Optineurin 15 68 -0.19 0.20 0.38
Q13416 Origin recognition complex subunit 2 3 3 0.04 -0.09 -0.04
O43913 Origin recognition complex subunit 5 1 1 0.53 -0.02 -0.55
P04181 Ornithine aminotransferase, mitochondrial 4 5 0.31 0.15 -0.16
Q92882 Osteoclast-stimulating factor 1 8 76 -0.35 0.75 0.90 3 5
Q01804 OTU domain-containing protein 4 3 10 -0.15 0.20 0.36
Q8N6M0 OTU domain-containing protein 6B 2 6 -0.01 -0.01 0.05
Q6GQQ9 OTU domain-containing protein 7B 1 2 -0.08 0.57 0.66
Q5BJF6 Outer dense fiber protein 2 2 3 0.19 0.14 -0.05
Q15743 Ovarian cancer G-protein coupled receptor 1 2 2 0.46 0.72 0.24
Q8WZ82 Ovarian cancer-associated gene 2 protein 3 8 -0.13 0.13 0.27
Q8TAD7 Overexpressed in colon carcinoma 1 protein 1 11 -0.37 0.43 0.67 3
Q8N573 Oxidation resistance protein 1 7 11 -0.29 0.09 0.52
Q9BUP3 Oxidoreductase HTATIP2 3 3 -0.03 0.34 0.14
Q5BKU9 Oxidoreductase-like domain-containing protein 1 1 2 0.16 -0.29 -0.45
P56715 Oxygen-regulated protein 1 1 3 0.24 -0.11 -0.35
P22059 Oxysterol-binding protein 1 10 25 0.15 0.15 -0.21
Q9BXB4 Oxysterol-binding protein-related protein 11 2 4 0.04 0.43 0.40
Q9H4L5 Oxysterol-binding protein-related protein 3 4 6 0.13 0.28 0.24
Q9H0X9 Oxysterol-binding protein-related protein 5 1 3 -1.87 -0.42 1.44
Q9BZF2 Oxysterol-binding protein-related protein 7 3 9 0.08 0.28 0.21
Q9BZF1 Oxysterol-binding protein-related protein 8 4 19 0.16 -0.07 -0.18
Q9NWT1 p21-activated protein kinase-interacting protein 1 3 5 0.21 -0.30 -0.38
Q96G91 P2Y purinoceptor 11 1 2 0.05 0.79 0.74
Q9NUG6 p53 and DNA damage-regulated protein 1 1 2 -0.13 -0.20 -0.06
Q58A45 PAB-dependent poly(A)-specific ribonuclease subunit 3 2 2 -1.52 -0.49 1.05
Q8N7B6 PACRG-like protein 1 1 0.30 0.43 0.11
Q96ST3 Paired amphipathic helix protein Sin3a 18 58 -0.14 -0.07 -0.03
P50897 Palmitoyl-protein thioesterase 1 7 37 0.18 -0.18 -0.38 5
Q9C0B5 Palmitoyltransferase ZDHHC5 3 6 -0.31 0.25 0.48
Q9BZ23 Pantothenate kinase 2, mitochondrial 2 7 0.22 0.14 -0.16
Q9NVE7 Pantothenate kinase 4 13 46 0.24 -0.20 -0.42
Q8NDF8 PAP-associated domain-containing protein 5 3 4 0.05 -0.11 -0.15
Q6P1J9 Parafibromin 12 42 -0.08 0.04 0.04
Q9UQ90 Paraplegin 2 11 0.06 -0.19 -0.13
Q8WXF1 Paraspeckle component 1 14 83 -0.03 -0.07 -0.07
P20962 Parathymosin 4 33 1.10 1.15 0.09 4 4
Q8NB37 Parkinson disease 7 domain-containing protein 1 2 15 0.27 -0.26 -0.35
Q9BRP8 Partner of Y14 and mago 9 38 0.02 -0.20 -0.05
Q9Y5B6 PAX3- and PAX7-binding protein 1 3 8 0.08 0.10 0.06
P49023 Paxillin 11 74 -0.72 0.17 1.06 5 5
Q6ZW49 PAX-interacting protein 1 1 1 -0.78 -0.44 0.33
O75475 PC4 and SFRS1-interacting protein 22 132 0.13 -0.64 -0.70 5 4
Q5JVF3 PCI domain-containing protein 2 1 7 0.09 0.12 0.00
Q9Y365 PCTP-like protein 2 3 -0.32 0.24 0.54
O00151 PDZ and LIM domain protein 1 7 30 -1.36 -0.19 0.93 5 5
Q96JY6 PDZ and LIM domain protein 2 14 112 -0.23 0.14 0.44
Q96HC4 PDZ and LIM domain protein 5 14 44 -0.22 0.06 0.32
Q9NR12 PDZ and LIM domain protein 7 1 2 -1.56 -1.27 0.28
Q5EBL8 PDZ domain-containing protein 11 1 3 0.44 0.63 0.19
Q76G19 PDZ domain-containing protein 4 1 2 -0.45 0.51 0.94
O14908 PDZ domain-containing protein GIPC1 2 6 -0.16 0.13 0.36
Q8TF64 PDZ domain-containing protein GIPC3 2 3 -0.32 -1.02 -0.70
Q9UBV8 Peflin 3 29 0.13 0.04 -0.05
Q96EY7 Pentatricopeptide repeat domain-containing protein 3, mitochondrial 1 6 0.10 -0.02 -0.15
Q9HBH1 Peptide deformylase, mitochondrial 1 1 0.61 -0.08 -0.68
Q96IV0 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase 3 5 -0.23 -0.07 0.17
P62937 Peptidyl-prolyl cis-trans isomerase A 15 975 -0.17 -0.24 -0.19
P23284 Peptidyl-prolyl cis-trans isomerase B 18 180 -0.09 0.42 0.66 3
Q6UX04 Peptidyl-prolyl cis-trans isomerase CWC27 homolog 4 13 0.25 -0.39 0.11
Q08752 Peptidyl-prolyl cis-trans isomerase D 4 22 -0.31 -0.14 0.11
Q9UNP9 Peptidyl-prolyl cis-trans isomerase E 6 26 -0.28 -0.33 -0.02
P30405 Peptidyl-prolyl cis-trans isomerase F, mitochondrial 8 33 -0.32 -0.18 0.16
Q9NYL4 Peptidyl-prolyl cis-trans isomerase FKBP11 4 13 0.96 1.08 0.04 4
P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A 5 81 -0.22 -0.39 -0.25 5
P26885 Peptidyl-prolyl cis-trans isomerase FKBP2 3 18 0.28 0.65 0.28 3
Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 10 30 0.10 -0.03 -0.21
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4 18 79 0.21 -0.08 -0.33
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5 18 66 0.40 -0.23 -0.61 5
Q14318 Peptidyl-prolyl cis-trans isomerase FKBP8 8 26 0.04 0.03 -0.12
Q13427 Peptidyl-prolyl cis-trans isomerase G 5 12 0.08 0.00 -0.04
O43447 Peptidyl-prolyl cis-trans isomerase H 5 32 0.14 -0.01 -0.20
Q13526 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 4 14 -0.30 0.02 0.39
Q9Y237 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 3 15 0.05 -0.15 -0.15
Q9Y3C6 Peptidyl-prolyl cis-trans isomerase-like 1 5 26 -0.05 -0.14 -0.12
Q13356 Peptidyl-prolyl cis-trans isomerase-like 2 5 17 -0.39 -0.06 0.13
Q9H2H8 Peptidyl-prolyl cis-trans isomerase-like 3 4 28 -0.17 -0.34 -0.19
Q8WUA2 Peptidyl-prolyl cis-trans isomerase-like 4 4 11 0.13 -0.07 -0.29
Q96BP3 Peptidylprolyl isomerase domain and WD repeat-containing protein 1 7 25 0.02 -0.26 -0.35
Q9Y3E5 Peptidyl-tRNA hydrolase 2, mitochondrial 1 1 NA NA NA
Q14197 Peptidyl-tRNA hydrolase ICT1, mitochondrial 3 4 0.08 -0.21 -0.29
P55201 Peregrin 7 14 0.03 0.19 -0.01
P14222 Perforin-1 18 178 -2.30 0.26 2.74 5 5
O95613 Pericentrin 11 23 0.20 -0.03 -0.26
Q15154 Pericentriolar material 1 protein 4 6 0.24 -0.09 -0.38
O60664 Perilipin-3 16 129 -0.55 -0.04 0.42
Q13610 Periodic tryptophan protein 1 homolog 2 4 -0.26 -0.40 -0.14
Q15269 Periodic tryptophan protein 2 homolog 1 1 0.15 -0.31 -0.46
Q8NEY8 Periphilin-1 1 4 -0.11 0.11 0.07
Q06830 Peroxiredoxin-1 14 292 0.61 -0.22 -0.98 5
P32119 Peroxiredoxin-2 13 339 0.89 -0.51 -1.31 5 4 5
Q13162 Peroxiredoxin-4 3 79 -0.13 0.05 0.09
P30044 Peroxiredoxin-5, mitochondrial 12 192 -0.62 -0.12 0.52 5
P30041 Peroxiredoxin-6 18 141 0.28 -0.33 -0.81 4
Q9NUI1 Peroxisomal 2,4-dienoyl-CoA reductase 1 1 NA NA NA
Q15067 Peroxisomal acyl-coenzyme A oxidase 1 1 1 0.00 -0.14 -0.13
O15254 Peroxisomal acyl-coenzyme A oxidase 3 1 1 0.07 -0.05 -0.12
P40855 Peroxisomal biogenesis factor 19 1 1 -0.42 -0.12 0.31
O96011 Peroxisomal membrane protein 11B 1 1 0.15 0.27 0.12
O75381 Peroxisomal membrane protein PEX14 4 7 0.00 -0.14 -0.13
P51659 Peroxisomal multifunctional enzyme type 2 18 52 -0.06 -0.03 0.13
Q9BY49 Peroxisomal trans-2-enoyl-CoA reductase 6 12 -0.06 -0.11 -0.23
O75420 PERQ amino acid-rich with GYF domain-containing protein 1 1 5 -0.30 -0.33 -0.03
Q6Y7W6 PERQ amino acid-rich with GYF domain-containing protein 2 7 13 -0.25 -0.02 0.14
O95571 Persulfide dioxygenase ETHE1, mitochondrial 9 62 0.16 0.21 0.05
O00541 Pescadillo homolog 7 19 0.28 -0.22 -0.29
Q8WW12 PEST proteolytic signal-containing nuclear protein 13 64 0.07 -0.21 -0.29
Q8NDX1 PH and SEC7 domain-containing protein 4 4 25 -0.22 0.23 0.42
Q9P1Y6 PHD and RING finger domain-containing protein 1 5 9 -0.27 0.01 0.14
O43189 PHD finger protein 1 2 3 0.49 -0.01 -0.49
Q8WUB8 PHD finger protein 10 2 3 -0.13 -0.11 0.03
Q96QT6 PHD finger protein 12 1 2 -0.18 0.20 0.39
O94880 PHD finger protein 14 1 1 -0.06 -0.17 -0.11
Q9BVI0 PHD finger protein 20 2 2 0.19 0.10 -0.09
A8MW92 PHD finger protein 20-like protein 1 1 1 -2.54 -1.55 1.00
Q96BD5 PHD finger protein 21A 1 1 0.14 0.64 0.48
Q9BUL5 PHD finger protein 23 6 18 -0.20 -0.25 -0.16
Q92576 PHD finger protein 3 14 23 0.08 -0.17 -0.16
Q8IWS0 PHD finger protein 6 3 6 -0.26 -0.18 0.02
Q7RTV0 PHD finger-like domain-containing protein 5A 4 20 -0.23 -0.35 0.16
Q9Y285 Phenylalanine--tRNA ligase alpha subunit 11 92 0.39 -0.29 -0.78 5
Q9NSD9 Phenylalanine--tRNA ligase beta subunit 20 144 0.36 -0.19 -0.61 5
O95363 Phenylalanine--tRNA ligase, mitochondrial 1 2 0.85 0.73 -0.11
Q8WWQ0 PH-interacting protein 10 28 0.06 -0.27 -0.32
Q9H2J4 Phosducin-like protein 3 3 5 0.16 0.02 0.10
O75167 Phosphatase and actin regulator 2 11 23 1.48 1.80 0.14 4 4
Q8IZ21 Phosphatase and actin regulator 4 3 7 -0.17 -0.15 0.15
Q00325 Phosphate carrier protein, mitochondrial 9 54 0.18 0.26 0.02
O95674 Phosphatidate cytidylyltransferase 2 2 10 -0.03 -0.05 -0.08
Q9UKL6 Phosphatidylcholine transfer protein 2 2 -0.94 -0.11 0.81
P30086 Phosphatidylethanolamine-binding protein 1 12 247 0.86 -0.21 -1.06 4 4
Q8WUK0 Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 1 2 0.22 0.06 -0.16
Q9NTJ5 Phosphatidylinositide phosphatase SAC1 10 44 0.02 0.39 0.48
P60484 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN1 1 -0.22 -0.14 0.07
Q92835 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 35 158 -0.44 0.31 0.84 5
O15357 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 5 19 -0.27 0.12 0.38
Q8TCU6 Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein 22 78 -0.49 0.35 0.73 4
Q8NEB9 Phosphatidylinositol 3-kinase catalytic subunit type 3 6 16 -0.21 0.14 0.26
P27986 Phosphatidylinositol 3-kinase regulatory subunit alpha 12 62 -0.12 0.14 0.13
O00459 Phosphatidylinositol 3-kinase regulatory subunit beta 2 19 -0.23 -0.16 0.08
P42338 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 1 3 0.72 0.26 -0.46
O00329 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform 8 23 0.12 -0.03 -0.39
P48736 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 1 3 -0.51 0.17 0.68
P42356 Phosphatidylinositol 4-kinase alpha 1 1 0.17 0.32 0.13
Q9UBF8 Phosphatidylinositol 4-kinase beta 1 1 -0.10 0.41 0.52
O00443 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha 1 1 -0.30 -0.26 0.04
O60331 Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma 2 3 -0.17 -0.09 0.09
P48426 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 9 102 0.04 0.52 0.36 5
P78356 Phosphatidylinositol 5-phosphate 4-kinase type-2 beta 3 40 -0.14 0.02 0.05
Q8TBX8 Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma 8 24 -0.50 0.20 0.71 4
Q00169 Phosphatidylinositol transfer protein alpha isoform 5 21 0.11 0.24 0.16
P48739 Phosphatidylinositol transfer protein beta isoform 6 30 0.09 0.10 0.00
Q13492 Phosphatidylinositol-binding clathrin assembly protein 6 30 -0.50 0.15 0.59 5
O95394 Phosphoacetylglucosamine mutase 2 2 0.35 0.17 -0.18
Q16822 Phosphoenolpyruvate carboxykinase, mitochondrial 7 12 0.30 0.16 -0.17
Q6VY07 Phosphofurin acidic cluster sorting protein 1 27 141 0.02 -0.14 -0.10
Q86VP3 Phosphofurin acidic cluster sorting protein 2 3 7 -0.01 0.11 0.14
P36871 Phosphoglucomutase-1 24 112 -0.02 0.18 0.27
Q96G03 Phosphoglucomutase-2 13 79 -0.29 -0.08 0.06
P00558 Phosphoglycerate kinase 1 34 1051 0.25 -0.47 -0.72 4 5
P07205 Phosphoglycerate kinase 2 2 136 0.15 -0.57 -0.70 3 4
P18669 Phosphoglycerate mutase 1 19 267 0.05 0.02 -0.09
A6NDG6 Phosphoglycolate phosphatase 5 9 -0.28 0.01 0.43
Q6ZUJ8 Phosphoinositide 3-kinase adapter protein 1 2 2 -0.04 1.00 1.04
Q99570 Phosphoinositide 3-kinase regulatory subunit 4 5 10 -0.10 -0.26 -0.16
Q96FE7 Phosphoinositide-3-kinase-interacting protein 1 1 8 -0.19 -0.56 -0.36 4
Q9Y263 Phospholipase A-2-activating protein 7 10 -0.06 0.23 0.25
Q6P4A8 Phospholipase B-like 1 1 1 0.76 0.27 -0.49
P36969 Phospholipid hydroperoxide glutathione peroxidase, mitochondrial 7 33 0.36 -0.11 -0.53
Q9H008 Phospholysine phosphohistidine inorganic pyrophosphate phosphatase 7 40 0.68 -0.22 -0.91 3 5
O15305 Phosphomannomutase 2 6 18 0.26 0.19 -0.19
Q15126 Phosphomevalonate kinase 7 26 0.14 0.47 0.21
Q9HAB8 Phosphopantothenate--cysteine ligase 7 17 0.05 0.07 -0.07
Q9NWQ8 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 9 19 0.57 0.08 -0.31
Q14558 Phosphoribosyl pyrophosphate synthase-associated protein 1 7 41 0.17 0.00 -0.26
O60256 Phosphoribosyl pyrophosphate synthase-associated protein 2 8 61 0.06 -0.31 -0.28
O15067 Phosphoribosylformylglycinamidine synthase 16 30 0.02 -0.22 -0.26
P15735 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform 1 1 NA NA NA
P46019 Phosphorylase b kinase regulatory subunit alpha, liver isoform 5 7 0.12 0.12 -0.02
Q9H814 Phosphorylated adapter RNA export protein 4 10 -0.13 -0.38 -0.24
Q9H4Z3 Phosphorylated CTD-interacting factor 1 2 2 -0.21 -0.18 0.03
Q9Y617 Phosphoserine aminotransferase 2 3 0.02 -0.87 -0.90
P78330 Phosphoserine phosphatase 1 1 -0.08 -0.25 -0.17
Q96BW5 Phosphotriesterase-related protein 7 20 -0.11 -0.29 -0.12
Q6NYC8 Phostensin 22 112 -0.48 0.33 0.77 5
P36955 Pigment epithelium-derived factor 1 4 0.65 0.77 0.01
Q9NWS0 PIH1 domain-containing protein 1 4 8 -0.07 -0.32 -0.26
Q96BK5 PIN2/TERF1-interacting telomerase inhibitor 1 4 13 -0.02 -0.11 -0.20
Q9H307 Pinin 17 62 -0.21 -0.17 -0.07
Q9GZP4 PITH domain-containing protein 1 9 25 0.29 -0.02 -0.24
P20020 Plasma membrane calcium-transporting ATPase 1 3 42 0.42 0.46 0.05
P23634 Plasma membrane calcium-transporting ATPase 4 9 82 0.38 0.98 0.72 5 5
Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein 21 99 0.19 -0.25 -0.31
P05120 Plasminogen activator inhibitor 2 3 4 -0.10 0.03 0.20
Q9HBL7 Plasminogen receptor (KT) 1 15 -0.06 -0.09 -0.16
Q14651 Plastin-1 1 172 1.08 0.62 -0.45
P13796 Plastin-2 40 1792 0.04 0.51 0.34
P13797 Plastin-3 1 395 -0.34 0.28 0.42
P02775 Platelet basic protein 6 35 0.00 -0.12 0.03
P16284 Platelet endothelial cell adhesion molecule 7 16 -0.16 -0.47 -0.40 5
P02776 Platelet factor 4 4 14 0.12 -0.14 -0.47
P16671 Platelet glycoprotein 4 1 1 -0.01 -0.07 -0.05
P07359 Platelet glycoprotein Ib alpha chain 3 7 NA NA NA
P13224 Platelet glycoprotein Ib beta chain 1 1 NA NA NA
P14770 Platelet glycoprotein IX 1 1 -0.20 -0.18 0.01
Q9H7M9 Platelet receptor Gi24 2 3 0.13 0.49 0.37
Q99487 Platelet-activating factor acetylhydrolase 2, cytoplasmic 1 1 -0.71 -0.13 0.58
P43034 Platelet-activating factor acetylhydrolase IB subunit alpha 11 44 0.26 0.15 -0.05
P68402 Platelet-activating factor acetylhydrolase IB subunit beta 2 58 0.24 -0.25 -0.64 4
Q15102 Platelet-activating factor acetylhydrolase IB subunit gamma 8 41 0.74 -0.24 -0.96 5 5
P08567 Pleckstrin 10 32 -0.72 0.23 0.71 3 4
Q9HB21 Pleckstrin homology domain-containing family A member 1 4 18 -0.37 -0.15 0.56 4
Q9HB19 Pleckstrin homology domain-containing family A member 2 7 30 -0.26 0.13 0.39 5
Q96S99 Pleckstrin homology domain-containing family F member 1 1 15 -0.44 0.77 1.11 3
Q9H8W4 Pleckstrin homology domain-containing family F member 2 1 12 0.13 -0.02 -0.14
Q9Y4G2 Pleckstrin homology domain-containing family M member 1 1 1 0.19 0.10 -0.08
Q8IWE5 Pleckstrin homology domain-containing family M member 2 2 2 -0.17 -0.22 -0.04
Q53GL0 Pleckstrin homology domain-containing family O member 1 1 2 0.22 0.01 -0.20
Q8TD55 Pleckstrin homology domain-containing family O member 2 10 33 -0.40 0.25 0.70 5
Q15149 Plectin 197 1024 0.64 0.01 -0.75 5 5
O43660 Pleiotropic regulator 1 10 28 -0.14 -0.10 0.02
O15031 Plexin-B2 1 1 0.10 -0.20 -0.29
O00592 Podocalyxin 1 1 1.03 1.26 0.22
Q7Z3K3 Pogo transposable element with ZNF domain 8 19 -0.17 -0.08 0.06
P09874 Poly polymerase 1 48 387 0.43 -0.03 -0.42
Q53GL7 Poly polymerase 10 9 29 -0.22 0.09 0.39
Q9H0J9 Poly polymerase 12 5 14 -0.12 0.11 0.21
Q460N5 Poly polymerase 14 11 17 -0.03 0.17 0.24
Q9UGN5 Poly polymerase 2 1 1 -0.10 -0.18 -0.09
Q9UKK3 Poly polymerase 4 3 8 -0.37 -0.11 0.29
Q8N3A8 Poly polymerase 8 1 1 0.32 0.52 0.20
Q8IXQ6 Poly polymerase 9 3 10 0.14 0.08 -0.09
P51003 Poly(A) polymerase alpha 6 45 -0.06 -0.05 0.10
Q9BWT3 Poly(A) polymerase gamma 2 12 -0.15 -0.04 0.05
Q9NVV4 Poly(A) RNA polymerase, mitochondrial 1 2 NA NA NA
O95453 Poly(A)-specific ribonuclease PARN 5 6 0.07 -0.10 -0.16
Q9NX46 Poly(ADP-ribose) glycohydrolase ARH3 10 54 -0.01 -0.20 -0.23
Q15365 Poly(rC)-binding protein 1 10 318 -0.13 -0.08 -0.03
Q15366 Poly(rC)-binding protein 2 5 211 -0.02 -0.25 -0.26
P57721 Poly(rC)-binding protein 3 1 126 0.16 0.11 -0.04
P57723 Poly(rC)-binding protein 4 1 21 0.75 -0.46 -1.20
Q9UHX1 Poly(U)-binding-splicing factor PUF60 20 119 0.03 -0.20 -0.20
P11940 Polyadenylate-binding protein 1 24 288 0.16 0.16 -0.06
Q86U42 Polyadenylate-binding protein 2 9 36 -0.29 -0.17 0.07
Q13310 Polyadenylate-binding protein 4 7 88 0.12 -0.23 -0.39
Q9H074 Polyadenylate-binding protein-interacting protein 1 1 1 NA NA NA
Q9BPZ3 Polyadenylate-binding protein-interacting protein 2 1 1 0.28 0.01 -0.27
P35226 Polycomb complex protein BMI-1 2 3 0.53 0.20 -0.22
O75530 Polycomb protein EED 1 1 0.32 0.10 -0.21
Q15022 Polycomb protein SUZ12 2 7 -0.38 -0.07 0.17
O60828 Polyglutamine-binding protein 1 6 26 -0.28 -0.31 -0.01
Q8NDX5 Polyhomeotic-like protein 3 4 9 0.36 0.05 -0.16
Q9Y2S7 Polymerase delta-interacting protein 2 1 3 -0.15 -0.13 0.02
Q9BY77 Polymerase delta-interacting protein 3 14 68 -0.20 -0.09 0.16
P01833 Polymeric immunoglobulin receptor 1 2 0.94 1.53 0.60
Q5SY16 Polynucleotide 5'-hydroxyl-kinase NOL9 3 3 0.19 0.04 -0.14
Q10472 Polypeptide N-acetylgalactosaminyltransferase 1 1 1 -0.01 0.80 0.81
Q8IUC8 Polypeptide N-acetylgalactosaminyltransferase 13 1 11 -0.99 -0.32 0.68 3
P26599 Polypyrimidine tract-binding protein 1 16 177 0.01 -0.18 -0.18
O95758 Polypyrimidine tract-binding protein 3 7 87 0.05 -0.11 -0.27
Q92989 Polyribonucleotide 5'-hydroxyl-kinase Clp1 1 2 0.22 0.16 -0.07
Q8TCS8 Polyribonucleotide nucleotidyltransferase 1, mitochondrial 14 26 0.47 -0.02 -0.32
P08397 Porphobilinogen deaminase 3 4 0.18 -0.39 -0.45
P14859 POU domain, class 2, transcription factor 1 2 5 -0.13 0.14 0.33
O60831 PRA1 family protein 2 1 8 0.16 0.26 0.15
O75915 PRA1 family protein 3 4 80 -0.09 -0.16 0.01
P40425 Pre-B-cell leukemia transcription factor 2 1 2 -0.41 -0.27 0.14
Q96AQ6 Pre-B-cell leukemia transcription factor-interacting protein 1 9 24 0.61 0.62 -0.01 5
O60925 Prefoldin subunit 1 4 23 -0.20 -0.24 -0.10
Q9UHV9 Prefoldin subunit 2 7 36 -0.12 -0.32 -0.17
P61758 Prefoldin subunit 3 7 19 -0.03 -0.08 -0.09
Q9NQP4 Prefoldin subunit 4 5 21 -0.18 -0.30 -0.15
Q99471 Prefoldin subunit 5 6 28 -0.13 -0.41 -0.15
O15212 Prefoldin subunit 6 6 29 -0.24 -0.31 0.00
P02545 Prelamin-A/C 43 347 0.69 0.88 0.18 4 4
Q9C0J8 pre-mRNA 3' end processing protein WDR33 17 28 -0.09 -0.03 -0.04
Q6UN15 Pre-mRNA 3'-end-processing factor FIP1 9 44 0.02 -0.06 0.02
Q9Y3B4 Pre-mRNA branch site protein p14 5 16 -0.17 0.03 0.07
O94913 Pre-mRNA cleavage complex 2 protein Pcf11 2 2 0.38 0.22 -0.15
O60508 Pre-mRNA-processing factor 17 7 17 -0.20 -0.04 0.10
Q9UMS4 Pre-mRNA-processing factor 19 13 48 -0.18 -0.05 0.06
Q86UA1 Pre-mRNA-processing factor 39 2 5 0.20 -0.15 -0.28
O75400 Pre-mRNA-processing factor 40 homolog A 14 65 -0.24 -0.09 -0.07
O94906 Pre-mRNA-processing factor 6 23 71 -0.14 -0.10 -0.02
Q6P2Q9 Pre-mRNA-processing-splicing factor 8 43 148 0.06 -0.08 -0.05
Q8NAV1 Pre-mRNA-splicing factor 38A 3 11 -0.15 -0.26 -0.10
Q5VTL8 Pre-mRNA-splicing factor 38B 3 7 0.09 0.10 0.00
Q92620 Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 7 26 0.03 0.16 0.10
Q9NXE8 Pre-mRNA-splicing factor CWC25 homolog 2 4 -0.10 0.02 0.12
Q9ULR0 Pre-mRNA-splicing factor ISY1 homolog 5 33 -0.27 -0.21 0.15
Q9NW64 Pre-mRNA-splicing factor RBM22 5 29 -0.03 0.12 0.10
O95391 Pre-mRNA-splicing factor SLU7 2 3 0.09 -0.03 -0.11
O75934 Pre-mRNA-splicing factor SPF27 6 21 -0.30 -0.20 0.05
Q9HCS7 Pre-mRNA-splicing factor SYF1 7 18 0.00 -0.04 -0.18
O95926 Pre-mRNA-splicing factor SYF2 2 3 -0.14 0.10 0.25
Q15007 Pre-mRNA-splicing regulator WTAP 8 35 -0.25 -0.18 0.07
Q9UHG3 Prenylcysteine oxidase 1 5 6 0.40 -0.11 -0.64
Q8IY81 pre-rRNA processing protein FTSJ3 13 52 0.33 -0.11 -0.42 5
Q2NL82 Pre-rRNA-processing protein TSR1 homolog 4 8 0.35 0.18 -0.33
Q969E8 Pre-rRNA-processing protein TSR2 homolog 2 2 0.03 0.15 0.09
Q5JRX3 Presequence protease, mitochondrial 14 25 0.14 -0.12 -0.22
Q9H875 PRKR-interacting protein 1 5 26 -0.26 -0.12 -0.02
Q8NDH3 Probable aminopeptidase NPEPL1 4 12 0.18 0.30 0.26
Q5T160 Probable arginine--tRNA ligase, mitochondrial 1 1 -0.02 0.05 0.05
Q96I59 Probable asparagine--tRNA ligase, mitochondrial 1 1 0.94 0.01 -0.95
Q13206 Probable ATP-dependent RNA helicase DDX10 2 5 0.18 -0.29 -0.55
Q92841 Probable ATP-dependent RNA helicase DDX17 28 394 -0.05 -0.06 -0.08
Q9UHI6 Probable ATP-dependent RNA helicase DDX20 2 2 0.62 -0.21 -0.83
Q9BUQ8 Probable ATP-dependent RNA helicase DDX23 17 87 -0.25 -0.17 0.04
Q96GQ7 Probable ATP-dependent RNA helicase DDX27 18 51 0.34 -0.17 -0.54 5
Q9NUL7 Probable ATP-dependent RNA helicase DDX28 2 2 0.93 -0.07 -1.00
Q9UJV9 Probable ATP-dependent RNA helicase DDX41 8 13 0.03 -0.19 -0.15
Q7L014 Probable ATP-dependent RNA helicase DDX46 34 150 -0.11 -0.07 0.00
Q9H0S4 Probable ATP-dependent RNA helicase DDX47 8 26 0.69 -0.26 -1.07 5 5
Q9Y6V7 Probable ATP-dependent RNA helicase DDX49 1 1 NA NA NA
P17844 Probable ATP-dependent RNA helicase DDX5 17 222 -0.03 -0.11 0.09
Q9Y2R4 Probable ATP-dependent RNA helicase DDX52 1 4 0.41 -0.09 -0.56
Q9NY93 Probable ATP-dependent RNA helicase DDX56 4 15 0.19 -0.21 -0.33
O95786 Probable ATP-dependent RNA helicase DDX58 7 22 0.15 0.18 0.01
Q5T1V6 Probable ATP-dependent RNA helicase DDX59 2 18 -0.19 -0.11 0.08
P26196 Probable ATP-dependent RNA helicase DDX6 13 74 -0.17 0.17 0.03
Q8IY21 Probable ATP-dependent RNA helicase DDX60 15 50 0.38 0.11 -0.33
Q5H9U9 Probable ATP-dependent RNA helicase DDX60-like 1 1 -0.01 0.16 0.17
Q14147 Probable ATP-dependent RNA helicase DHX34 2 2 -0.28 -0.03 0.25
Q9H5Z1 Probable ATP-dependent RNA helicase DHX35 2 3 -0.93 0.14 1.05
Q9H2U1 Probable ATP-dependent RNA helicase DHX36 8 11 -0.01 -0.07 0.01
Q8IY37 Probable ATP-dependent RNA helicase DHX37 5 9 -0.03 -0.29 -0.25
Q8IX18 Probable ATP-dependent RNA helicase DHX40 2 3 NA NA NA
Q9H6S0 Probable ATP-dependent RNA helicase YTHDC2 2 2 -0.51 -0.24 0.25
Q9HD20 Probable cation-transporting ATPase 13A1 6 12 0.20 0.22 0.02
Q9HA77 Probable cysteine--tRNA ligase, mitochondrial 2 6 0.15 -0.06 -0.23
O76071 Probable cytosolic iron-sulfur protein assembly protein CIAO1 3 5 0.05 -0.02 -0.07
Q9UNQ2 Probable dimethyladenosine transferase 2 6 0.28 -0.26 -0.52
Q5GLZ8 Probable E3 ubiquitin-protein ligase HERC4 4 12 0.08 -0.10 -0.14
Q9H000 Probable E3 ubiquitin-protein ligase makorin-2 1 1 0.00 0.05 0.05
O75592 Probable E3 ubiquitin-protein ligase MYCBP2 21 35 0.08 -0.31 -0.42
Q9HAH7 Probable fibrosin-1 1 1 0.09 0.47 0.40
P51531 Probable global transcription activator SNF2L2 14 96 -0.12 -0.15 0.03
Q5T6J7 Probable gluconokinase 1 1 -1.02 -0.73 0.27
Q7Z333 Probable helicase senataxin 5 11 -0.08 -0.31 0.11
P42694 Probable helicase with zinc finger domain 3 10 -0.37 0.36 0.98 3
P49590 Probable histidine--tRNA ligase, mitochondrial 2 23 0.18 0.09 0.07
Q15652 Probable JmjC domain-containing histone demethylation protein 2C 2 5 0.28 0.16 -0.18
Q15031 Probable leucine--tRNA ligase, mitochondrial 1 5 0.08 0.09 0.10
Q9NUN5 Probable lysosomal cobalamin transporter 1 2 0.49 0.28 -0.20
Q13395 Probable methyltransferase TARBP1 1 2 0.33 -0.30 -0.63
Q5W0Z9 Probable palmitoyltransferase ZDHHC20 2 6 -0.15 0.31 0.46
Q86Y79 Probable peptidyl-tRNA hydrolase 1 2 0.09 -0.43 -0.50
Q9Y2Q0 Probable phospholipid-transporting ATPase IA 2 2 0.00 0.22 0.22
Q9Y2G3 Probable phospholipid-transporting ATPase IF 2 6 -0.25 0.28 0.53
Q9P241 Probable phospholipid-transporting ATPase VD 1 1 NA NA NA
Q7L3T8 Probable proline--tRNA ligase, mitochondrial 1 1 0.22 0.18 -0.04
Q9UHA3 Probable ribosome biogenesis protein RLP24 2 4 0.19 -0.42 -0.74
Q96CW6 Probable RNA polymerase II nuclear localization protein SLC7A6OS 1 1 0.06 0.15 0.09
Q9Y4C8 Probable RNA-binding protein 19 4 11 0.32 -0.13 -0.44
Q86U06 Probable RNA-binding protein 23 1 5 -0.69 -0.02 0.67
Q8N9N8 Probable RNA-binding protein EIF1AD 2 4 -0.03 -0.15 -0.12
Q99848 Probable rRNA-processing protein EBP2 8 29 0.54 -0.07 -0.44 5
A2RTX5 Probable threonine--tRNA ligase 2, cytoplasmic 2 3 0.05 0.06 0.02
Q9NPF4 Probable tRNA N6-adenosine threonylcarbamoyltransferase 9 53 -0.07 -0.11 0.01
Q8WWH5 Probable tRNA pseudouridine synthase 1 4 14 -0.14 0.00 0.05
Q9Y3A2 Probable U3 small nucleolar RNA-associated protein 11 2 3 0.34 0.10 -0.23
Q93008 Probable ubiquitin carboxyl-terminal hydrolase FAF-X 13 31 0.25 0.33 -0.02
Q9NQH7 Probable Xaa-Pro aminopeptidase 3 1 2 0.20 -0.30 -0.49
P09668 Pro-cathepsin H 2 8 1.92 2.11 0.17 4 4
Q8NBJ5 Procollagen galactosyltransferase 1 1 1 -0.34 0.43 0.78
O60568 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 1 6 -0.22 0.38 0.56
P07737 Profilin-1 16 1786 -0.42 -0.16 0.28
P35080 Profilin-2 3 14 0.68 -0.33 -1.26 5 5
Q8WXW3 Progesterone-induced-blocking factor 1 1 1 -0.14 -0.07 0.07
Q8WUM4 Programmed cell death 6-interacting protein 37 196 0.25 0.05 -0.09
Q9BUL8 Programmed cell death protein 10 7 28 -0.03 0.09 0.06
Q16342 Programmed cell death protein 2 1 1 1.21 0.15 -1.05
Q53EL6 Programmed cell death protein 4 24 222 0.93 0.37 -0.50 5 5
O14737 Programmed cell death protein 5 7 49 0.22 -0.01 -0.37
O75340 Programmed cell death protein 6 4 8 0.61 -0.14 -0.90
Q8N8D1 Programmed cell death protein 7 1 1 0.45 -0.01 -0.45
P35232 Prohibitin 19 294 0.19 0.14 -0.05
Q99623 Prohibitin-2 20 213 0.19 0.20 -0.01
Q14005 Pro-interleukin-16 34 370 -0.08 -0.39 -0.20
Q9HCU5 Prolactin regulatory element-binding protein 3 3 0.67 0.03 -0.63
P12273 Prolactin-inducible protein 1 1 -1.50 -1.01 0.50
P12004 Proliferating cell nuclear antigen 13 50 -0.06 0.05 0.13
Q9UQ80 Proliferation-associated protein 2G4 22 204 0.18 0.10 -0.13
O94903 Proline synthase co-transcribed bacterial homolog protein 10 61 -0.02 -0.18 -0.20
Q8IZL8 Proline-, glutamic acid- and leucine-rich protein 1 5 8 0.11 -0.11 -0.11
Q9ULL5 Proline-rich protein 12 3 6 0.05 0.16 0.33
Q9BWN1 Proline-rich protein 14 2 3 -0.29 0.56 0.58
Q16378 Proline-rich protein 4 1 2 NA NA NA
P85299 Proline-rich protein 5 1 4 0.17 0.28 0.11
Q92733 Proline-rich protein PRCC 5 41 -0.31 -0.16 0.10
O43586 Proline-serine-threonine phosphatase-interacting protein 1 12 44 -0.15 0.49 0.63 5 4
Q9H939 Proline-serine-threonine phosphatase-interacting protein 2 3 4 -1.19 -0.56 0.61
P13674 Prolyl 4-hydroxylase subunit alpha-1 1 1 0.48 0.46 0.00
P48147 Prolyl endopeptidase 11 45 0.01 0.22 0.28
P05165 Propionyl-CoA carboxylase alpha chain, mitochondrial 10 21 0.24 0.12 -0.16
P05166 Propionyl-CoA carboxylase beta chain, mitochondrial 8 21 0.12 -0.06 -0.14
P07602 Prosaposin 2 8 -0.60 0.04 0.73
Q9H7Z7 Prostaglandin E synthase 2 9 30 0.13 0.14 -0.05
Q15185 Prostaglandin E synthase 3 5 14 0.39 0.18 -0.20
Q8N8N7 Prostaglandin reductase 2 1 1 -0.18 -0.48 -0.30
P41222 Prostaglandin-H2 D-isomerase 1 1 NA NA NA
Q8TBF2 Prostamide/prostaglandin F synthase 1 2 0.19 -0.27 -0.46
Q9BRP4 Proteasomal ATPase-associated factor 1 3 7 -0.27 0.06 0.19
Q16186 Proteasomal ubiquitin receptor ADRM1 4 22 0.11 -0.01 -0.07
Q06323 Proteasome activator complex subunit 1 13 182 -0.02 0.10 0.04
Q9UL46 Proteasome activator complex subunit 2 9 76 0.34 0.26 -0.16
P61289 Proteasome activator complex subunit 3 8 28 -0.26 0.05 0.27
Q14997 Proteasome activator complex subunit 4 1 1 NA NA NA
O95456 Proteasome assembly chaperone 1 2 3 -0.28 -0.20 -0.35
Q969U7 Proteasome assembly chaperone 2 1 1 0.20 -0.22 -0.42
Q9BT73 Proteasome assembly chaperone 3 1 1 0.06 -0.08 -0.14
Q5JS54 Proteasome assembly chaperone 4 1 1 -0.51 -0.96 -0.47
Q92530 Proteasome inhibitor PI31 subunit 3 12 0.14 -0.26 -0.18
P25786 Proteasome subunit alpha type-1 18 146 -0.09 -0.09 -0.09
P25787 Proteasome subunit alpha type-2 10 84 -0.07 -0.02 0.00
P25788 Proteasome subunit alpha type-3 11 100 0.19 -0.01 -0.12
P25789 Proteasome subunit alpha type-4 9 42 0.23 0.06 -0.13
P28066 Proteasome subunit alpha type-5 8 126 0.01 -0.06 -0.15
P60900 Proteasome subunit alpha type-6 14 149 0.01 0.06 0.04
O14818 Proteasome subunit alpha type-7 16 135 0.13 -0.11 -0.17
P20618 Proteasome subunit beta type-1 11 76 0.08 0.09 -0.04
P40306 Proteasome subunit beta type-10 10 68 -0.18 -0.13 0.01
P49721 Proteasome subunit beta type-2 4 8 0.08 -0.03 -0.15
P49720 Proteasome subunit beta type-3 6 46 0.15 0.12 -0.03
P28070 Proteasome subunit beta type-4 8 112 -0.02 -0.01 0.05
P28072 Proteasome subunit beta type-6 2 2 NA NA NA
Q99436 Proteasome subunit beta type-7 2 6 -0.14 -0.25 -0.18
P28062 Proteasome subunit beta type-8 12 74 -0.09 -0.03 0.00
P28065 Proteasome subunit beta type-9 9 130 -0.10 -0.05 0.01
Q5VYK3 Proteasome-associated protein ECM29 homolog 15 39 0.45 0.40 -0.09
Q9NUX5 Protection of telomeres protein 1 1 1 -0.71 -0.07 0.65
P11171 Protein 4.1 22 103 0.30 -0.07 -0.27
Q9NY61 Protein AATF 5 11 0.15 -0.26 -0.66 3
P55197 Protein AF-10 1 1 0.03 -0.31 -0.34
P55198 Protein AF-17 3 4 0.09 0.23 0.13
Q5VTE6 Protein angel homolog 2 1 1 -0.04 0.05 0.09
Q8IWT0 Protein archease 1 1 NA NA NA
Q99873 Protein arginine N-methyltransferase 1 6 11 0.07 -0.05 0.00
O14744 Protein arginine N-methyltransferase 5 6 9 0.80 0.03 -0.78 5 5
Q9UL18 Protein argonaute-1 5 32 0.16 -0.17 -0.21
Q9UKV8 Protein argonaute-2 8 35 0.03 0.07 0.08
Q9H9G7 Protein argonaute-3 2 26 -0.28 -0.17 0.10
Q9NVM9 Protein asunder homolog 4 6 0.12 0.07 -0.19
Q8N9N5 Protein BANP 1 4 -0.08 0.14 0.17
Q8TD16 Protein bicaudal D homolog 2 4 10 -0.07 0.16 0.24
Q8WUW1 Protein BRICK1 6 24 -0.14 0.16 0.47
P41223 Protein BUD31 homolog 5 7 0.11 0.15 0.08
Q99622 Protein C10 2 4 -0.19 0.20 -0.32
Q9Y2B0 Protein canopy homolog 2 4 21 0.05 0.13 -0.02
Q9BT09 Protein canopy homolog 3 10 27 -0.34 -0.35 -0.05
Q8N129 Protein canopy homolog 4 4 4 0.00 -0.26 -0.43
Q96RK0 Protein capicua homolog 1 2 -0.21 0.03 0.25
O15234 Protein CASC3 3 4 -0.74 -0.24 0.51
Q13948 Protein CASP 1 2 -0.48 -0.06 0.42
Q9UKY7 Protein CDV3 homolog 9 84 0.12 -0.16 -0.44
Q96SW2 Protein cereblon 1 2 -0.27 -0.47 -0.21
P14921 Protein C-ets-1 7 15 0.12 -0.29 -0.49
Q8WUH1 Protein Churchill 1 3 -0.74 0.12 0.87
Q2KHT3 Protein CLEC16A 1 1 -0.23 0.20 0.42
Q9BQ75 Protein CMSS1 3 3 0.19 -0.45 -0.63
Q5IJ48 Protein crumbs homolog 2 1 1 NA NA NA
O60888 Protein CutA 3 46 -0.58 -0.13 -0.06
Q96DE9 Protein CXorf40B 1 1 0.08 0.57 0.50
Q9P219 Protein Daple 8 13 -0.13 -0.09 0.38
Q5TDH0 Protein DDI1 homolog 2 10 45 0.08 -0.05 -0.24
P35659 Protein DEK 14 131 0.17 0.14 0.00
P80370 Protein delta homolog 1 1 8 -0.02 -0.15 -0.01
Q96DF8 Protein DGCR14 3 6 -0.15 0.22 0.37
O60610 Protein diaphanous homolog 1 39 201 -0.10 -0.15 0.11
O60879 Protein diaphanous homolog 2 2 3 0.52 0.32 -0.20
P07237 Protein disulfide-isomerase 32 272 0.05 0.61 0.56 5 4
P30101 Protein disulfide-isomerase A3 40 571 -0.29 0.40 0.67 4
P13667 Protein disulfide-isomerase A4 30 256 0.06 0.56 0.47 4 4
Q14554 Protein disulfide-isomerase A5 2 4 0.41 0.06 -0.09
Q15084 Protein disulfide-isomerase A6 14 195 -0.15 0.78 0.82 5 4
Q96JJ7 Protein disulfide-isomerase TMX3 3 15 0.00 0.30 0.42
Q99497 Protein DJ-1 16 265 -0.12 -0.20 -0.06
Q5JWR5 Protein dopey-1 1 1 NA NA NA
Q9Y3R5 Protein dopey-2 1 6 0.10 0.10 0.01
Q9C005 Protein dpy-30 homolog 3 5 -0.13 -0.08 -0.05
Q01658 Protein Dr1 5 26 -0.20 -0.20 0.19
Q14156 Protein EFR3 homolog A 2 3 0.53 0.57 0.05
Q8WYP5 Protein ELYS 23 64 -0.14 -0.01 0.15
Q7Z589 Protein EMSY 9 15 -0.13 -0.05 0.06
Q03111 Protein ENL 1 1 -0.09 -0.16 -0.07
P49257 Protein ERGIC-53 6 22 0.17 0.53 0.01 3
P34910 Protein EVI2B 1 3 0.41 0.07 0.09
Q13158 Protein FADD 2 2 0.27 -0.25 -0.52
Q8N5W9 Protein FAM101B 2 4 0.42 -0.28 -0.70 3
Q5T9C2 Protein FAM102A 2 5 0.67 -0.19 -0.73 3
Q969W3 Protein FAM104A 1 6 -0.36 0.07 0.50
Q9H098 Protein FAM107B 9 23 0.23 -0.18 -0.04
Q9NRY5 Protein FAM114A2 4 12 0.07 0.09 -0.07
A6NFQ2 Protein FAM115C 1 1 0.47 0.01 -0.45
Q6P1L5 Protein FAM117B 1 1 -0.03 -1.35 -1.34
Q5BKY9 Protein FAM133B 2 4 -0.26 -0.18 -0.03
Q8NC44 Protein FAM134A 1 3 0.58 0.20 -0.37
Q86VR2 Protein FAM134C 2 3 -0.18 0.03 0.20
Q9P2D6 Protein FAM135A 1 1 NA NA NA
Q96C01 Protein FAM136A 3 15 -0.43 -0.10 0.40
Q8WW52 Protein FAM151A 1 1 NA NA NA
Q92567 Protein FAM168A 1 1 -0.45 -0.40 0.03
Q8WUF8 Protein FAM172A 5 8 -0.15 -0.05 0.08
Q8N128 Protein FAM177A1 1 5 -0.37 -0.10 0.37
Q9GZU8 Protein FAM192A 3 7 -0.19 -0.14 0.03
C9JLW8 Protein FAM195B 4 8 -0.73 -0.15 0.69
Q6UWH4 Protein FAM198B 1 1 NA NA NA
P0CB43 Protein FAM203B 4 13 -0.09 -0.12 -0.14
Q9NSI2 Protein FAM207A 2 6 0.25 0.13 -0.12
Q9UK61 Protein FAM208A 5 6 0.48 0.19 -0.04
Q5VWN6 Protein FAM208B 1 1 NA NA NA
Q9Y421 Protein FAM32A 3 11 -0.08 -0.40 -0.41
Q92520 Protein FAM3C 3 4 -0.17 0.27 0.50
Q6NSW5 Protein FAM45B 2 3 0.31 0.09 -0.20
Q9NUQ9 Protein FAM49B 16 133 -0.50 0.25 0.74 4
Q14320 Protein FAM50A 4 5 0.19 0.33 0.00
Q9Y4F9 Protein FAM65B 7 28 -0.03 -0.04 0.02
Q8TAV0 Protein FAM76A 1 1 -1.57 -1.10 0.49
Q5HYJ3 Protein FAM76B 2 2 -1.42 -0.83 0.59
Q96KN1 Protein FAM84B 1 1 -0.07 -0.19 -0.13
Q8N7N1 Protein FAM86B1 1 2 NA NA NA
Q658Y4 Protein FAM91A1 1 1 -0.12 0.43 0.55
Q8NCA5 Protein FAM98A 2 12 -0.05 0.00 0.07
Q52LJ0 Protein FAM98B 4 71 0.18 -0.23 -0.37
Q17RN3 Protein FAM98C 2 2 0.11 -0.31 -0.40
P49354 Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha 1 3 0.22 0.44 0.22
Q13045 Protein flightless-1 homolog 19 97 0.06 0.12 0.00
Q70Z53 Protein FRA10AC1 1 1 -1.46 -1.34 0.13
Q14331 Protein FRG1 5 14 -0.16 -0.04 -0.04
O94915 Protein furry homolog-like 9 16 -0.09 0.00 0.01
O94992 Protein HEXIM1 1 2 -2.42 -1.23 1.20
Q9UJC3 Protein Hook homolog 1 4 5 0.08 -0.66 -0.69
Q86VS8 Protein Hook homolog 3 10 32 -0.14 -0.02 0.16
Q9P2X3 Protein IMPACT 1 5 0.07 -0.31 -0.38
Q96ST2 Protein IWS1 homolog 3 5 -0.16 -0.19 -0.03
Q9NQC1 Protein Jade-2 2 7 -0.02 -0.14 -0.19
Q8N5M9 Protein jagunal homolog 1 1 7 0.14 0.04 -0.07
O15037 Protein KHNYN 1 1 0.11 0.13 0.01
P17252 Protein kinase C alpha type 4 31 0.30 -0.95 -1.24 5 5
Q9BY11 Protein kinase C and casein kinase substrate in neurons protein 1 2 3 -0.11 0.30 0.47
Q9UNF0 Protein kinase C and casein kinase substrate in neurons protein 2 7 22 -0.06 -0.05 0.03
P05771 Protein kinase C beta type 10 46 -0.05 -0.01 -0.06
Q05655 Protein kinase C delta type 8 23 -0.10 0.37 0.43
P24723 Protein kinase C eta type 8 42 -0.57 0.01 0.39
Q04759 Protein kinase C theta type 2 3 -0.01 -0.04 -0.04
Q9ULU4 Protein kinase C-binding protein 1 3 5 -0.03 0.02 0.08
Q92832 Protein kinase C-binding protein NELL1 1 1 -0.24 0.00 0.23
Q8N9T8 Protein KRI1 homolog 6 19 0.11 -0.12 -0.24
Q96EK9 Protein KTI12 homolog 2 4 -0.27 -0.06 0.19
Q96RT1 Protein LAP2 9 23 -0.27 0.09 0.49
Q53QV2 Protein LBH 4 7 -0.59 0.40 0.99
Q96GY3 Protein lin-37 homolog 1 4 -0.07 -0.19 -0.12
Q6MZP7 Protein lin-54 homolog 4 6 -0.47 -0.06 0.47
Q9NUP9 Protein lin-7 homolog C 3 13 0.09 -0.06 -0.15
Q3MHD2 Protein LSM12 homolog 1 3 -0.11 -0.16 -0.07
Q8ND56 Protein LSM14 homolog A 2 28 -0.26 -0.26 0.01
Q9BX40 Protein LSM14 homolog B 1 29 -0.25 0.09 0.35
Q96GA3 Protein LTV1 homolog 2 3 -0.30 -0.22 0.07
Q9C0E8 Protein lunapark 2 10 0.03 0.36 0.31
Q86UE4 Protein LYRIC 14 82 0.45 0.16 -0.16
Q8WZA0 Protein LZIC 4 8 -0.31 -0.09 0.36
P61326 Protein mago nashi homolog 6 17 0.01 -0.12 -0.13
Q9BXY0 Protein MAK16 homolog 2 2 -0.12 -0.35 -0.25
P61244 Protein max 5 17 -0.34 -0.62 -0.09 3
Q96FH0 Protein MEF2BNB 1 2 -0.60 0.32 0.93
Q9Y316 Protein MEMO1 2 6 0.01 0.24 0.23
Q9H081 Protein MIS12 homolog 1 1 -0.12 -0.66 -0.55
Q9Y2Z2 Protein MTO1 homolog, mitochondrial 1 1 1.18 0.47 -0.70
Q92597 Protein NDRG1 10 92 0.61 0.53 -0.06 5 4
Q9UN36 Protein NDRG2 2 5 0.36 -0.14 -0.50
Q9UGV2 Protein NDRG3 3 18 -0.12 -0.05 0.02
Q8NHV4 Protein NEDD1 4 7 0.03 -0.27 -0.26
Q9BZQ8 Protein Niban 9 37 0.92 1.36 0.53 4 4
Q9BPW8 Protein NipSnap homolog 1 7 55 0.29 -0.19 -0.42
O75323 Protein NipSnap homolog 2 4 27 0.02 -0.11 -0.07
Q7RTR2 Protein NLRC3 5 10 -0.09 0.07 0.23
Q14207 Protein NPAT 1 1 0.10 0.41 0.32
Q9H7Z3 Protein NRDE2 homolog 1 2 0.32 -0.40 -0.72
Q96AB6 Protein N-terminal asparagine amidohydrolase 2 6 -0.36 -0.19 0.16
P49757 Protein numb homolog 2 6 -0.04 0.12 0.13
Q8NBL1 Protein O-glucosyltransferase 1 1 2 -0.44 -0.36 0.08
Q86TB9 Protein PAT1 homolog 1 4 5 0.04 0.16 0.10
Q9BVG4 Protein PBDC1 6 22 0.05 -0.12 -0.20
Q9BRX2 Protein pelota homolog 2 2 0.19 0.01 -0.18
Q96T49 Protein phosphatase 1 regulatory inhibitor subunit 16B 2 2 -0.19 0.20 0.40
O14974 Protein phosphatase 1 regulatory subunit 12A 27 110 -0.28 0.08 0.41
O60237 Protein phosphatase 1 regulatory subunit 12B 1 2 0.16 -0.13 -0.29
Q9BZL4 Protein phosphatase 1 regulatory subunit 12C 15 41 -0.04 0.16 0.13
Q96A00 Protein phosphatase 1 regulatory subunit 14A 1 2 -0.18 -2.60 -2.42
Q96C90 Protein phosphatase 1 regulatory subunit 14B 1 2 0.12 0.56 0.45
Q6ZMI0 Protein phosphatase 1 regulatory subunit 21 10 24 -0.05 -0.21 -0.14
O95685 Protein phosphatase 1 regulatory subunit 3D 1 1 -1.30 0.03 1.35
Q9H7J1 Protein phosphatase 1 regulatory subunit 3E 3 3 -0.18 -0.41 -0.19
Q15435 Protein phosphatase 1 regulatory subunit 7 16 83 0.00 -0.13 0.04
P35813 Protein phosphatase 1A 9 42 -0.47 0.03 0.31
O75688 Protein phosphatase 1B 10 77 -0.01 -0.07 -0.05
P49593 Protein phosphatase 1F 5 23 -0.24 -0.25 0.04
O15355 Protein phosphatase 1G 19 86 -0.19 -0.11 0.08
Q8N3J5 Protein phosphatase 1K, mitochondrial 1 1 0.48 0.44 -0.03
P41236 Protein phosphatase inhibitor 2 11 101 -0.04 -0.49 -0.50 5
Q9Y570 Protein phosphatase methylesterase 1 6 16 -0.10 -0.15 -0.11
Q8NI37 Protein phosphatase PTC7 homolog 3 11 -0.14 -0.19 0.00
Q8WYL5 Protein phosphatase Slingshot homolog 1 1 2 0.21 -0.08 -0.28
Q76I76 Protein phosphatase Slingshot homolog 2 2 2 0.08 0.21 0.14
Q8TE77 Protein phosphatase Slingshot homolog 3 1 1 -0.51 -0.29 0.20
P29590 Protein PML 25 101 -0.37 -0.18 0.17
Q8WVV4 Protein POF1B 1 2 3.00 2.60 -0.39
Q86U86 Protein polybromo-1 15 29 -0.50 -0.15 0.32
Q96M27 Protein PRRC1 8 40 0.22 -0.01 -0.16
P48634 Protein PRRC2A 13 42 -0.04 -0.07 0.13
Q5JSZ5 Protein PRRC2B 4 4 -0.25 -0.03 0.10
Q9Y520 Protein PRRC2C 25 72 -0.10 -0.13 -0.02
Q86TP1 Protein prune homolog 2 3 -0.11 -0.49 -0.49
Q5XKP0 Protein QIL1 2 5 0.22 -0.06 -0.28
Q96PU8 Protein quaking 8 71 -0.43 0.17 0.61 5
Q9P258 Protein RCC2 16 71 -0.21 -0.36 -0.14 5
Q13123 Protein Red 12 73 -0.20 -0.26 -0.12
Q14690 Protein RRP5 homolog 17 53 0.49 -0.14 -0.67 5
Q9BY42 Protein RTF2 homolog 4 15 -0.03 -0.33 -0.25
Q7L099 Protein RUFY3 1 2 NA NA NA
P60903 Protein S100-A10 2 11 0.92 1.30 0.25 3 5
P31949 Protein S100-A11 6 107 0.62 0.77 0.64 5 3
P80511 Protein S100-A12 1 3 0.49 0.25 -0.13
Q9HCY8 Protein S100-A14 1 1 NA 5.01 NA
P26447 Protein S100-A4 8 305 1.06 1.43 0.42 4 5
P33763 Protein S100-A5 1 2 -0.34 -0.43 -0.08
P06703 Protein S100-A6 7 80 1.18 0.45 -0.54 4 4
P31151 Protein S100-A7 2 32 0.00 -0.09 -0.09
P05109 Protein S100-A8 6 81 0.73 0.00 -1.00 3 3
P06702 Protein S100-A9 8 100 0.34 0.14 -0.15
P04271 Protein S100-B 1 13 0.20 -0.92 -1.26 4 5
P25815 Protein S100-P 1 1 2.68 2.19 -0.48
Q96ER3 Protein SAAL1 1 1 -0.23 -0.05 0.19
Q99590 Protein SCAF11 13 23 -0.12 0.00 0.07
Q9UPN6 Protein SCAF8 4 7 -0.85 -0.35 0.49
O75880 Protein SCO1 homolog, mitochondrial 2 8 0.41 0.05 -0.33
O43819 Protein SCO2 homolog, mitochondrial 3 4 -0.01 -0.20 -0.19
Q14160 Protein scribble homolog 10 14 -0.17 0.23 0.41
Q9NVU7 Protein SDA1 homolog 5 6 0.28 0.06 -0.21
Q6IQ49 Protein SDE2 homolog 6 13 -0.14 -0.27 -0.12
P55735 Protein SEC13 homolog 4 15 -0.46 0.10 0.59
Q9UBV2 Protein sel-1 homolog 1 2 3 -0.18 0.22 0.40
Q01105 Protein SET 12 78 0.04 -0.10 -0.13
Q8ND04 Protein SMG8 3 10 -0.12 0.19 0.28
Q9H0W8 Protein SMG9 2 3 -0.20 -0.19 0.01
P18583 Protein SON 34 127 -0.18 -0.11 0.02
Q68D10 Protein SPT2 homolog 3 7 0.04 0.21 0.22
Q15532 Protein SSXT 2 4 0.05 0.12 0.07
A3KN83 Protein strawberry notch homolog 1 4 15 0.39 -0.07 -0.39
Q9Y2G9 Protein strawberry notch homolog 2 1 8 NA NA NA
Q9BRJ7 Protein syndesmos 1 2 0.11 0.16 0.04
Q5T011 Protein SZT2 1 2 NA NA NA
Q969Z0 Protein TBRG4 3 3 0.19 0.13 -0.07
Q92734 Protein TFG 6 19 0.18 0.35 0.22
Q8WUY1 Protein THEM6 2 4 0.35 0.29 -0.10
Q8N1K5 Protein THEMIS 11 24 0.97 -0.69 -1.65 5 4 5
Q5TEJ8 Protein THEMIS2 8 19 -0.22 0.29 0.52
O15027 Protein transport protein Sec16A 18 59 -0.13 0.12 0.20
Q15436 Protein transport protein Sec23A 8 54 0.12 0.29 0.25
Q15437 Protein transport protein Sec23B 2 10 0.23 0.65 0.54 4
O95486 Protein transport protein Sec24A 1 4 NA NA NA
O95487 Protein transport protein Sec24B 4 12 -0.04 0.06 -0.07
P53992 Protein transport protein Sec24C 15 76 0.21 0.53 0.31 5
O94855 Protein transport protein Sec24D 1 3 -0.14 0.61 0.75
O94979 Protein transport protein Sec31A 19 59 0.03 0.05 0.15
P61619 Protein transport protein Sec61 subunit alpha isoform 1 2 6 0.74 0.87 0.11 3
P60468 Protein transport protein Sec61 subunit beta 3 40 0.03 0.87 0.59 5 4
Q53HC9 Protein TSSC1 2 9 0.02 0.13 0.08
Q9Y5U2 Protein TSSC4 4 15 0.01 0.14 0.11
Q14761 Protein tyrosine phosphatase receptor type C-associated protein 4 14 0.77 0.33 -0.29 3
Q12974 Protein tyrosine phosphatase type IVA 2 1 1 NA NA NA
A6NIH7 Protein unc-119 homolog B 3 7 0.38 -0.03 -0.45
Q8NB66 Protein unc-13 homolog C 1 1 -3.23 -1.11 2.12
Q70J99 Protein unc-13 homolog D 11 46 0.09 0.24 0.28
Q9H3U1 Protein unc-45 homolog A 15 38 0.04 0.23 0.19
Q08AM6 Protein VAC14 homolog 3 16 0.14 0.19 -0.02
Q69YN4 Protein virilizer homolog 1 4 0.05 0.25 0.10
Q9Y4B6 Protein VPRBP 6 14 0.19 0.13 -0.05
O95785 Protein Wiz 6 20 -0.12 -0.17 0.06
O75695 Protein XRP2 2 5 -0.19 0.33 0.52
Q5BJH7 Protein YIF1B 1 1 -0.16 0.16 0.32
Q9GZM5 Protein YIPF3 1 1 -0.40 -0.31 0.10
Q969M3 Protein YIPF5 1 8 0.09 0.25 0.09
P62699 Protein yippee-like 5 2 5 -0.24 0.02 0.27
Q08188 Protein-glutamine gamma-glutamyltransferase E 1 1 0.79 0.77 -0.01
P22735 Protein-glutamine gamma-glutamyltransferase K 2 4 2.93 2.24 -0.68
P22061 Protein-L-isoaspartate(D-aspartate) O-methyltransferase 14 84 -0.11 -0.30 -0.38
Q8TDZ2 Protein-methionine sulfoxide oxidase MICAL1 9 17 -0.09 -0.12 -0.01
Q7RTP6 Protein-methionine sulfoxide oxidase MICAL3 2 5 -0.67 -0.14 0.54
Q14289 Protein-tyrosine kinase 2-beta 19 65 -0.46 0.17 0.54 4
O60704 Protein-tyrosine sulfotransferase 2 1 1 -0.53 -0.12 0.41
Q04941 Proteolipid protein 2 1 4 1.55 0.76 -0.86 4 3 4
P06454 Prothymosin alpha 7 211 0.11 -0.52 -0.67 3
Q04864 Proto-oncogene c-Rel 8 23 -0.89 0.16 1.23 5 5
P12931 Proto-oncogene tyrosine-protein kinase Src 2 12 -0.46 0.16 0.62
P15498 Proto-oncogene vav 10 23 -0.17 0.06 0.10
P50336 Protoporphyrinogen oxidase 4 6 -0.40 0.21 0.64
Q14242 P-selectin glycoprotein ligand 1 1 1 -0.55 -0.29 0.27
Q08623 Pseudouridine-5'-monophosphatase 5 21 0.45 -0.09 -0.52
Q96PZ0 Pseudouridylate synthase 7 homolog 3 3 0.28 0.01 -0.27
P61457 Pterin-4-alpha-carbinolamine dehydratase 1 1 0.54 1.13 0.61
Q9H0N5 Pterin-4-alpha-carbinolamine dehydratase 2 1 3 0.20 0.19 -0.03
Q15397 Pumilio domain-containing protein KIAA0020 2 5 0.26 -0.11 -0.68
Q14671 Pumilio homolog 1 3 16 -0.18 0.06 0.16
Q8TB72 Pumilio homolog 2 3 14 -0.14 -0.27 -0.13
P00491 Purine nucleoside phosphorylase 15 136 0.82 0.41 -0.26 4 4
P55786 Puromycin-sensitive aminopeptidase 24 94 0.11 -0.09 -0.29
O43865 Putative adenosylhomocysteinase 2 9 43 0.23 0.28 0.04
Q96HN2 Putative adenosylhomocysteinase 3 6 39 0.08 -0.11 -0.11
Q16740 Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial 4 11 -0.14 -0.01 0.15
Q7L2E3 Putative ATP-dependent RNA helicase DHX30 10 29 0.12 -0.22 -0.32
Q5T1J5 Putative coiled-coil-helix-coiled-coil-helix domain-containing protein CHCHD2P9, mitochondrial2 14 0.08 0.13 0.03
Q6ZU45 Putative C-type lectin domain-containing protein LINC00083 1 1 1.65 0.85 -0.80
Q6P1N9 Putative deoxyribonuclease TATDN1 4 10 0.29 0.06 -0.35
Q9Y315 Putative deoxyribose-phosphate aldolase 5 19 -0.27 -0.02 0.23
Q8N806 Putative E3 ubiquitin-protein ligase UBR7 3 6 -0.07 -0.13 0.03
A6NKF9 Putative Golgi pH regulator C 2 2 -0.13 0.19 0.32
Q9GZT8 Putative GTP cyclohydrolase 1 type 2 NIF3L1 7 15 0.23 -0.14 -0.44
O43824 Putative GTP-binding protein 6 3 8 0.10 -0.10 -0.28
Q58FF6 Putative heat shock protein HSP 90-beta 4 1 76 0.03 -0.39 -0.41
Q9HCE1 Putative helicase MOV-10 5 10 0.12 0.11 -0.04
O75884 Putative hydrolase RBBP9 2 3 0.21 0.28 0.08
Q5T013 Putative hydroxypyruvate isomerase 1 1 0.43 0.00 -0.45
A6NK58 Putative lipoyltransferase 2, mitochondrial 1 2 0.53 -0.63 -1.16
Q96P11 Putative methyltransferase NSUN5 6 10 0.01 -0.24 -0.29
Q96A73 Putative monooxygenase p33MONOX 4 7 0.09 -0.14 -0.14
Q9Y303 Putative N-acetylglucosamine-6-phosphate deacetylase 4 6 0.09 0.27 0.01
Q9BZK3 Putative nascent polypeptide-associated complex subunit alpha-like protein 1 28 0.26 -0.01 -0.34
A8MVU1 Putative neutrophil cytosol factor 1C 1 1 -0.42 -0.04 0.38
Q49A26 Putative oxidoreductase GLYR1 13 84 0.03 -0.09 -0.02
Q6GMV3 Putative peptidyl-tRNA hydrolase PTRHD1 3 6 -1.03 -0.51 0.53
Q8NHP8 Putative phospholipase B-like 2 5 10 0.25 0.68 0.34 4
O43143 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 30 188 0.01 -0.14 -0.04
O60231 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 7 30 -0.07 0.05 0.32
Q6P2P2 Putative protein arginine N-methyltransferase 10 2 2 -0.01 -0.22 -0.22
Q6ZMU1 Putative protein C3P1 1 1 NA NA NA
P58557 Putative ribonuclease 1 1 -0.55 -0.20 0.36
P46087 Putative ribosomal RNA methyltransferase NOP2 16 74 0.33 -0.23 -0.48
Q8N0V3 Putative ribosome-binding factor A, mitochondrial 1 1 0.01 -0.56 -0.59
Q8IXW5 Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2 3 5 0.05 0.22 0.13
Q96T37 Putative RNA-binding protein 15 15 62 -0.34 -0.26 0.05
Q8NDT2 Putative RNA-binding protein 15B 4 11 0.01 0.06 0.09
P98179 Putative RNA-binding protein 3 3 29 -0.02 -0.11 0.01
Q9NQ29 Putative RNA-binding protein Luc7-like 1 1 48 0.23 -0.13 -0.43
Q9Y383 Putative RNA-binding protein Luc7-like 2 11 164 -0.12 -0.20 -0.12
P0C7V7 Putative signal peptidase complex catalytic subunit SEC11B 1 2 -0.86 -0.29 0.57
Q9HBR0 Putative sodium-coupled neutral amino acid transporter 10 1 2 -0.51 -0.11 0.40
Q5T440 Putative transferase CAF17, mitochondrial 5 14 0.36 0.07 -0.31
A6NL28 Putative tropomyosin alpha-3 chain-like protein 4 82 -0.38 -0.15 0.26
I3L1I5 Putative uncharacterized protein LOC100996504 1 3 0.05 -0.73 -0.77
C4AMC7 Putative WAS protein family homolog 3 1 14 -0.12 -0.10 0.02
Q9BRQ0 Pygopus homolog 2 1 2 -0.36 -0.13 0.23
Q8WU10 Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 1 1 1 -0.01 0.14 0.15
O00764 Pyridoxal kinase 10 23 0.43 0.28 -0.42
Q96GD0 Pyridoxal phosphate phosphatase 4 18 -0.65 -0.18 0.52 4
Q6P996 Pyridoxal-dependent decarboxylase domain-containing protein 1 3 5 -0.53 0.25 0.69 3
Q9NVS9 Pyridoxine-5'-phosphate oxidase 2 2 0.82 0.55 -0.26
Q6K0P9 Pyrin and HIN domain-containing protein 1 13 85 -0.16 0.70 0.95 5 5
Q96C36 Pyrroline-5-carboxylate reductase 2 4 7 0.25 -0.29 -0.53
Q53H96 Pyrroline-5-carboxylate reductase 3 4 7 0.07 0.06 0.01
P08559 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 12 63 0.35 0.03 -0.33
P11177 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 13 134 0.30 -0.01 -0.29
Q8NCN5 Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial 7 15 0.26 0.22 -0.14
O00330 Pyruvate dehydrogenase protein X component, mitochondrial 11 30 0.03 -0.12 -0.01
P14618 Pyruvate kinase PKM 41 624 0.57 -0.10 -0.65 5 5
Q9BXR0 Queuine tRNA-ribosyltransferase 2 4 NA NA NA
Q08257 Quinone oxidoreductase 17 78 -0.03 -0.07 -0.02
O95825 Quinone oxidoreductase-like protein 1 1 6 -0.01 -0.26 -0.20
Q9Y3T6 R3H and coiled-coil domain-containing protein 1 1 1 0.29 0.00 -0.30
Q15032 R3H domain-containing protein 1 2 4 -0.75 -0.58 0.25 3 4
Q9Y2K5 R3H domain-containing protein 2 2 2 -0.81 -0.19 0.63
P31150 Rab GDP dissociation inhibitor alpha 16 118 0.60 0.65 -0.22 5 5
P50395 Rab GDP dissociation inhibitor beta 12 168 0.21 0.33 0.03
Q9Y3P9 Rab GTPase-activating protein 1 6 13 0.24 0.15 0.00
Q5R372 Rab GTPase-activating protein 1-like 5 17 -0.18 0.26 0.35
Q15276 Rab GTPase-binding effector protein 1 13 24 -0.03 0.01 -0.07
Q9H5N1 Rab GTPase-binding effector protein 2 11 31 -0.52 0.00 0.48 5
Q6WKZ4 Rab11 family-interacting protein 1 7 12 -0.69 0.52 1.08 4
Q6BDI9 Rab15 effector protein 1 1 -1.05 0.79 1.85
Q15042 Rab3 GTPase-activating protein catalytic subunit 5 9 0.25 -0.37 -0.63 4
Q9H2M9 Rab3 GTPase-activating protein non-catalytic subunit 6 25 0.13 -0.19 -0.40
Q9UJ41 Rab5 GDP/GTP exchange factor 2 2 -0.23 0.02 0.25
Q7Z6M1 Rab9 effector protein with kelch motifs 1 1 -0.26 -0.66 -0.42
Q9H1K0 Rabenosyn-5 1 1 0.14 0.20 0.06
Q9UBK7 Rab-like protein 2A 1 4 -0.12 -0.04 0.08
Q5HYI8 Rab-like protein 3 4 13 0.07 -0.08 -0.07
Q3YEC7 Rab-like protein 6 6 11 -0.10 0.21 0.25
P31749 RAC-alpha serine/threonine-protein kinase 4 16 -0.15 0.21 0.32
P31751 RAC-beta serine/threonine-protein kinase 2 10 -0.10 0.03 -0.14
Q9HA92 Radical S-adenosyl methionine domain-containing protein 1, mitochondrial 2 2 -0.15 -0.09 0.06
P35241 Radixin 5 404 -0.02 0.40 0.63 3
P04049 RAF proto-oncogene serine/threonine-protein kinase 2 7 0.00 0.30 0.30
Q14699 Raftlin 7 28 -0.46 0.11 0.72 3
Q6IAA8 Ragulator complex protein LAMTOR1 6 22 -0.12 -0.04 0.09
Q9Y2Q5 Ragulator complex protein LAMTOR2 2 8 -0.11 0.00 0.12
Q9UHA4 Ragulator complex protein LAMTOR3 1 5 0.25 0.45 0.21
O43504 Ragulator complex protein LAMTOR5 1 11 -0.44 -0.33 0.25 5
Q6GYQ0 Ral GTPase-activating protein subunit alpha-1 2 5 -0.57 -0.05 0.52
Q2PPJ7 Ral GTPase-activating protein subunit alpha-2 2 11 0.09 0.34 0.24
Q86X10 Ral GTPase-activating protein subunit beta 2 8 0.20 0.30 0.10
Q15311 RalA-binding protein 1 5 8 0.03 0.20 -0.08
Q96D71 RalBP1-associated Eps domain-containing protein 1 10 26 -0.03 -0.15 0.06
P46060 Ran GTPase-activating protein 1 20 90 0.00 0.16 0.04
Q9HD47 Ran guanine nucleotide release factor 1 1 0.39 0.04 -0.34
Q6VN20 Ran-binding protein 10 2 4 -0.44 -0.15 0.30
Q9H6Z4 Ran-binding protein 3 8 37 -0.05 -0.19 -0.15
Q96S59 Ran-binding protein 9 3 4 0.16 0.43 0.28
Q9BYM8 RanBP-type and C3HC4-type zinc finger-containing protein 1 7 21 0.01 0.05 0.04
P43487 Ran-specific GTPase-activating protein 6 34 -0.02 -0.08 -0.23
Q13905 Rap guanine nucleotide exchange factor 1 7 15 -0.06 0.05 0.46
Q8TEU7 Rap guanine nucleotide exchange factor 6 8 20 0.09 -0.20 -0.26
Q684P5 Rap1 GTPase-activating protein 2 15 40 -1.14 0.35 1.40 4 4
P52306 Rap1 GTPase-GDP dissociation stimulator 1 8 22 0.02 0.24 0.27
Q6R327 Rapamycin-insensitive companion of mTOR 2 2 -0.18 0.24 0.41
Q8TB24 Ras and Rab interactor 3 6 15 -0.88 -0.54 0.26 4
Q9NS23 Ras association domain-containing protein 1 2 3 -0.50 0.49 0.99
P50749 Ras association domain-containing protein 2 10 50 0.86 0.31 -0.85 5 3
Q9H2L5 Ras association domain-containing protein 4 1 10 -1.63 -0.13 1.51 4 4
Q8WWW0 Ras association domain-containing protein 5 5 15 -0.28 -0.09 0.49
P20936 Ras GTPase-activating protein 1 1 2 0.31 0.02 -0.28
Q15283 Ras GTPase-activating protein 2 2 80 0.13 -0.27 -0.26
Q14644 Ras GTPase-activating protein 3 16 37 -0.14 -0.24 0.08
Q13283 Ras GTPase-activating protein-binding protein 1 10 59 0.02 0.09 0.19
Q9UN86 Ras GTPase-activating protein-binding protein 2 3 9 0.38 0.21 -0.74
P46940 Ras GTPase-activating-like protein IQGAP1 75 675 -0.31 0.51 0.85 4 3
Q13576 Ras GTPase-activating-like protein IQGAP2 38 192 -0.30 0.41 0.68 3
O95267 RAS guanyl-releasing protein 1 1 1 0.59 0.56 -0.02
Q7LDG7 RAS guanyl-releasing protein 2 6 26 -0.19 -0.24 0.09
Q86YV0 RAS protein activator like-3 33 200 0.05 0.19 0.29
Q15404 Ras suppressor protein 1 8 38 0.03 0.27 0.25
P63000 Ras-related C3 botulinum toxin substrate 1 5 64 0.31 0.38 -0.30
P15153 Ras-related C3 botulinum toxin substrate 2 7 213 0.05 -0.29 -0.22
Q7L523 Ras-related GTP-binding protein A 1 3 -0.20 0.11 0.24
Q9HB90 Ras-related GTP-binding protein C 4 5 0.33 0.29 -0.03
P61026 Ras-related protein Rab-10 5 79 0.23 0.25 -0.04
Q15907 Ras-related protein Rab-11B 10 82 -0.12 0.11 0.19
P61106 Ras-related protein Rab-14 10 66 -0.05 0.22 0.10
Q9NP72 Ras-related protein Rab-18 6 18 0.73 0.63 0.17 5 5
P62820 Ras-related protein Rab-1A 6 138 0.14 0.13 0.05
Q9H0U4 Ras-related protein Rab-1B 7 172 -0.17 0.07 0.36
Q9UL25 Ras-related protein Rab-21 4 20 0.00 0.19 0.23
Q9UL26 Ras-related protein Rab-22A 2 3 0.24 0.41 0.16
Q969Q5 Ras-related protein Rab-24 1 2 -0.36 -0.17 0.20
P51159 Ras-related protein Rab-27A 2 10 0.09 0.83 0.77 4 3
O00194 Ras-related protein Rab-27B 1 1 -0.12 -0.09 0.03
P51157 Ras-related protein Rab-28 2 2 0.23 -0.03 -0.26
P61019 Ras-related protein Rab-2A 2 19 0.12 0.33 0.21
Q8WUD1 Ras-related protein Rab-2B 1 14 -0.36 0.06 0.42
Q9H082 Ras-related protein Rab-33B 1 11 0.45 0.55 0.11
Q15286 Ras-related protein Rab-35 3 73 0.21 0.42 0.20
Q96AX2 Ras-related protein Rab-37 3 10 -0.57 0.00 0.63
Q96DA2 Ras-related protein Rab-39B 2 10 0.11 -0.02 -0.15
O95716 Ras-related protein Rab-3D 1 15 0.32 0.60 0.29
Q96S21 Ras-related protein Rab-40C 1 8 1.24 0.96 -0.28
Q86YS6 Ras-related protein Rab-43 1 6 0.06 -0.50 -0.55
P61018 Ras-related protein Rab-4B 3 17 -0.43 0.13 0.61
P20339 Ras-related protein Rab-5A 4 29 0.02 0.40 0.29
P61020 Ras-related protein Rab-5B 5 84 -0.08 0.06 0.27
P51148 Ras-related protein Rab-5C 8 81 -0.20 0.17 0.36
P20340 Ras-related protein Rab-6A 4 58 0.22 0.52 0.43 5
Q9NRW1 Ras-related protein Rab-6B 1 24 2.08 1.69 -0.39
Q9H0N0 Ras-related protein Rab-6C 1 2 0.12 0.42 0.30
P51149 Ras-related protein Rab-7a 13 103 0.11 0.11 0.04
O14966 Ras-related protein Rab-7L1 3 13 -0.23 0.59 0.97 5 4
P61006 Ras-related protein Rab-8A 5 130 -0.16 0.27 0.48
Q92930 Ras-related protein Rab-8B 6 177 -0.29 0.34 0.64 3
P51151 Ras-related protein Rab-9A 2 11 0.17 0.76 0.47 5
P11233 Ras-related protein Ral-A 3 16 0.34 -0.05 -0.44
P11234 Ras-related protein Ral-B 3 11 -0.28 0.06 0.34
P62834 Ras-related protein Rap-1A 1 107 0.35 0.04 -0.06
P61224 Ras-related protein Rap-1b 2 128 -0.44 -0.03 0.41
P61225 Ras-related protein Rap-2b 7 32 -0.33 0.33 0.50
P62070 Ras-related protein R-Ras2 5 41 0.17 0.71 0.62 5 4
Q00765 Receptor expression-enhancing protein 5 6 26 0.48 0.78 0.13 5 5
O00559 Receptor-binding cancer antigen expressed on SiSo cells 1 1 0.18 -0.26 -0.46
Q13546 Receptor-interacting serine/threonine-protein kinase 1 6 16 -0.10 0.05 0.25
O43353 Receptor-interacting serine/threonine-protein kinase 2 1 1 -0.60 -0.30 0.31
Q9Y572 Receptor-interacting serine/threonine-protein kinase 3 1 3 -0.78 -0.36 0.40
P18433 Receptor-type tyrosine-protein phosphatase alpha 1 13 -0.49 0.63 1.13
P08575 Receptor-type tyrosine-protein phosphatase C 38 379 0.21 0.40 0.26
P23469 Receptor-type tyrosine-protein phosphatase epsilon 1 3 -0.23 0.19 0.43
Q12913 Receptor-type tyrosine-protein phosphatase eta 9 19 -0.25 0.33 0.72 5
Q06330 Recombining binding protein suppressor of hairless 6 8 0.23 0.24 -0.13
Q15493 Regucalcin 1 3 1.94 2.23 0.30
Q96P16 Regulation of nuclear pre-mRNA domain-containing protein 1A 1 7 0.07 0.13 0.13
Q9NQG5 Regulation of nuclear pre-mRNA domain-containing protein 1B 8 46 -0.19 -0.15 -0.13
Q5VT52 Regulation of nuclear pre-mRNA domain-containing protein 2 14 36 -0.05 -0.10 -0.08
Q9H4X1 Regulator of cell cycle RGCC 1 3 -2.62 -1.53 1.10
P18754 Regulator of chromosome condensation 11 65 0.12 0.18 -0.02
O43665 Regulator of G-protein signaling 10 11 108 0.39 -1.42 -1.68 5 5
O43566 Regulator of G-protein signaling 14 10 42 0.34 0.17 -0.11
Q9NS28 Regulator of G-protein signaling 18 1 1 0.30 0.27 -0.05
P49795 Regulator of G-protein signaling 19 3 9 0.59 1.06 0.44 3
P49796 Regulator of G-protein signaling 3 11 59 -0.90 0.41 1.30 5 5
Q96DB5 Regulator of microtubule dynamics protein 1 6 30 -0.03 0.14 0.13
Q96TC7 Regulator of microtubule dynamics protein 3 2 15 -0.77 0.44 1.21 4 5
Q92900 Regulator of nonsense transcripts 1 27 116 0.09 0.09 0.03
Q9HAU5 Regulator of nonsense transcripts 2 7 30 0.00 -0.16 -0.12
Q9H1J1 Regulator of nonsense transcripts 3A 3 4 -0.10 -0.57 -0.52
Q9BZI7 Regulator of nonsense transcripts 3B 4 6 0.23 0.06 -0.04
O00287 Regulatory factor X-associated protein 1 1 -1.49 -0.56 0.95
Q8N122 Regulatory-associated protein of mTOR 1 1 0.13 0.05 -0.10
Q96T23 Remodeling and spacing factor 1 10 17 -0.03 0.05 0.02
P35251 Replication factor C subunit 1 11 30 0.04 -0.08 -0.18
P35250 Replication factor C subunit 2 3 9 -0.05 -0.06 0.00
P40938 Replication factor C subunit 3 3 11 -0.08 -0.18 -0.05
P35249 Replication factor C subunit 4 14 28 -0.10 -0.19 -0.06
P40937 Replication factor C subunit 5 1 2 0.49 0.21 -0.27
Q9BWE0 Replication initiator 1 1 4 -1.18 -0.33 1.12
P35244 Replication protein A 14 kDa subunit 3 19 -0.06 -0.11 -0.16
P15927 Replication protein A 32 kDa subunit 8 59 0.20 -0.06 -0.13
P27694 Replication protein A 70 kDa DNA-binding subunit 25 189 -0.12 -0.11 -0.09
Q9H063 Repressor of RNA polymerase III transcription MAF1 homolog 1 1 -0.18 0.01 0.20
Q9UKL0 REST corepressor 1 2 2 0.00 -0.04 -0.04
Q9P2K3 REST corepressor 3 1 2 -1.47 -0.65 0.83
Q15293 Reticulocalbin-1 1 1 -0.09 0.67 0.74
Q14257 Reticulocalbin-2 5 8 0.25 -0.22 -0.39
Q96D15 Reticulocalbin-3 1 1 0.24 0.43 0.19
Q9NQC3 Reticulon-4 3 20 -0.40 -0.29 0.46
Q8WWV3 Reticulon-4-interacting protein 1, mitochondrial 2 5 -0.05 -0.29 -0.23
O43924 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta 1 2 0.04 0.26 0.21
Q15291 Retinoblastoma-binding protein 5 10 28 -0.04 -0.07 -0.11
Q08999 Retinoblastoma-like protein 2 4 7 -0.42 -0.34 0.09
P28702 Retinoic acid receptor RXR-beta 2 4 0.23 -0.06 -0.20
Q7Z5J4 Retinoic acid-induced protein 1 2 3 -0.25 -0.15 0.08
Q9HB40 Retinoid-inducible serine carboxypeptidase 3 9 -0.33 -0.14 0.13
Q8TC12 Retinol dehydrogenase 11 3 12 0.04 0.13 0.22
Q8NBN7 Retinol dehydrogenase 13 10 31 -0.07 0.02 -0.07
Q9HBH5 Retinol dehydrogenase 14 7 21 -0.12 0.00 0.11
O95980 Reversion-inducing cysteine-rich protein with Kazal motifs 1 1 -0.02 -0.03 -0.01
P52565 Rho GDP-dissociation inhibitor 1 11 135 0.29 0.22 -0.07
P52566 Rho GDP-dissociation inhibitor 2 15 228 0.13 -0.33 -0.50 4
Q07960 Rho GTPase-activating protein 1 10 36 -0.25 0.32 0.72 3
Q53QZ3 Rho GTPase-activating protein 15 9 31 -0.08 -0.46 -0.42 5
Q68EM7 Rho GTPase-activating protein 17 11 30 -0.32 -0.19 0.19
Q8N392 Rho GTPase-activating protein 18 4 5 -0.38 0.18 0.64
P42331 Rho GTPase-activating protein 25 27 172 -0.01 0.32 0.37
Q9UNA1 Rho GTPase-activating protein 26 2 5 -0.09 0.22 0.44
Q6ZUM4 Rho GTPase-activating protein 27 5 10 -0.63 0.08 0.72
Q7Z6I6 Rho GTPase-activating protein 30 12 43 -0.45 -0.05 0.47
Q9NRY4 Rho GTPase-activating protein 35 1 1 -0.03 0.27 0.31
P98171 Rho GTPase-activating protein 4 22 86 0.06 -0.09 -0.09
Q9BRR9 Rho GTPase-activating protein 9 10 33 -0.34 -0.18 0.15
Q92888 Rho guanine nucleotide exchange factor 1 31 266 -0.17 -0.06 0.11
Q9HCE6 Rho guanine nucleotide exchange factor 10-like protein 1 1 0.04 0.40 0.36
Q6ZSZ5 Rho guanine nucleotide exchange factor 18 17 42 0.22 -0.26 -0.48 5
Q92974 Rho guanine nucleotide exchange factor 2 16 63 -0.27 -0.15 0.30
Q15052 Rho guanine nucleotide exchange factor 6 10 44 0.12 0.04 0.02
Q14155 Rho guanine nucleotide exchange factor 7 6 28 0.34 0.55 0.13
Q13464 Rho-associated protein kinase 1 23 87 -0.18 -0.03 0.21
O75116 Rho-associated protein kinase 2 4 46 -0.22 0.16 0.49
Q8TEB9 Rhomboid-related protein 4 1 1 0.02 0.30 0.26
P08134 Rho-related GTP-binding protein RhoC 1 71 -0.77 1.32 2.07 3
Q9HBH0 Rho-related GTP-binding protein RhoF 3 8 0.12 0.36 0.35
P84095 Rho-related GTP-binding protein RhoG 8 72 0.00 0.06 0.18
Q15669 Rho-related GTP-binding protein RhoH 3 5 -0.10 -0.47 -0.35
Q9H477 Ribokinase 1 3 0.37 -0.15 -0.21
O75792 Ribonuclease H2 subunit A 6 13 0.03 -0.23 -0.28
Q5TBB1 Ribonuclease H2 subunit B 4 10 -0.40 -0.34 -0.03
Q8TDP1 Ribonuclease H2 subunit C 3 11 -0.14 -0.07 -0.05
P13489 Ribonuclease inhibitor 13 95 0.20 0.04 -0.23
O95059 Ribonuclease P protein subunit p14 1 3 NA NA NA
O75817 Ribonuclease P protein subunit p20 1 3 -0.03 -0.18 -0.14
Q9BUL9 Ribonuclease P protein subunit p25 2 10 0.13 -0.30 -0.32
Q8N5L8 Ribonuclease P protein subunit p25-like protein 1 1 -0.43 -0.05 0.40
O95707 Ribonuclease P protein subunit p29 2 3 0.72 0.40 -0.31
P78346 Ribonuclease P protein subunit p30 3 4 0.36 -0.04 -0.26
P78345 Ribonuclease P protein subunit p38 1 3 0.19 0.03 -0.16
O75818 Ribonuclease P protein subunit p40 1 2 NA NA NA
O00584 Ribonuclease T2 4 39 0.68 0.25 -0.27 5
P52758 Ribonuclease UK114 4 9 0.02 -0.22 -0.24
Q5D1E8 Ribonuclease ZC3H12A 1 1 0.05 -0.13 -0.17
Q99575 Ribonucleases P/MRP protein subunit POP1 5 17 -0.08 -0.18 -0.13
Q8IY67 Ribonucleoprotein PTB-binding 1 7 36 -0.05 -0.02 -0.06
Q9HCJ3 Ribonucleoprotein PTB-binding 2 1 1 0.70 0.87 0.19
P23921 Ribonucleoside-diphosphate reductase large subunit 1 1 0.50 0.31 -0.18
Q7LG56 Ribonucleoside-diphosphate reductase subunit M2 B 1 1 0.03 0.17 0.15
P49247 Ribose-5-phosphate isomerase 9 41 0.00 -0.65 -0.73 4 5
P60891 Ribose-phosphate pyrophosphokinase 1 5 77 0.37 0.01 -0.47
P11908 Ribose-phosphate pyrophosphokinase 2 5 58 0.00 -0.35 -0.20
Q9Y4W2 Ribosomal biogenesis protein LAS1L 4 7 0.05 -0.14 -0.18
O76021 Ribosomal L1 domain-containing protein 1 17 102 0.51 -0.03 -0.47 5 5
Q9BQC6 Ribosomal protein 63, mitochondrial 2 9 0.14 -0.08 -0.06
Q15418 Ribosomal protein S6 kinase alpha-1 7 51 -0.29 0.04 0.40
P51812 Ribosomal protein S6 kinase alpha-3 21 186 0.72 0.44 -0.19 5 5
O75676 Ribosomal protein S6 kinase alpha-4 4 10 0.01 0.29 0.25
O75582 Ribosomal protein S6 kinase alpha-5 5 6 0.10 0.22 0.25
P23443 Ribosomal protein S6 kinase beta-1 2 3 0.04 -0.06 -0.08
Q9UBS0 Ribosomal protein S6 kinase beta-2 1 4 -0.22 0.05 0.26
Q9Y6S9 Ribosomal protein S6 kinase-like 1 1 1 -0.48 -0.42 0.07
P56182 Ribosomal RNA processing protein 1 homolog A 7 21 0.46 -0.16 -0.73 3
Q14684 Ribosomal RNA processing protein 1 homolog B 16 42 0.22 -0.27 -0.49 4
Q96EU6 Ribosomal RNA processing protein 36 homolog 3 3 0.15 -0.15 -0.31
Q92979 Ribosomal RNA small subunit methyltransferase NEP1 4 14 0.25 -0.23 -0.54 5
Q9Y3A4 Ribosomal RNA-processing protein 7 homolog A 2 4 0.45 -0.11 -0.56
O43159 Ribosomal RNA-processing protein 8 5 8 -0.07 0.02 0.12
O43709 Ribosome biogenesis methyltransferase WBSCR22 3 9 -0.08 -0.29 -0.15
Q14692 Ribosome biogenesis protein BMS1 homolog 9 22 0.19 -0.04 -0.20
Q14137 Ribosome biogenesis protein BOP1 7 16 0.19 0.04 -0.15
Q8TDN6 Ribosome biogenesis protein BRX1 homolog 2 13 0.53 -0.14 -0.67 5
O95478 Ribosome biogenesis protein NSA2 homolog 1 1 0.59 -0.21 -0.82
Q9GZL7 Ribosome biogenesis protein WDR12 5 10 0.20 -0.05 -0.28
Q15050 Ribosome biogenesis regulatory protein homolog 7 25 0.61 0.18 -0.54 4
Q9Y3A5 Ribosome maturation protein SBDS 7 25 0.39 -0.24 -0.63 3
Q9H9Y2 Ribosome production factor 1 2 2 0.34 -0.05 -0.38
Q9H7B2 Ribosome production factor 2 homolog 1 6 1.30 0.50 -0.82
Q9P2E9 Ribosome-binding protein 1 44 130 -0.43 0.36 0.86 5
Q96E11 Ribosome-recycling factor, mitochondrial 4 6 0.19 -0.21 -0.10
Q969S9 Ribosome-releasing factor 2, mitochondrial 2 5 0.66 0.33 -0.33
P16083 Ribosyldihydronicotinamide dehydrogenase 5 9 -0.09 0.04 0.23
Q96AT9 Ribulose-phosphate 3-epimerase 3 10 -0.51 -0.16 0.44
Q96PM5 RING finger and CHY zinc finger domain-containing protein 1 1 2 NA NA NA
O15541 RING finger protein 113A 4 11 0.01 -0.07 0.08
Q9Y508 RING finger protein 114 3 12 -0.16 -0.15 0.09
Q9BXT8 RING finger protein 17 1 1 0.51 1.23 0.70
Q8ND24 RING finger protein 214 4 6 0.09 -0.09 -0.03
Q5W0B1 RING finger protein 219 1 1 -0.11 -0.16 -0.06
Q9C0B0 RING finger protein unkempt homolog 4 13 0.06 -0.07 -0.10
Q8N488 RING1 and YY1-binding protein 1 5 -0.29 -0.09 0.24
O00442 RNA 3'-terminal phosphate cyclase 5 40 0.14 0.05 -0.11
Q9Y2P8 RNA 3'-terminal phosphate cyclase-like protein 2 3 0.58 -0.21 -0.62
Q96E39 RNA binding motif protein, X-linked-like-1 4 261 -0.01 -0.36 0.05
Q6P6C2 RNA demethylase ALKBH5 8 22 -0.11 -0.25 -0.25
Q9GZR2 RNA exonuclease 4 1 1 0.35 -0.46 -0.80
Q9HC36 RNA methyltransferase-like protein 1 1 1 0.41 -0.03 -0.44
P55199 RNA polymerase II elongation factor ELL 4 13 0.25 0.83 0.72
Q9Y5B0 RNA polymerase II subunit A C-terminal domain phosphatase 8 15 -0.14 -0.11 -0.22
Q9NP77 RNA polymerase II subunit A C-terminal domain phosphatase SSU72 3 4 0.07 -0.26 -0.33
Q8N7H5 RNA polymerase II-associated factor 1 homolog 7 17 0.04 0.01 -0.05
Q9BWH6 RNA polymerase II-associated protein 1 3 3 -0.25 -0.01 0.23
Q9H6T3 RNA polymerase II-associated protein 3 7 24 -0.02 -0.27 -0.31
Q6PD62 RNA polymerase-associated protein CTR9 homolog 7 16 -0.07 0.08 0.08
Q8WVC0 RNA polymerase-associated protein LEO1 1 1 -0.16 0.32 0.46
Q92541 RNA polymerase-associated protein RTF1 homolog 11 23 -0.10 -0.03 0.05
Q8IZ73 RNA pseudouridylate synthase domain-containing protein 2 1 1 -0.16 -0.39 -0.23
P38159 RNA-binding motif protein, X chromosome 9 362 -0.48 -0.45 0.23 5
Q9Y388 RNA-binding motif protein, X-linked 2 1 1 -0.13 -0.20 -0.08
P29558 RNA-binding motif, single-stranded-interacting protein 1 3 4 -0.20 0.47 0.70
P98175 RNA-binding protein 10 18 50 -0.17 -0.11 0.07
Q9NTZ6 RNA-binding protein 12 12 50 0.01 -0.08 -0.05
Q8IXT5 RNA-binding protein 12B 3 4 -0.02 0.00 0.02
Q96PK6 RNA-binding protein 14 19 184 -0.22 -0.17 0.02
P49756 RNA-binding protein 25 15 63 -0.11 -0.25 -0.04
Q5T8P6 RNA-binding protein 26 14 48 -0.06 -0.27 -0.19
Q9P2N5 RNA-binding protein 27 6 28 -0.35 -0.15 0.21
Q9NW13 RNA-binding protein 28 11 26 0.25 0.05 -0.18
Q96EV2 RNA-binding protein 33 8 12 -0.35 -0.23 0.24
P42696 RNA-binding protein 34 11 30 0.04 -0.25 -0.13
Q9H0Z9 RNA-binding protein 38 3 6 -0.36 -0.08 0.27
Q14498 RNA-binding protein 39 17 145 -0.18 -0.13 0.09
Q9BWF3 RNA-binding protein 4 2 73 -0.22 -0.38 -0.06
Q9BTD8 RNA-binding protein 42 4 13 -0.01 -0.22 -0.12
Q8IUH3 RNA-binding protein 45 1 5 -0.33 -0.19 0.00
Q9BQ04 RNA-binding protein 4B 2 56 -0.19 0.05 0.31
P52756 RNA-binding protein 5 11 23 -0.07 -0.06 -0.01
P78332 RNA-binding protein 6 8 10 -0.05 -0.07 -0.05
Q9Y580 RNA-binding protein 7 3 13 -0.24 0.05 0.29
Q9Y5S9 RNA-binding protein 8A 5 73 -0.17 -0.13 0.01
Q01844 RNA-binding protein EWS 6 75 0.16 0.03 0.02
P35637 RNA-binding protein FUS 9 91 -0.12 -0.27 -0.06
Q96DH6 RNA-binding protein Musashi homolog 2 1 3 -0.14 -0.23 -0.09
Q9ULX3 RNA-binding protein NOB1 1 2 -0.03 -0.41 -0.37
Q9NRX1 RNA-binding protein PNO1 6 18 0.08 -0.26 -0.56
Q9UKM9 RNA-binding protein Raly 18 177 -0.44 -0.10 0.40 5
Q93062 RNA-binding protein with multiple splicing 1 2 NA NA NA
Q15287 RNA-binding protein with serine-rich domain 1 6 39 -0.14 -0.11 0.05
Q5TZA2 Rootletin 16 49 0.14 -0.06 -0.06
Q5TC82 Roquin-1 1 1 -0.27 -0.14 0.13
Q5VWQ0 Round spermatid basic protein 1 4 8 0.25 -0.21 -0.20
Q6PCB5 Round spermatid basic protein 1-like protein 1 1 -0.04 -0.23 -0.20
P22087 rRNA 2'-O-methyltransferase fibrillarin 20 284 0.49 0.04 -0.64 5 5
Q6IN84 rRNA methyltransferase 1, mitochondrial 1 2 0.44 -0.24 -0.68
Q9Y324 rRNA-processing protein FCF1 homolog 1 1 0.24 -0.03 -0.27
Q9BRU9 rRNA-processing protein UTP23 homolog 2 3 0.32 -0.38 -0.71
Q5JTH9 RRP12-like protein 6 13 0.18 -0.22 -0.39
Q9Y3B9 RRP15-like protein 1 4 0.52 -0.08 -0.74 3
Q96T51 RUN and FYVE domain-containing protein 1 9 35 -0.42 -0.22 0.21
Q92622 Run domain Beclin-1 interacting and cysteine-rich containing protein 1 5 -0.62 0.17 0.78
Q01196 Runt-related transcription factor 1 5 17 0.10 0.18 0.01
Q13950 Runt-related transcription factor 2 3 15 0.70 0.79 -0.18
Q13761 Runt-related transcription factor 3 5 50 -0.54 0.03 0.50 5
Q9Y265 RuvB-like 1 24 211 0.10 -0.13 -0.20
Q9Y230 RuvB-like 2 22 193 0.13 -0.01 -0.17
Q92736 Ryanodine receptor 2 1 2 -0.17 0.17 0.33
Q8N5C6 S1 RNA-binding domain-containing protein 1 1 1 -1.11 -1.25 -0.12
Q96BU1 S100P-binding protein 1 2 -0.02 0.11 0.13
Q8NBX0 Saccharopine dehydrogenase-like oxidoreductase 4 19 0.05 -0.10 -0.15
Q00266 S-adenosylmethionine synthase isoform type-1 1 2 0.59 0.79 0.21
P31153 S-adenosylmethionine synthase isoform type-2 11 92 -0.02 0.06 0.00
Q9NWH9 SAFB-like transcription modulator 18 48 -0.10 -0.14 -0.07
O75995 SAM and SH3 domain-containing protein 3 10 67 -0.06 0.08 0.11
Q9NSI8 SAM domain-containing protein SAMSN-1 5 13 -0.13 0.06 0.12
P82979 SAP domain-containing ribonucleoprotein 11 84 -0.30 -0.14 0.19
Q9UHR5 SAP30-binding protein 5 28 -0.21 -0.24 0.20
P16615 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 12 61 -0.05 0.43 0.42
Q93084 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 18 169 0.15 0.30 0.08
Q9UL12 Sarcosine dehydrogenase, mitochondrial 1 1 0.47 0.81 0.35
Q15424 Scaffold attachment factor B1 11 114 -0.18 -0.22 -0.10
Q14151 Scaffold attachment factor B2 9 91 -0.03 -0.22 -0.41
Q7Z7L1 Schlafen family member 11 1 20 0.18 0.21 0.04
Q08AF3 Schlafen family member 5 17 181 -0.20 -0.04 0.00
Q6P3W7 SCY1-like protein 2 1 3 0.02 0.01 0.00
Q8WVM8 Sec1 family domain-containing protein 1 14 51 0.09 0.05 -0.01
O76054 SEC14-like protein 2 2 2 0.10 -1.18 -1.29
Q9Y6Y8 SEC23-interacting protein 5 10 -0.07 0.07 0.02
Q12765 Secernin-1 9 53 0.94 1.07 0.10 5 5
Q96FV2 Secernin-2 2 4 -0.39 -0.10 0.41
P55000 Secreted Ly-6/uPAR-related protein 1 1 1 -0.34 -2.12 -1.80
O15126 Secretory carrier-associated membrane protein 1 4 7 -0.17 0.19 0.37
O15127 Secretory carrier-associated membrane protein 2 3 17 -0.47 0.12 0.51
O14828 Secretory carrier-associated membrane protein 3 4 27 -0.18 -0.26 -0.05
Q9UHJ6 Sedoheptulokinase 6 14 -0.10 -0.10 0.02
O14641 Segment polarity protein dishevelled homolog DVL-2 1 7 0.02 0.02 0.01
Q92997 Segment polarity protein dishevelled homolog DVL-3 1 7 0.20 0.38 0.18
P49903 Selenide, water dikinase 1 8 41 0.10 -0.28 -0.39
Q99611 Selenide, water dikinase 2 1 2 -0.12 -0.10 0.01
Q93073 Selenocysteine insertion sequence-binding protein 2-like 1 1 0.31 0.12 -0.19
Q96I15 Selenocysteine lyase 9 56 0.02 -0.10 -0.27
P57772 Selenocysteine-specific elongation factor 8 42 0.00 -0.15 -0.24
Q8IZQ5 Selenoprotein H 8 54 0.11 -0.64 -0.62 5 4
Q9BVL4 Selenoprotein O 1 1 -0.08 0.02 0.10
Q9BQE4 Selenoprotein S 2 3 0.01 0.32 0.26
P63302 Selenoprotein W 1 1 -0.28 -0.28 -0.02
Q92854 Semaphorin-4D 4 4 0.12 0.15 0.03
Q9P0U3 Sentrin-specific protease 1 2 2 -0.11 0.18 0.29
Q9H4L4 Sentrin-specific protease 3 4 8 -0.24 -0.15 0.02
Q9BQF6 Sentrin-specific protease 7 4 12 -0.10 -0.21 0.04
Q8WYJ6 Septin-1 17 154 -0.10 -0.20 -0.21
Q9NVA2 Septin-11 6 119 -0.45 -0.32 0.37
Q15019 Septin-2 18 226 -0.06 0.14 0.09
O43236 Septin-4 1 1 NA NA NA
Q14141 Septin-6 13 232 0.08 -0.13 -0.09
Q16181 Septin-7 22 220 -0.06 -0.10 0.08
Q9UHD8 Septin-9 31 294 -0.12 -0.14 -0.13
Q13501 Sequestosome-1 4 16 -0.21 0.22 0.51
P83111 Serine beta-lactamase-like protein LACTB, mitochondrial 7 17 0.15 0.28 -0.01
P34896 Serine hydroxymethyltransferase, cytosolic 2 6 0.02 0.14 0.13
P34897 Serine hydroxymethyltransferase, mitochondrial 15 61 -0.07 0.33 0.31
O15269 Serine palmitoyltransferase 1 2 4 -0.31 -0.13 0.19
O15270 Serine palmitoyltransferase 2 1 1 -0.55 0.31 0.86
P83110 Serine protease HTRA3 1 2 -0.18 0.02 0.20
Q8IYB3 Serine/arginine repetitive matrix protein 1 7 34 0.03 -0.29 -0.04
Q9UQ35 Serine/arginine repetitive matrix protein 2 30 233 -0.25 -0.03 0.17
Q96IZ7 Serine/Arginine-related protein 53 2 3 -0.06 -0.50 0.03
Q07955 Serine/arginine-rich splicing factor 1 15 265 -0.19 -0.18 -0.03
O75494 Serine/arginine-rich splicing factor 10 5 25 -0.47 -0.19 0.29
Q05519 Serine/arginine-rich splicing factor 11 6 72 -0.16 -0.15 -0.01
Q01130 Serine/arginine-rich splicing factor 2 6 168 -0.04 -0.09 -0.06
P84103 Serine/arginine-rich splicing factor 3 7 38 -0.05 -0.06 -0.24
Q08170 Serine/arginine-rich splicing factor 4 5 55 -0.31 -0.13 0.17
Q13243 Serine/arginine-rich splicing factor 5 5 43 -0.10 -0.21 -0.37
Q13247 Serine/arginine-rich splicing factor 6 3 53 -0.03 -0.32 -0.03
Q16629 Serine/arginine-rich splicing factor 7 7 70 -0.04 -0.11 0.05
Q9BRL6 Serine/arginine-rich splicing factor 8 1 43 0.08 -0.43 -0.45
Q13242 Serine/arginine-rich splicing factor 9 5 20 -0.50 -0.32 0.19
O94804 Serine/threonine-protein kinase 10 26 201 -0.46 0.25 0.73 5
Q8N1F8 Serine/threonine-protein kinase 11-interacting protein 2 5 0.03 0.15 0.29
O94768 Serine/threonine-protein kinase 17B 2 3 0.26 -0.25 -0.51
Q9Y6E0 Serine/threonine-protein kinase 24 8 67 0.53 0.28 -0.17
Q86UX6 Serine/threonine-protein kinase 32C 1 1 -0.33 -0.17 0.17
Q15208 Serine/threonine-protein kinase 38 7 25 -0.19 0.02 0.19
Q9Y2H1 Serine/threonine-protein kinase 38-like 1 4 NA NA NA
Q13043 Serine/threonine-protein kinase 4 25 185 0.00 -0.03 0.01
P10398 Serine/threonine-protein kinase A-Raf 4 22 -0.28 -0.03 0.09
Q9BZL6 Serine/threonine-protein kinase D2 5 48 -0.44 -0.14 0.18
Q8IWU2 Serine/threonine-protein kinase LMTK2 1 1 0.20 -0.29 -0.49
Q7KZI7 Serine/threonine-protein kinase MARK2 8 25 -0.17 -0.01 0.15
Q9P289 Serine/threonine-protein kinase MST4 8 106 -0.16 0.01 0.16
P42345 Serine/threonine-protein kinase mTOR 5 16 -0.13 -0.16 -0.09
Q16512 Serine/threonine-protein kinase N1 18 88 -0.32 0.02 0.40
Q96PY6 Serine/threonine-protein kinase Nek1 1 1 -0.01 -0.24 -0.22
Q6ZWH5 Serine/threonine-protein kinase Nek10 1 13 -0.21 -0.32 -0.16
P51957 Serine/threonine-protein kinase Nek4 1 1 NA NA NA
Q8TDX7 Serine/threonine-protein kinase Nek7 7 34 0.59 0.54 -0.15 5 5
Q8TD19 Serine/threonine-protein kinase Nek9 16 65 0.15 -0.20 -0.40
O95747 Serine/threonine-protein kinase OSR1 9 51 0.20 0.16 -0.06
Q13153 Serine/threonine-protein kinase PAK 1 4 44 -0.20 -0.70 -0.30 5
Q13177 Serine/threonine-protein kinase PAK 2 20 220 0.12 0.08 -0.07
Q13523 Serine/threonine-protein kinase PRP4 homolog 12 24 -0.18 -0.12 0.03
Q9Y2K2 Serine/threonine-protein kinase SIK3 2 4 0.30 0.24 0.03
Q96Q15 Serine/threonine-protein kinase SMG1 1 8 -0.13 0.21 0.34
Q9UL54 Serine/threonine-protein kinase TAO2 1 2 -0.10 -0.06 0.04
Q9H2K8 Serine/threonine-protein kinase TAO3 11 29 -0.32 0.03 0.39
Q9UHD2 Serine/threonine-protein kinase TBK1 6 26 0.12 0.66 0.29 5
Q9UKI8 Serine/threonine-protein kinase tousled-like 1 2 7 0.23 0.03 -0.20
Q86UE8 Serine/threonine-protein kinase tousled-like 2 2 7 -1.98 -0.90 1.09
O75385 Serine/threonine-protein kinase ULK1 1 1 -0.30 0.44 0.76
Q6PHR2 Serine/threonine-protein kinase ULK3 1 1 NA NA NA
Q99986 Serine/threonine-protein kinase VRK1 4 6 -0.07 -0.19 -0.25
Q9H4A3 Serine/threonine-protein kinase WNK1 11 27 0.11 -0.09 -0.17
O75460 Serine/threonine-protein kinase/endoribonuclease IRE1 1 1 0.90 1.65 0.73
Q96QC0 Serine/threonine-protein phosphatase 1 regulatory subunit 10 2 4 -0.16 -0.11 0.05
P63151 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform 12 29 -0.02 0.08 -0.03
Q15172 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform 3 7 -0.09 0.30 0.36
Q14738 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform 2 9 0.12 -0.04 0.16
Q16537 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform 2 7 -0.21 0.13 0.35
Q13362 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform 1 8 -0.02 0.04 0.07
P30153 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 16 169 0.02 0.10 0.13
P30154 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform 2 36 -0.11 -0.15 -0.05
Q15257 Serine/threonine-protein phosphatase 2A activator 6 15 -0.18 0.14 0.24
P67775 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform 6 12 -0.23 -0.03 0.14
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 5 35 -0.06 0.57 0.60 5 4
P16298 Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform 6 38 -0.17 -0.07 0.03
P48454 Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform 4 15 -0.17 -0.33 -0.21
P60510 Serine/threonine-protein phosphatase 4 catalytic subunit 1 3 -0.35 0.07 0.35
Q8TF05 Serine/threonine-protein phosphatase 4 regulatory subunit 1 4 5 0.24 0.42 0.19
Q9NY27 Serine/threonine-protein phosphatase 4 regulatory subunit 2 4 6 0.00 0.03 0.09
Q6IN85 Serine/threonine-protein phosphatase 4 regulatory subunit 3A 7 31 -0.18 -0.11 0.02
Q5MIZ7 Serine/threonine-protein phosphatase 4 regulatory subunit 3B 1 10 -0.67 -0.28 0.39
P53041 Serine/threonine-protein phosphatase 5 14 64 -0.25 0.00 0.20
O00743 Serine/threonine-protein phosphatase 6 catalytic subunit 4 15 -0.04 -0.09 -0.04
O15084 Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A 1 18 -0.07 0.04 0.11
Q8N8A2 Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B 22 104 0.08 0.07 -0.01
Q9UPN7 Serine/threonine-protein phosphatase 6 regulatory subunit 1 7 29 -0.01 0.03 0.24
O75170 Serine/threonine-protein phosphatase 6 regulatory subunit 2 8 21 -0.08 -0.04 0.22
Q5H9R7 Serine/threonine-protein phosphatase 6 regulatory subunit 3 1 1 0.40 0.42 0.00
Q96HS1 Serine/threonine-protein phosphatase PGAM5, mitochondrial 6 16 -0.14 0.09 0.16
P62136 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 4 55 -0.27 0.18 0.42
P62140 Serine/threonine-protein phosphatase PP1-beta catalytic subunit 1 51 0.20 0.23 0.03
P36873 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 1 31 -0.22 0.06 0.28
Q13315 Serine-protein kinase ATM 30 91 0.12 -0.19 -0.28
Q9H7U1 Serine-rich coiled-coil domain-containing protein 2 1 1 0.03 0.46 0.43
Q9Y3F4 Serine-threonine kinase receptor-associated protein 11 56 0.02 -0.01 -0.04
P49591 Serine--tRNA ligase, cytoplasmic 9 40 0.15 -0.17 -0.23
Q9NP81 Serine--tRNA ligase, mitochondrial 11 19 -0.01 -0.03 0.08
Q96C92 Serologically defined colon cancer antigen 3 1 1 -0.09 -0.26 -0.16
P48595 Serpin B10 1 4 0.14 -0.52 -0.68
Q96P63 Serpin B12 1 2 0.69 0.51 -0.17
P29508 Serpin B3 5 10 1.85 0.79 -0.91
P35237 Serpin B6 13 105 -0.57 -0.48 0.17
P50452 Serpin B8 5 81 0.18 -0.01 -0.29
P50453 Serpin B9 24 270 0.49 0.09 -0.62 4 3
P50454 Serpin H1 1 6 -0.21 0.06 0.26
Q9BXP5 Serrate RNA effector molecule homolog 19 102 0.00 -0.22 -0.22
P02768 Serum albumin 14 406 0.63 0.21 -0.16 5
O95810 Serum deprivation-response protein 6 17 -0.46 -0.49 0.09
Q15165 Serum paraoxonase/arylesterase 2 1 1 -0.73 0.20 0.93
P11831 Serum response factor 2 10 -0.09 -0.02 -0.07
Q8NEF9 Serum response factor-binding protein 1 2 4 0.23 -0.13 -0.31
Q6GMV2 SET and MYND domain-containing protein 5 1 1 0.60 -0.47 -1.07
Q9UBL3 Set1/Ash2 histone methyltransferase complex subunit ASH2 2 9 0.01 -0.11 -0.16
Q8N228 Sex comb on midleg-like protein 4 1 5 NA NA NA
P10768 S-formylglutathione hydrolase 8 63 0.42 -0.17 -0.67 5
O60880 SH2 domain-containing protein 1A 4 8 -0.24 0.43 0.37
Q9NP31 SH2 domain-containing protein 2A 6 17 -0.11 0.80 1.29 4 5
Q8N5H7 SH2 domain-containing protein 3C 2 8 -0.66 0.41 0.99 4 5 5
O75368 SH3 domain-binding glutamic acid-rich-like protein 11 105 -0.10 -0.26 0.01
Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3 5 146 -0.72 -0.31 0.45 3
Q9Y3L3 SH3 domain-binding protein 1 21 225 -0.16 -0.15 0.05
Q7L8J4 SH3 domain-binding protein 5-like 1 1 NA NA NA
Q96B97 SH3 domain-containing kinase-binding protein 1 30 216 0.00 -0.14 -0.08
Q8TBC3 SH3KBP1-binding protein 1 1 2 -0.11 0.27 0.36
Q9H0F6 Sharpin 4 7 0.20 0.11 0.06
P29353 SHC-transforming protein 1 3 7 0.16 0.33 0.15
P45954 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial 7 17 0.07 0.06 -0.05
Q8NEX9 Short-chain dehydrogenase/reductase family 9C member 7 2 2 2.48 1.68 -0.80
P16219 Short-chain specific acyl-CoA dehydrogenase, mitochondrial 11 84 -0.26 -0.12 0.03
Q9NR45 Sialic acid synthase 8 29 0.30 0.22 -0.11
Q9Y286 Sialic acid-binding Ig-like lectin 7 3 5 -0.57 0.70 1.04 3
Q9Y336 Sialic acid-binding Ig-like lectin 9 2 4 -0.49 0.31 0.68
Q9H9B4 Sideroflexin-1 12 86 0.42 -0.58 -0.93 4 5
Q9BWM7 Sideroflexin-3 6 40 0.11 0.50 0.45 5
Q15005 Signal peptidase complex subunit 2 5 27 0.15 0.50 0.27
P61009 Signal peptidase complex subunit 3 3 14 0.20 0.60 0.44 3
P37108 Signal recognition particle 14 kDa protein 12 129 -0.04 -0.50 -0.54 5 5
P09132 Signal recognition particle 19 kDa protein 3 12 0.07 -0.03 -0.28
P61011 Signal recognition particle 54 kDa protein 10 40 0.28 0.06 -0.23
P49458 Signal recognition particle 9 kDa protein 7 30 0.17 -0.21 -0.44
P08240 Signal recognition particle receptor subunit alpha 13 32 0.66 0.43 -0.22 3 5
Q9Y5M8 Signal recognition particle receptor subunit beta 4 23 0.60 0.34 -0.13 4
Q9UHB9 Signal recognition particle subunit SRP68 14 35 0.18 0.08 -0.21
O76094 Signal recognition particle subunit SRP72 16 40 0.36 0.12 -0.06
P42224 Signal transducer and activator of transcription 1-alpha/beta 28 148 0.20 -0.31 -0.50 4
P52630 Signal transducer and activator of transcription 2 4 16 -0.07 0.13 0.27
P40763 Signal transducer and activator of transcription 3 10 24 0.10 0.10 0.01
Q14765 Signal transducer and activator of transcription 4 7 23 0.04 0.72 0.40 5
P42229 Signal transducer and activator of transcription 5A 4 44 0.37 -0.13 -0.56
P51692 Signal transducer and activator of transcription 5B 3 46 0.83 0.39 -0.35 5
P42226 Signal transducer and activator of transcription 6 3 12 -0.03 -0.15 -0.15
Q92783 Signal transducing adapter molecule 1 3 5 -0.24 0.11 0.24
O75886 Signal transducing adapter molecule 2 2 2 -0.30 0.37 0.66
O43166 Signal-induced proliferation-associated 1-like protein 1 7 8 0.26 0.54 0.13 3
Q96FS4 Signal-induced proliferation-associated protein 1 27 130 -0.03 0.30 0.34
Q13291 Signaling lymphocytic activation molecule 1 1 2.15 1.73 -0.43
Q9Y3P8 Signaling threshold-regulating transmembrane adapter 1 6 22 1.01 0.17 -0.90 4 4
Q5TFQ8 Signal-regulatory protein beta-1 isoform 3 1 1 0.55 0.83 0.29
Q9P1W8 Signal-regulatory protein gamma 2 2 -0.14 -0.13 0.01
Q9H7L9 Sin3 histone deacetylase corepressor complex component SDS3 3 3 -0.62 -0.53 0.15
Q6IA17 Single Ig IL-1-related receptor 4 19 -0.47 0.48 0.99 4 5
Q9BWW4 Single-stranded DNA-binding protein 3 2 3 -0.73 -0.03 0.70
Q9BWG4 Single-stranded DNA-binding protein 4 2 2 -0.23 1.28 1.49
Q04837 Single-stranded DNA-binding protein, mitochondrial 10 74 0.39 -0.15 -0.37
Q29RF7 Sister chromatid cohesion protein PDS5 homolog A 24 103 -0.03 -0.12 -0.10
Q9NTI5 Sister chromatid cohesion protein PDS5 homolog B 23 70 -0.11 -0.08 0.01
O43805 Sjoegren syndrome nuclear autoantigen 1 1 1 0.05 0.51 0.47
Q9P270 SLAIN motif-containing protein 2 13 35 -0.14 0.10 0.27
Q9UIB8 SLAM family member 5 1 1 0.36 -0.31 -0.67
Q96DU3 SLAM family member 6 4 15 0.08 0.46 0.41
Q9NR83 SLC2A4 regulator 1 2 NA NA NA
Q9H5Y7 SLIT and NTRK-like protein 6 1 2 -0.10 -0.15 -0.05
Q8TAD8 Smad nuclear-interacting protein 1 3 5 -0.07 -0.15 0.01
O00193 Small acidic protein 3 9 -0.43 -0.06 0.44
P84101 Small EDRK-rich factor 2 2 5 0.28 0.14 -0.14
O43765 Small glutamine-rich tetratricopeptide repeat-containing protein alpha 5 30 0.14 -0.03 -0.12
Q96EQ0 Small glutamine-rich tetratricopeptide repeat-containing protein beta 2 3 0.30 -0.78 -1.07
Q96EX1 Small integral membrane protein 12 1 1 -0.02 -0.14 -0.12
Q8N5G0 Small integral membrane protein 20 1 9 0.00 -0.02 -0.12
P62304 Small nuclear ribonucleoprotein E 4 34 -0.16 -0.14 -0.07
P62306 Small nuclear ribonucleoprotein F 3 193 -0.30 -0.43 -0.22 4
A8MWD9 Small nuclear ribonucleoprotein G-like protein 4 42 -0.38 -0.41 -0.20 5
P62314 Small nuclear ribonucleoprotein Sm D1 2 30 -0.06 0.02 -0.11
P62316 Small nuclear ribonucleoprotein Sm D2 7 117 -0.15 -0.20 -0.12
P62318 Small nuclear ribonucleoprotein Sm D3 8 118 -0.19 -0.13 0.00
P14678 Small nuclear ribonucleoprotein-associated proteins B and B' 5 165 -0.30 -0.23 0.05
O75691 Small subunit processome component 20 homolog 5 12 0.33 -0.14 -0.40
P63165 Small ubiquitin-related modifier 1 2 9 -0.22 -0.16 -0.12
P61956 Small ubiquitin-related modifier 2 1 50 -0.41 0.07 0.47
P55854 Small ubiquitin-related modifier 3 1 50 -1.09 -0.60 0.50
Q8NHG7 Small VCP/p97-interacting protein 1 8 0.51 -0.12 -0.69
Q13126 S-methyl-5'-thioadenosine phosphorylase 8 44 0.64 -0.09 -0.68 3 5
O95295 SNARE-associated protein Snapin 5 23 -0.12 0.13 0.26
Q9NRH2 SNF-related serine/threonine-protein kinase 1 1 1.06 -0.21 -1.27
Q13573 SNW domain-containing protein 1 14 53 -0.20 -0.20 0.11
Q9Y6M7 Sodium bicarbonate cotransporter 3 1 2 0.38 -0.10 -0.48
Q8NBS3 Sodium bicarbonate transporter-like protein 11 1 2 -0.08 -0.49 -0.40
P05023 Sodium/potassium-transporting ATPase subunit alpha-1 26 165 0.62 0.37 -0.20
P54709 Sodium/potassium-transporting ATPase subunit beta-3 3 8 0.68 0.18 -0.48 3
Q9Y6X4 Soluble lamin-associated protein of 75 kDa 8 27 0.01 0.06 0.11
Q9UHW9 Solute carrier family 12 member 6 1 3 NA NA NA
P11166 Solute carrier family 2, facilitated glucose transporter member 1 1 6 -0.20 0.23 0.54
P11169 Solute carrier family 2, facilitated glucose transporter member 3 2 15 0.04 0.55 0.52
Q96AG3 Solute carrier family 25 member 46 3 10 -0.19 -0.07 0.14
Q8N357 Solute carrier family 35 member F6 1 4 -0.20 0.34 0.54
Q9UIG8 Solute carrier organic anion transporter family member 3A1 1 1 0.25 0.86 0.61
Q9NQZ2 Something about silencing protein 10 4 8 0.46 -0.17 -0.81
Q00796 Sorbitol dehydrogenase 4 14 0.06 -0.11 -0.16
P30626 Sorcin 5 39 0.36 0.15 0.06
Q92673 Sortilin-related receptor 5 9 -0.02 0.32 0.30
Q9Y512 Sorting and assembly machinery component 50 homolog 4 8 -0.28 -0.46 -0.18
Q13596 Sorting nexin-1 8 48 -0.35 0.19 0.50
Q9Y5W9 Sorting nexin-11 2 3 0.27 0.31 0.05
Q9UMY4 Sorting nexin-12 3 25 -0.43 0.00 0.32
Q9NRS6 Sorting nexin-15 2 3 0.13 0.07 -0.06
Q15036 Sorting nexin-17 2 12 -0.22 0.09 0.42
Q96RF0 Sorting nexin-18 6 20 -1.53 -0.38 1.40 5 5
O60749 Sorting nexin-2 12 64 0.08 0.00 -0.06
Q96L92 Sorting nexin-27 2 6 -0.05 0.17 0.24
O60493 Sorting nexin-3 5 30 -0.51 0.03 0.61 5 5
O95219 Sorting nexin-4 1 1 0.04 -0.05 -0.10
Q9Y5X3 Sorting nexin-5 8 19 0.15 0.41 0.22
Q9UNH7 Sorting nexin-6 14 68 -0.15 0.09 0.19
Q9Y5X1 Sorting nexin-9 2 7 0.96 -0.18 -1.02 3 4
Q9NRY2 SOSS complex subunit C 1 4 -0.46 -0.13 0.42
Q9HB58 Sp110 nuclear body protein 11 18 -0.11 -0.28 -0.06
Q8N0X7 Spartin 1 3 0.13 -0.44 -0.61
Q9UBP0 Spastin 2 8 0.08 0.01 -0.08
Q96JI7 Spatacsin 1 4 0.16 0.12 -0.15
Q9NUQ6 SPATS2-like protein 1 1 0.60 1.22 0.62
Q13813 Spectrin alpha chain, non-erythrocytic 1 107 454 0.27 -0.42 -0.59 4 5
P11277 Spectrin beta chain, erythrocytic 1 3 -1.52 -1.56 -0.03
Q01082 Spectrin beta chain, non-erythrocytic 1 90 624 0.21 -0.49 -0.73 5 5
O75391 Sperm-associated antigen 7 6 11 -0.09 -0.14 -0.07
Q96N96 Spermatogenesis-associated protein 13 2 9 -0.55 0.27 0.78 4
Q8TB22 Spermatogenesis-associated protein 20 2 2 0.03 0.10 0.07
Q8NB90 Spermatogenesis-associated protein 5 4 30 0.33 0.15 -0.29
Q9BVQ7 Spermatogenesis-associated protein 5-like protein 1 4 9 0.03 -0.06 -0.18
Q9H9C1 Spermatogenesis-defective protein 39 homolog 1 3 0.01 0.14 0.06
P19623 Spermidine synthase 9 27 0.84 -0.17 -0.75 5 4
P52788 Spermine synthase 2 3 -0.20 -0.24 -0.03
P63208 S-phase kinase-associated protein 1 6 28 -0.01 0.16 0.06
Q9H228 Sphingosine 1-phosphate receptor 5 1 1 0.46 1.39 0.94
O95470 Sphingosine-1-phosphate lyase 1 8 18 0.05 0.29 0.26
Q9BX95 Sphingosine-1-phosphate phosphatase 1 2 6 -0.41 -0.01 0.40
Q8N0Z3 Spindle and centriole-associated protein 1 1 1 0.49 0.15 -0.33
Q9Y657 Spindlin-1 4 9 -0.22 -0.32 -0.10
Q13838 Spliceosome RNA helicase DDX39B 6 139 0.00 -0.08 -0.09
Q9P013 Spliceosome-associated protein CWC15 homolog 4 27 -0.25 -0.22 0.09
Q15637 Splicing factor 1 13 120 -0.16 -0.03 0.00
Q15459 Splicing factor 3A subunit 1 28 122 -0.15 -0.16 -0.02
Q15428 Splicing factor 3A subunit 2 8 31 -0.17 -0.29 0.04
Q12874 Splicing factor 3A subunit 3 12 79 -0.06 -0.12 -0.16
O75533 Splicing factor 3B subunit 1 37 165 -0.01 -0.12 -0.02
Q13435 Splicing factor 3B subunit 2 35 236 0.01 -0.14 0.00
Q15393 Splicing factor 3B subunit 3 28 156 0.02 -0.03 -0.02
Q15427 Splicing factor 3B subunit 4 3 9 0.02 0.02 -0.01
Q9BWJ5 Splicing factor 3B subunit 5 2 3 -1.49 -0.75 0.75
Q96I25 Splicing factor 45 13 45 -0.32 -0.17 0.10
Q01081 Splicing factor U2AF 35 kDa subunit 3 22 -0.12 0.27 0.29
P26368 Splicing factor U2AF 65 kDa subunit 11 67 -0.09 -0.04 0.05
O95104 Splicing factor, arginine/serine-rich 15 6 21 -0.09 -0.24 0.06
Q9H7N4 Splicing factor, arginine/serine-rich 19 9 29 -0.02 -0.03 0.18
P23246 Splicing factor, proline- and glutamine-rich 35 428 -0.10 -0.06 -0.07
Q12872 Splicing factor, suppressor of white-apricot homolog 4 5 -0.16 -0.10 -0.03
Q8WXA9 Splicing regulatory glutamine/lysine-rich protein 1 5 9 -0.35 -0.26 -0.02
Q8WW59 SPRY domain-containing protein 4 1 2 0.61 0.23 -0.37
Q5W111 SPRY domain-containing protein 7 1 1 -0.05 0.33 0.36
Q15020 Squamous cell carcinoma antigen recognized by T-cells 3 22 107 0.01 -0.22 -0.10
Q9GZT3 SRA stem-loop-interacting RNA-binding protein, mitochondrial 3 10 0.19 0.08 -0.20
Q86WV1 Src kinase-associated phosphoprotein 1 5 34 -0.22 -1.31 -1.19 5 5
O75563 Src kinase-associated phosphoprotein 2 3 5 -0.19 0.23 0.42
Q14247 Src substrate cortactin 1 3 0.00 -0.01 0.11
Q9H6Q3 Src-like-adapter 2 1 2 -0.73 0.15 0.86
Q96SB4 SRSF protein kinase 1 3 8 0.26 0.41 0.15
P78362 SRSF protein kinase 2 4 11 -0.53 -0.11 0.40
Q9UHA2 SS18-like protein 2 1 1 0.21 0.20 -0.01
O95630 STAM-binding protein 4 9 0.38 0.27 -0.09
Q7KZF4 Staphylococcal nuclease domain-containing protein 1 34 239 0.60 0.38 -0.12 5
Q9NSY2 StAR-related lipid transfer protein 5 1 1 0.56 -0.19 -0.74
P16949 Stathmin 11 66 -1.08 -0.67 0.33 5 5
Q9UEW8 STE20/SPS1-related proline-alanine-rich protein kinase 3 8 -0.16 0.06 0.41
Q9H2G2 STE20-like serine/threonine-protein kinase 20 87 -0.08 0.28 0.36 5
Q6SZW1 Sterile alpha and TIR motif-containing protein 1 2 7 0.00 -0.15 -0.24
Q5K651 Sterile alpha motif domain-containing protein 9 7 26 -0.16 0.27 0.24
Q9HD15 Steroid receptor RNA activator 1 4 11 -0.31 -0.17 0.18
Q15738 Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating 3 3 -0.17 0.07 0.23
Q86WV6 Stimulator of interferon genes protein 2 6 -0.33 -0.20 0.15
Q9UJZ1 Stomatin-like protein 2, mitochondrial 11 49 0.05 0.16 0.06
Q96BY9 Store-operated calcium entry-associated regulatory factor 1 1 0.05 -0.19 -0.24
P38646 Stress-70 protein, mitochondrial 41 399 0.03 -0.16 -0.16
P31948 Stress-induced-phosphoprotein 1 36 215 0.09 -0.12 -0.14
O43815 Striatin 15 84 -0.42 0.05 0.35
Q13033 Striatin-3 2 10 -0.02 0.00 -0.05
Q9NRL3 Striatin-4 4 14 -0.09 -0.10 0.13
Q5VSL9 Striatin-interacting protein 1 5 26 -0.26 -0.09 0.16
Q99470 Stromal cell-derived factor 2 1 1 NA NA NA
Q9HCN8 Stromal cell-derived factor 2-like protein 1 2 6 -0.46 0.05 0.58
Q13586 Stromal interaction molecule 1 19 51 -0.40 -0.10 0.31
Q8IYB5 Stromal membrane-associated protein 1 1 4 0.12 0.72 0.59 3
Q8WU79 Stromal membrane-associated protein 2 8 29 -0.19 -0.45 -0.20
A6NHR9 Structural maintenance of chromosomes flexible hinge domain-containing protein 1 35 114 0.01 -0.18 -0.18
Q14683 Structural maintenance of chromosomes protein 1A 55 252 -0.12 -0.14 0.00
O95347 Structural maintenance of chromosomes protein 2 2 2 -0.23 -0.04 0.19
Q9UQE7 Structural maintenance of chromosomes protein 3 49 237 -0.14 -0.15 -0.06
Q9NTJ3 Structural maintenance of chromosomes protein 4 1 1 -0.34 0.09 0.44
Q8IY18 Structural maintenance of chromosomes protein 5 3 3 -0.25 0.04 0.27
Q96SB8 Structural maintenance of chromosomes protein 6 1 3 -0.18 -0.38 -0.23
Q9NX18 Succinate dehydrogenase assembly factor 2, mitochondrial 1 1 -0.73 -0.05 0.69
P31040 Succinate dehydrogenase flavoprotein subunit, mitochondrial 19 122 0.34 0.08 -0.18
P21912 Succinate dehydrogenase iron-sulfur subunit, mitochondrial 10 43 0.21 -0.18 -0.43
P51649 Succinate-semialdehyde dehydrogenase, mitochondrial 9 43 0.29 -0.51 -0.80 4 5
P53597 Succinyl-CoA ligase subunit alpha, mitochondrial 12 107 0.12 -0.13 -0.19
Q96I99 Succinyl-CoA ligase subunit beta, mitochondrial 28 213 0.28 -0.18 -0.36
Q9P2R7 Succinyl-CoA ligase subunit beta, mitochondrial 15 72 0.24 0.07 -0.13
P55809 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial 17 107 0.37 0.07 -0.37
Q8NBK3 Sulfatase-modifying factor 1 1 1 -0.28 -0.11 0.15
Q8NBJ7 Sulfatase-modifying factor 2 4 15 -0.51 -0.65 -0.18 3
Q9Y6N5 Sulfide:quinone oxidoreductase, mitochondrial 26 179 0.39 0.61 0.03 4
O43704 Sulfotransferase family cytosolic 1B member 1 4 8 -0.91 -1.14 -0.25 4 4
Q9UBE0 SUMO-activating enzyme subunit 1 15 118 -0.12 -0.43 -0.29 4
Q9UBT2 SUMO-activating enzyme subunit 2 16 66 -0.13 -0.36 -0.15
P63279 SUMO-conjugating enzyme UBC9 5 17 -0.13 -0.28 0.06
O94901 SUN domain-containing protein 1 1 12 -0.07 0.07 0.17
Q9UH99 SUN domain-containing protein 2 25 127 -0.09 -0.04 0.18
P42285 Superkiller viralicidic activity 2-like 2 11 36 0.13 -0.09 -0.24
P00441 Superoxide dismutase 13 62 0.41 -0.04 -0.40
P04179 Superoxide dismutase, mitochondrial 7 25 0.75 0.04 -0.83 4 4
O95425 Supervillin 7 17 0.06 0.10 -0.17
Q9Y2Z0 Suppressor of G2 allele of SKP1 homolog 11 27 -0.06 -0.02 0.09
Q9BRV8 Suppressor of IKBKE 1 2 4 -0.48 0.40 0.88 3
Q9NQ55 Suppressor of SWI4 1 homolog 5 6 -0.03 -0.78 -0.75
Q8TDW4 Suppressor of tumorigenicity 7 protein-like 1 1 0.12 -0.21 -0.33
Q6UWP8 Suprabasin 2 10 0.03 -0.10 -0.03
Q15526 Surfeit locus protein 1 1 1 0.14 -0.01 -0.15
Q15527 Surfeit locus protein 2 1 4 0.38 -0.32 -0.59
O75683 Surfeit locus protein 6 8 14 0.53 -0.01 -0.43
Q8IWZ8 SURP and G-patch domain-containing protein 1 7 19 -0.09 -0.19 -0.03
Q8IX01 SURP and G-patch domain-containing protein 2 5 6 -0.36 -0.05 0.36
Q16637 Survival motor neuron protein 1 1 0.38 -0.45 -0.83
O75940 Survival of motor neuron-related-splicing factor 30 5 30 -0.12 -0.13 0.15
Q7Z422 SUZ domain-containing protein 1 3 7 -0.40 -0.09 0.44
Q92922 SWI/SNF complex subunit SMARCC1 2 49 -0.06 0.15 0.21
Q8TAQ2 SWI/SNF complex subunit SMARCC2 20 138 -0.15 -0.04 0.07
O60264 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 521 76 0.12 -0.15 -0.20
Q9NZC9 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 12 5 -0.19 -0.08 0.08
Q12824 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 15 17 0.13 0.06 -0.06
Q96GM5 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 13 11 -0.02 0.17 -0.34
Q92925 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 29 18 -0.12 0.09 0.15
Q969G3 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 111 49 -0.39 -0.03 0.29
Q9P0W2 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related1 1 -0.47 0.07 0.55
Q9UH65 Switch-associated protein 70 1 3 -0.59 -0.31 0.28
Q92797 Symplekin 9 18 -0.02 -0.06 -0.05
Q96A49 Synapse-associated protein 1 2 2 0.11 0.17 0.06
Q99536 Synaptic vesicle membrane protein VAT-1 homolog 8 38 -0.17 0.45 0.55 4 4
O15498 Synaptobrevin homolog YKT6 4 14 0.15 0.37 0.24
O43426 Synaptojanin-1 1 1 -0.17 -0.14 0.01
O15056 Synaptojanin-2 4 10 -0.13 0.20 0.34
P57105 Synaptojanin-2-binding protein 1 2 0.16 0.06 -0.09
O00161 Synaptosomal-associated protein 23 4 18 -0.17 0.10 0.20
O95721 Synaptosomal-associated protein 29 8 42 -0.42 0.35 0.73 5
Q8IYJ3 Synaptotagmin-like protein 1 8 43 -0.33 0.36 0.72 5 4
Q9HCH5 Synaptotagmin-like protein 2 13 36 0.07 0.96 0.82 5 5
Q4VX76 Synaptotagmin-like protein 3 2 4 -0.25 1.19 1.45 3
Q96C24 Synaptotagmin-like protein 4 1 2 -0.18 -0.27 -0.10
Q9NPQ8 Synembryn-A 7 23 0.04 0.17 0.12
O15061 Synemin 3 4 1.08 0.80 -0.20
Q9UMZ2 Synergin gamma 10 11 0.02 0.00 -0.10
O60499 Syntaxin-10 1 1 -0.18 -0.62 -0.43
O75558 Syntaxin-11 2 3 -0.63 0.28 0.57
Q86Y82 Syntaxin-12 1 2 -0.31 0.09 0.40
O14662 Syntaxin-16 1 1 -0.46 0.01 0.48
P56962 Syntaxin-17 1 1 0.66 0.10 -0.54
Q12846 Syntaxin-4 6 18 0.16 0.22 0.08
Q13190 Syntaxin-5 6 16 -0.16 0.17 0.30
O43752 Syntaxin-6 1 1 -0.68 -0.29 0.40
O15400 Syntaxin-7 7 29 -1.15 0.22 1.34 5 5
Q9UNK0 Syntaxin-8 4 6 0.15 0.18 0.16
P61764 Syntaxin-binding protein 1 1 1 NA NA NA
Q15833 Syntaxin-binding protein 2 15 39 -0.15 0.25 0.37
O00186 Syntaxin-binding protein 3 13 37 0.46 0.37 -0.01
Q5T5C0 Syntaxin-binding protein 5 4 12 -0.37 0.01 0.36
O00560 Syntenin-1 1 3 NA NA NA
Q9Y6J9 TAF6-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 6L1 4 0.24 0.11 -0.13
Q9Y490 Talin-1 131 1787 -0.26 0.26 0.41
Q9Y4G6 Talin-2 1 228 0.11 0.41 0.30
Q8N9U0 Tandem C2 domains nuclear protein 1 1 0.11 0.14 0.03
O15533 Tapasin 4 56 -0.20 0.26 0.30
Q9BX59 Tapasin-related protein 1 2 -0.31 0.23 0.54
Q4KMQ1 Taperin 1 1 -0.82 0.14 0.96
Q13148 TAR DNA-binding protein 43 7 82 -0.09 -0.20 -0.10
Q96GM8 Target of EGR1 protein 1 1 4 -0.06 -0.11 -0.06
O60784 Target of Myb protein 1 3 12 -0.02 0.05 0.11
Q9BPZ7 Target of rapamycin complex 2 subunit MAPKAP1 1 5 0.08 0.21 0.13
Q9BVC4 Target of rapamycin complex subunit LST8 1 6 -0.20 -0.20 0.00
P13686 Tartrate-resistant acid phosphatase type 5 1 1 -0.44 -0.02 0.42
P82094 TATA element modulatory factor 6 11 0.09 0.29 0.28
O14981 TATA-binding protein-associated factor 172 6 13 0.01 -0.10 -0.07
Q92804 TATA-binding protein-associated factor 2N 5 23 0.04 0.29 0.25
P20226 TATA-box-binding protein 2 4 -0.07 -0.16 -0.09
Q86VP1 Tax1-binding protein 1 1 1 -0.03 -0.34 -0.29
O14907 Tax1-binding protein 3 1 1 -0.92 -0.37 0.56
Q8TEA7 TBC domain-containing protein kinase-like protein 1 1 -0.25 0.11 0.37
Q86TI0 TBC1 domain family member 1 5 12 0.00 -0.17 -0.16
Q9BXI6 TBC1 domain family member 10A 4 11 -0.08 -0.13 0.09
Q4KMP7 TBC1 domain family member 10B 7 17 -0.27 0.17 0.34
Q9NVG8 TBC1 domain family member 13 3 4 0.00 0.03 0.04
Q8TC07 TBC1 domain family member 15 6 18 0.20 -0.06 -0.35
Q9HA65 TBC1 domain family member 17 3 9 0.05 -0.16 -0.16
Q8WUA7 TBC1 domain family member 22A 3 5 -0.02 0.01 0.27
Q9NUY8 TBC1 domain family member 23 1 1 NA NA NA
Q9ULP9 TBC1 domain family member 24 1 1 0.15 0.15 0.00
Q9UPU7 TBC1 domain family member 2B 8 17 0.27 0.21 -0.17
Q96DN5 TBC1 domain family member 31 1 3 0.37 0.00 -0.33
O60343 TBC1 domain family member 4 1 5 0.31 -0.10 -0.41
Q92609 TBC1 domain family member 5 14 40 -0.13 0.20 0.31
Q66K14 TBC1 domain family member 9B 4 7 -0.11 0.11 0.27
Q9UL17 T-box transcription factor TBX21 10 39 -1.29 0.35 1.31 5 5
Q8N103 T-cell activation Rho GTPase-activating protein 2 3 0.02 0.62 0.37
P09564 T-cell antigen CD7 3 7 -0.55 0.11 0.79 4
P30203 T-cell differentiation antigen CD6 5 22 1.39 0.25 -1.04 4 5
P01848 T-cell receptor alpha chain C region 2 8 0.19 -0.88 -1.06
P01850 T-cell receptor beta-1 chain C region 1 1 NA NA NA
Q6PIZ9 T-cell receptor-associated transmembrane adapter 1 1 8 0.96 0.35 -0.58 4
P06729 T-cell surface antigen CD2 6 19 0.51 0.13 0.08
P04234 T-cell surface glycoprotein CD3 delta chain 1 12 1.22 1.01 -0.12
P07766 T-cell surface glycoprotein CD3 epsilon chain 4 18 1.70 -0.07 -1.76 4 4
P20963 T-cell surface glycoprotein CD3 zeta chain 8 57 -0.63 0.24 0.96 4 5
P06127 T-cell surface glycoprotein CD5 9 27 0.78 -0.51 -1.28 4 4 5
P01732 T-cell surface glycoprotein CD8 alpha chain 4 27 1.28 -0.24 -1.59 4 4
P10966 T-cell surface glycoprotein CD8 beta chain 3 3 0.29 -0.59 -0.89
P0C1Z6 TCF3 fusion partner 1 1 0.07 0.05 -0.02
P17987 T-complex protein 1 subunit alpha 28 294 0.21 -0.10 -0.32
P78371 T-complex protein 1 subunit beta 34 421 0.17 -0.14 -0.34
P50991 T-complex protein 1 subunit delta 32 248 0.23 -0.23 -0.44
P48643 T-complex protein 1 subunit epsilon 27 206 0.18 -0.14 -0.29
Q99832 T-complex protein 1 subunit eta 30 260 0.14 -0.18 -0.31
P49368 T-complex protein 1 subunit gamma 31 313 0.20 -0.06 -0.34
P50990 T-complex protein 1 subunit theta 38 434 0.19 -0.11 -0.25
P40227 T-complex protein 1 subunit zeta 24 264 0.23 -0.17 -0.33
Q9NUJ3 T-complex protein 11-like protein 1 1 1 0.45 0.74 0.29
Q7Z6L1 Tectonin beta-propeller repeat-containing protein 1 3 9 -0.09 -0.62 -0.79 4 4
Q99973 Telomerase protein component 1 2 11 -0.21 -0.33 -0.11
Q86US8 Telomerase-binding protein EST1A 1 1 -0.28 -0.06 0.22
Q5UIP0 Telomere-associated protein RIF1 4 9 -0.13 -0.15 -0.13
P54274 Telomeric repeat-binding factor 1 2 3 -0.34 0.07 0.41
Q15554 Telomeric repeat-binding factor 2 9 34 -0.02 -0.10 -0.05
Q9NYB0 Telomeric repeat-binding factor 2-interacting protein 1 10 57 -0.10 0.02 0.11
Q5TAX3 Terminal uridylyltransferase 4 2 3 0.04 0.11 0.08
Q5VYS8 Terminal uridylyltransferase 7 1 6 -0.10 0.43 0.41
Q92563 Testican-2 5 10 0.87 1.22 0.26 4 4
P0DJG4 Testicular haploid expressed gene protein-like 1 2 -1.15 -0.29 0.86
Q9UGI8 Testin 28 240 -0.32 0.05 0.38
Q9NXF1 Testis-expressed sequence 10 protein 3 69 0.01 -0.19 -0.19
Q9Y6I9 Testis-expressed sequence 264 protein 1 11 -0.77 -0.20 0.25 3
Q6SA08 Testis-specific serine/threonine-protein kinase 4 1 3 0.39 0.70 0.31
Q9H0U9 Testis-specific Y-encoded-like protein 1 3 6 0.32 0.17 -0.10
Q9BZE9 Tether containing UBX domain for GLUT4 3 4 -0.07 0.04 0.23
P05452 Tetranectin 1 2 0.29 0.31 0.03
Q8NG11 Tetraspanin-14 2 4 0.68 0.70 -0.15
Q99614 Tetratricopeptide repeat protein 1 3 14 -0.06 -0.04 -0.11
Q96N46 Tetratricopeptide repeat protein 14 1 1 -0.45 -0.46 0.00
Q6P3X3 Tetratricopeptide repeat protein 27 1 1 -0.25 -0.01 0.24
Q6PGP7 Tetratricopeptide repeat protein 37 7 15 0.36 0.05 -0.29
Q5R3I4 Tetratricopeptide repeat protein 38 5 15 -0.74 0.56 1.17 3 4
Q8N584 Tetratricopeptide repeat protein 39C 2 4 -0.03 0.23 0.27
O95801 Tetratricopeptide repeat protein 4 2 6 0.07 -0.11 -0.15
Q8IYW2 Tetratricopeptide repeat protein 40 1 25 NA NA NA
Q92623 Tetratricopeptide repeat protein 9A 3 7 0.64 -0.05 -0.43
Q8N5M4 Tetratricopeptide repeat protein 9C 1 1 -0.26 0.07 0.33
P19447 TFIIH basal transcription factor complex helicase XPB subunit 3 5 0.06 -0.03 -0.10
P18074 TFIIH basal transcription factor complex helicase XPD subunit 2 2 -0.28 -0.20 0.07
P37173 TGF-beta receptor type-2 1 1 -0.03 -0.41 -0.37
Q15750 TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 7 16 0.00 -0.05 0.03
Q9NYJ8 TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 1 2 -0.07 -0.22 -0.15
Q96EK4 THAP domain-containing protein 11 1 1 -0.06 -0.12 -0.08
Q8WY91 THAP domain-containing protein 4 1 4 -0.23 -0.40 0.28
Q9BU02 Thiamine-triphosphatase 2 7 -0.15 0.06 0.26
P52888 Thimet oligopeptidase 8 26 -0.07 -0.09 0.05
P51580 Thiopurine S-methyltransferase 4 9 0.04 0.22 0.30
P10599 Thioredoxin 5 32 0.08 -0.03 0.35
O95881 Thioredoxin domain-containing protein 12 5 36 0.08 0.08 0.19
Q9BRA2 Thioredoxin domain-containing protein 17 5 42 -0.12 -0.20 0.03
Q8NBS9 Thioredoxin domain-containing protein 5 3 10 0.18 0.67 0.50
O14530 Thioredoxin domain-containing protein 9 2 5 0.37 -0.04 -0.40
Q16881 Thioredoxin reductase 1, cytoplasmic 13 60 -0.21 0.00 0.22
Q9NNW7 Thioredoxin reductase 2, mitochondrial 8 21 0.13 -0.16 -0.21
P30048 Thioredoxin-dependent peroxide reductase, mitochondrial 8 75 0.27 -0.11 -0.39
O43396 Thioredoxin-like protein 1 9 47 -0.09 -0.03 0.07
P83876 Thioredoxin-like protein 4A 2 11 -0.19 -0.33 -0.16
Q9H3N1 Thioredoxin-related transmembrane protein 1 4 49 0.19 0.24 0.08
Q9Y320 Thioredoxin-related transmembrane protein 2 2 2 -0.74 -0.15 0.59
Q9H1E5 Thioredoxin-related transmembrane protein 4 2 17 0.41 0.56 -0.07 3
Q16762 Thiosulfate sulfurtransferase 1 2 -0.82 0.08 0.90
Q8NFU3 Thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1 6 47 -0.01 -0.39 -0.38
Q96FV9 THO complex subunit 1 8 21 -0.06 -0.03 0.07
Q8NI27 THO complex subunit 2 13 22 -0.14 -0.08 0.03
Q96J01 THO complex subunit 3 2 2 -0.34 -0.08 0.25
Q86V81 THO complex subunit 4 8 64 -0.34 -0.23 0.00
Q13769 THO complex subunit 5 homolog 2 2 -0.04 -0.11 -0.06
Q86W42 THO complex subunit 6 homolog 10 28 -0.11 -0.15 -0.07
Q9NSU2 Three prime repair exonuclease 1 1 5 -0.48 -0.39 0.08
Q9H6P5 Threonine aspartase 1 3 5 -0.09 -0.33 -0.32
Q8IYQ7 Threonine synthase-like 1 1 6 0.39 -0.35 -0.89 4
P26639 Threonine--tRNA ligase, cytoplasmic 8 35 0.32 0.25 -0.05
Q9BW92 Threonine--tRNA ligase, mitochondrial 3 4 -0.10 -0.26 -0.17
P07996 Thrombospondin-1 15 56 -0.11 -0.12 0.05
P24557 Thromboxane-A synthase 1 4 -0.75 0.13 0.79 3
Q9NXG2 THUMP domain-containing protein 1 11 51 0.02 -0.26 -0.15
P19971 Thymidine phosphorylase 13 46 -0.15 0.35 0.36
P23919 Thymidylate kinase 9 20 0.04 0.01 0.16
Q9P016 Thymocyte nuclear protein 1 12 87 0.21 -0.82 -0.90 5 5
P63313 Thymosin beta-10 4 16 -0.06 -0.51 -0.14
P62328 Thymosin beta-4 5 25 0.43 -0.27 -0.10
Q9Y2W1 Thyroid hormone receptor-associated protein 3 22 146 -0.16 -0.15 0.07
Q15643 Thyroid receptor-interacting protein 11 4 4 0.39 0.58 0.20
Q9P031 Thyroid transcription factor 1-associated protein 26 2 5 0.30 -0.19 -0.50
P05543 Thyroxine-binding globulin 1 1 0.56 0.95 0.40
Q5JTD0 Tight junction-associated protein 1 3 5 0.34 0.11 -0.11
O75663 TIP41-like protein 6 20 -0.07 0.05 0.07
P04066 Tissue alpha-L-fucosidase 1 5 -0.54 -0.08 0.38
Q8WZ42 Titin 2 10 0.81 0.13 -0.74 4 4
Q6P9B6 TLD domain-containing protein 1 1 4 -0.02 -0.03 0.00
Q13077 TNF receptor-associated factor 1 2 2 -0.55 -0.31 0.25
Q12933 TNF receptor-associated factor 2 3 5 -0.38 -0.28 0.09
Q15025 TNFAIP3-interacting protein 1 2 14 -1.10 -0.80 0.31
Q8NFZ5 TNFAIP3-interacting protein 2 1 2 -0.51 0.14 0.65
Q9H0E2 Toll-interacting protein 4 14 -0.35 -0.05 0.21
Q6ZVM7 TOM1-like protein 2 2 2 -0.09 -0.22 -0.14
O14656 Torsin-1A 2 3 -0.18 0.24 0.33
Q5JTV8 Torsin-1A-interacting protein 1 17 150 -0.08 0.24 0.22
Q8NFQ8 Torsin-1A-interacting protein 2 1 1 0.29 0.33 0.02
O14657 Torsin-1B 1 7 -0.42 0.13 0.60 5
Q5JU69 Torsin-2A 1 1 -0.97 -0.47 0.50
Q9NXH8 Torsin-4A 2 8 -1.49 0.61 2.11 3 4 4
O94842 TOX high mobility group box family member 4 7 15 -0.10 0.02 0.15
Q96S44 TP53-regulating kinase 5 27 -0.07 -0.01 -0.08
O15050 TPR and ankyrin repeat-containing protein 1 5 14 0.02 0.29 0.25
Q9H4I3 TraB domain-containing protein 1 11 -0.54 0.10 0.52
Q92844 TRAF family member-associated NF-kappa-B activator 1 5 -0.06 0.33 0.26
Q9UKE5 TRAF2 and NCK-interacting protein kinase 6 23 0.21 0.29 0.06
Q9Y228 TRAF3-interacting JNK-activating modulator 18 113 -0.10 -0.22 -0.12
P48553 Trafficking protein particle complex subunit 10 3 3 -0.24 0.17 0.42
Q7Z392 Trafficking protein particle complex subunit 11 2 4 -0.29 -0.06 0.24
Q8WVT3 Trafficking protein particle complex subunit 12 2 4 -0.15 0.10 0.26
P0DI81 Trafficking protein particle complex subunit 2 1 1 -0.55 -0.14 0.39
Q9UL33 Trafficking protein particle complex subunit 2-like protein 2 3 -0.27 0.15 0.34
O43617 Trafficking protein particle complex subunit 3 4 9 -0.13 0.07 0.23
Q9Y296 Trafficking protein particle complex subunit 4 2 4 -0.13 -0.04 0.03
Q8IUR0 Trafficking protein particle complex subunit 5 2 3 -1.22 -0.38 0.82
Q86SZ2 Trafficking protein particle complex subunit 6B 2 2 -0.68 -0.29 0.40
Q9Y2L5 Trafficking protein particle complex subunit 8 2 2 -0.38 -0.29 0.09
Q96Q05 Trafficking protein particle complex subunit 9 6 16 -0.23 0.07 0.33
O14545 TRAF-type zinc finger domain-containing protein 1 4 12 -0.80 -0.23 0.42
Q9BV79 Trans-2-enoyl-CoA reductase, mitochondrial 2 3 0.21 0.03 -0.17
P37837 Transaldolase 20 259 0.10 -0.71 -0.92 5 5
P51532 Transcription activator BRG1 8 38 -0.08 -0.01 0.08
Q9NPA8 Transcription and mRNA export factor ENY2 2 5 -0.32 -0.22 0.42
P23193 Transcription elongation factor A protein 1 19 181 0.06 -0.20 -0.34
O75764 Transcription elongation factor A protein 3 1 1 NA NA NA
Q15170 Transcription elongation factor A protein-like 1 1 1 -0.38 0.53 0.93
Q969E4 Transcription elongation factor A protein-like 3 8 15 -0.17 -0.43 -0.43
Q15369 Transcription elongation factor B polypeptide 1 6 33 0.10 0.01 -0.10
Q15370 Transcription elongation factor B polypeptide 2 6 29 -0.07 0.05 0.07
P63272 Transcription elongation factor SPT4 2 4 0.10 0.05 -0.05
O00267 Transcription elongation factor SPT5 19 65 -0.01 -0.07 -0.07
Q7KZ85 Transcription elongation factor SPT6 18 42 -0.10 -0.02 -0.07
O14776 Transcription elongation regulator 1 15 57 0.03 -0.33 -0.24
Q9UGU0 Transcription factor 20 12 14 -0.04 -0.06 0.16
Q7RTU1 Transcription factor 23 1 1 -0.19 -0.01 0.18
Q9BQ70 Transcription factor 25 5 8 -0.29 0.09 0.43
P36402 Transcription factor 7 3 17 -0.23 -0.62 -0.33 4
Q00059 Transcription factor A, mitochondrial 8 29 0.39 -0.13 -0.66 4
P05412 Transcription factor AP-1 1 2 -0.59 0.05 0.65
Q01664 Transcription factor AP-4 1 1 -0.46 -0.34 0.10
P20290 Transcription factor BTF3 9 87 0.09 -0.13 -0.18
Q96K17 Transcription factor BTF3 homolog 4 3 12 0.07 0.30 0.28
Q16254 Transcription factor E2F4 3 4 -0.05 -0.45 -0.40
Q66K89 Transcription factor E4F1 1 1 0.01 0.34 0.34
P31629 Transcription factor HIVEP2 3 3 -0.25 -0.35 -0.10
Q92994 Transcription factor IIIB 90 kDa subunit 3 7 -0.30 -0.06 0.24
P17275 Transcription factor jun-B 4 15 0.19 0.26 0.08
P17535 Transcription factor jun-D 4 14 0.12 0.68 0.44 5
Q9ULX9 Transcription factor MafF 2 12 -0.47 0.49 0.97 4
Q04206 Transcription factor p65 9 38 0.33 0.14 -0.19
Q01201 Transcription factor RelB 5 9 0.09 0.16 0.13
Q9Y651 Transcription factor SOX-21 1 3 -0.26 0.07 0.34
P08047 Transcription factor Sp1 2 8 0.09 -0.05 0.10
Q02086 Transcription factor Sp2 3 10 -0.39 -0.04 0.29
Q02447 Transcription factor Sp3 3 17 -0.12 0.04 0.15
Q02446 Transcription factor Sp4 2 5 0.13 0.58 0.49
P52655 Transcription initiation factor IIA subunit 1 1 1 -0.06 0.04 0.11
P52657 Transcription initiation factor IIA subunit 2 2 5 0.25 0.24 0.00
Q00403 Transcription initiation factor IIB 10 33 0.12 -0.16 -0.21
P29084 Transcription initiation factor IIE subunit beta 3 6 -0.24 -0.11 0.20
P21675 Transcription initiation factor TFIID subunit 1 2 4 0.14 0.47 0.34
Q12962 Transcription initiation factor TFIID subunit 10 4 17 -0.50 -0.20 0.28
Q5VWG9 Transcription initiation factor TFIID subunit 3 2 4 0.03 -0.06 -0.09
O00268 Transcription initiation factor TFIID subunit 4 12 41 -0.25 -0.05 0.20
Q15542 Transcription initiation factor TFIID subunit 5 4 11 -0.12 -0.10 0.06
P49848 Transcription initiation factor TFIID subunit 6 5 14 -0.32 -0.18 0.00
Q15545 Transcription initiation factor TFIID subunit 7 1 1 -1.04 -0.62 0.43
Q7Z7C8 Transcription initiation factor TFIID subunit 8 1 1 -0.11 -0.13 -0.01
Q16594 Transcription initiation factor TFIID subunit 9 2 12 -0.26 -0.36 0.08
Q9HBM6 Transcription initiation factor TFIID subunit 9B 2 6 -0.33 -0.32 0.02
Q13263 Transcription intermediary factor 1-beta 25 280 -0.15 -0.30 -0.04
Q9BYV9 Transcription regulator protein BACH2 1 3 -0.06 -0.10 -0.17
Q15361 Transcription termination factor 1 1 1 -0.66 0.03 0.70
Q00577 Transcriptional activator protein Pur-alpha 9 48 0.11 0.03 -0.08
Q96QR8 Transcriptional activator protein Pur-beta 5 33 -0.20 0.19 0.33
Q86TJ2 Transcriptional adapter 2-beta 1 65 -0.04 -0.14 -0.08
O75528 Transcriptional adapter 3 1 2 NA NA NA
P46100 Transcriptional regulator ATRX 14 29 -0.15 -0.06 0.01
P49711 Transcriptional repressor CTCF 6 18 0.11 -0.07 -0.09
Q12986 Transcriptional repressor NF-X1 1 1 -0.57 -0.04 0.51
Q86YP4 Transcriptional repressor p66-alpha 23 159 -0.33 0.07 0.44
Q8WXI9 Transcriptional repressor p66-beta 11 73 -0.12 -0.16 -0.07
P25490 Transcriptional repressor protein YY1 11 32 -0.16 -0.21 -0.18
Q96PN7 Transcriptional-regulating factor 1 3 5 -0.38 -0.23 0.16
Q9Y4P3 Transducin beta-like protein 2 3 6 0.42 0.54 0.01 3
Q12788 Transducin beta-like protein 3 7 11 0.20 -0.13 -0.33
Q04724 Transducin-like enhancer protein 1 2 2 -0.36 0.00 0.36
Q04726 Transducin-like enhancer protein 3 3 12 -0.08 -0.76 -0.80 5 4
Q9Y4A5 Transformation/transcription domain-associated protein 6 10 0.02 -0.20 -0.31
Q13595 Transformer-2 protein homolog alpha 3 28 -0.18 -0.26 -0.06
P62995 Transformer-2 protein homolog beta 6 65 -0.20 -0.43 -0.11
O75410 Transforming acidic coiled-coil-containing protein 1 12 25 -0.07 0.10 0.18
Q9Y6A5 Transforming acidic coiled-coil-containing protein 3 11 31 0.06 -0.58 -0.63 5 4
P01137 Transforming growth factor beta-1 2 2 -0.06 0.24 0.29
Q8WUH2 Transforming growth factor-beta receptor-associated protein 1 2 5 -0.15 -0.09 -0.24
P61586 Transforming protein RhoA 2 113 0.14 0.24 -0.02
P37802 Transgelin-2 13 571 -0.18 0.00 0.36
O43493 Trans-Golgi network integral membrane protein 2 4 5 0.16 0.00 -0.16
Q9Y5S1 Transient receptor potential cation channel subfamily V member 2 4 11 -0.03 0.42 0.45 5 5
P55072 Transitional endoplasmic reticulum ATPase 46 504 0.04 0.12 0.12
P29401 Transketolase 32 404 0.04 -0.45 -0.43
Q14232 Translation initiation factor eIF-2B subunit alpha 3 9 -0.42 0.05 0.48
P49770 Translation initiation factor eIF-2B subunit beta 5 5 0.34 0.07 -0.19
Q9UI10 Translation initiation factor eIF-2B subunit delta 8 35 0.03 0.08 0.03
Q13144 Translation initiation factor eIF-2B subunit epsilon 4 6 -0.13 0.02 0.21
Q9NR50 Translation initiation factor eIF-2B subunit gamma 9 15 0.11 -0.06 -0.06
P46199 Translation initiation factor IF-2, mitochondrial 4 7 0.23 -0.03 -0.31
Q9H2K0 Translation initiation factor IF-3, mitochondrial 2 7 0.16 0.14 -0.01
Q96EY4 Translation machinery-associated protein 16 2 2 -0.01 -0.07 -0.07
Q9Y2S6 Translation machinery-associated protein 7 4 63 0.23 -0.53 -0.68 3 3
Q92616 Translational activator GCN1 36 113 0.44 0.24 -0.20
Q9BSH4 Translational activator of cytochrome c oxidase 1 5 8 -0.05 -0.27 -0.02
P13693 Translationally-controlled tumor protein 7 72 0.52 0.45 0.13
Q15631 Translin 8 90 0.50 -0.08 -0.46
Q99598 Translin-associated protein X 12 41 0.04 -0.28 -0.39
Q99442 Translocation protein SEC62 3 10 0.71 0.33 -0.39 4
Q9UGP8 Translocation protein SEC63 homolog 2 8 0.35 0.44 0.10
P43307 Translocon-associated protein subunit alpha 3 16 0.52 0.40 -0.14
P51571 Translocon-associated protein subunit delta 5 18 0.40 0.42 0.13
Q9UNL2 Translocon-associated protein subunit gamma 1 5 0.16 0.45 0.18
P48230 Transmembrane 4 L6 family member 4 1 4 NA NA NA
Q9HD45 Transmembrane 9 superfamily member 3 2 7 0.07 0.38 0.26
Q92544 Transmembrane 9 superfamily member 4 1 1 NA NA NA
Q9UM00 Transmembrane and coiled-coil domain-containing protein 1 2 8 0.33 0.20 -0.07
Q9ULS5 Transmembrane and coiled-coil domains protein 3 1 1 NA NA NA
Q96BF3 Transmembrane and immunoglobulin domain-containing protein 2 1 9 0.02 0.52 0.51
Q9BVT8 Transmembrane and ubiquitin-like domain-containing protein 1 1 2 0.04 0.07 0.03
Q7Z403 Transmembrane channel-like protein 6 3 4 0.04 0.56 0.52
P49755 Transmembrane emp24 domain-containing protein 10 7 44 0.44 0.62 -0.04 5
Q15363 Transmembrane emp24 domain-containing protein 2 1 1 0.18 0.07 -0.13
Q7Z7H5 Transmembrane emp24 domain-containing protein 4 2 26 -0.21 0.68 0.37 4
Q9Y3A6 Transmembrane emp24 domain-containing protein 5 1 2 0.32 0.42 0.11
Q9BVK6 Transmembrane emp24 domain-containing protein 9 2 22 -0.21 0.41 0.70
Q9BVC6 Transmembrane protein 109 2 26 0.44 0.62 0.08 3
P17152 Transmembrane protein 11, mitochondrial 1 1 NA NA NA
Q9NX00 Transmembrane protein 160 1 2 0.06 -0.27 -0.32
Q8IY95 Transmembrane protein 192 1 1 0.16 -1.19 -1.34
Q9UHN6 Transmembrane protein 2 4 5 -0.74 -0.25 0.50
Q6UW68 Transmembrane protein 205 1 1 0.35 0.47 0.11
Q96SK2 Transmembrane protein 209 2 4 -0.04 0.09 0.24
Q6NUQ4 Transmembrane protein 214 1 3 0.36 0.42 -0.02
Q9H0R3 Transmembrane protein 222 1 1 NA NA NA
Q96A57 Transmembrane protein 230 1 8 0.25 0.11 -0.19
Q9H330 Transmembrane protein 245 1 9 -0.07 -0.57 -0.62 3 4
Q9BRR3 Transmembrane protein 246 1 1 -0.04 -0.06 -0.04
P61165 Transmembrane protein 258 1 2 NA NA NA
Q8WWA1 Transmembrane protein 40 1 1 -0.21 -0.14 0.06
Q5BJD5 Transmembrane protein 41B 1 1 -0.14 -0.93 -0.78
Q9BTV4 Transmembrane protein 43 9 35 0.47 0.41 0.25
O94886 Transmembrane protein 63A 1 1 1.20 1.24 0.02
Q6UWD8 Transmembrane protein C16orf54 1 5 0.22 0.47 0.25
Q6ZT21 Transmembrane protein with metallophosphoesterase domain 1 1 -0.16 -0.06 0.11
Q92973 Transportin-1 8 38 0.17 0.23 0.02
Q13428 Treacle protein 43 266 0.40 0.24 -0.23
P40939 Trifunctional enzyme subunit alpha, mitochondrial 40 333 0.21 0.12 -0.06
P55084 Trifunctional enzyme subunit beta, mitochondrial 21 212 0.35 0.10 -0.24
P22102 Trifunctional purine biosynthetic protein adenosine-3 26 81 0.21 -0.09 -0.33
Q96RS0 Trimethylguanosine synthase 1 1 0.53 0.42 -0.10
O15417 Trinucleotide repeat-containing gene 18 protein 1 2 -0.04 0.19 0.23
Q9UPQ9 Trinucleotide repeat-containing gene 6B protein 5 9 0.02 0.09 0.09
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein 1 4 NA NA NA
P60174 Triosephosphate isomerase 25 925 -0.23 -0.13 -0.03
Q14142 Tripartite motif-containing protein 14 1 4 0.20 0.22 0.17
Q12899 Tripartite motif-containing protein 26 3 4 0.10 0.32 0.28
O00635 Tripartite motif-containing protein 38 4 7 0.02 -0.20 -0.33
Q9C037 Tripartite motif-containing protein 4 3 4 -0.14 -0.01 0.14
Q9C035 Tripartite motif-containing protein 5 2 2 -0.43 -0.11 0.31
Q6PJ69 Tripartite motif-containing protein 65 5 10 0.27 0.20 0.03
O14773 Tripeptidyl-peptidase 1 4 46 -0.47 0.10 0.42
P29144 Tripeptidyl-peptidase 2 16 62 -0.04 -0.20 -0.15
Q7Z2T5 TRMT1-like protein 1 3 0.15 -0.04 -0.19
Q9UJA5 tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6 4 10 -0.08 -0.22 -0.10
Q9BVS5 tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial 1 1 0.08 -0.10 -0.17
Q08J23 tRNA (cytosine(34)-C(5))-methyltransferase 22 104 -0.13 -0.10 -0.02
Q9NXH9 tRNA (guanine(26)-N(2))-dimethyltransferase 6 11 0.02 -0.17 -0.48
Q9UBP6 tRNA (guanine-N(7)-)-methyltransferase 1 2 -0.04 -0.40 -0.38
P57081 tRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit WDR4 1 2 -0.03 -0.21 -0.18
Q9H3H1 tRNA dimethylallyltransferase, mitochondrial 1 1 0.56 0.24 -0.31
Q9UI30 tRNA methyltransferase 112 homolog 4 26 0.18 -0.35 -0.64 5
Q969Y2 tRNA modification GTPase GTPBP3, mitochondrial 4 6 0.08 -0.08 -0.09
Q9Y606 tRNA pseudouridine synthase A, mitochondrial 4 13 0.27 -0.19 -0.56 4
Q9NX07 tRNA selenocysteine 1-associated protein 1 2 4 0.17 0.15 -0.08
Q6P1R4 tRNA-dihydrouridine(16/17) synthase-like 1 4 -0.08 -0.11 -0.04
Q9NX74 tRNA-dihydrouridine(20) synthase-like 2 2 -0.47 -0.25 0.22
Q9BUB4 tRNA-specific adenosine deaminase 1 1 2 0.30 0.44 0.14
Q8WW01 tRNA-splicing endonuclease subunit Sen15 1 1 0.01 0.04 0.04
Q9BSV6 tRNA-splicing endonuclease subunit Sen34 1 1 -0.71 -0.01 0.69
Q7Z6J9 tRNA-splicing endonuclease subunit Sen54 1 2 0.21 -0.30 -0.50
Q9Y3I0 tRNA-splicing ligase RtcB homolog 21 144 0.15 -0.22 -0.32
Q9NZR1 Tropomodulin-2 2 10 0.68 0.08 -0.18 3
Q9NYL9 Tropomodulin-3 14 115 -0.14 -0.09 0.07
P09493 Tropomyosin alpha-1 chain 2 133 -0.82 -0.13 0.70
P06753 Tropomyosin alpha-3 chain 6 337 -0.08 -0.19 0.07
P67936 Tropomyosin alpha-4 chain 16 311 -0.52 -0.02 0.94 4 5
P23381 Tryptophan--tRNA ligase, cytoplasmic 11 66 0.02 0.17 0.10
Q9UGM6 Tryptophan--tRNA ligase, mitochondrial 2 4 0.56 0.14 -0.33
O75157 TSC22 domain family protein 2 3 5 0.24 0.23 0.00
Q99576 TSC22 domain family protein 3 1 3 -0.10 -0.22 -0.33
Q9Y3Q8 TSC22 domain family protein 4 8 37 -0.21 -0.08 0.01
P49815 Tuberin 1 4 -0.36 -0.35 0.57
P68363 Tubulin alpha-1B chain 1 462 0.24 1.58 1.33
Q9BQE3 Tubulin alpha-1C chain 0 411 NA NA NA
P68366 Tubulin alpha-4A chain 6 380 0.67 -0.14 -1.06 5 5
Q9NY65 Tubulin alpha-8 chain 1 134 -0.11 -0.13 -0.01
P07437 Tubulin beta chain 5 979 -0.17 0.02 0.13
Q9H4B7 Tubulin beta-1 chain 9 232 -0.15 -0.13 0.08
Q13885 Tubulin beta-2A chain 1 784 0.33 -0.11 -0.44
P04350 Tubulin beta-4A chain 3 739 0.33 0.20 -0.51
P68371 Tubulin beta-4B chain 2 897 -0.12 0.26 0.50
Q9BUF5 Tubulin beta-6 chain 2 328 -0.29 0.10 0.28
P23258 Tubulin gamma-1 chain 4 18 -0.27 -0.36 -0.15
Q99426 Tubulin-folding cofactor B 11 60 -0.33 -0.05 0.36
O75347 Tubulin-specific chaperone A 10 70 -0.29 -0.23 0.09
Q15814 Tubulin-specific chaperone C 3 4 -0.54 -0.45 0.09
Q5QJ74 Tubulin-specific chaperone cofactor E-like protein 1 1 -0.71 -0.01 0.68
Q9BTW9 Tubulin-specific chaperone D 3 9 -0.05 -0.20 -0.17
Q14166 Tubulin--tyrosine ligase-like protein 12 5 25 0.21 0.00 -0.29
Q9Y2W6 Tudor and KH domain-containing protein 2 6 0.25 0.30 0.05
Q9H7E2 Tudor domain-containing protein 3 2 3 0.11 0.00 -0.12
Q8NHU6 Tudor domain-containing protein 7 1 1 -0.16 0.34 0.50
Q9UBB9 Tuftelin-interacting protein 11 6 17 -0.06 -0.05 0.04
P21580 Tumor necrosis factor alpha-induced protein 3 8 16 0.52 0.74 0.10 4 5
O95379 Tumor necrosis factor alpha-induced protein 8 4 17 0.53 0.18 -0.34
Q6P589 Tumor necrosis factor alpha-induced protein 8-like protein 2 2 4 -0.76 -0.38 0.39
Q9Y275 Tumor necrosis factor ligand superfamily member 13B 1 3 -1.95 -1.49 0.46
P20333 Tumor necrosis factor receptor superfamily member 1B 1 5 -0.26 1.59 1.85 3 4
O95407 Tumor necrosis factor receptor superfamily member 6B 1 2 NA NA NA
Q15628 Tumor necrosis factor receptor type 1-associated DEATH domain protein 9 33 0.45 0.24 -0.24
P55327 Tumor protein D52 8 34 -0.14 0.44 0.48 4
O43399 Tumor protein D54 13 91 -0.20 -0.20 0.07
O14683 Tumor protein p53-inducible protein 11 1 1 0.16 0.26 0.11
Q12888 Tumor suppressor p53-binding protein 1 17 41 -0.08 -0.10 -0.15
Q99816 Tumor susceptibility gene 101 protein 10 38 -0.17 0.31 0.43
Q12792 Twinfilin-1 4 7 0.01 0.18 0.17
Q6IBS0 Twinfilin-2 15 99 -0.15 -0.07 0.07
Q86T03 Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase 1 1 -0.19 -0.30 -0.11
Q96PE3 Type I inositol 3,4-bisphosphate 4-phosphatase 12 38 -0.07 0.21 0.18
P32019 Type II inositol 1,4,5-trisphosphate 5-phosphatase 1 1 0.12 0.48 0.34
O15327 Type II inositol 3,4-bisphosphate 4-phosphatase 1 1 1.66 0.28 -1.37
Q6RW13 Type-1 angiotensin II receptor-associated protein 1 4 -1.32 0.44 1.83 4 4
O43914 TYRO protein tyrosine kinase-binding protein 2 6 -2.00 0.52 2.50 3 3
P00519 Tyrosine-protein kinase ABL1 4 6 -0.16 0.01 0.45
Q9UIG0 Tyrosine-protein kinase BAZ1B 26 82 0.13 -0.19 -0.29
P51451 Tyrosine-protein kinase Blk 1 1 NA NA NA
P41240 Tyrosine-protein kinase CSK 19 141 -0.41 0.01 0.38
P07332 Tyrosine-protein kinase Fes/Fps 1 1 -3.81 1.41 5.23
P06241 Tyrosine-protein kinase Fyn 4 21 0.15 0.60 0.48
Q08881 Tyrosine-protein kinase ITK/TSK 1 1 -0.47 -0.88 -0.41
P23458 Tyrosine-protein kinase JAK1 9 26 0.01 0.39 0.35
P52333 Tyrosine-protein kinase JAK3 2 5 0.13 -0.17 -0.32
P06239 Tyrosine-protein kinase Lck 13 94 0.53 0.16 -0.41
P07948 Tyrosine-protein kinase Lyn 6 18 -1.02 0.38 1.36 4 4
Q86YV5 Tyrosine-protein kinase SgK223 6 18 -0.34 -0.54 -0.56
P43405 Tyrosine-protein kinase SYK 5 24 -0.83 0.00 0.89 3 3
P43403 Tyrosine-protein kinase ZAP-70 28 243 -0.52 0.29 0.83 4
P18031 Tyrosine-protein phosphatase non-receptor type 1 7 19 0.12 0.17 -0.09
Q06124 Tyrosine-protein phosphatase non-receptor type 11 11 40 -0.02 0.04 -0.20
Q05209 Tyrosine-protein phosphatase non-receptor type 12 14 45 -1.21 -0.08 1.19 5 5
Q12923 Tyrosine-protein phosphatase non-receptor type 13 1 1 NA NA NA
Q99952 Tyrosine-protein phosphatase non-receptor type 18 5 30 -0.23 0.15 0.24
P17706 Tyrosine-protein phosphatase non-receptor type 2 3 8 -0.31 0.18 0.54
Q9Y2R2 Tyrosine-protein phosphatase non-receptor type 22 1 3 -0.02 0.56 0.53
Q9H3S7 Tyrosine-protein phosphatase non-receptor type 23 11 20 0.06 0.03 -0.16
P29074 Tyrosine-protein phosphatase non-receptor type 4 3 7 -0.75 0.61 1.55 3 5 5
P29350 Tyrosine-protein phosphatase non-receptor type 6 28 276 -0.32 -0.09 0.13
P35236 Tyrosine-protein phosphatase non-receptor type 7 4 23 -0.16 0.08 0.10
P43378 Tyrosine-protein phosphatase non-receptor type 9 2 8 -0.07 0.70 0.93 3 4
P54577 Tyrosine--tRNA ligase, cytoplasmic 27 132 -0.09 0.45 0.50
Q9Y2Z4 Tyrosine--tRNA ligase, mitochondrial 4 6 0.08 -0.18 -0.28
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 4 7 -0.07 -0.11 -0.19
O95551 Tyrosyl-DNA phosphodiesterase 2 4 12 0.04 -0.25 -0.24
P08621 U1 small nuclear ribonucleoprotein 70 kDa 17 99 -0.05 -0.23 -0.03
P09012 U1 small nuclear ribonucleoprotein A 6 31 -0.17 -0.10 0.02
P09234 U1 small nuclear ribonucleoprotein C 3 9 -0.05 -0.16 -0.11
P09661 U2 small nuclear ribonucleoprotein A' 15 97 -0.08 -0.17 -0.10
P08579 U2 small nuclear ribonucleoprotein B'' 6 31 -0.17 0.03 0.19
O15042 U2 snRNP-associated SURP motif-containing protein 15 64 -0.13 -0.30 -0.02
Q9NV31 U3 small nucleolar ribonucleoprotein protein IMP3 1 2 0.70 -0.44 -1.14
Q96G21 U3 small nucleolar ribonucleoprotein protein IMP4 2 3 -0.23 -0.23 -0.17
O00566 U3 small nucleolar ribonucleoprotein protein MPP10 7 25 0.11 -0.19 -0.45
Q9BVJ6 U3 small nucleolar RNA-associated protein 14 homolog A 17 38 0.16 -0.21 -0.41
Q8TED0 U3 small nucleolar RNA-associated protein 15 homolog 2 5 0.26 -0.17 -0.32
Q9Y5J1 U3 small nucleolar RNA-associated protein 18 homolog 8 29 0.33 -0.21 -0.52 4
Q9NYH9 U3 small nucleolar RNA-associated protein 6 homolog 3 3 0.14 -0.18 -0.32
O43818 U3 small nucleolar RNA-interacting protein 2 5 12 0.08 -0.23 -0.33
O43395 U4/U6 small nuclear ribonucleoprotein Prp3 13 30 -0.10 -0.16 0.05
Q8WWY3 U4/U6 small nuclear ribonucleoprotein Prp31 11 66 -0.12 -0.18 -0.02
O43172 U4/U6 small nuclear ribonucleoprotein Prp4 10 38 -0.21 -0.24 0.05
Q8WVK2 U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein 3 4 -0.34 -0.19 0.06
O43290 U4/U6.U5 tri-snRNP-associated protein 1 30 142 -0.16 -0.16 0.03
Q53GS9 U4/U6.U5 tri-snRNP-associated protein 2 10 23 -0.32 -0.27 -0.01
O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase 35 179 -0.01 -0.04 0.00
Q96DI7 U5 small nuclear ribonucleoprotein 40 kDa protein 6 35 -0.23 -0.18 0.00
O15116 U6 snRNA-associated Sm-like protein LSm1 2 12 -0.20 -0.03 0.06
Q9Y333 U6 snRNA-associated Sm-like protein LSm2 7 41 -0.06 -0.25 -0.22
P62310 U6 snRNA-associated Sm-like protein LSm3 4 41 -0.12 -0.17 -0.11
Q9Y4Z0 U6 snRNA-associated Sm-like protein LSm4 5 54 -0.25 -0.36 0.00
Q9Y4Y9 U6 snRNA-associated Sm-like protein LSm5 1 1 0.25 0.02 -0.23
P62312 U6 snRNA-associated Sm-like protein LSm6 6 34 -0.17 -0.43 -0.12
Q9UK45 U6 snRNA-associated Sm-like protein LSm7 3 23 0.10 -0.14 -0.28
P83369 U7 snRNA-associated Sm-like protein LSm11 1 1 NA NA NA
Q96DE0 U8 snoRNA-decapping enzyme 1 2 0.77 0.25 -0.50
Q96QD9 UAP56-interacting factor 10 35 -0.17 -0.13 0.00
Q9NPG3 Ubinuclein-1 4 5 -0.35 -0.09 0.17
Q6ZU65 Ubinuclein-2 1 1 0.96 0.13 -0.81
Q9UMX0 Ubiquilin-1 3 56 0.06 0.06 -0.14
Q9UHD9 Ubiquilin-2 4 38 0.34 -0.05 -0.83
Q9NRR5 Ubiquilin-4 4 18 0.60 0.39 -0.27
Q9BRT2 Ubiquinol-cytochrome-c reductase complex assembly factor 2 1 2 -0.14 0.20 0.35
Q9Y2Z9 Ubiquinone biosynthesis monooxygenase COQ6 2 3 -0.14 -0.50 -0.38
Q99807 Ubiquinone biosynthesis protein COQ7 homolog 4 12 -0.09 -0.52 -0.45
O75208 Ubiquinone biosynthesis protein COQ9, mitochondrial 3 21 0.06 -0.35 -0.28
Q14694 Ubiquitin carboxyl-terminal hydrolase 10 10 32 -0.09 -0.15 -0.07
P51784 Ubiquitin carboxyl-terminal hydrolase 11 6 8 0.51 0.02 -0.24
P54578 Ubiquitin carboxyl-terminal hydrolase 14 14 109 0.23 0.03 -0.21
Q9Y4E8 Ubiquitin carboxyl-terminal hydrolase 15 7 13 0.27 0.22 -0.10
O94966 Ubiquitin carboxyl-terminal hydrolase 19 3 5 -0.13 -0.03 -0.01
Q9UPU5 Ubiquitin carboxyl-terminal hydrolase 24 12 21 0.03 -0.01 -0.19
Q9UHP3 Ubiquitin carboxyl-terminal hydrolase 25 4 9 -0.21 -0.09 0.03
Q96RU2 Ubiquitin carboxyl-terminal hydrolase 28 4 9 -0.62 0.20 0.70 5 5
Q9Y6I4 Ubiquitin carboxyl-terminal hydrolase 3 2 3 -0.10 0.11 0.20
Q8TEY7 Ubiquitin carboxyl-terminal hydrolase 33 1 1 -1.45 -1.39 0.07
Q9P275 Ubiquitin carboxyl-terminal hydrolase 36 1 4 0.42 0.14 -0.25
Q13107 Ubiquitin carboxyl-terminal hydrolase 4 2 6 0.08 -0.19 -0.26
Q96K76 Ubiquitin carboxyl-terminal hydrolase 47 24 79 0.10 0.03 0.12
P45974 Ubiquitin carboxyl-terminal hydrolase 5 20 124 0.15 -0.25 -0.28
Q93009 Ubiquitin carboxyl-terminal hydrolase 7 26 108 0.24 0.07 -0.10
P40818 Ubiquitin carboxyl-terminal hydrolase 8 4 9 0.16 -0.01 -0.22
Q9NQC7 Ubiquitin carboxyl-terminal hydrolase CYLD 6 15 0.02 0.04 0.04
P15374 Ubiquitin carboxyl-terminal hydrolase isozyme L3 5 19 0.05 -0.09 -0.17
Q9Y5K5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 11 39 -0.04 0.10 0.09
O95155 Ubiquitin conjugation factor E4 B 2 4 0.14 0.27 0.07
O14562 Ubiquitin domain-containing protein UBFD1 2 3 -0.07 -0.12 -0.05
Q92890 Ubiquitin fusion degradation protein 1 homolog 8 37 0.03 -0.03 0.08
Q96FW1 Ubiquitin thioesterase OTUB1 11 47 0.14 0.02 -0.28
Q96BN8 Ubiquitin thioesterase otulin 5 11 0.01 0.28 0.26
O14933 Ubiquitin/ISG15-conjugating enzyme E2 L6 4 7 -0.45 0.12 0.17
P62979 Ubiquitin-40S ribosomal protein S27a 13 509 -0.06 0.20 0.27
P57075 Ubiquitin-associated and SH3 domain-containing protein A 2 4 0.52 -0.12 -0.65
Q8TF42 Ubiquitin-associated and SH3 domain-containing protein B 1 1 0.00 -0.36 -0.35
Q9BSL1 Ubiquitin-associated domain-containing protein 1 4 10 0.11 -0.09 -0.20
Q8NBM4 Ubiquitin-associated domain-containing protein 2 1 3 -0.24 -0.23 0.38
Q9NZ09 Ubiquitin-associated protein 1 3 11 0.29 0.50 0.25 5
Q5T6F2 Ubiquitin-associated protein 2 7 10 -0.10 -0.04 0.12
Q14157 Ubiquitin-associated protein 2-like 12 45 -0.01 -0.02 -0.01
P51668 Ubiquitin-conjugating enzyme E2 D1 2 4 -0.12 0.14 0.31
P61077 Ubiquitin-conjugating enzyme E2 D3 2 4 -0.06 -0.28 -0.22
P61086 Ubiquitin-conjugating enzyme E2 K 5 22 0.04 -0.20 0.01
P68036 Ubiquitin-conjugating enzyme E2 L3 8 44 0.03 0.19 0.17
P61088 Ubiquitin-conjugating enzyme E2 N 6 101 0.35 0.03 -0.29
Q9C0C9 Ubiquitin-conjugating enzyme E2 O 11 25 0.14 0.03 -0.09
P49427 Ubiquitin-conjugating enzyme E2 R1 1 1 1.17 0.35 -0.81
Q712K3 Ubiquitin-conjugating enzyme E2 R2 1 2 0.22 0.00 -0.22
Q13404 Ubiquitin-conjugating enzyme E2 variant 1 3 57 0.11 -0.01 -0.22
Q15819 Ubiquitin-conjugating enzyme E2 variant 2 4 67 -0.03 -0.10 -0.29
Q8IX04 Ubiquitin-conjugating enzyme E2 variant 3 1 2 -0.40 0.53 0.92
Q9H832 Ubiquitin-conjugating enzyme E2 Z 4 14 0.21 0.05 -0.22
P61960 Ubiquitin-fold modifier 1 4 15 0.11 0.24 0.22
Q9Y3C8 Ubiquitin-fold modifier-conjugating enzyme 1 2 22 -0.08 0.04 0.14
Q8WVY7 Ubiquitin-like domain-containing CTD phosphatase 1 6 27 -0.23 -0.03 0.16
P22314 Ubiquitin-like modifier-activating enzyme 1 43 522 0.09 -0.15 -0.24
Q9GZZ9 Ubiquitin-like modifier-activating enzyme 5 7 27 0.02 0.24 0.19
A0AVT1 Ubiquitin-like modifier-activating enzyme 6 17 66 0.28 0.06 -0.20
P41226 Ubiquitin-like modifier-activating enzyme 7 8 35 -0.33 0.00 0.26
O95352 Ubiquitin-like modifier-activating enzyme ATG7 1 1 0.29 0.09 -0.20
P11441 Ubiquitin-like protein 4A 6 13 0.07 -0.01 -0.16
Q9BZL1 Ubiquitin-like protein 5 3 14 -0.24 -0.32 -0.08
O94817 Ubiquitin-like protein ATG12 2 7 0.22 0.19 -0.25
P05161 Ubiquitin-like protein ISG15 4 21 -0.46 0.17 0.67
Q9NT62 Ubiquitin-like-conjugating enzyme ATG3 9 43 0.06 -0.11 -0.08
Q05086 Ubiquitin-protein ligase E3A 12 33 0.06 -0.10 -0.08
Q15386 Ubiquitin-protein ligase E3C 1 1 0.22 0.34 0.12
Q04323 UBX domain-containing protein 1 8 20 -0.39 -0.21 0.20
P68543 UBX domain-containing protein 2A 1 1 -0.40 0.31 0.72
Q92575 UBX domain-containing protein 4 4 31 0.22 -0.11 -0.33
Q9BZV1 UBX domain-containing protein 6 5 11 -0.02 0.15 0.18
O94888 UBX domain-containing protein 7 2 17 -0.07 -0.18 -0.11
Q9C0J1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 1 4 0.19 -1.25 -1.43
Q14376 UDP-glucose 4-epimerase 1 2 -0.54 0.28 0.83
O60701 UDP-glucose 6-dehydrogenase 5 11 0.49 0.81 0.06 5
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 27 124 -0.02 0.21 0.19
O15294 UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit 12 27 0.01 -0.09 -0.13
Q16222 UDP-N-acetylhexosamine pyrophosphorylase 2 7 0.10 0.31 0.25
Q3KQV9 UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 1 2 0.04 -0.52 -0.56
Q6BDS2 UHRF1-binding protein 1 1 5 -0.13 0.17 0.31
P30085 UMP-CMP kinase 10 66 -0.06 -0.08 0.07
Q5EBM0 UMP-CMP kinase 2, mitochondrial 5 14 -0.25 0.14 0.39
Q6ZUT1 Uncharacterized protein C11orf57 1 1 -0.06 0.14 0.21
Q96C57 Uncharacterized protein C12orf43 5 12 0.02 0.09 -0.11
Q9BXV9 Uncharacterized protein C14orf142 4 28 0.01 -0.04 -0.03
Q8NEP4 Uncharacterized protein C17orf47 1 1 -0.67 0.05 0.73
Q96GS4 Uncharacterized protein C17orf59 11 44 -0.08 0.05 0.47
Q9BQA9 Uncharacterized protein C17orf62 2 7 -0.47 0.28 0.75
Q9BSJ5 Uncharacterized protein C17orf80 1 1 0.76 -0.38 -1.14
Q53F19 Uncharacterized protein C17orf85 9 37 -0.34 -0.07 0.26
A1L188 Uncharacterized protein C17orf89 1 1 -0.37 -0.17 0.18
Q96B23 Uncharacterized protein C18orf25 1 1 -0.81 -0.71 0.10
Q96DM3 Uncharacterized protein C18orf8 2 3 -0.18 0.13 0.37
Q9BQ61 Uncharacterized protein C19orf43 5 24 -0.19 -0.01 0.35
Q8N9M1 Uncharacterized protein C19orf47 3 4 -0.51 -0.08 0.43
Q9BSF4 Uncharacterized protein C19orf52 2 4 0.02 -0.07 -0.01
Q9NX04 Uncharacterized protein C1orf109 1 1 NA NA NA
Q6ZSJ8 Uncharacterized protein C1orf122 1 1 -0.22 0.08 0.27
Q8NDD1 Uncharacterized protein C1orf131 2 2 -0.10 0.17 0.28
Q9BV19 Uncharacterized protein C1orf50 1 4 -0.23 -0.29 -0.02
Q8WWC4 Uncharacterized protein C2orf47, mitochondrial 1 3 0.27 0.00 -0.33
Q6NW34 Uncharacterized protein C3orf17 1 1 -0.32 -0.15 0.18
Q8N8J7 Uncharacterized protein C4orf32 1 1 0.95 -0.03 -0.98
Q9P0P8 Uncharacterized protein C6orf203 1 1 NA NA NA
Q9BRJ6 Uncharacterized protein C7orf50 6 15 0.16 -0.27 -0.49
Q5T280 Uncharacterized protein C9orf114 3 10 -0.14 -0.08 0.08
Q9BUH6 Uncharacterized protein C9orf142 13 193 0.11 0.38 0.30 5
Q9NZ63 Uncharacterized protein C9orf78 9 17 0.00 -0.33 -0.41
Q8TB03 Uncharacterized protein CXorf38 1 3 -0.06 -0.01 0.05
Q6ZSR9 Uncharacterized protein FLJ45252 12 71 0.14 0.08 -0.04
Q6ZRH9 Uncharacterized protein FLJ46347 1 7 0.39 -0.17 -0.38
Q96AT1 Uncharacterized protein KIAA1143 7 22 -0.31 0.00 -0.04
Q9P2H0 Uncharacterized protein KIAA1377 1 1 -0.63 -0.11 0.53
Q9HCM1 Uncharacterized protein KIAA1551 1 2 -0.38 -0.39 -0.01
Q9BY89 Uncharacterized protein KIAA1671 1 1 -0.91 -0.66 0.27
Q5JYT7 Uncharacterized protein KIAA1755 1 5 0.03 0.25 0.13
O00160 Unconventional myosin-If 29 154 -0.13 1.39 1.32 5 5
B0I1T2 Unconventional myosin-Ig 36 262 0.02 0.59 0.36 4
Q13459 Unconventional myosin-IXb 16 52 -0.35 -0.03 0.21
Q9Y4I1 Unconventional myosin-Va 7 12 0.29 0.54 0.20 5
Q9UM54 Unconventional myosin-VI 1 1 0.29 0.42 0.14
Q92614 Unconventional myosin-XVIIIa 38 93 0.12 0.40 0.32 4
O94763 Unconventional prefoldin RPB5 interactor 1 2 4 0.12 -0.16 -0.16
Q14146 Unhealthy ribosome biogenesis protein 2 homolog 1 2 0.82 0.12 -0.69
Q9HB07 UPF0160 protein MYG1, mitochondrial 4 17 0.01 -0.10 -0.13
Q9BSU1 UPF0183 protein C16orf70 1 2 -0.31 0.02 0.31
Q8WUR7 UPF0235 protein C15orf40 1 6 0.13 -0.11 -0.28
Q7Z3D6 UPF0317 protein C14orf159, mitochondrial 4 20 0.50 0.35 -0.07 5
Q9H993 UPF0364 protein C6orf211 3 12 0.10 0.22 0.22
Q96GQ5 UPF0420 protein C16orf58 1 1 0.02 -0.06 -0.07
Q9H5V9 UPF0428 protein CXorf56 4 10 -0.20 -0.19 -0.01
Q8WUH6 UPF0444 transmembrane protein C12orf23 5 32 -0.02 -0.28 -0.22
Q9UFG5 UPF0449 protein C19orf25 3 5 -0.18 -0.19 0.11
Q7Z6I8 UPF0461 protein C5orf24 2 3 -0.70 0.05 0.75
Q9Y6A4 UPF0468 protein C16orf80 2 2 -0.12 -0.15 -0.03
Q7Z7F0 UPF0469 protein KIAA0907 2 2 -0.29 0.21 0.51
Q9H7E9 UPF0488 protein C8orf33 5 12 0.03 -0.19 -0.30
Q49AR2 UPF0489 protein C5orf22 2 6 0.00 0.01 -0.08
Q9P2B7 UPF0501 protein KIAA1430 1 1 0.03 0.03 -0.02
Q7Z3J2 UPF0505 protein C16orf62 1 4 0.15 0.16 -0.01
Q9NUL5 UPF0515 protein C19orf66 3 21 -0.05 0.25 0.32
Q6NTE8 UPF0544 protein C5orf45 1 1 -0.14 -0.41 -0.26
Q5T6V5 UPF0553 protein C9orf64 3 14 -0.07 -0.22 0.01
Q969H8 UPF0556 protein C19orf10 5 23 -0.65 -0.19 0.36 3
Q2NKX9 UPF0561 protein C2orf68 1 2 -0.32 0.19 0.52
Q8N8R5 UPF0565 protein C2orf69 1 1 0.00 -0.10 -0.10
Q9Y224 UPF0568 protein C14orf166 11 101 0.21 0.01 -0.17
Q96S19 UPF0585 protein C16orf13 5 9 -0.08 -0.22 -0.07
Q9NWV4 UPF0587 protein C1orf123 7 23 -0.31 0.00 -0.06
Q6P1X6 UPF0598 protein C8orf82 1 1 NA NA NA
Q9NWY4 UPF0609 protein C4orf27 3 6 -0.19 -0.10 0.02
Q5T2E6 UPF0668 protein C10orf76 1 1 -0.01 -0.03 -0.01
Q9GZN8 UPF0687 protein C20orf27 1 1 -0.05 -0.32 -0.27
Q8IYL3 UPF0688 protein C1orf174 4 19 -0.53 -0.33 0.37
Q8N6N3 UPF0690 protein C1orf52 1 8 -0.21 -0.06 0.14
Q96B45 UPF0693 protein C10orf32 5 17 -0.22 0.13 0.22
Q9H3H3 UPF0696 protein C11orf68 4 8 0.16 0.15 -0.07
P57076 UPF0769 protein C21orf59 1 7 0.20 -0.16 -0.31
Q96IX5 Up-regulated during skeletal muscle growth protein 5 2 5 0.41 0.20 -0.01
P22415 Upstream stimulatory factor 1 2 4 -0.01 0.28 0.28
Q15853 Upstream stimulatory factor 2 1 7 -0.04 0.04 0.15
Q9NZI7 Upstream-binding protein 1 2 6 -0.02 0.15 0.14
Q96BW1 Uracil phosphoribosyltransferase homolog 1 2 -0.48 0.29 0.78
P13051 Uracil-DNA glycosylase 2 3 0.11 0.29 0.17
P11172 Uridine 5'-monophosphate synthase 7 17 0.08 -0.07 -0.43
Q16831 Uridine phosphorylase 1 3 13 -0.25 0.50 0.68
Q9NWZ5 Uridine-cytidine kinase-like 1 1 1 0.42 0.25 -0.17
P06132 Uroporphyrinogen decarboxylase 1 2 0.44 0.15 -0.29
P10746 Uroporphyrinogen-III synthase 2 3 -0.04 0.04 0.08
Q16851 UTP--glucose-1-phosphate uridylyltransferase 27 134 0.16 -0.22 -0.40
P46939 Utrophin 25 56 -0.37 0.29 0.69 3
P54725 UV excision repair protein RAD23 homolog A 3 31 0.32 0.06 -0.06
P54727 UV excision repair protein RAD23 homolog B 12 98 -0.08 0.08 0.18
Q9P2Y5 UV radiation resistance-associated gene protein 1 1 -0.19 0.38 0.58
P86790 Vacuolar fusion protein CCZ1 homolog B 3 3 0.05 0.09 0.04
Q7L1V2 Vacuolar fusion protein MON1 homolog B 1 2 -0.19 -0.07 0.11
Q9H270 Vacuolar protein sorting-associated protein 11 homolog 4 12 -0.18 0.13 0.29
Q96RL7 Vacuolar protein sorting-associated protein 13A 2 3 -0.06 -0.33 -0.27
Q709C8 Vacuolar protein sorting-associated protein 13C 24 88 0.48 0.21 -0.28
Q5THJ4 Vacuolar protein sorting-associated protein 13D 1 1 0.39 0.20 -0.18
Q9H269 Vacuolar protein sorting-associated protein 16 homolog 5 21 -0.20 0.02 0.26
Q9P253 Vacuolar protein sorting-associated protein 18 homolog 5 8 -0.01 0.12 0.24
O75436 Vacuolar protein sorting-associated protein 26A 3 10 0.29 0.08 0.06
Q4G0F5 Vacuolar protein sorting-associated protein 26B 7 28 -0.22 0.15 0.36
Q9UK41 Vacuolar protein sorting-associated protein 28 homolog 2 4 -0.36 0.13 0.46
Q9UBQ0 Vacuolar protein sorting-associated protein 29 9 44 0.05 0.12 0.00
Q96AX1 Vacuolar protein sorting-associated protein 33A 3 5 -0.24 -0.01 0.23
Q9H267 Vacuolar protein sorting-associated protein 33B 4 7 -0.03 0.02 -0.02
Q96QK1 Vacuolar protein sorting-associated protein 35 11 47 0.00 0.11 0.05
Q8NEZ2 Vacuolar protein sorting-associated protein 37A 2 3 0.14 0.22 0.07
Q9H9H4 Vacuolar protein sorting-associated protein 37B 4 25 -0.32 0.30 0.68 5
Q86XT2 Vacuolar protein sorting-associated protein 37D 1 5 NA NA NA
P49754 Vacuolar protein sorting-associated protein 41 homolog 1 1 -0.09 0.21 0.30
Q9NRW7 Vacuolar protein sorting-associated protein 45 3 6 -0.22 -0.03 0.14
Q9UN37 Vacuolar protein sorting-associated protein 4A 5 57 -0.03 -0.11 0.02
O75351 Vacuolar protein sorting-associated protein 4B 14 80 -0.18 0.10 0.30
Q9UID3 Vacuolar protein sorting-associated protein 51 homolog 5 8 0.09 0.04 -0.01
Q8N1B4 Vacuolar protein sorting-associated protein 52 homolog 6 13 -0.02 0.00 0.02
Q5VIR6 Vacuolar protein sorting-associated protein 53 homolog 1 1 0.10 0.12 0.03
Q15906 Vacuolar protein sorting-associated protein 72 homolog 1 1 -0.91 -0.07 0.85
Q8N3P4 Vacuolar protein sorting-associated protein 8 homolog 2 3 -0.10 -0.17 -0.08
Q9NP79 Vacuolar protein sorting-associated protein VTA1 homolog 3 16 0.09 0.06 -0.06
Q9BRG1 Vacuolar protein-sorting-associated protein 25 2 7 -0.25 -0.03 0.12
Q86VN1 Vacuolar protein-sorting-associated protein 36 6 16 -0.28 -0.03 0.28
Q96H20 Vacuolar-sorting protein SNF8 5 15 -0.15 -0.03 0.17
P26640 Valine--tRNA ligase 25 163 0.31 0.15 -0.20
Q5ST30 Valine--tRNA ligase, mitochondrial 2 3 -0.03 -0.07 -0.02
Q96JC1 Vam6/Vps39-like protein 3 5 0.03 0.19 0.28
Q14119 Vascular endothelial zinc finger 1 3 7 0.00 0.07 0.11
P50552 Vasodilator-stimulated phosphoprotein 21 222 -0.65 -0.09 0.52 5 5
P49748 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 22 121 0.19 0.26 0.09
Q6Y1H2 Very-long-chain (3R)-3-hydroxyacyl-[acyl-carrier protein] dehydratase 2 1 3 0.54 0.42 -0.13
Q9P035 Very-long-chain (3R)-3-hydroxyacyl-[acyl-carrier protein] dehydratase 3 2 3 0.26 0.13 -0.12
Q9NZ01 Very-long-chain enoyl-CoA reductase 2 2 0.30 0.14 -0.16
Q9Y3E0 Vesicle transport protein GOT1B 1 1 -0.10 0.38 0.49
Q12981 Vesicle transport protein SEC20 2 2 0.96 0.47 -0.48
O95562 Vesicle transport protein SFT2B 1 2 NA NA NA
Q96AJ9 Vesicle transport through interaction with t-SNAREs homolog 1A 1 2 -1.67 -0.73 0.95
Q9UEU0 Vesicle transport through interaction with t-SNAREs homolog 1B 7 12 -0.24 -0.05 0.18
P63027 Vesicle-associated membrane protein 2 2 21 -0.01 0.01 0.01
Q15836 Vesicle-associated membrane protein 3 1 8 -0.21 0.38 0.57
O75379 Vesicle-associated membrane protein 4 1 1 -0.21 -0.04 0.18
O95183 Vesicle-associated membrane protein 5 1 13 0.13 0.27 0.13
Q9BV40 Vesicle-associated membrane protein 8 4 40 -0.50 0.45 0.98 4
Q9P0L0 Vesicle-associated membrane protein-associated protein A 6 33 0.04 0.16 0.14
O95292 Vesicle-associated membrane protein-associated protein B/C 6 24 0.00 0.08 0.03
P46459 Vesicle-fusing ATPase 19 78 0.08 0.02 -0.08
O75396 Vesicle-trafficking protein SEC22b 12 115 0.31 0.20 0.13
Q12907 Vesicular integral-membrane protein VIP36 7 26 0.20 0.37 0.42
Q00341 Vigilin 15 28 0.24 0.33 0.12 5
P08670 Vimentin 53 2133 0.82 0.01 -0.89 5 5
P18206 Vinculin 72 625 -0.28 0.49 0.89 5 5
Q9H0V9 VIP36-like protein 1 3 0.34 0.45 0.05
P02774 Vitamin D-binding protein 2 3 1.48 1.46 -0.02
P04004 Vitronectin 1 1 0.94 0.65 -0.28
P21796 Voltage-dependent anion-selective channel protein 1 20 196 0.08 0.27 0.26
P45880 Voltage-dependent anion-selective channel protein 2 12 143 -0.06 0.23 0.11
Q9Y277 Voltage-dependent anion-selective channel protein 3 11 93 0.05 0.15 -0.12
Q9NY47 Voltage-dependent calcium channel subunit alpha-2/delta-2 7 14 0.76 1.47 0.62 3 3
Q96D96 Voltage-gated hydrogen channel 1 2 2 -1.21 0.02 1.23
Q13303 Voltage-gated potassium channel subunit beta-2 16 91 -0.13 0.29 0.39
P04275 von Willebrand factor 2 8 0.03 -0.42 -0.53
O00534 von Willebrand factor A domain-containing protein 5A 5 6 -0.71 -0.77 0.15
A3KMH1 von Willebrand factor A domain-containing protein 8 13 25 0.66 0.36 -0.34 5
Q9Y487 V-type proton ATPase 116 kDa subunit a isoform 2 1 1 -0.08 0.27 0.36
Q13488 V-type proton ATPase 116 kDa subunit a isoform 3 2 3 -0.63 0.00 0.63
P38606 V-type proton ATPase catalytic subunit A 13 94 -0.10 -0.04 0.13
P21281 V-type proton ATPase subunit B, brain isoform 17 86 -0.10 -0.03 -0.04
P21283 V-type proton ATPase subunit C 1 6 15 -0.20 0.19 0.29
Q9Y5K8 V-type proton ATPase subunit D 3 7 -0.18 -0.11 0.06
P61421 V-type proton ATPase subunit d 1 1 3 0.15 0.55 0.56
P36543 V-type proton ATPase subunit E 1 9 44 -0.22 -0.16 0.18
O75348 V-type proton ATPase subunit G 1 3 10 -0.01 -0.05 0.08
Q9UI12 V-type proton ATPase subunit H 4 21 -0.08 -0.06 0.08
Q15904 V-type proton ATPase subunit S1 1 2 0.03 -0.04 -0.08
Q9NQA3 WAS protein family homolog 6 1 14 -0.33 -0.48 -0.15
O43516 WAS/WASL-interacting protein family member 1 15 175 -0.34 0.17 0.50 5
Q2M389 WASH complex subunit 7 4 12 0.01 -0.19 -0.20
Q9Y3C0 WASH complex subunit CCDC53 1 1 NA NA NA
Q5SNT6 WASH complex subunit FAM21B 3 31 -0.21 -0.04 0.18
Q9Y4E1 WASH complex subunit FAM21C 3 31 -0.05 -0.12 -0.07
Q12768 WASH complex subunit strumpellin 1 4 -0.04 0.06 0.10
Q8IWB7 WD repeat and FYVE domain-containing protein 1 1 1 -0.17 0.26 0.43
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